Stada Arzneimittel AG Annual Report 2014

← All annual reports

FY2014 Annual Report · Stada Arzneimittel AG

Loading PDF…

STADA Key Figures

STADA KEY FIGURES

Key figures for the Group in € million

2014

Previous year1)

± %

Group sales

• Generics (core segment)

• Branded Products (core segment)

Operating profit

Operating profit, adjusted 2) 3)

EBITDA (Earnings before interest, taxes, depreciation and amortization)

EBITDA (Earnings before interest, taxes, depreciation and amortization), adjusted 2) 3)

EBIT (Earnings before interest and taxes)

EBIT (Earnings before interest and taxes), adjusted 2) 3)

EBT (Earnings before taxes)

EBT (Earnings before taxes), adjusted 2) 4)

Net income

Net income, adjusted 2) 4)

Cash flow from operating activities

Capital expenditure

Depreciation and amortization (net of write-ups)

Employees (average number calculated on the basis of full-time employees Jan. 1 – Dec. 31)5)

Employees (as of the balance sheet date calculated on the basis of full-time employees)

2,062.2

1,217.7

800.5

188.5

320.7

418.8

431.9

190.3

322.4

124.7

253.3

64.6

186.2

223.8

279.0

228.5

10,209

10,363

2,003.9

1,227.9

704.4

248.3

303.1

382.6

414.3

252.4

307.1

189.3

240.7

121.4

160.6

203.7

365.0

130.2

8,841

9,825

+3%

-1%

+14%

-24%

+6%

+9%

+4%

-25%

+5%

-34%

+5%

-47%

+16%

+10%

-24%

+76%

+15%

+5%

Key share figures

2014

Previous year

± %

Market capitalization (year-end) in € million

Year-end closing price (XETRA®) in €

Number of shares (year-end)

Average number of shares (without treasury shares)

Earnings per share in €

Earnings per share in €, adjusted 2) 4)

Diluted earnings per share in €

Diluted earnings per share in €, adjusted 2) 4)

Dividend per share in €

Total dividend payments in € million

Distribution ratio as a percentage

1,530.8

25.25

60,626,700

60,408,501

2,171.7

35.93

60,442,500

59,571,959

1.07

3.08

1.05

3.04

0.666)

40.06)

62%6)

2.04

2.70

2.00

2.65

0.66

39.8

33%

-30%

+1%

-48%

+14%

-48%

+15%

+88%

1) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.).
2) The deduction of such effects which have an impact on the presentation of STADA’s earnings situation and
the derived key figures aims at improving the comparability of key figures with previous years. To achieve this,
STADA uses adjusted key figures, which, as so called pro forma figures, are not governed by the accounting
requirements in accordance with IFRS. As other companies may not calculate the pro forma figures presented
by STADA in the same way, STADA’s pro forma figures are only comparable with similarly designated
disclosures by other companies to a limited extent.

3) Within the context of this annual report, adjustments in connection with the operating profit, EBITDA
and EBIT generally relate to one-time special effects.
4) Within the context of this annual report, adjustments in connection with EBT, net income, earnings per
share and diluted earnings per share generally relate to one-time special effects and effects from the
measurement of derivative financial instruments under financial income and expenses.
5) This average number includes changes in the scope of consolidation on a pro-rata basis.
6) Proposed.

STADA AT A GLANCE

STADA BUSINESS MODEL

• Focus on products with off-patent active pharmaceutical ingredients in the health care and, in particular, in the pharmaceutical market

• Core segments

– Generics (59% of Group sales)

– Branded Products (39% of Group sales)

• Strategic success factors

– Orientation on long-term growth markets

– Comprehensive generics portfolio and numerous attractive-margin branded products

– Strong product development without cost-intensive research

– International sales structure

– Active acquisition policy, particularly in the area of branded products, including experienced integration management

– Functionally organized Group with short decision-making channels and close to market sales companies

– Culture of continuous cost optimization including efficient cost management

STADA FINANCIAL YEAR 2014

• Group sales rise by 3% to € 2.06 billion – Group sales adjusted for currency and portfolio effects records slight growth of 1%

• Reported key earnings figures

– Reported EBITDA increases by 9% to € 418.8 million

– Reported net income decreases significantly by 47% to € 64.6 million

– Earnings per share records a substantial decrease of 48% to € 1.07

• Adjusted key earnings figures

– Adjusted EBITDA records growth by 4% to € 431.9 million

– Adjusted net income rises substantially by 16% to € 186.2 million

– Adjusted earnings per share increases clearly by 14% to € 3.08

• Pleasing development in Central Europe with a sales increase of 11% and in Asia & Pacific with sales growth of 52%

• Further expansion of the self-pay patient portfolio from high sales growth of 14% in branded products – share of branded products

in adjusted operating profit of core segments rises to 52%

• Introduction of a centralized portfolio management structure including a decentralized marketing

• Successful product development with 626 product launches worldwide

• Further acquisitions to strengthen the Branded Products segment

• Successful securing of promissory notes in the amount of € 270 million

• Dividend proposal of € 0.66 per STADA common share unchanged to the previous year

STADA OUTLOOK

• Outlook for 2015

– Slight growth in Group sales adjusted for currency and portfolio effects

– Substantial decrease in adjusted EBITDA and adjusted net income

– Ratio of net debt, excluding further acquisitions, to adjusted EBITDA at a level of nearly 3

STADA at a Glance04

Table of Contents

LETTER TO SHAREHOLDERS FROM THE CHAIRMAN
OF THE EXECUTIVE BOARD

REPORT OF THE SUPERVISORY BOARD

OVERVIEW

BOARDS OF THE COMPANY
THE STADA SUPERVISORY BOARD

THE STADA EXECUTIVE BOARD

THE STADA ADVISORY BOARD

THE STADA SHARE

CORPORATE GOVERNANCE REPORT

MANAGEMENT REPORT OF THE EXECUTIVE BOARD 36

BASIS OF THE GROUP

Business Model of the Group

Product Development

Procurement, Production and Quality Management

Sales and Marketing

Employees

Goals and Strategies

Controlling

Responsibility and Sustainability

ECONOMIC REPORT

General Economic and Industry-Specific Situation

Business Development and Situation

Development of 2014 Compared to Outlook

Development of Performance Indicators

Earnings Situation

Development of Sales

Development of Earnings and Costs

Development of Segments

Financial Situation

Assets Situation

General Statements of the Executive Board

on Business Development in 2014

Table of Contents

STADA CONSOLIDATED FINANCIAL STATEMENTS

130

REMUNERATION REPORT

SUPPLEMENTARY REPORT

OPPORTUNITIES REPORT

RISK REPORT

TAKEOVER-RELEVANT INFORMATION

PROGNOSIS REPORT

102

103

105

124

126

CONSOLIDATED INCOME STATEMENT

CONSOLIDATED STATEMENT

OF COMPREHENSIVE INCOME

CONSOLIDATED BALANCE SHEET

CONSOLIDATED CASH FLOW STATEMENT

CONSOLIDATED STATEMENT OF

CHANGES IN SHAREHOLDERS’ EQUITY

NOTES TO THE

CONSOLIDATED FINANCIAL STATEMENTS

General Information

Notes to the Consolidated Income Statement

Notes to the Consolidated Balance Sheet

Other Disclosures

RESPONSIBILITY STATEMENT

AUDITOR’S REPORT

GLOSSARY FROM A TO Z

FINANCIAL CALENDAR

PUBLISHING INFORMATION

OVERVIEW OF SALES

132

133

134

135

136

138

168

180

212

237

238

239

241

242

244

FIVE-YEAR CONSOLIDATED FINANCIAL SUMMARY 245

LETTER TO SHAREHOLDERS FROM THE CHAIRMAN
OF THE EXECUTIVE BOARD

Dear Shareholders,

In 2014, we were confronted with challenging framework conditions both in the market region Germany and in the market region CIS / Eastern

Europe. Overall, we had to report high one-time special effects that primarily resulted from impairments on goodwill and on further

intangible assets as a consequence of the significantly changed interest rate and currency environment as well as ongoing higher risks in

the market region CIS / Eastern Europe.

Despite the challenges, we were able to reach our sales and earnings targets at Group level. Group sales increased and we were able to

achieve strong sales growth, especially in the Branded Products business segment, which is becoming increasingly important for us. The

earnings development was characterized by an increase in operating performance as shown by growth in all of the Group’s adjusted key

earnings figures. In view of the high one-time special effects, reported net income decreased by nearly half as compared to the previous

year. However, adjusted net income recorded substantial growth. Our adjusted Group tax rate, which we were able to reduce significantly,

also developed well. We were also very satisfied with the development of adjusted free cashflow; its increase primarily resulted from a

cash-effective decrease in trade accounts receivable as well as from lower income tax payments.

Looking at the regional sales development, worth noting is, on the one hand, Central Europe with a significant increase which was achieved

despite a strong basis for comparison in the previous year and which is based in particular on sales increases in the United Kingdom, Italy,

Belgium and Spain. On the other hand, the market region Asia & Pacific developed very positively with a significant rise in sales primarily

attributable to the consolidation of the Vietnamese STADA Vietnam and the Chinese STADA Pharmaceuticals (Beijing) as subsidiaries.

Within the scope of our active acquisition policy, we made further progress in financial year 2014, strengthening our branded products

portfolio in Russia as well as in the United Kingdom through attractive takeovers.

We were once again able to demonstrate the degree of success of our product development through the global introduction of a large

number of products. In addition, within the scope of our biosimilar activities, we began with the sale of the filgrastim product Grastofil®,

in-licensing of Teriparatide and achieved further progress in initial negotiations on the in-licensing of a biosimilar for Adalimumab (Humira®).

We were able to further strengthen the financing structure of the Group in the reporting year through the securing of additional promissory

notes at good conditions. We continue to have a balanced maturity dates profile and a stable financing structure with financial instruments

that have staggered maturities. In general, it is clear, both within the framework of our refinancing talks as well as on the basis of the

conditions for the promissory notes, that the participants in the refinancing market continue to have a strong level of confidence in our

business model and the further growth opportunities of STADA.

Letter to Shareholders from the Chairman of the Executive Board07

The successes that we achieved in 2014 are attributable, first and foremost, to the outstanding performance and the untiring commitment

of our employees. For this, on behalf of the entire Executive Board, I would like to express my sincere appreciation. Our gratitude also

extends to our Supervisory Board and Advisory Board for their continued constructive and professional cooperation.

Overall, we expect continued positive development for the Group’s outlook. We have, however, been confronted in the current financial year

with very difficult framework conditions, especially as a result of the CIS crisis. In light of this, we expect to be able to achieve slight growth

in Group sales adjusted for currency and portfolio effects. Due to the recent developments of the Russian ruble and increased risks in

connection with consumer mood and the general market situation, we anticipate a decreased earnings contribution from Russia. Taking

these developments into account and based on current currency relations, we expect a substantial decrease in adjusted EBITDA and

adjusted net income. We expect the ratio of net debt, excluding further acquisitions, to adjusted EBITDA to be at a level of nearly 3.

Hartmut Retzlaff

Chairman of the Executive Board

Letter to Shareholders from the Chairman of the Executive Board08

REPORT OF THE SUPERVISORY BOARD

Dear Shareholders,

In financial year 2014, the Supervisory Board of STADA Arzneimittel AG carefully executed the duties imposed on it in accordance with the

law and the Articles of Incorporation. The Supervisory Board monitored the management of the Company and advised the Executive Board

regularly in the management of the Group. In all decisions of fundamental importance for the Company, the Executive Board involved the

Supervisory Board regularly, directly and in a timely manner. Within the scope of its supervisory and consultative duties, the Supervisory

Board had the Executive Board inform it comprehensively through monthly oral and written reports on business development, the strategy

and corporate planning including financial, investment and personnel planning as related to the Company and the STADA Group. At all times,

the members of the Supervisory Board had the opportunity in the committees and in the plenum to critically examine the reports and

proposed resolutions submitted by the Executive Board and to present input of their own. In particular, the Supervisory Board intensively

discussed all business transactions of importance for the Company and reviewed them for their plausibility on the basis of the Executive

Board reports. The Executive Board briefed the Supervisory Board – also between the regular meetings – regarding all questions of strategy,

planning, business development, the risk situation, risk management and compliance. The Executive Board also briefed the Chairman of the

Supervisory Board on the progress of business including the sales development and profitability, important business events and issues of

particular importance. In addition, the Supervisory Board monitored the accounting process and the measures taken by the Executive Board

for risk management, the internal control system, the internal auditing system as well as the compliance measures taken. The Executive

Board explained in detail to the members of the Supervisory Board eventual deviations in the business development from the plans and

objectives.

All issues which, in accordance with the Articles of Incorporation and rules of procedure, require the approval of the Supervisory Board were

submitted to the Supervisory Board. The Supervisory Board treated and reviewed these procedures in detail and discussed them with the

Executive Board, whereby the focus was regularly placed on the benefits, the risks and effects of the respective procedure.

Meetings of the Supervisory Board and focus of activities

The Supervisory Board convened for a total of nine meetings in financial year 2014 (on January 17, March 26, May 6, June 3, July 9,

August 6, October 8, November 11 and December 11).

These meetings focused on the following themes:

• the Company strategy and its operative implementation,

• the acquisition policy,

• the economic situation of the Group, its segments and subsidiaries and, in particular, their respective sales, sales volume, costs and

earnings development, the development of working capital, the cash flow, inventories, the balances and terms of receivables as well as

the effects of the global financial and economic crisis,

• the market structures, development of demand, the competitive situation and the price, conditions and discount development in the

individual market regions and in particular the development of market shares of the Group and the relevant competitors,

• the assets situation of the Group and its finance and liquidity situation considering especially the investment plans in the Group, the

financing structures and refinancing strategies as well as the development of the debt-to-equity ratio,

• the risk and opportunities management and the significant risks for the Group that were revealed as a result as well as the internal

control and auditing systems, contemplated, planned and executed acquisitions, disposals and cooperations of the Group as well as the

integration of acquired companies and products in the Group,

Report of the Supervisory Board09

• the impact of economic and political developments in the market region CIS / Eastern Europe, in particular considering the CIS crisis,

• the effects of regulatory state interventions on the Group and/or on the individual subsidiaries and the necessary reactions to these,

especially in the German home market with regard to discount agreements with health insurance organizations,

• the evaluation of cost-optimized process allocations, process and control optimizations and improvements including the partial transfer

of operations of the German logistics activities.

• the product development and product portfolio of the Group,

• the realignment of the German sales organization,

• STADA’s capital market position,

• Executive Board personnel issues, compensation questions and questions relating to company pension plans,

• questions on the composition and the efficiency of the Supervisory Board,

• issues of corporate governance and compliance and

• the Annual Report and the interim reports of the Group prior to their respective publication.

Composition of the Executive Board and the Supervisory Board

The composition of the Executive Board remained unchanged in financial year 2014.

With the completion of the Annual General Meeting on June 4, 2014, there were – as a result of a regular new election in May – changes

in the employee representatives on STADA’s Supervisory Board. Since that date, the newly elected Dr. Ute Pantke, Halil Duru and

Jens Steegers have been members of the Supervisory Board as employee representatives. In its meeting on July 9, 2014, the Supervisory

Board elected Carl Ferdinand Oetker deputy Chairman of the Supervisory Board.

Work of the committees

The committees established by the Supervisory Board, the Audit Committee and the Human Resources Committee, supported the Super-

visory Board in its duties in the reporting year.

The Audit Committee convened for four meetings in financial year 2014 (on March 25, May 5, August 5 and November 10). Within the

framework of these meetings, it dealt primarily with the results, key figures, accounting, Group financing principles, internal risk manage-

ment, internal audit and compliance in the Group. Furthermore, the auditor reported to the Supervisory Board in a meeting on the audit of

the condensed interim consolidated financial statements and the interim Group Management Report of June 30, 2014.

The Human Resources Committee convened for two meetings in financial year 2014 (on March 25 and December 5) and in addition

constantly coordinated via telephone. At these meetings the committee dealt with Executive Board personnel issues, compensation questions

and issues relating to company pension plans.

Report of the Supervisory Board10

Due to the size of STADA’s Supervisory Board with six shareholder representatives, the Supervisory Board believes that a Nomination

Committee as recommended by the German Corporate Governance Code in the version of June 24, 2014 is structurally superfluous. The

Supervisory Board, however, created a Nomination Panel consisting of the Chairmen of the Human Resources Committee and the Audit

Committee.

The Chairmen of the committees informed the Supervisory Board Plenum at its ordinary meetings regularly and thoroughly on their work.

Corporate governance

In financial year 2014, too, the Supervisory Board and Executive Board dealt in detail with the further development of corporate governance

in the Company while taking the current version of the German Corporate Governance Code into account. The new joint Declaration of

Compliance pursuant to Section 161 of the German Stock Corporation Act issued by the Executive Board and the Supervisory Board on

November 11, 2014 on the basis of the German Corporate Governance Code as amended on June 24, 2014 is printed in this Annual Report

in the chapter “Corporate Governance Report” and is publicly available on the Company’s website at www.stada.de or www.stada.com.

No conflicts of interest arose in the reporting year which had to be disclosed to the Supervisory Board and about which the Annual General

Meeting must be informed.

Annual and consolidated financial statements, audit

The Supervisory Board satisfied itself that the Company is being properly managed. The annual financial statements of STADA Arznei-

mittel AG and the consolidated financial statements as well as the Company’s Management Report for financial year 2014 were audited by

PKF Deutschland GmbH, Wirtschaftsprüfungsgesellschaft, Hamburg, and issued with an unqualified audit opinion. The Supervisory Board

had no doubts with regard to the independence of the auditor. The auditor submitted the Statement of Independence as required by the

Code. The main areas of the audit were established by the Supervisory Board within the scope of the commissioning of the auditor. The

Audit Committee reviewed the annual financial statements and consolidated financial statements as well as the Management Report and

the Group Management Report as well as the proposal for the appropriation of profits and also included the reports of the auditor on the

audit of the financial statements in its review. The auditor reported on significant results of the audit in a meeting of the Audit Committee

and was available for questions to the members of the Committee. The members of the Audit Committee dealt extensively with the sub-

missions from the Executive Board and the audit reports and discussed these with the auditor. The Audit Committee raised no objections

and recommended to the Supervisory Board to approve the financial statements and the Management Report as well as the Group

Management Report and assent to the Executive Board’s proposal for the appropriation of profits.

On the basis of the preparation by the Audit Committee, the Supervisory Board examined the annual financial statements and the consoli-

dated financial statements prepared by the Executive Board, the Management Report and the Group Management Report of the Executive

Board on the financial year 2014 as well as the Executive Board’s proposal for the appropriation of profits. The Chairman of the Audit

Committee reported to the Supervisory Board on the work and the audit results of the Audit Committee. The auditor reported to the Super-

visory Board on significant results of the audit and was available for questions from members of the Supervisory Board. The Supervisory

Board discussed the submissions mentioned above and the conclusions of the auditor in detail with the auditor and the Executive Board.

Also following the final results of the Supervisory Board’s own examination, the Supervisory Board had no objections to the annual financial

statements, the Management Report, the consolidated financial statements and the Group Management Report on the financial year 2014

and concurred with the outcome of the audit. The auditor also determined that the Executive Board had implemented an appropriate

information and monitoring system which, in its concept and use, is suitable for the early recognition of any developments that could

threaten the continuation of the Company.

Report of the Supervisory Board11

The Supervisory Board approved the annual financial statements and the consolidated financial statements prepared by the Executive

Board. The annual financial statements are thus adopted. The Supervisory Board concurred with the individual assessments of the business

situation and the outlook as given in the Management Report of the Executive Board and with the proposal of the Executive Board for the

appropriation of profits that provides for a dividend of € 0.66 per STADA common share.

The Supervisory Board wishes to express its gratitude to all of the Group’s employees, the Executive Board and management for their

tremendous commitment to their work and the good result in financial year 2014, in particular against the backdrop of the difficult frame-

work conditions in the market regions CIS / Eastern Europe and Germany.

Bad Vilbel, March 25, 2015

Dr. Martin Abend

Chairman of the Supervisory Board

Report of the Supervisory Board12

OVERVIEW

Five-year comparison in € million

Group sales

Operating profit

Operating profit, adjusted

EBITDA2)

EBITDA, adjusted

EBIT3)

EBIT, adjusted

EBT4)

EBT, adjusted

Net income

Net income, adjusted

2014

2,062.2

188.5

320.7

418.8

431.9

190.3

322.4

124.7

253.3

64.6

186.2

20131)

2,003.9

248.3

303.1

382.6

414.3

252.4

307.1

189.3

240.7

121.4

160.6

20121)

1,837.5

202.1

266.2

323.7

367.4

205.9

270.0

135.6

200.5

86.5

147.9

20111)

1,715.4

120.1

257.6

223.2

337.2

121.2

258.7

69.5

205.8

22.0

146.6

20101)

1,627.0

161.8

239.3

268.8

315.9

162.1

239.6

109.0

186.2

68.4

133.3

Solid business development despite challenging framework conditions

In 2014, the STADA Group was confronted by challenging framework conditions in the market regions of Germany and CIS / Eastern Europe.

Overall, there were one-time special effects and effects from the measurement of derivative financial instruments under financial income

and expenses in the reporting year of € 128.6 million before or € 121.6 million after taxes, which include impairments on goodwill in the

amount of € 54.0 million before and after taxes as well as on further intangible assets in the amount of € 22.0 million before or € 21.7 mil-

lion after taxes as a result of the significantly changed interest rate and currency environment as well as on ongoing higher risks in the

market region CIS / Eastern Europe.5)

Regardless of the challenges, Group sales increased – with mixed development in the individual market regions – by 3% to € 2,062.2 mil-

lion (previous year6): € 2,003.9 million). When effects on sales based on changes in the Group portfolio and currency effects are deducted,

Group sales grew slightly by 1% to € 2,014.3 million.

The earnings development in 2014 was characterized by an increase in operating performance as shown by growth in all of the Group’s

adjusted key earnings figures.

In 2014, reported operating profit decreased significantly by 24% to € 188.5 million (previous year6): € 248.3 million), mainly due to impair-

ments of goodwill in the market regions CIS / Eastern Europe as well as Asia / Pacific & MENA. Reported EBITDA increased by 9% to

€ 418.8 million (previous year6): € 382.6 million). In view of high one-time special effects, reported net income recorded a substantial

decrease of 47% to € 64.6 million (previous year: € 121.4 million).

1) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.). For
reasons of the practicability caveat as specified under IAS 8.43 ff., the previous year figures for financial year
2012 and earlier were not adjusted.
2) Earnings before interest, taxes, depreciation and amortization.
3) Earnings before interest and taxes.

4) Earnings before taxes.
5) See the Company’s ad hoc release of February 19, 2015.
6) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.).

Overview13

After adjusting the key earnings figures for influences distorting the year comparison resulting from one-time special effects, the adjusted

operating profit increased by 6% in financial year 2014 to € 320.7 million (previous year1): € 303.1 million). Adjusted EBITDA recorded

growth of 4% to € 431.9 million (previous year1): € 414.3 million). Net income, adjusted for one-time special effects and effects from the

measurement of derivative financial instruments under financial income and expenses, increased substantially by 16% to € 186.2 million

(previous year: € 160.6 million).

The Group’s adjusted tax rate saw very pleasing developments. While the reported tax rate was at 43.8% primarily as a result of impair-

ments on goodwill not deductible for tax purposes in the market regions CIS / Eastern Europe and Asia / Pacific & MENA (previous year1):

35.1%), the adjusted tax rate decreased to 24.2% in financial year 2014 compared to the previous year (previous year1): 32.7%).

In consideration of the challenging framework conditions in the two market regions of Germany and CIS / Eastern Europe, STADA, in the

estimation of the Executive Board, achieved a solid result in 2014 based on the Group’s sustainable business model focused on market

regions with long-term growth potential. Despite the difficult regulatory and economic environment STADA was able to maintain its market

positions in the major national markets.

Stable financial position

The financial position of the STADA Group remained stable in the reporting year.

As of December 31, 2014, the equity-to-assets ratio was 27.1% (December 31, 2013 : 29.6%) and was thereby satisfactory in the opinion

of the Executive Board. Net debt amounted to € 1,327.5 million as of the balance sheet date (December 31, 2013: € 1,306.8 million).

The net debt to adjusted EBITDA ratio improved to 3.1 in financial year 2014 (previous year1): 3.2).

The refinancing of the Group as of December 31, 2014 was provided for by a five-year corporate bond that was placed in 2010 in the

amount of € 350 million with an interest rate of 4.00% p.a. which will reach maturity in April of the current financial year. For the purpose

of long-term refinancing, as of the balance sheet date, there was a five-year bond placed in the second quarter of 2013 in the amount of

€ 350 million with an interest rate of 2.25% p.a. As of the December 31, 2014, furthermore, there were promissory notes with maturities

in the area of 2015 to 2019 in the total amount of € 552.5 million. In the first quarter of 2014, STADA secured € 200 million of this with a

term of five years, of which € 124 million have a fixed interest rate of 2.30%. A variable interest rate of currently 1.40% applies for € 76 mil-

lion. In the second quarter of 2014, STADA secured further promissory notes in the amount of € 20 million with maturity in 2019 and a

variable interest rate of currently 1.33%. In the fourth quarter of 2014, STADA secured further promissory notes in the amount of € 50 mil-

lion with a term of five years and a fixed interest rate of 1.33%. Overall, STADA continues to have a balanced maturity dates profile and a

stable financing structure based on financial instruments with staggered maturities.

Cash flow from operating activities in financial year 2014 amounted to € 223.8 million (previous year1): € 203.7 million). Free cash flow

amounted to € -38.2 million (previous year1): € -108.2 million). Free cash flow adjusted for payments for significant investments or

acquisitions and proceeds from significant disposals amounted to € 157.4 million (previous year1): € 133.3 million).

Overview14

Strong product development with a well-filled pipeline and promising biosimilar activities

The STADA Group has a strong product development. With the expansion of the product portfolio and 626 individual product launches

worldwide (previous year1): 706 product launches), STADA once again proved the successes of the Group-wide development activities in the

reporting year.

The Group also made further progress in the course of its biosimilar activities. In the third quarter of 2014, STADA subsidiary cell pharm

started the sale of the Filgrastim product Grastofil®, which the Group had already in-licensed in 2013.2) In addition, STADA in-licensed

Teriparatid in 2014, which is expected to be launched under the STADA label throughout Europe following the expiration of the patent of the

original product, Forsteo® in 2019.3) In addition, STADA and the biotech specialist mAbxience started to negotiate over the in-licensing of

an Adalimumab (Humira®) biosimilar in the fourth quarter of 2014.4)

In consideration of the well-filled product pipeline, the Executive Board expects to be able to continuously introduce new products to the

individual national markets of the respective market regions in future as well. The focus here remains on generics in the EU countries. In its

biosimilar activities, the Group continues to consistently pursue its strategy of relying on cooperation with highly specialized partners to add

high-quality products to its portfolio at favorable conditions.

Active acquisition policy with attractive purchases

In financial year 2014, the Group continued to pursue an active acquisition policy to accelerate organic growth with external growth

impulses. In this context, STADA concentrates, on the one hand, on regional expansion of business activities with a focus on high-growth

emerging markets. On the other hand, a top focus is the expansion and internationalization of the core segments, in particular branded

products as they are generally characterized by better margins and less regulatory interventions than generics.

The Group made further progress in the context of this active acquisition policy in the reporting year.

In the first quarter of 2014 – after fulfillment of extensive completion conditions particularly in the areas of production documentation and

supply chain – the contract was completed as planned for the purchase of the Russian branded product portfolio Aqualor® by the Russian

STADA subsidiary AO Nizhpharm, which comprises ten prescription-free (OTC) product presentations based on seawater in the form of

sprays and drops with the local regulatory status of medical products for the treatment of sinusitis (infection of the paranasal sinus) and

sore throat.5)

The British STADA subsidiary Thornton & Ross Ltd. acquired the production and distribution rights for the branded product portfolio Flexitol®

for the United Kingdom and Ireland in the second quarter of 2014.6)

1) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.).
2) See the Company‘s press releases of October 28, 2013 and August 6, 2014.
3) See the Company’s press release of October 13, 2014.

4) See the Company’s press release of November 18, 2014.
5) See the Company’s ad hoc release of October 18, 2013 and ad hoc update of February 28, 2014.
6) See the Company’s press release of June 30, 2014.

Overview15

In the fourth quarter of 2014, the Russian STADA subsidiary Nizhpharm signed a purchase contract for the two branded products AndroDoz®

and NeroDoz®, which are positioned in the area of men’s health and until now have been sold under a licensing agreement. The acquisition

was completed in the current first quarter of 2015.1)

In addition, the British STADA subsidiary STADA UK Holdings Ltd. acquired the British Internis Pharmaceuticals Ltd., which is active in the

prescription therapeutic treatments for vitamin D3 deficiency, in the fourth quarter of 2014.

Volatile development of the STADA share price

The development of the STADA share price was relatively volatile in 2014, but was mainly burdened by the CIS crisis and in particular by

the significant devaluation of the Russian ruble in relation to the Group currency euro. In 2014, share prices of companies with a relatively

high business share in Russia were affected in general. STADA could also not avoid this influence with a sales contribution of approx. 17%

from the Russian market. Whereas the share price closed 2013 at € 35.93, it was listed at a closing price of € 25.25 at the end of 2014.

This was a decrease of 30% in total. Whereas STADA’s market capitalization was € 2.172 billion at the end of 2013, it was € 1.531 billion

at the end of 2014.

Dividend proposal

Due to the decrease in reported net income, the Executive Board recommends the Supervisory Board to propose an unchanged dividend

for financial year 2014 in the amount of € 0.66 per STADA common share to the next Annual General Meeting on June 3, 2015.2) The

resulting total dividend payments of € 40.0 million (previous year: € 39.8 million) represent a significantly higher distribution ratio than in

the previous year with approx. 62% of reported net income (previous year: approx. 33%).

Comprehensive opportunities and risk management

The comprehensive risk management system in the STADA Group aims to continuously identify important risks that may jeopardize the

Company’s continued existence, to assess their effects to the Group and to determine measures that can be taken in due time if necessary.

Looking to the current state of the risk management system, there are currently no recognizable risks that could jeopardize the continued

existence of the Group in the Executive Board’s opinion.

The opportunities management, which focuses on the recognition and realization of new growth potential and on ensuring and expanding

upon existing growth opportunities, aims to secure the short, middle and long-term success of the Group. This is based on strategic success

factors which primarily include strong product development, an international sales structure, an active acquisition policy, a functionally

organized group, efficient cost management and qualified employees.

1) See the Company’s press release of February 4, 2015.
2) See the Company’s ad hoc release of February 19, 2015.

Overview16

Outlook

Overall, the future sales and earnings development of the Group will continue to be characterized by both growth-stimulating and challenging

framework conditions in the individual markets of STADA’s respective market regions. In the current financial year, the Group has been

confronted with very difficult framework conditions, especially as a result of the CIS crisis. In light of this, for financial year 2015, the

Executive Board expects to be able to achieve slight growth in Group sales adjusted for currency and portfolio effects. Due to the recent

developments of the Russian ruble and increased risks in connection with consumer mood and the general market situation, it anticipates

a decreased earnings contribution from Russia. Taking these developments into account and based on current currency relations, the

Executive Board expects a substantial decrease in adjusted EBITDA and adjusted net income. The Executive Board expects the ratio of net

debt, excluding further acquisitions, to adjusted EBITDA to be at a level of nearly 3 in 2015. More details on the outlook can be found in the

Prognosis Report of the Management Report in this Annual Report.

Overview
Overview | Boards of the Company | The STADA Supervisory Boards

BOARDS OF THE COMPANY

THE STADA SUPERVISORY BOARD
(as of March 1, 2015)

Dr. Martin Abend, Dresden (Chairman)

Carl Ferdinand Oetker, Düsseldorf (Deputy Chairman)

Dr. Eckhard Brüggemann, Herne

Halil Duru1), Frankfurt am Main

Dr. K. F. Arnold Hertzsch, Dresden

Dieter Koch, Kiel

Constantin Meyer, Seelze

Dr. Ute Pantke1), Wettenberg

Jens Steegers1), Bad Vilbel

The Supervisory Board members can be contacted via STADA Arzneimittel AG’s business address.

1) Employee representative.

THE STADA EXECUTIVE BOARD
(as of March 1, 2015)

Hartmut Retzlaff

Chairman of the Executive Board

Executive Board member since 1992

Chairman of the Executive Board since 1993

Contract until August 31, 2016

Helmut Kraft

Chief Financial Officer

Executive Board member since 2010

Contract until December 31, 2018

Dr. Matthias Wiedenfels

Chief Business Development & Central Services Officer

Executive Board member since 2013

Contract until December 31, 2016

The Executive Board members can be contacted via STADA Arzneimittel AG’s business address.

Boards of the CompanyBoards of the Company | The STADA Executive Board | The STADA Advisory Board

THE STADA ADVISORY BOARD
(as of March 1, 2015)

Members of the STADA Advisory Board are appointed by the Chairman of the Supervisory Board on the recommendation of the Executive

Board and the Supervisory Board. According to the Company’s Articles of Incorporation, the duty of the Advisory Board is to support and

advise the Executive and Supervisory Boards. Furthermore, members of the Advisory Board are available to act as proxy for shareholders

who do not wish to exercise their voting rights in person at the Annual General Meeting. The Advisory Board, appointed for five years from

2014 through 2018, currently includes the following members:

Dr. Thomas Meyer, Seelze (Chairman)

Dr. Frank-R. Leu, Gießen (Deputy Chairman)

Rika Aschenbrenner, Mainburg

Wolfgang Berger, Gießen

Gerd Berlin, Haßloch

Alfred Böhm, Munich

Jürgen Böhm, Kirchhain

Axel Boos, Darmstadt

Reimar Michael von Kolczynski, Stuttgart

Dr. Wolfgang Schlags, Mayen

Jürgen Schneider, Offenbach

The Advisory Board members can be contacted via STADA Arzneimittel AG’s business address.

THE STADA SHARE

STADA share codes

Identification numbers

Ticker symbols

Capital structure

ISIN: DE0007251803, WKN: 725180

Reuters: STAGn.DE, Bloomberg: SAZ:GR

As of December 31, 2014, the subscribed share capital of STADA Arzneimittel AG was at an amount of € 157,629,420.00 (December 31,

2013: € 157,150,500) con sisting of 60,626,700 registered shares with restricted transferability1) (December 31, 2013: 60,442,500 reg-

istered shares), each with an arithmetical share in share capital of € 2.60. Changes from the previous year resulted from the exercising of

9,210 warrants 2000/20152). As of December 31, 2014, 88,176 warrants 2000/2015 for the subscription of 1,763,520 registered shares

with restricted transferability were thus still outstanding.

Capital structure of STADA Arzneimittel AG

Dec. 31, 2014

Dec. 31, 2013

Number of issued registered shares with restricted transferability

Number of outstanding warrants 2000/20152)

Number of potential shares from warrants 2000/20152)

60,626,700

60,442,500

88,176

1,763,520

97,386

1,947,720

Volatile development of the STADA share price

The development of the STADA share price was relatively volatile in 2014, but was mainly burdened by the CIS crisis and in particular by

the significant devaluation of the Russian ruble in relation to the Group currency euro. In 2014, share prices of companies with a relatively

high business share in Russia were affected in general. STADA also could not avoid this influence with a share of Russian sales in Group

sales of approx. 17%. Whereas the share price closed 2013 at € 35.93, it was listed at a closing price of € 25.25 at the end of 2014. This

corresponded to a total decrease of 30%.

The relevant national comparative indices for STADA showed percentage-rate differences in their share price development during the

course of 2014. The German benchmark index DAX® 3) rose by 3% as compared to the previous year. MDAX® 4), the index which the STADA

share belongs to, increased by 2% in the same period. Both developments relate to their XETRA® 5) closing prices.

At year-end 2014, the STADA market capitalization amounted to € 1.531 billion. At the end of 2013, this figure was € 2.172 billion. Based

on Deutsche Börse AG’s index system, which only considers free float, STADA occupied position 24 in terms of market capitalization in the

MDAX® in 2014. STADA had been at place 17 in this category in the previous year.

1) Under the Company’s Articles of Incorporation, STADA’s registered shares with restricted transferability
can only be entered into the share register with the consent of the Company and, pursuant to the statutes,
grant one vote each in the Annual General Meeting. Shareholders are only those who are registered as such
in the share registry and only such persons are authorized to participate in the Annual General Meeting and
to exercise voting rights. No shareholder and no shareholder group shall have any special rights.
2) The legally binding option terms and conditions are published on the Company website under
www.stada.de and www.stada.com.

3) DAX® is the index of Deutsche Börse AG, largely consisting of the 30 biggest companies by market
capitalization and order book volume.
4) MDAX® is the index of Deutsche Börse AG for midcap companies, largely consisting of the 50 next-biggest
companies by market capitalization and order book volume below the DAX®, thus also including the STADA
share.
5) XETRA® is the electronic trading system of Deutsche Börse AG.

The STADA Share21

The average daily volume of the STADA share in the trading volume at the XETRA® trading and the Frankfurt Stock Exchange amounted to

€ 13.7 million in 2014. In 2013, the average trading volume per day of the STADA share was € 11.1 million. Thus in trading volume based

on Deutsche Börse AG’s index system, STADA occupied place 8 in 2014. In the previous year, STADA had occupied position 13 in this area.

STADA key share data

Number of shares (year-end)

Number of treasury shares (year-end)

Average number of shares (without treasury shares)

Year-end closing price (XETRA®) in €

High (XETRA® closing price) in €

Low (XETRA® closing price) in €

2014

2013

60,626,700

60,442,500

89,835

91,989

60,408,501

59,571,959

25.25

38.72

24.64

35.93

42.41

24.95

Market capitalization (XETRA®) in € million (year-end)

1,530.8

2,171.7

Earnings per share in €

Adjusted earnings per share in €

Diluted earnings per share in €

Adjusted diluted earnings per share in €

Dividend per share in €

1.07

3.08

1.05

3.04

0.661)

2.04

2.70

2.00

2.65

0.66

Broadly based shareholder structure with 100% free float

On December 31, 2014, a total of approx. 42,000 shareholders held share capital of STADA Arzneimittel AG. Based on results of regularly

occurring analyses of the Company’s shareholder structure, STADA assumes that approx. 58% of STADA’s shares are held by institutional

investors and approx. 11% are held by pharmacists and doctors.

As part of an employee share ownership program, STADA sold 2,154 of its own shares in 2014 at an average price of € 31.62. As of

December 31, 2014, STADA held 89,835 treasury shares, compared to 91,989 shares which were held by the Company as of December

31, 2013.

In 2014, the Group published all of the received voting rights notices according to Section 26 of the German Securities Trading Act (WpHG).

These 26 received voting rights notices, as well as any received later, can be viewed on the website at www.stada.de or www.stada.com.

Directors’ Dealings

In financial year 2014, according to information available to the Company, STADA reported the following Director’s Dealings. On September

29, 2014, Hartmut Retzlaff, Chairman of the Executive Board, sold 2,000 STADA warrants at a price of € 311.1325 per warrant.

On October 17, 2014, Silvia Retzlaff, the wife of Hartmut Retzlaff, purchased 400 STADA shares at a price of € 16.45 (purchase due to

option exercise).

1) Proposed.

The STADA Share22

Successful progress of the Annual General Meeting

On June 4, 20141), the STADA Annual General Meeting resolved a dividend of € 0.66 per common share that was significantly higher than

the previous year by 32%. The total dividend payments of € 39.8 million (previous year: € 29.6 million) thus represent a distribution ratio of

approx. 33% of reported net income (previous year: approx. 34%). In addition, the Annual General Meeting confirmed the Executive Board

and the Supervisory Board with a high level of approval. The Annual General Meeting furthermore approved the adjustment of existing

control and profit transfer agreements of STADA Arzneimittel AG with some of its subsidiaries in order to adapt to a change in legislation. In

addition, there were – as a result of a regular new election in May this year – changes in the employee representatives2) on STADA’s

Supervisory Board.

1) The voting results of the decisions taken at the Annual General Meeting of June 4, 2014 are
published on the Company’s website at www.stada.de and www.stada.com at least until the end of
the current financial year.
2) New employee representatives: Dr. Ute Pantke, Halil Duru and Jens Steegers.

The STADA ShareThe STADA Share | Corporate Governance Report

CORPORATE GOVERNANCE REPORT

The Corporate Governance Report pursuant to Section 3.10 of the German Corporate Governance Code and the Declaration of Corporate

Governance pursuant to Section 289a of the German Commercial Code (HGB) are available on the STADA website at www.stada.de/cg and

www.stada.com/cg.

DECLARATION OF CORPORATE GOVERNANCE

The Declaration of Corporate Governance according to Section 289a of the German Commercial Code includes the declaration on the

German Corporate Governance Code pursuant to § 161 of the German Stock Corporation Act (AktG), the relevant information on corporate

management practices and a description of the working practices of the Executive Board and the Supervisory Board as well as the

composition and working practices of the Supervisory Board committees.

1. Declaration of Compliance 2014
Joint Declaration of the Executive Board and the Supervisory Board of STADA Arzneimittel AG
concerning the German Corporate Governance Code pursuant to § 161 of the German Stock
Corporation Act (AktG)

Since the most recent Declaration of Compliance issued on November 12, 2013, STADA Arzneimittel AG (“STADA”) has complied with the

recommendations of the German Corporate Governance Code in the version of May 13, 2013 (published on June 10, 2013 in the Federal

Gazette) with the deviations listed and will comply with the recommendations of the German Corporate Governance Code in the version of

June 24, 2014 (published on September 30, 2014 in the Federal Gazette) with the following deviations:

Section 5.3.3: Nomination Committee for Supervisory Board elections

In view of the size of STADA’s Supervisory Board with six shareholder representatives the Supervisory Board believes that such an additional

committee is structurally superfluous, but assigned the task of a nomination panel to the Chairmen of the Human Resources Committee and

the Audit Committee; the additional remuneration, which pursuant to the articles of incorporation would be payable to Supervisory Board

members involved in such a committee, is thus avoided.

Section 6.3: Shares held by members of the Executive Board and Supervisory Board

The purchase and sale of STADA shares and options by members of the Executive Board and the Supervisory Board and by closely related

persons mentioned in the law are reported to the Company itself and to the German Federal Financial Supervisory Authority (BaFin) in

accordance with legal requirements and are published in accordance with legal requirements. However, the respective holdings of shares

and options to purchase and sell such shares by individual members of the Executive Board and Supervisory Board are not published in the

Corporate Governance Report. The Supervisory Board and the Executive Board are of the opinion that compliance with the legal require-

ments provides sufficient transparency.

For STADA, the recommendations of the German Corporate Governance Code serve as a general basis for the Company’s activity. In daily

practice, however, individual situations may occur in which the application of the Code would lead to limitations in the flexibility of the

Company or in the proven corporate practice. In the interest of good corporate governance deviations from the recommendations of the

Code may take place in those individual cases. STADA will, however, regularly review and, if necessary correct compliance with the code

and the above mentioned exceptions.

Bad Vilbel, November 11, 2014

signed

Dr. Martin Abend

signed

Hartmut Retzlaff

Chairman of the Supervisory Board

Chairman of the Executive Board

Corporate Governance Report

2. Relevant information on Company practices
Corporate Governance

STADA Arzneimittel AG is a joint stock corporation under German law and has a dual management and monitoring structure which consists

of the Executive Board and the Supervisory Board. The third body of the Company is the Annual General Meeting. Furthermore, there is an

Advisory Board according to the Articles of Incorporation.

In the Executive Board and Supervisory Board’s view, good corporate governance is an important basis for the Company’s success. The

Executive Board and the Supervisory Board of STADA view corporate governance as a comprehensive concept of responsible, transparent

and value-based corporate management. The Executive Board, Supervisory Board and management staff ensure that corporate governance

is actively approached and continuously developed in all areas at STADA. In addition to legal and regulatory requirements as well as the

German Corporate Governance Code, corporate governance at STADA also comprises the standards of the internal control system and

compliance, the regulations on organizational and supervisory duties in the Company, as well as STADA’s internal business guidelines and

shared principles and values.

Risk Management and Internal Auditing

The responsible handling of risks is an element of good corporate governance. STADA has systematic risk management and a control

system that puts the Executive Board in the position to recognize risks and market trends at an early stage and to immediately react to

relevant changes in the risk profile. STADA’s risk management and control system thus contributes to the success of the Company. Risk

management is part, in regular intervals, of the annual audit of financial statements as well as Internal Auditing. Details hereof can be found

in the Management Report in this Annual Report under “Risk Report”.

Furthermore, Internal Auditing supports the Executive Board as an independent department outside of the daily operational business. The

department evaluates internal procedures and processes from an objective perspective and with the distance necessary. The goal is to

reach optimized business processes, reduced costs and increased efficiency, and to achieve internally determined goals, by way of improved

internal controls.

Strong compliance culture

Compliance comprises all actions taken by a company in line with legal requirements as well as the drafting and monitoring of internal

regulations which a company places on itself. The goal of all compliance efforts is to avoid possible damage to the company and to prevent

wrong-doing. At STADA, compliance is embedded in the mission statement of a responsible company leadership and corporate governance.

All of STADA’s business processes and Group activities are carried out exclusively within the framework of respective laws in force.

STADA’s Code of Conduct details Group-wide, binding behavioral guidelines for the entire management and staff of the STADA Group and

provides the basis for all compliance activities. The goal of the Code of Conduct is to support all employees in legal and ethical challenges

in their daily work and to provide them orientation for correct behavior. Furthermore, internal guidelines, the so-called Corporate Policies,

make these behavioral guidelines more concrete for specific topics.

With the aid of various measures such as e-learning measures, traditional training, regular newsletters and leaflets with compliance-

relevant content, STADA employees are informed on an ongoing basis of relevant legal requirements and internal guidelines.

Corporate Governance Report 26

The Chief Compliance Officer who is responsible for the Compliance Management System is a member of the Executive Board, coordinates

the entire system and receives complaints and information – also anonymously if needed. The officer is supported in Germany and inter-

nationally by Compliance Managers, and by an external Ombudsman in Germany. In order to guarantee the adherence to legal regulations

and internal company policies of compliance in an effective manner, STADA regularly controls and further develops the Compliance

Management System.

Quality and safety, sustainability and environment, and the STADA mission statement

Details on the topics of “quality”, “safety”, “sustainability” and “environment” and the mission statement of STADA can be found in the

Management Report of this Annual Report in the chapters “Procurement, Production and Quality Management” and “Responsibility and

Sustainability”.

3. Description of the working practices of the Executive Board and the Supervisory Board
as well as the composition and working practices of their committees

The Executive Board and the Supervisory Board of STADA work in close cooperation for the good of the Company and, after extensive

consultation, make fundamental strategic decisions in the context of their legal responsibilities. The Executive Board briefs the Supervisory

Board – in the context of its legal obligation to make reports – regularly, promptly and comprehensively regarding all Company-relevant

questions of strategy, planning, business development, the risk situation, risk management and compliance. It confirms the strategic orien-

tation of the Company with the Supervisory Board and, in the course of the implementation of the strategy, discusses the respective status

at regular intervals. Furthermore, the Chairman of the Supervisory Board maintains regular contact with the Executive Board, particularly

with the Chairman of the Executive Board, and discusses with them the strategy, planning, business development, the risk situation, risk

management and the compliance of the Company and the Group. The Executive Board and the Supervisory Board adhere to the rules of

proper corporate management and have each established their own rules of procedure.

a) Executive Board

The Executive Board is appointed and dismissed in accordance with legal regulations. The Articles of Incorporation do not provide special

provisions on the appointment or dismissal of individual and all members of the Executive Board. Only the Supervisory Board is responsible

for the appointment and dismissal. It appoints Executive Board members for a maximum period of five years. A repeated appointment or

extension of the term is allowed, for a maximum of five years each.

Tasks and responsibilities

The Executive Board manages the Company with the goal of sustainable added value in its own responsibility in consideration of the

concerns of the shareholders, its employees and other groups connected to the Company. The members of the Executive Board are jointly

responsible for corporate governance. The Executive Board runs the businesses in accordance with the legal requirements, the Articles of

Incorporation, the rules of procedure and the schedule of responsibilities.

STADA’s Executive Board comprises at least two people in accordance with the Articles of Incorporation.

Corporate Governance Report27

As of the balance sheet date, the Executive Board consisted of three members responsible for the following areas:

• Hartmut Retzlaff, Chairman of the Executive Board (under contract until August 31, 2016), is the Executive Board member responsible

for the areas of Marketing and Sales, Corporate Strategy, Corporate Communications, Production, Purchasing and Procurement,

Research and Development, as well as Biotechnology.

• Helmut Kraft, Chief Financial Officer (under contract until December 31, 2018), is responsible for, in addition to the area of Finance

(Controlling and Accounting, Treasury and Taxes), the areas of Internal Auditing, IT, as well as Investor Relations.

• Dr. Matthias Wiedenfels, Chief Business Development & Central Services Officer (under contract until December 31, 2016), is the

member of the STADA Executive Board responsible for Business Development, Portfolio Management, Human Resources, Legal,

IP/Patents, Compliance, Export Control, Risk Management, Facility Management, as well as Quality Assurance and Quality Control.

Working practices of the Executive Board

Despite the overall responsibility of the Executive Board, each member of the Executive Board manages his area of the business in his own

responsibility. The distribution of the business areas to individual members of the Executive Board results from a schedule of responsibilities

that is a component of the rules of procedure for the Executive Board. The Executive Board as a whole decides upon all matters of

fundamental and/or strategic significance or of particular importance for the Company. All members of the Executive Board are to inform

themselves of the significant proceedings within the business areas. Regarding proceedings that also impact the business area of another

member of the Executive Board, a member of the Executive Board must confer with other affected members of the Executive Board before

coming to a decision.

According to the rules of procedure for the Executive Board, the Chairman of the Executive Board is responsible for the coordination of the

Executive Board as a whole. The Chairman of the Executive Board represents the Executive Board and the Company in public matters, in

particular concerning authorities, associations, economic organizations and publication outlets. He can delegate this task to another member

of the Executive Board for particular areas or in individual cases.

The Executive Board regularly holds Executive Board meetings that are convened by the Chairman of the Executive Board. Upon request of

a member of the Executive Board, the Chairman must convene an Executive Board meeting. The Executive Board can make resolutions

when all members have been invited and at least half of the members take part in the resolution. The Executive Board passes resolutions

with a simple majority of votes cast. Absent members of the Executive Board can cast their votes in written form, via text or telephone. The

use of a representative is not permitted. Resolution by circulation procedure is also possible provided no member of the Executive Board

objects. In case of a tie, the Chairman of the Executive Board shall have the deciding vote. If the Chairman of the Executive Board is absent

or delayed, the proposed resolution is rejected in the case of a tie.

For certain business defined in the Executive Board’s rules of procedure, the Executive Board must first obtain the approval of the Super-

visory Board.

The STADA Executive Board has not established any Executive Board committees.

Corporate Governance Report 28

Conflicts of interest

According to the rules of procedure of the Executive Board, every member of the Executive Board is required to disclose conflicts of interest

without delay to the Supervisory Board and to inform the other members of the Executive Board of this. Carrying out ancillary activities,

particularly taking on Group-external Supervisory Board positions, requires the prior approval of the Supervisory Board.

Remuneration report

The Remuneration Report, which can be found in the Management Report of the Executive Board, presents the principles of the remuner-

ation system of the Executive Board of STADA as well as individual details of the remuneration of individual members of the Executive Board.

b) Supervisory Board

In accordance with the provisions of the One-Third Participation Act, the STADA Supervisory Board is comprised of nine members of which

six are representatives of the shareholders and three represent the employees. The Annual General Meeting elects the representatives of

the shareholders, and the employees elect the employee representatives.

Tasks and responsibilities

The Supervisory Board appoints the members of the Executive Board. Furthermore, the Supervisory Board monitors and advises the

Executive Board in the running of its business operations. Through a regular dialog with the Executive Board, the Supervisory Board is

informed of the business development, strategy, corporate planning, the risk situation, risk management and compliance. It agrees the

company planning and approves the annual financial statements of STADA Arzneimittel AG and the consolidated financial statements of the

STADA Group.

The Supervisory Board included the following members on the balance sheet date:

• Dr. Martin Abend, Attorney, Dresden (Chairman)

• Carl Ferdinand Oetker, Banker, Düsseldorf (Deputy Chairman)

• Dr. Eckhard Brüggemann, Doctor, Herne

• Halil Duru, Deputy Chairman of the Worker’s Council released from duty, Frankfurt am Main (Employee Representative)

• Dr. K. F. Arnold Hertzsch, Pharmacist, Dresden

• Dieter Koch, Pharmacist, Kiel

• Constantin Meyer, Pharmacist, Seelze

• Dr. Ute Pantke, Director Internal Communications, Wettenberg (Employee Representative)

• Jens Steegers, Chairman of the Worker’s Council released from duty, Bad Vilbel (Employee Representative)

The term of all of the shareholder representatives on the Supervisory Board ends with the completion of the Annual General Meeting 2018.

Corporate Governance Report29

Working practices of the Supervisory Board

The Chairman of the Supervisory Board is responsible for the coordination of work, chairing Supervisory Board meetings and handling the

external matters of the Supervisory Board.

The Chairman of the Supervisory Board convenes the Supervisory Board in writing at least 14 days prior to a meeting according to need.

Meetings of the Supervisory Board should convene at least once per quarter and must convene twice within a half year. The meetings of the

Supervisory Board and its committees shall as a rule be by personal attendance. In exceptional cases with good reason, the Chairman of

the Supervisory Board can elect to hold the meetings of the Supervisory Board and its committees in the form of a telephone or video

conference, or permit individual members of the Supervisory Board to participate via telephone or video connection.

The Supervisory Board generally passes resolutions in meetings. Outside of meetings, resolutions made via telephone or in written form (via

telefax or with the aid of other common means of communication such as e-mail) are permitted. The Supervisory Board shall constitute a

quorum if at least two thirds of its members, including the Chairman of the Supervisory Board or the deputy, are present, or absent members

have had another member of the Supervisory Board submit their written vote. Supervisory Board resolutions are passed with a simple

majority of votes cast. In case of a tie, the chairman of the meeting shall have the casting vote.

Composition and working practices of the Supervisory Board committees

According to the rules of procedure of the Supervisory Board, the following Supervisory Board committees exist: the Audit Committee and

the Human Resources Committee. Other committees, such as a Nomination Committee, are created as needed.

• Audit Committee

The Audit Committee deals in particular with monitoring the accounting process, the effectiveness of the internal control system and that

of the internal auditing system, the risk management system and compliance. Furthermore, the Audit Committee deals with the financial

statement audits, in particular the required independence of the auditor, the additional tasks rendered by the auditor, the award of the

audit contract to the auditor, the determination of the main areas for the audit and the fees agreement with the auditor. In addition, it

discusses the annual and interim reports with the Executive Board prior to their publication.

The Chairman of the Audit Committee must have specialist knowledge and experience in the application of accounting principles and

internal control processes. Furthermore, the Chairman of the Audit Committee shall be independent and neither the Chairman of the

Supervisory Board, nor a former member of the Executive Board whose position ended less than two years ago.

As of the balance sheet date, the Audit Committee included the following members from the shareholders: Carl Ferdinand Oetker

(Chairman), Dr. Martin Abend and Dr. K. F. Arnold Hertzsch.

Corporate Governance Report 30

• Human Resources Committee

The Chairman of the Supervisory Board is also the Chairman of the Human Resources Committee. The Human Resources Committee

prepares the personnel decisions of the Supervisory Board. The committee discusses, in particular, the conditions of the employment

contracts for the members of the Executive Board and prepares the resolutions of the Supervisory Board regarding the remuneration

system of the Executive Board in that it recommends to the Supervisory Board the structure of the remuneration system and the ranges

of the fixed and variable components of the remuneration of the Executive Board. In addition, it ensures together with the Executive Board

that long-term succession planning takes place.

Moreover, the Human Resources Committee consults with the Executive Board regarding the strategic personnel development of STADA

Arzneimittel AG and prepares the decisions of the Supervisory Board in this area.

As of the balance sheet date, the members of the Human Resources Committee from the shareholders were Dr. Martin Abend (Chairman),

Dieter Koch and Constantin Meyer.

• Nomination Panel

As the declaration on the German Corporate Governance Code already submitted on November 11, 2014 describes in more detail, the

Super visory Board appointed a Nomination Panel, consisting of the Chairmen of the Human Resources Committee and the Audit

Committee, to develop objectives and a profile for the composition of the Supervisory Board.

The members of the Nomination Panel on the balance sheet date were Dr. Martin Abend and Carl Ferdinand Oetker.

Goals for the composition of the Supervisory Board

In financial year 2012, the Nomination Panel presented to the Supervisory Board Plenum goals as well as an appointment plan for the

composition of the members of the Supervisory Board to be elected at the Annual General Meeting on June 5, 2013 as representatives of

the shareholders.

In the first quarter of 2012, the Supervisory Board concluded the following goals for its composition at its meeting on January 23, 2012

in accordance with Section 5.4.1 of the German Corporate Governance Code (GCGC):

1. General goals

The Company’s Supervisory Board is to be composed in a manner that its members as a whole have the required knowledge, abilities and

specialist experience in order to appropriately assume the tasks (Section 5.4.1 GCGC), so that all competencies required for the Company’s

Supervisory Board are actually represented within the Supervisory Board, or rather among the representatives of the shareholders.

The general knowledge of the Supervisory Board members includes, in particular, theoretical knowledge and practical experience in the

areas legal principles and compliance, accounting and risk controlling.

Supervisory Board members are to be familiar with the core segments of the operations of the Company, the development and marketing

of products with, generally, active pharmaceutical ingredients which are free of commercial property rights, particularly patents, and

regularly also prescription drugs and products required to be or only sold in pharmacies.

Corporate Governance Report31

Furthermore, the international activities of STADA Arzneimittel AG are to be considered in the composition of the shareholder representatives

in the Supervisory Board. Here, criteria include, in addition to fluency in written and spoken English, the understanding of global economic

connections and an international Group structure.

In particular, candidates should be recommended who, as a result of their integrity and personality, are in the position to take on the tasks

of a Supervisory Board member of the publicly listed STADA Arzneimittel AG. Furthermore, diversity is to be considered.

2. Concrete goals, appointment plan

a) required knowledge, abilities and specialist experience

Each member of the Supervisory Board is to fulfill the following requirements – in addition to the general requirements of reliability and the

specific knowledge required to assume the control function as well as to evaluate, monitor and consult the Executive Board of STADA

Arzneimittel AG:

– general understanding of the business activities carried out by STADA Arzneimittel AG, the industry and market environment, and the

strategic positioning of the Company,

– the ability to understand and evaluate the reports submitted to the Supervisory Board in order to draw independent conclusions from

these; additionally the ability to evaluate and assess the decisions of the Executive Board and the transactions arising as well as to be

able to analyze economic connections,

– the ability to understand the documentation submitted for the financial statements and to be able to evaluate these in consideration of

company-specific issues, if necessary, with the support of an auditor,

– communicative abilities.

Each member of the Supervisory Board is to contribute as particular in-depth specialist knowledge and sound experience as possible in one

or several areas, in order to support the Supervisory Board as a whole in the task of monitoring and consulting.

The above-mentioned specialist knowledge and experience is to be as widely represented as possible.

b) personal requirements

Candidates are to be recommended who fulfill the determined personal requirements of the most current version of the German Corporate

Governance Code. The personal requirements according to the most current version of the German Corporate Governance Code are also to

be upheld during the active term of a Supervisory Board member.

It is also to be ensured that the Supervisory Board members are independent. For candidate recommendations to the Annual General

Meeting, it is to be ensured that the individual candidate does not hold a management or consulting function at, nor is in the supervisory

bodies of competitor companies, suppliers, significant lenders or customers, so that conflicts of interest can be avoided from the start.

Corporate Governance Report 32

c) appointment plan

Diversity is to be considered in the recommendation of candidates for the election of shareholder representatives by the Annual General

Meeting. Diversity in the Supervisory Board is reflected, among other things, in the various occupational careers and areas of activity, as

well as with respect to the internationality of STADA Arzneimittel AG, in the diverse spectrum of experience of the shareholder representatives

in the Supervisory Board.

The chairmen of the Human Resources Committee and of the Audit Committee provided the Supervisory Board the following appointment

plan for the new election of shareholder representatives at the Annual General Meeting in June 2013:

– a practicing pharmacist,

– an experienced and knowledgeable pharmacist, in particular in the areas of medicinal care – patent-protected and generic RX and

OTC products – at pharmacies, of advise on self-medication and of resulting opportunities thus available for STADA Arzneimittel AG,

– a pharmacist with many years of experience in the pharmaceutical industry, e.g. as the head of production and quality control

(e.g. qualified person in the sense of Sections 14 f. of the German Pharmaceutical Act, AMG),

– an independent financial specialist with expertise in the areas of accounting and financial report auditing,

– an attorney experienced in corporate and industrial law.

For further candidates, expertise in the areas of future treatment methods, biotechnology, health care trends, health care systems (in and

out patient care), among other things, is desirable.

Furthermore, the Supervisory Board decided against the determination of an age limit and against a fixed diversity quota. Specific age

limits or fixed diversity quotas would only limit the selection of appropriate candidates.

Taking these goals into consideration, the Supervisory Board submitted a candidate recommendation at the 2013 Annual General Meeting,

which was approved at that Annual General Meeting. A review of the goals of the Supervisory Board will be carried out in due time prior to

the Supervisory Board election in 2018.

Conflicts of interest

According to the rules of procedure of the Supervisory Board, members of the Supervisory Board shall not be a member of any board at, or

provide consulting services to, significant competitors of the Company. Furthermore, the Supervisory Board members are required to

disclose conflicts of interest to the Supervisory Board, particularly those which may arise as a result of consultation or board membership

with customers, suppliers, banks or other third parties. Significant and not only temporary conflicts of interest for an individual in the

Supervisory Board shall result in termination of the position. In its report, the Supervisory Board informs the Annual General Meeting whether

conflicts of interest were recognized and how they were handled.

Corporate Governance Report33

Efficiency review

The Supervisory Board regularly reviews the efficiency of its activities. The subject of the efficiency review includes, in addition to the

qualitative criteria to be established by the Supervisory Board, in particular the procedural flows in the Supervisory Board and the flow of

information between the committees and the plenary as well as the prompt and sufficient internal distribution of information.

Remuneration report

The Remuneration Report, which can be found in the Management Report of the Executive Board, presents the principles of the remuneration

system of the STADA Supervisory Board as well as individual details of the remuneration of individual members of the Supervisory Board.

c) Advisory Board

The Chairman of the Supervisory Board convenes the members of the Advisory Board of STADA Arzneimittel AG upon recommendation of

the Executive and Supervisory Boards. According to the Company’s Articles of Incorporation, the duty of the Advisory Board is to support

and advise the Executive and Supervisory Boards. Furthermore, members of the Advisory Board are available to act as proxy for shareholders

who do not wish to exercise their voting rights in person at the Annual General Meeting. The Advisory Board had 11 members on the balance

sheet date. The currently elected 11 members of the Advisory Board are appointed until the end of financial year 2018. The remuneration

report, which can be found in the Management Report of this Annual Report, presents the principles of the remuneration system of the

STADA Advisory Board.

Corporate Governance Report 34

SHAREHOLDERS AND THE ANNUAL GENERAL MEETING

The shareholders1) assume their rights in the Annual General Meeting and exercise their voting rights. Each STADA share2) grants entitle-

ment to one vote. Shareholders have the option to exercise their voting right themselves in the Annual General Meeting or to have their

voting right exercised by an authorized representative of their choice or by way of a voting representative from the Company, who is bound

by instructions. Every shareholder is entitled to participate in the Annual General Meeting, to speak on individual agenda items there and to

request information about Company issues, if this is required for the appropriate assessment of an item on the agenda.

The Annual General Meeting passes resolutions, among other things, on the allocation of profits, the approval of the Executive Board and

Supervisory Board, the selection of the auditor as well as on any changes to the Articles of Incorporation and capital-changing measures.

TRANSPARENT CORPORATE GOVERNANCE

In order to ensure transparent corporate governance, STADA informs shareholders, financial analysts, other capital market participants, the

media and the interested public regularly and promptly about the situation of the Company and about any significant business changes.

In order to ensure the equal treatment of all users and to provide market participants the same information in terms of content and in due

time, STADA provides all the important documentation on the STADA website at www.stada.de and www.stada.com. There, all interested

individuals are provided access, in particular, to all compulsory information such as financial reports (annual and interim reports) and ad hoc

releases, voting rights notices, information on the Annual General Meeting, as well as other comprehensive Company and share information

such as press releases, Company profile, financial calendar, presentations and current share price information on STADA (including peer

group comparisons). The Company generally publishes up-to-date presentations on its website for the capital markets.

The reporting about the situation and results of STADA Arzneimittel AG and the STADA Group is delivered by the Annual Report, the interim

reports and at press and analysts’ conferences which can generally be followed live and can be viewed for some time as a recording on the

STADA website at www.stada.de and www.stada.com.

1) For capital and shareholder structure see “The STADA Share”.
2) Under the Company’s Articles of Incorporation, STADA’s registered shares with restricted transferability
can only be entered into the share register with the consent of the Company and, pursuant to the statutes,
grant one vote each in the Annual General Meeting. Shareholders are only those who are registered as such
in the share registry and only such persons are authorized to participate in the Annual General Meeting and
to exercise voting rights. No shareholder and no shareholder group shall have any special rights.

Corporate Governance Report35

FINANCIAL REPORTING AND FINANCIAL STATEMENT AUDIT

STADA prepares the consolidated financial statements and the consolidated interim financial statements in accordance with the relevant

international financial reporting standards and the annual financial statements of STADA Arzneimittel AG in accordance with the rules and

regulations of the German Commercial Code.

The auditor and Supervisory Board audit the consolidated financial statements and the consolidated interim financial statements for the first

half of the year provided by the Executive Board. The Audit Committee discusses the interim financial reports with the Executive Board prior

to their publishing.

STADA publishes the annual financial statements of STADA Arzneimittel AG (including the Management Report) and the consolidated

financial statements of the STADA Group (including the Group Management Report) within 90 days of the end of the respective financial

year and, in addition, informs shareholders and third parties during the year via interim financial reports within 45 days of the end of the

reporting period. The interim financial report for the first half of the year is voluntarily audited by the auditor elected by the Annual General

Meeting for this purpose.

The Company does not have a stock option plan or similar share-based incentive systems.

The significant investments of the Company as well as the related parties are presented in the Notes to the Consolidated Financial

Statements.

Prior to submitting the nomination, the Audit Committee receives a declaration from the selected auditor of whether and to what extent

commercial, financial, personal or other relationships exist between the auditor, its board members and head auditors, on one side, and

STADA and its board members on the other side, which could represent any doubts regarding the independence of the auditor. The

declaration also covers to what extent in the past financial year other services were provided – or have been contractually agreed upon for

the following year – to the Company, in particular in the area of consultancy.

The Supervisory Board agreed with the auditor that the Chairman of the Supervisory Board or Audit Committee shall be informed without

delay of any possible grounds for exclusion or bias arising during the audit insofar as these are not remedied immediately.

Furthermore, the Supervisory Board agreed with the auditor that the auditor shall report without delay on all facts and events of importance

for the tasks of the Supervisory Board which arise during the performance of the audit, as well as that the auditor shall disclose and/or note

in the Auditor’s Report if, during the performance of the audit, the auditor comes across facts which show a misstatement by the Executive

Board and Supervisory Board in the declaration on the German Corporate Governance Code.

The auditor participates in the meetings of the Supervisory Board regarding the semi annual, annual and consolidated financial statements

and reports the significant results of the audit.

Corporate Governance Report 36

Management Report of the Executive BoardManagement Report of the Executive Board | Table of Contents

REMUNERATION REPORT

SUPPLEMENTARY REPORT

OPPORTUNITIES REPORT

RISK REPORT

TAKEOVER-RELEVANT INFORMATION

PROGNOSIS REPORT

102

103

105

124

126

BASIS OF THE GROUP

Business Model of the Group

Product Development

Procurement, Production and Quality Management

Sales and Marketing

Employees

Goals and Strategies

Controlling

Responsibility and Sustainability

ECONOMIC REPORT

General Economic and Industry-Specific Situation

Business Development and Situation

Development of 2014 Compared to Outlook

Development of Performance Indicators

Earnings Situation

Development of Sales

Development of Earnings and Costs

Development of Segments

Financial Situation

Assets Situation

General Statements of the Executive Board

on Business Development in 2014

BASIS OF THE GROUP
Group Business Model

Focus on health care market concentrating on pharmaceutical market

STADA’s business model focuses on the health care market, whereby the pharmaceutical market, one of the global growth industries, in

particular is at the heart of the internationally focused Group activities

The global health care and pharmaceutical markets recorded further increase in 2014. Sales in the international pharmaceutical market

increased by approx. 8.1%1) to approx. € 856.2 billion1) as compared to the previous year.

In the Executive Board’s assessment, numerous national health care and, in particular, pharmaceutical markets will continue to provide high

growth opportunities that are relatively independent of economic activity in the future as well. On one hand, this is based on general growth

drivers in the form of the global population increase, an aging society in industrialized countries and further medical progress. On the other

hand, the growth opportunities are based on generics-specific drivers such as progressive generics penetration as a result of increasing

spending restraints in individual national health systems and continuous patent expirations. This also applies to the future-oriented field of

biopharmaceuticals with high sales and profit potential.

In view of the continually rising demand in the health care market and the fact that drugs are viewed as relatively efficient in comparison to

other treatment methods, further growth is also expected for the international pharmaceutical market in the future. According to the fore-

casts, sales in the global pharmaceutical market will increase by 5% to 7% per year until 2019 (see “Prognosis Report”).1)

The STADA Group focuses on selected segments within the health care and pharmaceutical market. With regard to costs and risks, STADA

deliberately does not conduct any own research on, or marketing of new active pharmaceutical ingredients, but rather focuses on the

development and marketing of products with active ingredients – generally active pharmaceutical ingredients – which are free from

commercial property rights, particularly patents. In this context, the products sold by STADA are primarily positioned in the two core

segments of Generics and Branded Products.

With regard to regional divisions, STADA’s business activities are focused on the four market regions of Germany, Central Europe,

CIS / Eastern Europe and Asia & Pacific2).3)

Core segments and non-core activities

According to the Group’s strategic positioning, STADA focuses its business activities on products with off-patent active pharmaceutical

ingredients, which are positioned in the two core segments of Generics and Branded Products.

Whereas generics sales focus on low pricing and/or cross-product and cross-indication marketing, branded product marketing focuses on

specific product characteristics and, in particular, the brand name of the individual products.4)

1) IMS Market Prognosis, September 2014; IMS Market Prognosis Global, September 2014; IMS Syndicated
Analytics Service (September) 2014; prepared for STADA February 2015.
2) Since January 1, 2015, the former market region Asia & Pacific has been grouped together with the
activities of the MENA region and reported in the market region Asia / Pacific & MENA.
3) For a breakdown of the national sales activities of the STADA Group according to the four market regions,
see “Development of Segments”.
4) For a detailed segment definition see Notes to the Consolidated Financial Statements – 43.

Management Report of the Executive Board39

Apart from the different sales positioning, the two core segments are differentiated from one another in other areas such as the demand

structure, growth and margin expectations as well as the respective requirements of portfolio expansion and development strategies.

In the Generics segment, the requirements on the product portfolio are closely tied to the regulatory structure of the individual markets in

the respective market regions and the regional market power of the locally active STADA subsidiaries. STADA is generally positioned as a

so-called full-portfolio concept in this segment. This product portfolio includes numerous dosage forms and strengths for the most relevant

active pharmaceutical ingredients and thus partly also products with only a low significance for Group sales. In only a few markets such as

the United Kingdom, however – where STADA has been concentrating on the area of branded products even stronger in particular since the

acquisition of the British OTC supplier Thornton & Ross1) – STADA is active as a niche provider and offers a selected product portfolio with

special active pharmaceutical ingredients that have good sales prospects in the respective market. The Group adopts this kind of portfolio

structure if it seems promising based on specific local market conditions, and in particular taking earnings aspects into consideration.

The Group generally pursues a selective portfolio approach in the Branded Products core segment. In this context, STADA markets branded

products in consideration of availability and demand in selected markets of the individual market regions. The Group relies on a concept of

so-called “strong brands”, which – because of their high brand awareness, ideally as the local market leader – generate growth largely

independent of local market trends with comprehensive promotional and sales support.

Share of core segments and non-core activities in STADA Group sales

— Generics 59.1%

— Generics 61.3%

2014

— Branded Products 38.8%

20132)

— Branded Products 35.2%

— Commercial Business 2.1%
— Group holdings / other 0.0%

— Commercial Business 2.0%
— Group holdings / other 1.5%

In financial year 2014, the two core segments Generics and Branded Products had a total share of 97.9% (previous year2): 96.4%) of Group

sales. The core segment Generics contributed 59.1% of Group sales (previous year2): 61.3%); 89% of the generics were prescription

products (previous year2): 86%). The core segment Branded Products contributed 38.8% of Group sales (previous year2): 35.2%); 63% of

the branded products were non-prescription products (previous year2): 59%).3)

1) See the Company’s ad hoc release of August 6, 2013 and ad hoc update of August 16, 2013.
2) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.).
3) At Group level, prescription products contributed approx. 69% (previous year2): approx. 69%) and
non-prescription products approx. 31% (previous year2): approx. 31%) to Group sales (according to national
categorization).

Management Report of the Executive Board | Basis of the Group40

STADA includes business and investments in areas outside the two core segments under non-core activities.

The Commercial Business segment includes activities primarily with a trading character such as wholesaling activities. In the reporting

year, the segment’s share of Group sales amounted to 2.1% (previous year1): 2.0%).

Other non-core activities not presented separately as well as Group holding-related items are reported under Group holdings / other. In

financial year 2014, these made no contribution to Group sales (previous year1): 1.5%) .

Core segment Generics

In 2014, sales in the global generics market increased by 9.9%2) to approx. € 116.6 billion2) as compared to the previous year. The market

share of generics in the global pharmaceutical market amounted to approx. 13.6%2).

In the view of the Executive Board, Generics, in particular, has growth opportunities within the pharmaceutical market, as generics provide

a cost-effective medicative therapy without any loss in quality and thus counteract the increasing cost pressure in the individual health care

markets. In addition, the potential available for generics competition is constantly expanding due to the continuous expiration of patents or

other commercial property rights.

This assessment is also confirmed by forecasts of IMS Health, a leading international pharmaceutical market research institute (see

“Prognosis Report”).

In the generics area, biosimilars in particular will play an increasingly important role in the future, since, on the cost side, they can contribute

significantly to relieving the individual national health care markets. Overall, twelve of the strongest biologics in terms of sales will have lost

their patent protection by 20203). In the current year, a paradigm shift is pending in this connection since, for the first time ever, there will

be more patent expirations among biopharmaceutical products than chemical/synthetic products.

In light of this potential, STADA consequently pursues the strategy of selectively in-licensing biosimilars from high-profile partners, because

for the Group this represents the course with the lowest risk and, above all, lower costs than relying on in-house developments (see

“Product Development”).

Core segment Branded Products

For several years, the Executive Board has been pursuing the strategy of further strengthening the Branded Products segment from a growth

and earnings perspective, since it is generally subject to less regulatory intervention and is characterized by substantially more attractive

margins than the Generics segment.

The Group will increasingly leverage synergies for the international positioning of its branded products. With the introduction of a centralized

portfolio management structure and the advantages of decentralized marketing, STADA takes account of the growing Group-wide importance

of this segment. In this context, existing branded products will be introduced into new markets and the portfolio will be further expanded at

the same time, to thus further accelerate the expansion and internationalization of the Branded Products segment.

1) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.).
2) IMS Market Prognosis, September 2014; IMS Market Prognosis Global, September 2014; IMS Syndicated
Analytics Service (September) 2014; prepared for STADA February 2015.
3) Source: Deutsches Ärzteblatt of March 14, 2014; 111 (11): A-452 / B-388 / C-372:
“Biosimilars: Das Wettrennen ist in vollem Gange” (“Biosimilars: The race is well underway”).

Management Report of the Executive Board41

During the implementation of this strategy, the expertise of the British STADA subsidiary, which is currently number 4 in the British OTC

market and is working on new branded products for the globally operating STADA subsidiaries, will play a role in supporting STADA

Arzneimittel AG’s central “Center of OTC Excellence”. In light of Thornton & Ross’ competence, infrastructure and technical possibilities, new

opportunities in the area of OTC, consumer marketing and dermatology have opened up to the Group with the acquisition of the company.

In principle, STADA Arzneimittel AG’s “Center of OTC Excellence” was conceived as a think tank for the entire Group. The main objective is

the long-term pipeline and portfolio development in the areas of OTC and dermatology.

STADA is currently one of the fastest growing OTC companies within the top 10.1)

In 2014, sales in the global OTC market increased by 4.6%2) to approx. € 62.60 billion2) as compared to the previous year. The market share

of OTC products in the global pharmaceutical market amounted to approx. 8.2%2).

In the reporting year, STADA was able to strengthen the Branded Products segment through the acquisition of the Russian branded product

Aqualor® 3), the purchase of the rights for Flexitol® 4) for the United Kingdom and Ireland, the signing of the purchase contract for the two

Russian branded products AndroDoz® and NeroDoz® 5) as well as the acquisition of the British company Internis (see “Economic Report –

Business Development and Situation – Financial Situation”).

Operative alignment

STADA has a predominantly functional organizational structure in the areas of Development, Production, Procurement, Central Purchasing,

Quality Management, Finance, Risk Management, Compliance, Corporate Governance as well as overall responsibility for the Group strategy.

The sole targeted exception are parts of the sales functions, which are are focused locally and organized through the STADA market regions

with a primarily regional focus in order to ensure the greatest degree of market proximity in accordance with Group strategy. In this context,

the sales responsibility – which comprises sales and earnings of the market regions, their product portfolio and their personnel management

– lies with the respective regional management.

Despite the Group-wide harmonization and centralization that is needed in order to increase efficiency, with this operative alignment STADA

pursues the goal of possessing the flexibility and market proximity necessary for the business model. The Group’s objective in this is to be

able to react quickly to changed framework conditions.

In view of this, the division into the core segments Generics and Branded Products, as well as the non-core activity Commercial Business,

is based essentially on sales aspects. The different sales requirements of the respective product categories are thus also reflected in the

operational management of the Group.

1) Source: IMS Health MIDAS – EU28+RU+CH+NO+RS – Panel: Retail + Hospital – MAT/12/2014,
without cosmetics and RX branded products.
2) IMS Market Prognosis, September 2014; IMS Market Prognosis Global, September 2014; IMS Syndicated
Analytics Service (September) 2014; prepared for STADA February 2015. IMS MIDAS (September) 2014.
3) See the Company’s ad hoc release of October 18, 2013 and ad hoc update of February 28, 2014.
4) See the Company’s press release of June 30, 2014.
5) See the Company’s press release of February 4, 2015.

Management Report of the Executive Board | Basis of the Group42

Product Development

Strategic and organizational basis of development activities

On the basis of the business model and the strategic positioning of the Group, STADA deliberately does not conduct any of its own research

on new active pharmaceutical ingredients, but rather focuses on the development of products with active – generally pharmaceutical –

ingredients, which are no longer subject to any commercial property rights, particularly patents.

The Group-wide development activities concentrate on the development of new generics and branded products for international marketing

using Group-owned sales companies. Additional development activities focus on the expansion of the existing product portfolio by way of

additional dosage forms or strengths and the internationalization of nationally successful products. Furthermore, the Group concentrates on

the support of transfer projects, e.g. the transfer of knowledge in the production area, as well as on the optimization of products already

launched with the goal of reducing the cost of sales or to create improvements in potential areas of application.

Market readiness is at the center of development activities for new products. In the case of pharmaceuticals this usually involves receiving

national approval from the responsible regulatory authorities in the context of differentiated, partly supranational approval processes. In the

majority of cases, STADA prefers supranational, in particular EU-wide, approval procedures in order to achieve numerous national approvals

of a product in different countries nearly simultaneously. Approval procedures outside of the EU are carried out if possible based on the EU

dossier of the respective products, so that the Group can thereby fall back on a standardized formulation. With the international orientation

of development activities, STADA also aims at generating economy of scale effects through optimized batch sizes.

The Group-wide development activities are aimed at the long-term, in order to guarantee a continuous flow of new product launches and

thus drive organic growth, particularly in the segment Generics. In view of this, STADA is now already working on the development of generic

products with potential launch dates beyond 2024. STADA currently assumes an average regulatory preparation time including an approval

period of three years for generics with Group-wide relevance. STADA generally pursues a so-called “time and cheap to market” strategy

with the goal of launching new products not only at the earliest point in time, but also at the best possible cost of sales.

With a view to the great significance that strong product development has for the Group’s further success, the planning and organization of

development activities are mainly carried out centrally by STADA Arzneimittel AG. With regards to costs and thereby efficiency aspects, the

Group utilizes in-house as well as third-party development. Development centers for global projects are located in Bad Vilbel, Germany, and

Vrsac, Serbia. In the area of external development, there are currently four projects in cooperation with third-party developers from India. In

selected projects, STADA additionally relies on an international network of external development partners, from which the Group acquires

dossiers or approvals. STADA – as is usual in this sector in some cases – also enters into joint development projects with competitors. In

view of the great significance of strong product development, the punctual coordination of such a network, also in terms of costs and the

respective commercial property rights, ranks as one of the Group’s strategic success factors.

With the goal of increasing the number of in-house developments of strategically important and high-sales products and also under

consideration of cost reductions, STADA has continually expanded internal development activities in recent years. This allows for, among

other things, the optimization of procurement and production costs in the initial years, as the purchase of dossiers and their associated

initial supply commitments can be reduced. In addition, costs for in-house developments can be reduced by bundling them in low-cost

Management Report of the Executive Board43

Group locations. Meanwhile approx. 54% of ongoing Group-wide in-house developments of generics are thus processed by the develop-

ment center in Vrsac, Serbia. If products are not significant at the Group level, local business units also carry out their own development in

individual cases.

For the Group-wide management of all development projects, STADA has, on the basis of a Group management function of STADA

Arzneimittel AG, central project management with interface management which facilitates the transparent management of product devel-

opment in the Group.

Development activities clearly focus on the core segment Generics. Depending on the local patent and approval situation and on the relevant

market strategy, the decision, which active pharmaceutical ingredients are to be launched into a market and at what time, is made in

cooperation with the management of the respective market region. STADA generally aims to have completed the development of all

Group-relevant, according to sales, strengths and dosage forms of an active pharmaceutical ingredient as early as possible, in order to make

these and all required approvals available to individual sales companies as immediately as possible after the expiration of the respective

patent and/or commercial property right.

In determining a concrete launch date for a generic in a market, the respective commercial property rights that have to be observed are of

substantial importance, as their scope and duration can be very different from market to market. As a precautionary measure, the STADA

Group management and the regional management regularly receive legal recommendations on commercial property rights from both

internal and external experts. Nevertheless, before and after the launch of new generics, there can be, in some cases, legal disputes

commenced by initial suppliers, which generally involve the validity of commercial property rights such as patents, which stand in contrast

to the Group’s assessment and, in exceptional cases, can even lead to a negative result for STADA.

In the Branded Products core segment, the development activities are better targeted to individual markets and have a more flexible time

frame than Generics, as development activities for new branded products are oriented towards product and country-specific growth and/or

earnings opportunities as well as compatibility with the existing product range and Group

structures. During the implementation of this strategy, the “Center of OTC Excellence” of

STADA Arzneimittel AG plays a guiding role.

Sustainable development and approval strength

STADA’s sustainable development and approval strength is evident in the large number of

product launches every year. With the introduction of 626 individual products worldwide

(previous year1): 706) STADA was able to prove this strength once again in 2014.

The great importance of successful product development can be seen from the 5% share

in sales (previous year1): 7%) generated with products the Group introduced in the last two

years2) 3).

STADA’s product pipeline remains well-filled. This assessment is also confirmed by the

high number of running approval procedures as of December 31, 2014 totaling over

1,300 for over 150 active pharmaceutical ingredients and active ingredient combinations

for more than 55 countries. This applies in particular to generics in the EU. In addition, the

Group conducts approval activities also in markets outside of the EU where STADA has its

5-year development:
Number of product launches

7
1
7

6
0
7

6
2
6

0
0
6

2
7
5

own subsidiaries or is active in the export business.

20104) 20114) 20124) 20134)

2014

1) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.).
2) Reporting year and previous year.
3) Not including products and sales from acquisitions.
4) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.). For
reasons of the practicability caveat as specified under IAS 8.43 ff., the previous year figures for financial year
2012 and earlier were not adjusted.

Management Report of the Executive Board | Basis of the Group44

The high level of expertise in product development becomes clear not only through the high number of successful new launches in the area

of classic generics, but also considering activities in the area of the increasingly important field of biosimilars.

From a competition and margin perspective, STADA has been active in the area of biosimilars for quite some time now and has been

successful on the German market with SILAPO®, a biosimilar epoetin, since 2008.

In addition to the cooperation with Gedeon-Richter, which has existed since 2011, among other things, for the monoclonal antibody

Rituximab1), whose approval can be expected for 2018 from today’s perspective, the Group was able to achieve further progress in this

future-oriented field in financial year 2014.

In the third quarter of 2014, the German STADA subsidiary cell pharm started the sale of the Filgrastim product Grastofil®, which had already

been in-licensed by the Group in 2013.2) In addition, STADA in-licensed Teriparatid in the reporting year, which is expected to be launched

in 2019 under the STADA label throughout Europe following the expiration of the patent of the original product, Forsteo®.3) Furthermore,

STADA and the biotech specialist mAbxience started to negotiate over the in-licensing of an Adalimumab biosimilar (Humira®) in the fourth

quarter of 2014.4)

In light of the existing potential in the biosimilars area (see “Prognosis Report”), STADA will continue to pursue the strategy of selectively

in-licensing biosimilars from high-profile partners instead of relying on in-house developments, since this for the Group represents the

course with the lowest risk and lower costs. In view of this, STADA regularly reviews offers for in-licensing biosimilars for various indications,

which meanwhile also cover biosimilars for monoclonal antibodies whose patents expire as from 2020, in order to be in the position to

further expand the existing biosimilar portfolio in a targeted manner.

Expenses for research and development costs

The research and development costs amounted to € 56.9 million in financial year 2014 (previous year5): € 55.5 million) (see “Economic

Report – Business Development and Situation – Earnings Situation – Development of Earnings and Cost”). These costs relate only to

development costs as STADA, due to its business model, does not carry out any research into new active ingredients. In addition, the Group

capitalized development costs for new products in the amount of € 27.5 million in the reporting year (previous year: € 18.8 million). This

resulted in a capitalization rate of 32.6% (previous year5): 25.3%). Amortization of capitalized development costs amounted to approx.

€ 6 million (previous year: approx. € 6 million). In 2014, the Group had 571 employees in the area of product development (previous

year5): 524).

1) See the Company’s press release of August 30, 2011.
2) See the Company‘s press releases of October 28, 2013 and August 6, 2014.
3) See the Company’s press release of October 13, 2014.
4) See the Company’s press release of November 18, 2014.
5) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.).

Management Report of the Executive BoardManagement Report of the Executive Board | Basis of the Group

Procurement, Production and Quality Management

International network for procurement of active ingredients and auxiliary materials

Under flexibility and cost aspects, STADA has generally abstained from manufacturing any active ingredients or auxiliary materials necessary

for the Group’s pharmaceutical production, but utilizes an international network of raw materials suppliers. Thereby, STADA focuses –

particularly for the procurement of active pharmaceutical ingredients – on low-priced suppliers from low-cost countries, mainly from Asia.

Nevertheless, the Group does not generally rule out future cooperations in the area of active pharmaceutical ingredient production with the

goal of achieving greater vertical integration.

In consideration of the Group-wide, continuous cost optimization, both China and India have become important resource countries for

low-cost active ingredient procurement for STADA. STADA currently has a procurement office in Shanghai, the People’s Republic of China

and in Mumbai, India.

If the Group’s products are produced in the context of contract manufacturing, STADA is dependent on both global purchase price develop-

ments of the necessary raw and auxiliary materials and on the prices negotiated with contract manufacturers, which may fluctuate

significantly depending on the product. With the objective of minimizing the risk of market-related margin losses due to falling selling prices,

STADA involves suppliers – where possible – in this market price risk. This occurs, for example, by using price escalation clauses in which

procurement prices are linked to selling prices, subsequent negotiations or the agreement of special procurement prices for special sales

volumes, such as volumes that are put out to tender by public health insurance organizations in the context of discount agreements.

Centralized needs planning

In the area of supply chain, the Group’s needs planning for important products is carried out centrally. In addition, there are three supply

chain hubs at the locations in Bad Vilbel, Germany, Vrsac, Serbia, and Moscow, Russia, which are managed through the STADA Arznei-

mittel AG and where the centralized needs planning is carried out for the Group’s top products selected according to specified criteria. In

view of the corresponding pooling of individual services, the Group creates cost synergies and thus cost savings. In consideration of the

continuous cost optimization, the concept of this project, which was already concluded in financial year 2013, will be continuously devel-

oped in the context of an improvement process.

Supply chain and pharmaceutical production characterized by high flexibility and continuous cost optimization

With regard to the comprehensive product portfolio of more than 800 active pharmaceutical ingredients and over 16,000 product packagings

sold by the Group, each different in terms of its active ingredients and/or quantity of the active ingredients and/or dosage forms and/or

package sizes, STADA makes use of an international network of internal and external resources for the supply chain and pharmaceutical

production.

The concentration of production processes at its own locations was continued in 2014. This measure includes both the gradual assumption

of production volumes from contract manufacturing as well as the shifting of production volumes within Group-owned plants. The objective

of the concentration process is, on the one hand, to benefit from the structural cost advantages of the locations in low-cost countries in

particular, and, on the other hand, to reduce unit costs of respective products by increasing capacities.

Furthermore, STADA made investments in the reporting year to adjust the varying capacities of individual process stages of pharmaceutical

production to the respective capacities of individual locations.

The EU-GMP certified production facility in Huddersfield, United Kingdom, which was added to the Group’s internal production network in

the course of the acquisition of the British OTC supplier Thornton & Ross in 2013, was integrated in the production network of STADA

Arzneimittel AG to a greater extent in 2014. Central capacity utilization was further increased through various product transfers of previously

externally produced products, which has resulted in reduced unit prices.

The process optimization program in the area of production, which was launched in the previous years and has led to significant improve-

ments in results, was expanded to all technical areas in 2014. Ongoing improvement in all technical/operative processes is extremely

important for the STADA Group in order to continuously ensure competitiveness.

As of March 1, 2015, the Group had pharmaceutical production facilities in the following locations:

Market region Germany

· Bad Vilbel (Germany)

· Pfaffenhofen (Germany)

Market region Central Europe

· Huddersfield (United Kingdom)

Market region
CIS / Eastern Europe

· Banja Luka (Bosnia-Herzegovina)

· Dubovac (Serbia)

· Nizhny Novgorod (Russia)

· Obninsk (Russia)

· Podgorica (Montenegro)

· Sabac (Serbia)

· Vrsac (Serbia)

· Beijing1) (China)

Market region
Asia / Pacific & MENA

· Hoc Mon District1) (Greater Ho Chi Minh City) (Vietnam)

· Binh Duong Branch (Greater Ho Chi Minh City) (Vietnam)

· Tuy Hoa1) (Vietnam)

STADA generally makes adequate annual investments to ensure that all Group-owned production facilities and test laboratories are main-

tained at the level required by legal stipulations and technical production considerations. Investments in the expansion and renewal of

production facilities and plants as well as test laboratories, amounted to € 19.7 million in the reporting year (previous year2): € 27.3 million).

1) Production unit that is exclusively or primarily focused on local demand and not integrated in the Group.
2) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.).

Management Report of the Executive Board47

Highest quality and safety standards

As a health company, STADA places the highest priority on the quality and safety of its products. This focus relates to the quality of the raw

materials processed by the company, the products fabricated by STADA, the services the Group offers worldwide, and also to the working

conditions in which these services are carried out.

In the scope of comprehensive audits that take place regularly, Group Quality Management examines the quality standards established by

the Group, which in part go clearly beyond the provisions required by law, in the Group’s own production sites as well as in the facilities of

suppliers and contract manufacturers.

From the external side, inspections are carried out regularly by the respective nationally responsible regulatory authorities in the Group-

owned production facilities. Within the EU, these inspections take place every two to three years. In addition to inspection by national

authorities outside the EU, STADA also orders EU Good Manufacturing Compliance inspections (EU GMP compliance inspections) in order

to receive extensions of the required EU import authorizations valid for three years each. In the context of these inspections, the responsible

authorities review whether the inspected production facilities comply with the EU GMP standards. Between 2012 and 2014, twelve

inspections in total were successfully completed in third countries throughout the Group. They include inspections in the production facilities

of Hemofarm A.D., Vrsac, Serbia; Hemofarm Banja Luka d.o.o.; Banja Luka, Bosnia-Herzegovina; Hemofarm d.o.o., Sabac, Serbia; Hemomont

d.o.o., Podgorica, Montenegro; LCC Nizhpharm J.S.C., Nizhny Novgorod, Russia; Hemofarm LLC, Obninsk, Russia; Pymepharco Joint Stock

Company, Tuy Hoa, Vietnam; and STADA Vietnam J.V. Co., Ltd., Ho Chi Minh City, Vietnam.

Since the Group strives to secure, also in countries outside of the EU, EU quality standards for drugs, which often go beyond local

requirements, the Group-owned production facilities not located in the EU in Banja Luka, the greater Ho Chi Minh City area (Binh Duong

Branch), Nizhny Novgorod, Obninsk, Podgorica, Sabac, Tuy Hoa and Vrsac are set up for the production of certain pharmaceutical dosage

forms for EU countries and are therefore authorized by the responsible EU regulatory authorities for delivery to the EU according to the above

mentioned inspections.

In addition to legal provisions, STADA holds international certifications in accordance with external quality management systems. Therefore,

at numerous production sites, the Group not only focuses on GMP standards, but also on the relevant ISO standards. At several locations,

STADA holds various ISO certificates such as ISO-9001:2008 and ISO-14001:2004.

If individual quality problems occur despite all the preventative and controlling measures, the quality management area focuses on an active

approach to identify the root cause as quickly as possible and to find an appropriate solution. The procedure was also confirmed, for

example, at the Serbian production facility in Vrsac when, in the third quarter of 2011, technical problems arose in the injection substances

area which is primarily used for contract manufacturing. In the context of the ongoing GMP optimization program, STADA displayed the

willingness for re-inspections by the US regulatory authority FDA in the fourth quarter of 2014. The re-inspection was confirmed by this US

regulatory authority for the second quarter of 2015.

In general, the Group’s quality management through STADA Arzneimittel AG is focused centrally and internationally and on a low-cost

activity. In the course of the implementation of further optimization processes, STADA continued the second expansion phase already

initiated in 2012 of the Group-owned laboratory building in Timisoara, where the Group carries out laboratory tests for the purpose of

product authorizations, and, with the completion of the overall project in the first quarter of 2014, achieved the conditions for a doubling of

test capacities there.

Management Report of the Executive Board | Basis of the Group48

Sales and Marketing

Functionally organized Group with local and close to market sales companies

The international sales structure of the STADA Group is made up of numerous nationally aligned sales companies, and thus close market

proximity, which are strategically organized within STADA’s four market regions by central Group functions and regionally managed within

the locally oriented sales functions.

Depending on the market structure and the corresponding demand structure, the individual STADA subsidiaries focus on various target

groups – such as patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy cooperatives, hospitals, wholesalers

and other service providers in the health care market as well as on cost bearers in the form of public health insurance organizations or

private insurances – in the area of sales and marketing in coordination with the management of the respective market regions.

Generally, the sales activities are coordinated at the international level in the Group. This includes, for example, the structuring of the

portfolio in line with the further internationalization of individual products or sales activities such as wholesaling cooperations. If it is

necessary due to structural or legal framework conditions, STADA separates the marketing and sales activities of various sales companies

within the individual market regions.

In some cases, STADA is also active in selected market regions with parallel sales companies. While adhering to strategical Group regula-

tions, the individual subsidiaries are responsible for sales decisions in their respective local market so that they can optimally serve the

respective local needs of the target groups.

This market region-oriented sales concept enables STADA to respond promptly to changes in the individual markets of the respective

market region and to immediately adapt local sales to the corresponding requirements. These could include, for example, a different product

assignment, a modified market presentation or the diversification, expansion or reduction of local sales structures.

Continuous expansion and further internationalization of the Group-wide sales network

In the context of the active acquisitions policy, STADA will continue to pursue the goal of continuously expanding the existing sales network

in the future as well. On the one hand, this is to further reduce the dependencies on individual countries such as Germany, whose health

care system is characterized by difficult local framework conditions for generics. On the other hand, STADA intends to optimally use the

growth opportunities arising from the expansion.

As of March 1, 2015, the Group was active with numerous sales companies in the four market regions Germany, Central Europe, CIS / Eastern

Europe and Asia / Pacific & MENA. The sales focus in 2014 was on the market regions Germany, Central Europe and CIS / Eastern Europe.

In the Asia / Pacific & MENA market region, as of March 1, 2015, the Group operated its own sales companies in China, the Philippines,

Thailand, Vietnam as well as in Egypt and the United Arab Emirates.

More information on the development of Group activities in the individual market regions carried out in the reporting year is published under

“Economic Report – Situation – Earnings Situation – Development of Segments – Information by Market Region”.

Management Report of the Executive Board49

STADA sales structure (as of March 1, 2015)1)

The following overview shows STADA’s sales structure with all significant sales companies according to the allocation to the Group’s four

market regions.

Germany

Market region
Germany

Belgium

Denmark

Germany

France

United Kingdom

Ireland

Italy

Market region
Central Europe

The Netherlands

Austria

Poland

Portugal

Switzerland

Slovakia

Spain

· ALIUD PHARMA GmbH, Laichingen
· cell pharm Gesellschaft für pharmazeutische und diagnostische Präparate mbH, Bad Vilbel
· Hemopharm GmbH Pharmazeutisches Unternehmen2), Bad Homburg
· STADA GmbH3), Bad Vilbel
· STADApharm GmbH3), Bad Vilbel
· STADAvita GmbH, Bad Homburg

· S.A. Eurogenerics N.V., Brussels

· STADA Nordic ApS, Herlev

· STADA CEE GmbH2) 4), Bad Homburg

· EG Labo - Laboratoires Eurogenerics SAS, Boulogne-Billancourt
· Laboratoires d’études et de recherches en oligo éléments thérapie SA, Boulogne-Billancourt

· Britannia Pharmaceuticals Ltd., Newbury
· Internis Pharmaceuticals Ltd., London
· Thornton & Ross Ltd., Huddersfield

· Clonmel Healthcare Limited, Clonmel

· Crinos S.p.A., Milan
· EG S.p.A., Milan

· Centrafarm B.V., Etten-Leur
· Centrafarm Services B.V., Etten-Leur
· Healthypharm B.V., Etten-Leur
· Neocare B.V., Etten-Leur

· STADA Arzneimittel Gesellschaft m.b.H., Vienna

· STADA Poland Sp. z o.o., Warsaw

· Ciclum Farma, Unipessoal, LDA, Paco de Arcos

· Spirig HealthCare AG, Egerkingen

· STADA PHARMA Slovakia s.r.o., Bratislava

· Laboratorio STADA, S.L., Barcelona

Czech Republic

· STADA PHARMA CZ, s.r.o., Prague

Bosnia-Herzegovina

· Hemofarm Banja Luka d.o.o., Banja Luka

Market region
CIS / Eastern
Europe

Bulgaria

Kazakhstan

Lithuania

Montenegro

Romania

Russia

Serbia

Ukraine

China

· STADA PHARMA Bulgaria EOOD, Sofia

· Nizhpharm-Kasachstan TOO DO, Almaty

· UAB STADA-Nizhpharm-Baltija, Vilnius

· Hemomont d.o.o., Podgorica

· STADA M&D S.R.L., Bucarest

· OOO Hemofarm5), Obninsk
· ZAO Makiz-Pharma5), Moscow
· OAO Nizhpharm5), Nizhny Novgorod

· Hemofarm A.D.6), Vrsac

· Nizhpharm-Ukraine DO, Kiev

· STADA Import/Export International Ltd., Hong Kong
· STADA Pharmaceuticals (Asia) Ltd., Hong Kong
· STADA Pharmaceuticals (Beijing) Ltd., Beijing

Market region
Asia / Pacific
& MENA

The Philippines

· Croma Medic, Inc., Manila

Thailand

Vietnam

· STADA Thailand Company, Ltd., Bangkok

· Pymepharco Joint Stock Company, Tuy Hoa
· STADA Vietnam J.V. Co., Ltd., Ho Chi Minh City

United Arab Emirates

· STADA Mena DWC LLC, Dubai

Egypt

· STADA Egypt Ltd., Cairo

1) All significant companies with a STADA share of at least 50% have been listed.
2) Export sales.
3) Acting as commission agents on behalf of STADA Arzneimittel AG.

4) Allocated to the market region Central Europe for reasons of management responsibility.
5) Bundled under the umbrella brand STADA CIS.
6) Including various local sub-labels.

Management Report of the Executive Board | Basis of the Group

Employees

Long-term personnel policy

The basis of the STADA Group’s operative alignment is in principle the management of a comprehensive network of internal and external

resources. This applies in particular to procurement and production, product development as well as sales and marketing. In light of this,

the employees, with their extensive expertise, their substantial experience and their strong commitment, have a significant share in the

long-standing success of the Group.

Generally, STADA pursues a long-term personnel policy that focuses on optimally supporting employees, creating loyalty to the Group and

carrying out the personnel changes required for sustainable development. Furthermore, STADA’s personnel policy aims to attract those who

might be interested and to win them as employees.

Decentralized personnel management

In the area of personnel management, STADA relies on a decentralized organization in order to optimally target the different needs and

demands of its employees at the various locations of the individual market regions. In accordance with the Company guidelines, the inter-

national STADA subsidiaries are largely independent in many areas such as recruitment, training and remuneration. In this context, the

Group’s operational and strategic guidelines – in particular the compliance regulations – must be observed respectively.

Detailed information on the personnel policy of the Group companies that are located in Germany is published annually in STADA’s

personnel and social report, which is also available on the German Company website at www.stada.de.

Training and development as a fixed component of personnel management

In consideration of the major contribution to the successful Group development made by STADA’s employees, training and staff development

take on tremendous importance. Against this backdrop, STADA offers various career training programs in the pharmaceutical, administrative

and warehouse logistics area. The Group also provides internships to young people to introduce them to the processes of a pharmaceutical

company. The Group’s employees receive general support in their field and have the opportunity to update their knowledge, for example in

the form of foreign language training or specialist workshops and seminars.

Ongoing personnel development through targeted employee programs

STADA has established various employee programs which focus on personnel development by way of individual career planning and

institutional talent development for the optimal support of its employees.

And so the Group has, for example, development programs that specifically focus on individual career stages. Under the acronym “STARS

– Searching Talents in All Regions of STADA” the Group provides an international talent management and development program for the

early and targeted support for future managers. This enables STADA not only to recruit managers from an external pool of applicants but to

fill management positions from within its own ranks. Additionally, there is a highly individualized exchange program between the national

and international subsidiaries called “secondment” with the goal of growing through networking and promoting talent at an early stage with

Management Report of the Executive Board51

an individual and targeted approach within the STADA Group. Furthermore, STADA offers the so-called “Management College” to managers

at a certain level, a multi-day and multi-phase program in which selected employees are supported in their management role.

Employee dialog and employee participation as a fixed part of internal communications

In the area of internal communications, STADA has started, among numerous other measures, to give employees the opportunity to get into

contact with individual members of the Executive Board in order to gather information on important topics on the one hand, and, on the

other hand, to establish a mutual exchange in the context of a continuous employee dialog. Since this type of employee communication has

been exceedingly well-received since its introduction, and since it strengthens both cooperation and the feeling of belonging, STADA is

currently in the process of further expanding this instrument of communication.

Employee participation also plays an important role at STADA. For the Group, employee participation means – in addition to the financial

contribution that is made for employees when they buy STADA shares – participation in the form of ideas management including honoring

ideas with rewards. In order to optimize the previously existing system, the entire process is currently in redevelopment.

Development of the number of employees

Compared with 2013, the Group recorded a significant increase in the number of

employees in financial year 2014 – both on average and at the balance sheet date. In

2014, the average number of employees thus increased to 10,209 (previous year1):

8,841). When considered in relation to the balance sheet date, the number of employees

as of December 31, 2014 increased to 10,363 (December 31, 2013: 9,825).

The increase of the average number of employees in the Group is primarily due to the

acquisition of the British OTC supplier Thornton & Ross as of September 1, 2013 and the

control achieved over STADA Vietnam as of October 1, 2013. The inclusion of the

Chinese subsidiary STADA Pharmaceuticals (Beijing) Ltd. in the scope of consolidation

as of January 1, 2014 and an increase of the number of employees at the Serbian

Hemofarm A.D. due to increased utilization of production capacities also contributed to

this development.

The regional breakdown of the Group’s employees shows that there was an average of

1,318 employees in Germany in the reporting year (previous year: 1,269). Of these, an

average of 978 employees were located at the Group’s headquarters in Bad Vilbel

(previous year: 988). The average number of persons employed in international Group

STADA’s development
in the number of employees
on an annual average

9
0
2
,
0
1

1
4
8
,
8

0
8
0
,
8

6
2
8
,
7

4
1
8
,
7

companies amounted to 8,891 (previous year1): 7,572).

20102) 20112) 20122) 20132)

2014

1) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.).
2) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.). For
reasons of the practicability caveat as specified under IAS 8.43 ff., the previous year figures for financial year
2012 and earlier were not adjusted.

Management Report of the Executive Board | Basis of the Group52

The percentage distributions with regard to the Group’s average total number of employees were as follows for the individual functional

areas as of December 31, 2014:

STADA employees by functional area

Marketing / —
Sales 28%

Logistics 4% —

Finance / IT 7% —

— Administration1) 9%

— Product Development 6%

— Procurement /

Supply Chain 3%

Marketing / —
Sales 31%

— Administration1) 11%

— Product Development 6%

— Procurement /

Supply Chain 3%

Dec. 31, 2014

Dec. 31, 20132)

— Production /

Quality Management1) 43%

Logistics 4% —

Finance / IT 7% —

— Production /

Quality Management1) 38%

The Group-wide share of women in management positions amounted to approx. 51% in financial year 2014 (previous year: approx. 51%).

Personnel expenses

Personnel expenses in the reporting year amounted to € 305.1 million (previous year2): € 319.6 million). The personnel expenses ratio

amounted to 14.8% in 2014 (previous year2): 15.9%). The decrease in the personnel expenses ratio was mainly a result of earnings from

past service cost in connection with a change in the defined benefit plan for the Chairman of the Executive Board.

1) In 2013, facility management employees were exclusively recorded in the functional area Administration.
In 2014, the facility management employees in production are allocated to the functional area Production /
Quality Management and the other facility management employees are recorded in the functional area
Administration.
2) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.).

Management Report of the Executive Board53

2014
total

1,364

1,318

1,473

145

559

179

219

184

106

356

5,230

180

140

231

191

877

168

113

140

2,343

2,048

193

142

2,142

1,942

107

10,209

Personnel structure by market region and functional area

Average number of STADA employees in 2014

Marketing /
Sales

Logistics

Finance / IT

Production /
Quality
Manage-
ment1)

Procure-
ment /
Supply
Chain

Product
Develop-
ment

Ad-
ministra-
tion1)

Germany

• Germany

• Other2)

Central Europe

• Belgium

• France

• United Kingdom

• Italy

• The Netherlands

• Poland

• Spain

• Czech Republic

• Other2)

294

255

726

109

120

140

119

CIS / Eastern Europe

1,461

• Bosnia-Herzegovina

• Kazakhstan

• Montenegro

• Romania

• Russia

• Serbia

• Ukraine

• Other2)

Asia & Pacific

• Vietnam

• China

• Other2)

Group total

840

152

177

129

457

390

2,938

139

115

400

174

170

330

295

261

315

2,645

136

141

101

107

973

1,425

1,172

1,127

127

168

166

114

230

133

670

4,442

311

571

1) The facility management employees in production are allocated to the functional area Production /
Quality Management and the other facility management employees are recorded in the functional area
Administration.
2) Other countries of the respective market regions each have less than 50 employees.

Management Report of the Executive Board | Basis of the Group

Goals and Strategies

Active acquisition policy based on multi-pillar strategy

STADA’s business model focuses on the generation of further growth. In this context, STADA generally strives to maintain or achieve leading

positions in each relevant market segment with the subsidiaries in important markets within the individual market regions. In order to

achieve this, the Group focuses on both the expansion of organic growth and on acquisitions. In the context of an active acquisition policy,

STADA pursues a multi-pillar strategy that focuses on increasing the diversification of the portfolio. This aims at reducing potential risks and

at building upon existing opportunities. On the one hand, the multi-pillar strategy stipulates the regional expansion of business activities –

whereby the focus is on high-growth emerging markets. On the other hand, there should be an expansion and internationalization of the

Branded Products segment, which is generally characterized by less regulatory intervention and more attractive margins than the generics

area. The STADA Group also pursued these goals in financial year 2014.

Utilizing existing growth potential through strategic success factors

STADA’s strategic success factors create the basis for utilizing existing growth opportunities for securing sustainable Group success. They

include strong product development, an international sales structure, an active acquisitions policy including experienced integration

management, a functionally organized Group with short decision-making processes and close-to-market sales companies, as well as a

culture of continuous cost optimization including efficient cost management (see “Prognosis Report”).

The strong product development and thus a well-filled product pipeline are the basis of a steady flow of product launches and therefore an

ongoing expansion of the existing product portfolio, particularly in the Generics segment.

The international sales structure with four market regions is designed to market the products from the Group-wide product portfolio in a

way which is adapted to the different regulatory and competitive framework conditions in the individual markets of the respective market

regions.

In the context of the active acquisition policy, STADA aims to further expand the Group’s business activities. In this context, the Group

concentrates, on the one hand, on the regional expansion in selected markets focusing on high-growth emerging markets. On the other, the

focus is on the expansion and internationalization of the core segments, particularly of Branded Products, as they are generally characterized

by better margins and are subject to less regulatory intervention.

With respect to further Group growth, an important function is inherent in the organization by market region with short decision-making

channels while maintaining a strong local market presence at the same time. This predominately applies to sales activities, because the

ability to react to changes in the short-term plays an important role in both exploiting opportunities and reducing risks.

Furthermore, continuous cost optimization and efficient cost management are of great importance in consideration of earnings.

Management Report of the Executive Board
55

Controlling

The management of the corporate areas in the STADA Group is based on strategic and operative guidelines as well as on various financial

indicators. The financial performance indicators used by the Group as key figures for the operational management are Group sales and the

adjusted EBITDA, both of which are subject to controlling at the segment level, as well as adjusted net income and the net debt to adjusted

EBITDA ratio, both of which are managed at the Group level.

The development of Group sales is a key element to ensure business success. Top-line programs to increase sales in the STADA Group are

thus an important pillar for future development. For STADA, reported sales is essential, since the Group relies on growth both by organic

means and through acquisitions in the course of its growth strategy.

Adjusted EBITDA1) in the STADA Group corresponds to EBITDA adjusted for one-time special effects within operating profit with the

exception of one-time special effects that relate to impairments and write-ups of non-current assets. The Group utilizes the development of

adjusted EBITDA to measure the operational performance and the success of the individual business areas adjusted for influences distorting

the year-on-year comparison resulting from one-time special effects. Results from associated companies and investment income are

included.

Adjusted net income1) in the STADA Group is net income adjusted for one-time special effects and effects from the measurement of

derivative financial instruments under financial income and expenses. At STADA, the adjusted net income represents a key figure for the

measurement of the overall success in the Group.

The net debt to adjusted EBITDA ratio is an indication of the financial stability of the Group and is used as a benchmark for the borrowing

of funds.

1) The deduction of such effects which have an impact on the presentation of the earnings situation and the
derived key figures aims at improving the comparability of key figures with previous years. To achieve this,
STADA uses adjusted key figures, which, as so called pro forma figures, are not governed by the accounting
requirements in accordance with IFRS. As other companies may not calculate the pro forma figures presented
by STADA in the same way, STADA’s pro forma figures are only comparable with similarly designated
disclosures by other companies to a limited extent.

Management Report of the Executive Board | Basis of the Group56

The financial performance indicators of adjusted EBITDA, adjusted net income and net debt to adjusted EBITDA ratio are derived as follows:

Financial
performance indicators

Determined based on the consolidated income statement
and the consolidated balance sheet in accordance with IFRS

Result distributable to shareholders of STADA Arzneimittel AG (net income)

± One-time special effects

± Effects from the measurement of derivative financial instruments under financial income and expenses

Adjusted net income

= Adjusted net income

EBIT (Earnings before interest and taxes)

Balance from depreciation and amortization / write-ups on intangible assets (including goodwill), property,
plant and equipment and financial assets

= EBITDA (Earnings before interest, taxes, depreciation and amortization)

± One-time special effects within operating profit excluding one-time special effects that relate to

impairments and write-ups of non-current assets

Adjusted EBITDA

= Adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA)

Non-current financial liabilities

+ Current financial liabilities

= Gross debt

– Cash, cash equivalents and “available-for-sale” securities

= Net debt

÷ Adjusted EBITDA

Net debt to adjusted EBITDA ratio

= Net debt to adjusted EBITDA ratio

Management Report of the Executive Board

Responsibility and Sustainability

Strategic positioning in the name of sustainability

The strategic positioning of the STADA Group is characterized by sustainability by virtue of its essence alone because, with its low-cost and

high-quality medicines and health care products, the Company makes a significant contribution to more efficient health care and thus to a

sustainable utilization of resources in an area of life that is of great importance to people.

Care for people’s health and well-being is in the center of STADA’s activities. “All the best” describes the mission statement that, on the one

hand, represents a guideline for the over 10,000 employees and, on the other hand, reflects the quality of business activities: the quality of

the raw materials which the company processes, of the products that STADA produces, the services the Group offers worldwide and the

working conditions in which STADA’s services are carried out.

In order to ensure that the economic success of the Group is consistent with its environmental and social impact, responsible action and

sustainable economic activity are taken into consideration throughout the entire value chain at STADA. In order to demonstrate the

responsibility and the sustainable commitment of Group activities as well as to document and compare the status and future goals on an

annual basis, STADA plans to join the UN Global Compact.

“All the best” – a STADA initiative

In the autumn of 2014, STADA Arzneimittel AG launched the “All the best” initiative. Its objective is to provide people with useful information

to support their approach to health in their day-to-day lives. The STADA Health Report is the heart of the initiative. It provides interesting

insights into the attitude of Germans towards various health topics. The topic of the first Health Report, which is published once a year with

various focus topics, was about the attitudes, wishes and behavior of Germans regarding health in their day-to-day lives. With the

“All the best” initiative, STADA shows what every single person can do to stay fit and healthy, since health and well-being are essential

requirements for being able to cope with and manage life’s daily challenges. The initiative also enjoys the support of high-ranking experts

in the fields of medicine, science, sport and lifestyle. Not only STADA’s Chairman of the Executive Board Hartmut Retzlaff attended the

press conference to introduce the “All the best” initiative, but also former world-class swimmer Franziska van Almsick, trend analyst

Corinna Mühlhausen and Managing Director of Kantar Health, Werner Guminski, whose institution had conducted the representative

online-survey among 2,000 Germans between 18 and 70 years of age, were there and emphasized the content of the STADA Health Report

with their points of view. Current information on the initiative can be found at www.stada.de/initiative or www.stada.com/initiative.

Active promotion of health and sports

As a health company, STADA Arzneimittel AG and various subsidiaries support numerous sports projects for the general population, disabled

individuals and professionals. In addition, STADA supports opportunities for the employees not only to find out about health and sports, but

also to actively maintain their level of fitness. The health care center at Group headquarters in Bad Vilbel, Germany, offers, among other

things, fitness training, yoga classes and massage sessions. Furthermore, STADA conducts a health consultation within the Company for

employees on several days of the year.

Management Report of the Executive Board | Basis of the Group58

In 2014, STADA initiated a series of events in line with the motto “STADAktiv”, in the scope of which employees can participate in sports

and leisure events. STADAktiv aims at motivating and getting active together, thereby improving one’s health and well-being as well as

strengthening the sense of community. A winter sports trip to Oberstdorf, which started the new event series, was followed by active camps

with top triathletes for challenging running training and an event for playing pool. Highlights in which STADA participated included the

J.P. Morgan Corporate Challenge, a run in Frankfurt am Main with over 71,000 participants, and the “Firmen Datterich Ultra-Triathlon” in

Darmstadt, in which every runner had to cover one-tenth of the Ironman distance. STADAktiv closed 2014 with the pre-Christmas event of

cutting Christmas trees in the German Taunus region.

Since 1995, STADA has supported the Rollstuhlbasketball-Verein (RSV) Lahn-Dill, a very successful wheelchair basketball club in the

German Basketball Bundesliga and at the European level. In 2014, the successful paralympics team from Wetzlar clinched its eleventh cup

and the eleventh German Champion title.

In 2014, the German subsidiary STADAvita GmbH used its Magnetrans product to sponsor the “Deutsche Post Ladies Run”, a five and ten

kilometer run that took place in different German cities. Apart from the health-promoting physical exercise for the approximately 7,000 par-

ticipants, the event series supported a foundation for children and teenagers in need. Furthermore, STADAvita hosted a “STADA Family Day”

at the Nürburgring, in which STADA employees and their families could participate.

Since 2006, the STADA subsidiary ALIUD PHARMA GmbH has been supporting the two-time Olympic medalist and 2012 Paralympics

participant in London Hanne Breuer in dressage riding. The top athlete became a paraplegic in a riding accident and is an inspiration to

other disabled athletes due to her achievements that encourage them to face difficult challenges despite handicaps. In 2014, the athlete

and her horse “Woman of the World” won one gold and one silver in single competitions as well as bronze in the team ranking at the World

Equestrian Games. ALIUD PHARMA also supports the “Kleine Glücksritter e.V.” (small riders) club initiated by Hanne Brenner. It provides

quick and easy access to some happy hours with horses for seriously ill children and their siblings so they can forget about their difficulties

for at least a moment. Since the start of 2015, ALIUD PHARMA has also sponsored the gold medal team winner of the European champion-

ship in Para Archery, Lucia Kupczyk. The archer with disabilities, who has been bound to a wheelchair since 2005 as a result of a medical

condition, even set a new world record with her German team.

Social commitment

Since 2012, STADA Arzneimittel AG has supported the “Kinderzukunft” (Children’s Future) Foundation project that helps children in need.

One focus lies on the financial support of the children’s village in Timisoara, Romania, which celebrated its 20th anniversary in 2014. The

social institution that helps orphans and children without any perspective, provides not only care and safety to approximately 200 children

between three and 18 years, but also offers a holistic concept with education and the village’s own training centers with state-recognized

vocational training.

In cooperation with the Hochschule Fresenius in Idstein, Germany, STADA has supported the STADA foundation professorship in “health

management” since 2003 in order to provide new impetus to the discussion about cost optimization in the health care system. The

foundation professorship is aimed at the promotion of practice-related care research to optimize quality and efficiency in the health care

system.

Management Report of the Executive Board59

Since 2011, STADA Arzneimittel AG has been investing in a fund that provides financial relief to STADA employees in Germany, as well as

their families, who have come into difficulties by no fault of their own. 15 STADA employees have already benefited from the fund since it

was established.

One of STADA’s main regional promotion projects are the castle festivals in Bad Vilbel, Germany, which STADA has been sponsoring for

27 years now. In 2014, the culturally most important event at the Group’s headquarters attracted more than 100,000 visitors with its

entertaining performances. About a third of that total visited the shows especially intended for families and children.

After large parts of Serbia and Bosnia had been drastically flooded in May 2014 due to the most severe rainfalls in more than 120 years,

STADA’s Serbian subsidiary did not only send relief supplies to the affected areas, but it also supported disaster management with the help

of the company’s fire brigade and the commitment of numerous employees. Furthermore, STADA employees in Germany collected relief

supplies for the victims in the affected regions, and transport was financed by STADA. Additionally, the Executive Board of STADA covered

the costs of private damages from Hemofarm employees living in those areas.

STADA Arzneimittel AG has supported the non-profit association dolphin aid e.V. located in Düsseldorf, Germany, as a main sponsor since

2007. Dolphin aid promotes alternative therapies and enables ill and handicapped children to undertake “dolphin therapy”. With the help of

its sponsorship of dolphin aid, STADA deliberately decided in favor of supporting a therapy method that is not based on drugs to demonstrate

a holistic understanding of health that is not exclusively focused on drugs.

In cooperation with Charité-Universitätsmedizin Berlin, the German subsidiary STADApharm GmbH has now been supporting the so-called

“Deutschlandstipendium” (scholarship of Germany) for three years. This educational scholarship initiated by the federal government focuses

on supporting new talents and encouraging top performance as well as fostering a new scholarship culture in Germany. Half of the funding

for the Deutschlandstipendium is provided by the government while the other half is covered by private support.

ALIUD PHARMA has supported the educational program “Klasse 2000” of a first grade of an elementary school as a mentor since the

beginning of the school year 2013/14. Its objective is to strengthen the health and life competences of elementary school-aged children in

order to counteract addiction and violence potential at an early stage. This allows children to get in touch with physical exercise, nutrition

and relaxation and handling feelings such as stress. They also learn about strategies for problem and conflict solution.

Social commitment of international STADA subsidiaries

In 2012, the Spanish STADA subsidiary Laboratorio STADA initiated the “kNOW Alzheimer” project in cooperation with Spanish specialist

institutions. The project’s particular goal is to expand research opportunities and to raise awareness of Alzheimer’s disease and thereby to

improve the situation for patients. On the occasion of World Alzheimer’s Day on September 21, a campaign to raise public attention to this

disease was launched. The challenge of the campaign, which has its own website and is also represented in social media, is to collect

800,000 statements – one for every Alzheimer patient in Spain.

In summer 2014, the Spanish sunscreen division Ladival® and the “Cruz Roja Española” (the Spanish Red Cross) donated sunscreen in

order to increase awareness of sufficient sun protection and to thereby counteract premature skin aging and severe skin diseases. The

cooperation took place on 245 beaches where more than 1,500 lifeguards benefited from the project.

Management Report of the Executive Board | Basis of the Group60

Since 2012, Ladival® has supported the “Carrera de la Mujer” in Spain, the largest European sporting event for women with more than

90,000 participants, as one of the main sponsors. The five to seven-kilometer race that is held in eight cities in Spain every year supports

the Spanish association the fight against cancer. In the scope of the events, Ladival® particularly emphasizes the necessity of the correct

use and an early start of sun protection.

Since autumn 2013, the Swiss subsidiary Spirig HealthCare AG has sponsored the foundation “aha! Allergiezentrum Schweiz” – a patients’

organization that provides advice and help to people with allergies, asthma, neurodermatitis and food intolerances. In line with the goal of

increasing the affected patients’ standards of living, they are offered various information through the website, guides and seminars.

In 2011, the Russian Holding STADA CIS initiated the project “Medicine for life”, which aims to raise awareness of health care among

Russian citizens and to provide them with basic information on the use of medicines. Alongside brochures, its own radio programs, social

media activities and media events, the website which provides clear information on different topics was updated in 2014.

STADA CIS also got involved socially at a regional level in 2014. The Russian STADA subsidiary Nizhpharm, for example, became actively

involved as co-organizer at the award for the most popular doctors by the citizens of the Nizhny Novgorod region, which, among other things,

aims to promote the doctors’ positive image. Furthermore, STADA CIS supported children that suffer from leukemia and rheumatic diseases,

as well as those who have critical family backgrounds or have grown up in orphanages.

On the occasion of the 95th anniversary of the Nizhpharm subsidiary, STADA CIS organized the project “Mobile Diagnostics: Get Your Health

under Control” in September 2014. The project draws attention to non-infectious chronic diseases in particular that, statistically speaking,

make up more than 80% of all cases of work incapacity and mortality in Russia. The people were given the opportunity to be checked by

more than 50 leading specialists of the most diverse medical fields in regional hospitals and mobile medical centers. In the scope of this

thorough health check, 2,000 people from 31 districts of Nizhny Novgorod, including areas in which medical help is hard to find, were

examined within ten days. Among others, cases of high blood pressure, thyroids diseases, diabetes or vascular symptoms were diagnosed.

Depending on the disease, the patients were admitted to hospital for treatment or received corresponding health tips.

Furthermore, STADA CIS is actively involved in areas related to the pharmaceutical industry. The third edition of a photo book of “Profession

of a Doctor”, a photography project initiated by STADA, has now published. It shows around one hundred doctors from different Russian

cities who present their jobs in descriptive photographs. The objective is, on the one hand, to foster trust in the services that doctors provide

and, on the other, to encourage the public to have regular preventative check-ups.

The Serbian STADA subsidiary Hemofarm initiated numerous sustainable projects to support social issues in cooperation with the Hemofarm

Foundation. Apart from the above mentioned financial and human aid during the Balkan flood, Hemofarm donated, among other things,

medical equipment for anesthesia and intensive-care medicine as well as for gynecology and obstetrics to several hospitals in financial year

2014. In addition, Serbian institutions in need, e.g. schools and social clubs, received financial donations or donations in kind. The sports

events supported by the Serbian organization in 2014 comprised the Serbian championship of sports for people with disabilities and the

27th Belgrad Marathon. In the area of culture, Hemofarm provided, among other things, support for young pianists from Serbia in an

international competition and a national choir festival in Belgrade. Additionally, Hemofarm was the foundation partner of the 2014 Serbinale,

a festival for young Serbian artists living in Berlin. This enables, among other things, the merging of Serbian and German talents of the most

diverse arts. Furthermore, Hemofarm was actively involved in the field of education. Biology students from Belgrade thus received financial

support for the organization of their European winter conference and primary school pupils were able to participate in a quiz contest that

draws attention to young people’s risk of addiction.

Management Report of the Executive Board61

In addition, in cooperation with UNICEF Serbia, the Hemofarm Foundation conducted the study “Happiness and Families with Children in

Serbia”, which reveals that strong families are the most important factor of happiness. The conclusion is based on the finding that functions

and customs of families, the way of raising children and the strong bond with the close and wider social environment are the key to

happiness. The study aims to motivate Serbian families to treat each other with respect, to solve conflicts peacefully and to spend time with

their children. The project is accompanied by a media campaign, workshops and several family activities.

The STADA subsidiaries in the market region Asia & Pacific are socially engaged in various projects, too. In 2014, for example, some health

controls were organized in various parts of Vietnam, particularly in remote parts of the country and areas that are difficult to access. This

way, many children and people in need were provided with health care they otherwise had not been able to receive due to the lack of doctors

and medication. Apart from supporting several conferences that were conducted by hospitals and research institutes, STADA Vietnam

sponsored the organization of the Vietnam Doctors’ Day in February 2014 and the Children’s Day in June 2014. Furthermore, STADA

Vietnam got actively involved in the form of making monetary donations and donations in kind for hospitals and institutes for children,

disabled and elderly people. In 2014, the Vietnamese STADA subsidiary Pymepharco also supported social projects. In this context, poor or

disabled people, orphans and people in difficult life situations received, among other things, donations in kind in the form of medicine.

Further information on the social engagement of STADA and its subsidiaries is provided on the Company’s website at www.stada.de or

www.stada.com.

Responsible action for the environment

STADA also pursues responsible action in the area of environmental protection and continuously strives to improve procedures and

processes in order to conserve resources and minimize negative environmental effects and health risks. In this context, STADA’s production

processes are generally characterized by no or very little emissions as the Group intentionally forgoes the chemical synthesis of active

ingredients and auxiliary materials. Furthermore, STADA’s business model, which focuses on long-standing and proven active ingredients,

requires no types of genetic research with embryos.

The Group also promotes the environmental awareness of its employees. For example, STADA reimburses travel costs when using public

transportation and subsidizes car pools among employees.

Compliance system in the STADA Group

Compliance, or the adherence to laws and internal regulations, has been a fixed component of the STADA Group for many years. Detailed

information on compliance and the Code of Conduct at STADA can be found in the Management Report of this Annual Report in the chapter

“Corporate Governance Report”.

Management Report of the Executive Board | Basis of the Group62

ECONOMIC REPORT
General Economic and Industry-Specific Situation

Overall economic development

In 2014, the financial markets were characterized by uncertainty – particularly due to geopolitical developments in Eastern Europe and in

the Middle East. Additionally, the monetary policy decisions of the US American Federal Reserve, the European Central Bank (ECB) and

Russia’s central bank Rossii were noticeable. The oil price decreased significantly in the course of the year.

According to information from the International Monetary Fund (IMF), global economic output in 2014 increased by 3.3%.1) In the course of

this, the growth rates of the advanced countries at 1.8% and those of the emerging markets at 4.4% therefore slightly approached each

other.1) The economic output of the USA, the world’s largest economy, increased by 2.4%, while China’s economy grew by 7.4%.1) With

recorded growth of 0.8%, the EU countries returned to the growth path.1) While the gross domestic product (GDP) was positive in Germany

(1.5%), France (0.4%) and Spain (1.4%), it declined slightly in Italy (-0.4%).1) GDP in the so-called CIS countries (Commonwealth of

Independent States) grew by 0.9%, while Russia recorded a slight increase of 0.6%. The Emerging and Developing Europe2) region grew by

2.7%, while economic output in Serbia3) decreased slightly by 0.5%.

Industry-specific development

Sales in the global generics market increased by approx. 9.9%4) to approx. € 116.6 billion4) in 2014 as compared to the previous year.

The market share of generics in the global pharmaceutical market amounted to approx. 13.6%4). The sales development of generics in the

four STADA market regions in the same period was as follows: Germany approx. +6.3%5) to approx. € 6.28 billion5), Central Europe approx.

+3.9%5) to approx. € 23.10 billion5), CIS / Eastern Europe approx. +9.0%5) to approx. € 6.10 billion5), Asia & Pacific approx. +7.5%5) 6) to

approx. € 8.14 billion5) 6).

Sales of the global OTC market increased by approx. 4.6%7) to approx. € 62.60 billion7) as compared to the previous year. The market share

of OTC products amounted to approx. 8.2%7). The sales development of OTC products in the four STADA market regions in the same period

was as follows: Germany approx. +1.5%5) to approx. € 4.82 billion5), Central Europe approx. -1.4%5) to approx. € 11.40 billion5), CIS / Eastern

Europe approx. +6.0%5) to approx. € 5.44 billion5), Asia & Pacific approx. +5.6%5) 6) to approx. € 3.97 billion5) 6).

1) Source: International Monetary Fund: World Economic Outlook January 2015.
2) Including Bulgaria, Croatia, Lithuania, Poland, Romania, Serbia, Turkey and Hungary.
3) Source: International Monetary Fund: World Economic Outlook October 2014.
4) IMS Market Prognosis, September 2014; IMS Market Prognosis Global, September 2014; IMS Syndicated
Analytics Service (September) 2014; prepared for STADA February 2015.
5) IMS MIDAS (September) 2014, data based on the definition of STADA market regions.
6) Asia & Pacific excluding China.
7) IMS MIDAS (September) 2014.

Management Report of the Executive Board63

Effects of overall economic and industry-specific framework conditions

As the business model of STADA is oriented toward the health care market, where demand is relatively independent of the economy, the

international economic framework conditions generally have less of a direct influence on the business development of the Group than the

respective regulatory environment in the individual markets of the four STADA market regions.

Nevertheless, the economic framework conditions do have an influence on the Group’s business development because they are character-

ized by currency and interest rate fluctuation. Therefore, STADA regularly takes precautionary measures in order to react appropriately to

strong volatility in interest rates and Group-relevant currency relationships (see “Risk Report” as well as Notes to the Consolidated Financial

Statements – 46.). Furthermore, the economic influences have a stronger effect on the Group in the markets belonging to the so-called

self-pay markets, since the demand for STADA products, to a certain extent, depends on the financial means of the respective patients.

Depending on the respective economic development, there is also a more or less strong cost pressure in the individual health care systems

that can also have curbing effects on generics suppliers as a result of corresponding regulatory measures. Furthermore, macroeconomic

influences can directly affect STADA’s development, if individual state health care systems no longer have sufficient funds to finance

adequate health care for their people.

With a view to the currency effects in financial year 2014, an uneven development can be seen regarding translation of sales and earnings

in the national currencies most important for STADA of the Russian ruble, Serbian dinar and the pound sterling. Whereas the Russian ruble

showed significantly weaker and the Serbian dinar showed weaker development, the British pound sterling had a positive currency effect.

In addition, the Ukrainian hryvnia showed significantly weaker development. The currency relationships in other countries relevant for STADA

only had a small influence on the translation of sales and earnings in local currencies into the Group currency euro.

In view of the self-pay markets, the business development in the market region CIS / Eastern Europe – especially in Russia – was affected

by the CIS crisis in the reporting year. In addition to the above mentioned significantly weaker exchange rate, a reluctance to buy was noted

among end consumers through whom approx. 92% of STADA’s sales in Russia is generated. Furthermore, this development was also

influenced by a reduction in demand on the part of wholesalers.

Management Report of the Executive Board | Economic Report
64

Business Development and Situation | Development of 2014 Compared to Outlook

In the outlook for 2014, the Executive Board had envisaged slight growth in Group sales, adjusted EBIDTA and adjusted net income in the

Prognosis Report of the Annual Report 2013. In this context, the Executive Board had expected slight growth in sales in the core segment

Generics and significant growth in sales in the core segment Branded Products. Additionally, the core segment Generics was expected to

generate an adjusted EBITDA slightly above the level of financial year 2013. The core segment Branded Products was expected to generate

a significantly increased adjusted EBITDA as compared to the previous year. The Executive Board had aimed for a net debt to adjusted

EBITDA ratio at a level of 3 – whereby the outlook of this key figure was slightly adjusted to a level of nearly 3 in the Interim Report on the

First Nine Months of 2014.

Group sales in the reporting year increased, with varying developments in the individual market regions, by 3% to € 2,062.2 million. Sales

of the core segment Generics decreased, contrary to the Executive Board’s expectation, slightly by 1% to € 1,217.7 million. On the one

hand, this development was based on the difficult local framework conditions for generics in Germany as a result of intensive competition

for tenders for discount agreements. On the other, the significant weakness of the ruble, a reluctance to buy among end consumers and a

decrease in demand from wholesalers as a consequence of the CIS crisis had a noticeable curbing effect in Russia. Sales in the core

segment Branded Products increased significantly by 14% to € 800.5 million. Adjusted EBITDA grew by 4% to € 431.9 million, while

adjusted EBITDA of the core segment Generics increased by 7% to € 228.7 million. Adjusted EBITDA of the core segment Branded Products

increased by 7% to € 240.0 million. Adjusted net income increased substantially by 16% to € 186.2 million. The net debt to adjusted

EBITDA ratio improved to 3.1.

Management Report of the Executive Board
65

Business Development and Situation | Development of Performance Indicators

The development of the STADA Group’s financial performance indicators in financial year 2014 was as follows:

Financial performance indicators of the STADA Group

in € million

Group sales

• Generics

• Branded Products

Adjusted EBITDA

• Generics

• Branded Products

Adjusted net income

Net debt to adjusted EBITDA ratio

2014

2,062.2

1,217.7

800.5

431.9

228.7

240.0

186.2

3.1

20131)

2,003.9

1,227.9

704.4

414.3

213.4

225.1

160.6

3.2

±%

+3%

-1%

+14%

+4%

+7%

+16%

-3%

Further details on the development of STADA’s financial performance indicators can be found in the following information on the earnings

situation.

Non-financial performance indicators of the STADA Group

With regard to the non-financial performance indicators, please refer to the chapter “Responsibility and Sustainability” in this Annual Report.

Management Report of the Executive Board | Economic Report66

Business Development and Situation | Earnings Situation
Development of Sales

Increase in Group sales despite challenging framework conditions in two out of four

market regions

Group sales in € million
over 5 years

Despite challenging framework conditions and with mixed development in the individual

market regions, Group sales increased by 3% in the reporting year to € 2,062.2 million

(previous year1): € 2,003.9 million).

When effects on sales attributable to changes in the Group portfolio and currency effects are

deducted, Group sales increased slightly by 1% to € 2,014.3 million in the reporting year.

In 2014, portfolio changes amounted to a total of € 139.2 million or 6.9 percentage points

which are divided among the affected market regions as follows: market region Central Europe

€ 65.6 million, market region CIS / Eastern Europe € 40.9 million, market region Asia & Pacific

€ 32.7 million.

2
6
0
2

9
3
0
0

7
3
8
1

5
1
7
1

0
7
2
6

In detail, the effects on sales, which can be attributed to changes in the Group portfolio and

currency effects, were as follows:

20102) 20112) 20122) 20132)

2014

As a result of applying foreign exchange rates from the reporting year compared with the

previous year for the translation of local sales contributions into the Group currency euro,

STADA recorded a negative currency effect for Group sales in the amount of € 91.9 million or -4.6 percentage points because the develop-

ment of two of the three most important national currencies for STADA was weaker as compared to the Group currency euro. In this context,

the development of the Russian ruble was significantly weaker and the development of the Serbian dinar was weaker. However, the Group’s

third most important national currency, the pound sterling, recorded a positive currency effect. Furthermore, the development of the

Ukrainian hryvnia was significantly weaker as compared to the euro. The currency relationships in other countries relevant for STADA only

had a small influence on the translation of sales and earnings in local currencies into the Group currency euro.

To the extent that adjusted sales figures are reported in this Annual Report, this refers to sales adjusted for portfolio effects and currency

fluctuations respectively.

1) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.).
2) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.). For
reasons of the practicability caveat as specified under IAS 8.43 ff., the previous year figures for financial year
2012 and earlier were not adjusted.

Management Report of the Executive Board67

Business Development and Situation | Earnings Situation
Development of Earnings and Costs

Adjusted EBITDA
in € million

Adjusted EBIT
in € million

Adjusted net income
in € million

1
3
4

3
4
1
4

4
2
2
3

1
7
0
3

0
7
2

7
8
5
2

6
9
3
2

7
6
3

2
7
3
3

9
5
1
3

2
6
8
1

6
0
6
1

6
4
1

7
4
1

3
3
3
1

20101) 20111) 20121) 20131)

2014

20101) 20111) 20121) 20131)

2014

2010

2011

2012

2013

2014

Growth in operating performance – increase in all of the Group’s adjusted key earnings figures

The earnings development in the reporting year was characterized by an increase in operating performance as shown by growth in all of the

Group’s adjusted key earnings figures.

In 2014, reported operating profit decreased significantly by 24% to € 188.5 million (previous year2): € 248.3 million), mainly due to impair-

ments on goodwill in the market regions CIS / Eastern Europe and Asia / Pacific & MENA. Reported EBITDA increased by 9% to € 418.8 mil-

lion (previous year2): € 382.6 million). In view of high burdening one-time special effects, reported net income recorded a substantial

decrease of 47% to € 64.6 million (previous year: € 121.4 million).

After adjusting the key earnings figures for influences distorting the period comparison resulting from one-time special effects, adjusted

operating profit increased by 6% in financial year 2014 to € 320.7 million (previous year2): € 303.1 million). Adjusted EBITDA recorded

growth of 4% to € 431.9 million (previous year2): € 414.3 million). Net income, adjusted for one-time special effects and effects from the

measurement of derivative financial instruments under financial income and expenses, increased by a substantial 16% to € 186.2 million

(previous year: € 160.6 million).

1) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.). For
reasons of the practicability caveat as specified under IAS 8.43 ff., the previous year figures for financial year
2012 and earlier were not adjusted.
2) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.).

Management Report of the Executive Board | Economic Report
68

The disproportionate increase of adjusted net income could primarily be attributed to a substantial reduction of the adjusted tax rate as of

the first quarter of 2014. This development results from a changed profit allocation in the STADA Group, which has been primarily influenced

by the successful conclusion of the “STADA – build the future” project at the end of financial year 2013 and a connected adjustment of the

internal transfer pricing model.

In view of this, the adjusted tax rate in financial year 2014 decreased to 24.2% as compared to the previous year (previous year1): 32.7%).

The reported tax rate rose to 43.8% as compared to the previous year primarily as a result of impairments on goodwill not deductible for

tax purposes in the market regions CIS / Eastern Europe and Asia / Pacific & MENA (previous year1): 35.1%).

Influence on earnings due to one-time special effects

One-time special effects amounted to a net burden on earnings of € 132.2 million before or € 125.2 million after taxes in the reporting

year (previous year: net burden on earnings due to one-time special effects in the amount of € 54.8 million before or € 41.7 million

after taxes).

In detail, these were as follows:

• a burden in the amount of € 59.8 million before or € 59.8 million after taxes from impairments on goodwill

• a burden in the amount of € 45.8 million before or € 41.5 million after taxes in connection with impairments of further intangible assets

following impairment tests including the market region CIS / Eastern Europe

• a burden in the amount of € 25.0 million before or € 20.7 million after taxes in connection with currency translation expenses

recorded in the income statement resulting from the fluctuation of the Russian ruble as well as further significant currencies of the

market region CIS / Eastern Europe

• a burden in the amount of € 10.9 million before or € 10.6 million after taxes resulting from additional scheduled depreciation and other

measurement effects due to purchase price allocations as well as significant product acquisitions taking financial year 2013 as a basis

• a net relief in the amount of € 9.3 million before or € 7.4 million after taxes from several extraordinary expenses and income, among

other things, for payments made and received in connection with damage claims

Influence on earnings due to effects from the measurement of derivative financial instruments under

financial income and expenses

Effects from the measurement of derivative financial instruments under financial income and expenses amounted to a net relief

on earnings of € 3.6 million before or € 3.6 million after taxes in 2014 (previous year: net relief on earnings from effects from the measure-

ment of derivative financial instruments under financial income and expenses of € 3.4 million before or € 2.5 million after taxes).

To the extent that adjusted key earning figures are reported in this Annual Report, the earnings adjustments carried out include these effects

in total both for the reporting year as well as for the previous year. The deduction of such effects, which have an impact on the presentation

of the earnings situation and the derived key figures, aims at improving the comparability of key figures with previous years. To achieve this,

STADA uses adjusted key figures, which, as so called pro forma figures, are not governed by the accounting requirements in accordance

with IFRS. As other companies may not calculate the pro forma figures presented by STADA in the same way, STADA’s pro forma figures

are only comparable with similarly designated disclosures by other companies to a limited extent.

Management Report of the Executive BoardIn the charts below, further essential key earnings figures of the STADA Group as well as the resulting margins are each also reported

adjusted for the aforementioned one-time special effects or for the aforementioned one-time special effects and effects from the measure-

ment of derivative financial instruments under financial income and expenses for financial year 2014 and for the previous year to allow for

comparison.

Development of the STADA Group’s reported key earnings figures

in € million

Operating profit

• Operating segment result Generics

• Operating segment result Branded Products

EBITDA3)

EBIT4)

EBT5)

Net income

Earnings per share in €

Diluted earnings per share in €

2014

188.5

108.3

138.2

418.8

190.3

124.7

64.6

1.07

1.05

Development of the STADA Group’s adjusted 6) key earnings figures

in € million

Operating profit, adjusted

• Operating segment result Generics, adjusted

• Operating segment result Branded Products,

adjusted

EBITDA 3), adjusted

• EBITDA Generics, adjusted

• EBITDA Branded Products, adjusted

EBIT 4), adjusted

EBT 5), adjusted

Net income, adjusted

Earnings per share in €, adjusted

Diluted earnings per share in €, adjusted

2014

320.7

176.9

192.9

431.9

228.7

240.0

322.4

253.3

186.2

3.08

3.04

20131)

± %

Margin2)
2014

Margin2)
20131)

248.3

154.4

160.2

382.6

252.4

189.3

121.4

2.04

2.00

20131)

303.1

165.5

173.5

414.3

213.4

225.1

307.1

240.7

160.6

2.70

2.65

-24%

-30%

-14%

+9%

-25%

-34%

-47%

-48%

± %

+6%

+7%

+11%

+4%

+7%

+5%

+16%

+14%

+15%

9.1%

8.9%

17.3%

20.3%

9.2%

6.0%

3.1%

12.4%

12.6%

22.7%

19.1%

12.6%

9.4%

6.1%

Margin 2)
2014

Margin 2)
20131)

15.6%

14.5%

24.4%

21.0%

18.8%

30.3%

15.7%

12.3%

9.1%

15.1%

13.5%

24.6%

20.7%

17.4%

32.0%

15.3%

12.0%

8.0%

4) Earnings before interest and taxes.
5) Earnings before taxes.
6) Adjusted for one-time special effects and from the measurement of derivative financial instruments under
financial income and expenses.

Management Report of the Executive Board | Economic Report

Income statement as well as cost development

The consolidated income statement is presented in the chart below – both for the reporting year and for the previous year, each under

consideration of the effects to be adjusted, which are accordingly presented for financial year 2014 in detail under the items “Influence on

earnings due to one-time special effects” and “Influence on earnings due to effects from the measurement of derivative financial instruments

under financial income and expenses”.

Income statement
(abridged)

in € 000s

Sales

Cost of sales

Gross profit

Selling expenses

General and administrative expenses

Research and development expenses

Other income

Other expenses

Expenses in connection with the
“STADA – build the future” project

Result from associated companies

Investment income

Earnings before
interest and taxes (EBIT)

Financial income

Financial expenses

Earnings before taxes (EBT)

Income taxes

Earnings after taxes

Result distributable to
non-controlling interests

Result distributable to shareholders of
STADA Arzneimittel AG (net income)

Earnings per share in €

Earnings per share in € (diluted)

2014
without
deduction of
effects to be
adjusted

2014
effects to be
adjusted

2014
after
deduction of
effects to be
adjusted

20131)
without
deduction of
effects to be
adjusted

2013
effects to be
adjusted

2,053,597

1,055,685

2,003,912

1,024,475

2,062,247

1,070,441

991,806

458,381

152,817

56,905

20,067

155,243

-8,650

14,756

6,106

-5,972

132,012

997,912

458,381

152,817

56,905

14,095

23,231

1,595

132

190,254

4,833

70,393

124,694

54,586

70,108

132,146

-3,588

128,558

-6,816

121,742

1,595

132

322,400

1,245

70,393

253,252

61,402

191,850

979,437

488,162

159,537

55,473

53,754

72,629

9,064

248,326

3,700

340

252,366

6,865

69,930

189,301

66,490

122,811

2013 1)
after
deduction of
effects to be
adjusted

2,005,712

1,023,301

982,411

485,811

156,089

55,350

53,208

35,260

303,109

3,700

340

307,149

3,484

69,930

240,703

78,693

162,010

1,800

1,174

2,974

2,351

3,448

123

-546

37,369

9,064

54,783

-3,381

51,402

-12,203

39,199

5,546

5,639

1,385

64,562

121,649

186,211

121,426

39,199

160,625

1.07

1.05

3.08

3.04

2.04

2.00

2.70

2.65

Operating profit

188,527

132,146

320,673

EBIT

190,254

132,146

322,400

252,366

54,783

307,149

Balance from depreciation and
amortization/write-ups on intangible
assets (including goodwill), property, plant
and equipment and financial assets

Earnings before interest, taxes,
depreciation and amortization
(EBITDA)

228,521

-119,033

109,488

130,193

-23,071

107,122

418,775

13,113

431,888

382,559

31,712

414,271

Management Report of the Executive Board

Cost of sales amounted to € 1,070.4 million in financial year 2014 (previous year1): € 1,024.5 million). Gross profit i.e. sales after deducting

cost of sales thus amounted to € 991.8 million (previous year1): € 979.4 million).

Overall, cost of sales in the reporting year included impairment, depreciation and amortization in the amount of € 100.8 million (previous

year1): € 86.3 million), which primarily related to amortization on such intangible assets, which re present a necessary condition for the

marketing of the products manufactured – in particular drug approvals.

The cost of sales ratio, i.e. the share of cost of sales in overall sales, was 51.9% in 2014 (previous year1): 51.1%). The sales-related gross

margin, which is reciprocal to the cost of sales ratio, decreased to 48.1% in the reporting year (previous year1): 48.9%). This development

was primarily attributable to two factors. On the one hand, the gross margin was burdened by additional impairments from acquisitions like

the British OTC supplier Thornton & Ross2), the purchase of the Russian branded product portfolio Aqualor® 3) as well as the control acquired

over STADA Vietnam (see partly “Financial Situation – Acquisitions and disposals”). On the other hand, the burdens in the context of the CIS

crisis were notable (see “Earnings Situation – Development of Segments – Development by Market Region – Russia”).

Selling expenses, which at STADA are predominantly composed of costs for sales force and sales department employees, as well as

product-related marketing expenditure, decreased in the reporting year to € 458.4 million (previous year1): € 488.2 million). The decline was

particularly attributable to high savings from the new sales agreement in Belgium as well as cost savings within the CIS subgroup, which

streamlined its marketing activities for the purpose of a stronger focus on high-margin products. The selling expenses ratio amounted to

22.2% (previous year1): 24.4%).

General and administrative expenses decreased to € 152.8 million in 2014 (previous year1): € 159.5 million) and had a share of 7.4%

of Group sales (previous year1): 8.0%). The decrease resulted from net earnings in the amount of € 15.9 million, mainly from past service

cost in connection with a change in the defined benefit plan for the Chairman of the Executive Board and the resulting changes with regard

to the benefits awarded according to the former benefit plan.

Research and development costs were at € 56.9 million in financial year 2014 (previous year1): € 55.5 million). The sales-related ratio of

research and development costs amounted to 2.8% (previous year1): 2.8%).

STADA’s reported development costs include the non-capitalizable development costs, which are primarily made up of costs associated with

regulatory requirements and the optimization of existing products. Payments in connection with the development of new products are not

included in this cost item, as they are usually capitalized by STADA (see Notes to the Consolidated Financial Statements – 15.).4)

Other income decreased in the reporting year to € 20.1 million (previous year1): € 53.8 million). The reduction was, among other things,

due to the fact that in the previous year this item included earnings from the revaluation of the shares in the Vietnamese pharmaceutical

company Pymepharco and STADA Vietnam in the context of achieving control. Furthermore, there was a negative difference in connection

with the acquirement of the British OTC supplier Thornton & Ross due to the purchase price allocation for this business combination in the

previous year.

1) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.).
2) See the Company’s ad hoc release of August 6, 2013 and ad hoc update of August 16, 2013.
3) See the Company’s ad hoc release of October 18, 2013.
4) In financial year 2014, development expenses for new products in the amount of € 27.5 million (previous
year: € 18.8 million) were capitalized.

Management Report of the Executive Board | Economic Report72

Other expenses increased in financial year 2014 to € 155.2 million (previous year1): € 72.6 million). This development resulted mainly from

the recognized impairments on goodwill in the market regions CIS / Eastern Europe and Asia / Pacific & MENA, as well as from the strong

devaluation of the significant currencies of the market region CIS / Eastern Europe and the resulting currency translation expenses, which

are reported as one-time special effects. In addition, increased impairments of intangible assets that were also reported as one-time special

effects resulted in a corresponding increase of other expenses.

Within the other remaining expenses, personnel expenses are recognized in the amount of € 5.8 million (previous year: € 9.4 million).

The decrease in the result from investments measured at equity to € 1.6 million (previous year1): € 3.7 million) in 2014 was due to the

retrospective accounting for the company STADA Vietnam according to the equity method in the previous year pursuant to the new standard

IFRS 11. In the context of achieving control over STADA Vietnam, the company has been consolidated as a subsidiary since the fourth

quarter of 2013.

The financial result, which is primarily made up of financial income and financial expenses, was € -63.8 million in financial year 2014

(previous year1): € -59.0 million). The interest expense in the amount of € 70.4 million (previous year1): € 69.9 million) represented the

largest single operational item. Furthermore, the financial result in the reporting year also included effects from the measurement of

derivative financial instruments that amounted to a net relief on earnings of € 3.6 million (previous year: relief on earnings of € 3.4 million).

In 2014, the Group refinanced itself at interest rates of between 0.9% p.a. and 12.0% p.a. (previous year: between 0.8% p.a. and 13.8%

p.a.). On the balance sheet date of December 31, 2014, the weighted average interest rate for non-current financial liabilities was approx.

3.3% p.a. (previous year: approx. 3.5% p.a.) and for current financial liabilities approx. 4.6% p.a. (previous year: approx. 2.1% p.a.). For all

of the Group’s financial liabilities the weighted average interest rate amounted to approx. 3.7% p.a. (previous year: approx. 3.3% p.a.).

Income tax expense decreased in the financial year to € 54.6 million (previous year1): € 66.5 million). This development results from a

changed profit allocation in the STADA Group, which has been primarily influenced by the successful conclusion of the “STADA – build the

future” project at the end of financial year 2013 and a connected adjustment of the internal transfer pricing model.

The adjusted tax rate decreased in the reporting year to 24.2% (previous year1): 32.7%). The reported tax rate rose to 43.8% in the same

period (previous year1): 35.1%) primarily as a result of impairments on goodwill not deductible for tax purposes in the market regions

CIS / Eastern Europe and Asia / Pacific & MENA.

Management Report of the Executive Board
73

Business Development and Situation | Earnings Situation
Development of Segments: Information by operating segment

Development of core segments

The information by operating segment, according to the definition of segment used by STADA, is divided according to differentiation

possibilities in terms of sales and is therefore separated into the core segments of Generics and Branded Products as well as the non-core

segment Commercial Business (see “Basis of the Group – Business Model”).

Sales of both core segments Generics and Branded Products increased by a total of 4% in the reporting year. They thus contributed a

total of 97.9% to Group sales (previous year1): 96.4%). Sales of the two core segments adjusted for portfolio effects and currency influences

increased slightly by 2% (see “Economic Report– Business Development and Situation – Earnings Situation – Sales Development”).

Sales of the core segment Generics decreased slightly by 1% in financial year 2014 to € 1,217.7 million (previous year1): € 1,227.9 mil-

lion). This reduction is primarily attributable to the development in the markets of Germany and Russia. Generics contributed 59.1% to

Group sales (previous year1): 61.3%). Adjusted, Generics sales was at the same level of the previous year (see “Economic Report – Business

Development and Situation – Earnings Situation – Sales Development”).

Top 5 generic active ingredients in products of the STADA Group 2014

Active ingredient

Indication group

Omeprazole

Diclofenac

Tilidine

Atorvastatin

Phospholipide

Total

Stomach medicine

Antirheumatic drug

Opioid

Antilipemic

Liver medicine

Sales 2014
for products of
the STADA Group
in € million

Change from
previous year

24.8

24.6

23.8

23.1

22.8

119.1

+10%

+2%

-1%

+13%

-27%

In 2014, STADA generated sales in the total of € 119.1 million with products containing the Group’s top five active pharmaceutical

ingredients in terms of sales (previous year: € 124.9 million). These products thereby generated 9.8% of sales in the Generics segment

(previous year1): 10.3%).

In the reporting year, the stomach medicine Omeprazole was the best-selling active pharmaceutical ingredient in the core segment Generics.

Management Report of the Executive Board | Economic Report

Sales of the core segment Branded Products in the reporting year recorded a significant growth of 14% to € 800.5 million (previous year1):

€ 704.4 million). Branded products thus contributed 38.8% to Group sales (previous year1): 35.2%). The adjusted sales of the Branded

Products segment increased significantly by 6% to € 747.6 million (previous year1): € 704.3 million) (see “Economic Report – Business

Development and Situation – Earnings Situation – Sales Development”).

Top 5 branded products in the STADA Group in 2014

Branded product

Indication group

APO-go®

Aqualor®

Grippostad®

Snup®

Ladival®

Total

Parkinson medicine

Cold medicine based on seawater

Cold medicine

Nasal preparation

Sunscreen

Sales 2014
in € million

Change from
previous year

51.3

40.3

33.7

33.0

26.1

184.4

+18%

-2)

-14%

+34%

+62%

With the top five branded products in the Group in term of sales, STADA achieved sales in the amount of € 184.4 million in financial year

2014 (previous year: € 154.7 million). These products thus contributed 23.0% to sales in the Branded Products segment (previous year1):

22.0%).

With sales in the amount of € 51.3 million (previous year: € 43.5 million) the Parkinson’s medicine APO-go® was the strongest selling

product in the reporting year both within the Branded Products core segment and in the Group as a whole.

Non-core activities to support core segments

In the Commercial Business segment, which is not part of the core segments, sales grew to € 44.0 million in 2014 (previous year1):

€ 41.0 million). This development is based for the most part on the purchase of the pharmaceutical wholesale and commercial business in

Switzerland that has been consolidated since March 1, 2013.

Sales reported under the position Group holding / other was at € 30.6 million in the previous year. This amount primarily resulted from a

sale with subsequent back-licensing in the previous year, in the context of which intangible assets had been sold and licensed back at the

same time for further utilization in sales. In the reporting year, no sales were recorded under this position.

Management Report of the Executive Board

Operating profit by segment

In financial year 2014, reported operating profit in the Generics segment decreased significantly by 30% to € 108.3 million (previous

year1): € 154.4 million). This development was particularly due to the impairments on goodwill in the market region CIS / Eastern Europe and

on further intangible assets. Reported operating profit in the Branded Products segment decreased by 14% to € 138.2 million (previous

year1): € 160.2 million), mainly due to impairments on goodwill in the market region Asia / Pacific & MENA and on further intangible assets,

mainly in the market region CIS / Eastern Europe. The reported operating profit margin of Generics amounted to 8.9% (previous year1):

12.6%). The reported operating profit margin of Branded Products was at 17.3% (previous year1): 22.7%).

Adjusted operating profit in the Generics segment grew in the reporting year by 7% to € 176.9 million (previous year1): € 165.5 million).

Adjusted EBITDA of Generics increased by 7% to € 228.7 million (previous year1): € 213.4 million). Both developments were particularly

attributable to high savings as a result of the new sales agreement in Belgium. The adjusted operating profit margin of Generics

amounted to 14.5% (previous year1): 13.5%).

Adjusted operating profit in the Branded Products segment increased by 11% to € 192.9 million in 2014 (previous year1): € 173.5 mil-

lion). Adjusted EBITDA of Branded Products recorded an increase of 7% to € 240.0 million (previous year1): € 225.1 million). Both

developments were mainly based on the share of profits of the British OTC supplier Thornton & Ross, which has been consolidated since

September 1, 2013. The adjusted operating profit margin of Branded Products amounted to 24.4% (previous year1): 24.6%).

Reported operating profit in the Commercial Business segment decreased slightly to € 0.9 million in financial year 2014 (previous

year1): € 1.3 million).

Management Report of the Executive Board | Economic Report76

Business Development and Situation | Earnings Situation
Development of Segments: Information by Market Region

Development of the market regions

In the STADA Group, information by market region is based on the regional differentiation in market regions. In this context, in the individual

market regions, all relevant net sales according to segment to third parties generated by consolidated Group companies are reported. The

STADA Group is composed of four market regions in total: Germany, Central Europe, CIS / Eastern Europe and Asia & Pacific.

As of financial year 2015, the former market region Asia & Pacific will be expanded by substantial parts of the business activities in the

Middle East and North Africa (MENA region). In doing so, the activities in this region, which used to be allocated to market region Germany,

should be largely centralized. Thus, the market region will be referred to as market region Asia / Pacific & MENA from 2015.

When looking to the reported sales of individual market regions, it should generally be taken into consideration that they are allocated to the

market region in which the sales company that generated the sales is located. Accordingly, sales of the individual market regions include

both the sales of the respective sales companies recorded within the country they are located in, as well as the export sales they achieve.

Management Report of the Executive Board77

Sales in 2014 by segments, market regions and markets in € million

in € million

Germany

• Germany

• Export sales of the

market region Germany

Generics

Branded
products

300.5

265.3

146.8

124.0

35.2

22.8

Central Europe

• Italy

• Belgium

• United Kingdom

• Spain

• France

• Switzerland

• The Netherlands

• Poland

• Ireland

• Denmark

• Other / rest of Central Europe

• Export sales of the

611.3

150.5

141.6

17.0

101.0

75.5

19.0

36.1

0.6

14.9

7.2

46.5

market region Central Europe

1.4

311.3

30.7

8.6

118.2

12.0

19.9

12.6

3.4

25.2

7.5

2.4

33.7

37.1

CIS / Eastern Europe

• Russia

• Serbia

• Ukraine

• Bosnia- Herzegovina

• Kazakhstan

• Other / rest of

CIS / Eastern Europe

•

Export sales
of the market region
CIS / Eastern Europe

Asia & Pacific

• Vietnam

• China

• The Philippines

• Thailand

• Other / rest of Asia & Pacific

• Export sales of the

market region Asia & Pacific

247.9

118.0

315.5

242.7

76.8

6.4

13.7

1.6

22.0

9.4

58.0

42.3

11.1

1.6

1.1

1.5

0.4

16.6

20.7

1.6

11.8

22.0

0.1

26.9

24.2

0.7

0.0

1.0

0.9

0.1

Reconcili-
ation
Group
holdings /
other

Commer-
cial
business

33.7

20.6

0.5

12.6

0.0

1.1

0.0

0.1

1.0

9.2

6.8

2.3

0.1

Total
sales
2014

447.3

389.3

Share
in Group
sales
2014

Total
sales
previous
year1)

21.7%

18.9%

454.1

420.2

± %2)

-1.5%

-7.4%

±%
adjusted

-1.5%

-7.4%

58.0

2.8%

33.9

+71.1%

956.3

181.2

150.2

135.2

113.0

95.4

52.2

39.5

25.8

22.9

22.2

80.2

46.4%

8.8%

7.3%

6.6%

5.5%

4.6%

2.5%

1.9%

1.3%

1.1%

3.9%

858.7

169.5

147.7

79.1

107.7

95.0

51.3

37.6

20.3

23.0

19.7

70.8

+11.4%

+6.9%

+1.7%

+70.9%

+4.9%

+0.4%

+1.8%

+5.1%

+3.0%

+3.6%

+1.6%

+6.7%

+4.5%

-1.0%

-6.4%

+4.3%

+27.1%

+25.8%

-0.4%

-6.4%

+12.7%

+11.7%

+13.3%

+13.1%

38.5

1.9%

37.0

+4.1%

-14.9%

564.5

360.7

93.4

27.1

15.4

13.4

27.4%

17.5%

4.5%

1.3%

0.7%

0.6%

629.2

418.8

86.0

36.7

13.9

21.3

-10.3%

-13.9%

-1.2%

-5.6%

+8.6%

+11.9%

-26.2%

+4.8%

+10.8%

+10.4%

-37.1%

-25.5%

45.0

2.2%

40.3

+11.7%

+24.7%

9.5

94.1

73.3

11.8

3.9

2.2

2.4

0.5

0.5%

4.5%

3.5%

0.6%

0.2%

0.1%

0.0%

12.2

61.9

52.3

2.7

2.6

2.5

1.5

-22.1%

-19.6%

+52.0%

+40.2%

-0.4%

-1.3%

>100%

-36.0%

+50.0%

+55.4%

-12.0%

-9.4%

+60.0%

+15.9%

0.3

+66.7%

-8.3%

Management Report of the Executive Board | Economic Report

The following describes the development of STADA’s four market regions Germany, Central Europe, CIS / Eastern Europe and Asia & Pacific

in financial year 2014. Furthermore, within these market regions, development of the most important countries according to sales within

these market regions is also described.

Market region Germany

In the market region Germany, sales in the reporting year decreased by 2% to € 447.3 million (previous year: € 454.1 million). This

development was due to various effects. While sales generated in the Generics segment in this market region were at the level of the pre-

vious year due to an increase in export sales, a significant increase in sales was recorded in the Branded Products segment. In opposition,

the sale of intangible assets with subsequent back-licensing for further utilization in sales, which was carried out in the previous year, can

be seen in the sales of this market region. In the previous year, these sales were reported outside the operating segments under “Group

holdings / other”. Overall, this market region thus contributed 21.7% to Group sales (previous year1): 22.6%). Of the sales generated by the

market region Germany, € 58.0 million was attributable to export sales (previous year: € 33.9 million). Adjusted sales in this market region

decreased slightly by 2%.

Sales generated in Germany, i.e. sales excluding export sales of the market region Germany and excluding sales of other market regions

in Germany, decreased by 7% to € 389.3 million in 2014 (previous year: € 420.2 million).

The sales development reported in the German market was still attributable to the difficult local framework conditions for generics, which

stem from the intensive competition in tenders for discount agreements from public health insurance organizations. As a result, sales in the

German Generics segment in the reporting year decreased by 5% to € 265.3 million (previous year: € 278.9 million). Sales generated in

Germany with generics had a share of 68% in the overall sales achieved in the German market (previous year: 66%). In 2014, the market

share of generics sold in German pharmacies was slightly above the level of the previous year by volume with approx. 13.7%2) (previous

year: approx. 13.5%2)). Despite the development in the reporting year in the Generics segment in Germany, the STADA Group remains the

clear number 32) in the German generics market.

Sales of generics in Germany are almost exclusively generated with the sales companies ALIUD PHARMA GmbH, STADApharm GmbH and

cell pharm Gesellschaft für pharmazeutische und diagnostische Präparate mbH. Sales of the generics sales company cell pharm, a special

supplier for the indication areas oncology and nephrology, which are included in these figures, decreased in the reporting year by 8% to

€ 30.7 million (previous year: € 33.3 million).

Due to the increasingly difficult framework conditions in the German generics market in financial year 2014, it has been decided that now

only one of the previous two German subsidiaries will take part in tenders for discount agreements. Therefore, only ALIUD PHARMA shall

make bids in the context of these tenders whereas STADApharm has discontinued the submission of bids. Previously concluded contracts,

some of which continue until 2017, will still be fulfilled by STADApharm. With this step, the Group is following the longstanding and

communicated decision to always participate in German tenders for discount agreements following the primary objective of appropriate

operating profitability.

In 2014, STADA signed a letter of intent for handing the German logistics activities over to the global leading logistics company DHL.3) The

associated partial transfer of operations comprises the STADA logistics activities at the Florstadt and Bad Vilbel locations with approx.

160 employees. On the one hand, in light of increasing cost pressure in Germany and STADApharm’s corresponding withdrawal from the

tender business, the need for logistics services had changed in course of the reporting year. On the other hand, the Group needs to focus

increasingly on its core business in order to strengthen its competitiveness. In the current first quarter 2015, the contract for the transfer of

the German logistics activities was signed.4)

1) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.).
2) Data from IMS Health based on pharmacy sales to customers (source: IMS/Pharmascope national).
3) See the Company’s press release of October 10, 2014.
4) See the Company’s press release of March 23, 2015.

Management Report of the Executive Board79

Back in the fourth quarter of 2013, STADA had announced the optimization of the German sales activities and the foundation of STADAvita

GmbH.1) As a result, STADAvita took over from the beginning of 2014 the sales of preventative branded products, nutritional supplements

as well as plant-based products.

Sales generated with branded products in the German market – primarily with the two sales companies STADA GmbH, Bad Vilbel, and

STADAvita, Bad Homburg – increased substantially in financial year 2014 by 12% to € 124.0 million (previous year: € 110.7 million). Over-

all, the share of branded products in Germany amounted to 32% of the total sales achieved in the German market (previous year: 26%).

In the reporting year, important branded products of STADA continued to be counted as market leaders in their corresponding market

segments in the German pharmacy market. Examples for this are the cold medicine Grippostad® C with sales in Germany of € 33.9 million

(previous year: € 36.7 million) and a market share of approx. 32% in the market for flu drugs2) 3) as well as STADA’s sunscreen portfolio

under the brand Ladival® with sales in Germany of € 27.3 million4) (previous year: € 28.7 million4)). It clearly remains market leader in the

pharmacy market for sunscreens4) with a market share of approx. 36%4).

For financial year 2015, the Executive Board expects sales in the market region Germany to be below the level of the previous year with

operating profitability under Group average.

Market region Central Europe

In the market region Central Europe, sales in financial year 2014 increased significantly by 11% to € 956.3 million (previous year:

€ 858.7 million). This pleasing development is especially attributable to sales growth in the United Kingdom – predominantly due to the

purchase of the British OTC supplier Thornton & Ross –, as well as in Italy, in Belgium and in Spain, and took place despite a high

com parable basis of the previous year. Sales generated in this market region had a share of 46.4% of Group sales (previous year5): 42.9%).

Of the sales generated by market region Central Europe, € 38.5 million were attributable to export sales (previous year: € 37.0 million).

Adjusted sales in this market region increased by 3%.

The Executive Board expects growth in sales for financial year 2015 with operating profitability at Group average in the market region

Central Europe.

The countries of market region Central Europe saw varying developments in the reporting year. The development of business in the five

largest markets according to sales within this market region is described in detail below.

Sales generated in Italy increased by 7% to € 181.2 million in 2014 (previous year: € 169.5 million) and is attributable to continued positive

regulatory framework conditions. This positive development was visible both in the Generics as well as the Branded Products segment.

Sales generated in the Italian market with generics increased by 5% to € 150.5 million despite the high level of the previous year (previous

year: € 143.6 million). Generics contributed 83% to local sales (previous year: 85%). With a market share of approx. 14.8% (previous year:

approx. 14.6%), STADA occupied position 5 in the Italian generics market in financial year 2014.6)

Sales achieved in the Italian market with branded products rose significantly by 19% to € 30.7 million (previous year: € 25.9 million). The

share of branded products in Italian sales was at 17% (previous year: 15%).

1) See the Company’s press release of October 1, 2013.
2) Excluding anti-infective agents.
3) Data from IMS Health based on pharmacy sales to customers (source: IMS/Pharmascope national).
4) STADA estimate at pharmacy retail prices based on data from IMS Health.
5) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.).
6) STADA estimate based on IMS Health data at ex-factory prices.

Management Report of the Executive Board | Economic Report80

In Belgium, sales increased in financial year 2014 by 2% to € 150.2 million (previous year: € 147.7 million).

Sales recorded in the Belgian market with generics rose slightly by 1% to € 141.6 million (previous year: € 140.1 million). The increase

primarily resulted from strong growth in volume. Generics contributed 94% to local sales (previous year: 95%). With a market share of

approx. 50.0% (previous year: approx. 49.9%), STADA remained the clear market leader in the Belgian generics market in 2014.1)

Sales achieved in Belgium with branded products rose substantially by 13% to € 8.6 million (previous year: € 7.6 million). Branded products

contributed 6% to sales in Belgium (previous year: 5%).

Sales generated in the United Kingdom in the reporting year increased substantially applying the exchange rates of the previous year by

65%. In euro, sales rose even more significantly by 71% to € 135.2 million due to a positive currency effect of the pound sterling (previous

year: € 79.1 million). This pleasing development was primarily attributable to the consolidation of the British OTC supplier Thornton & Ross.

Adjusted, sales increased by 7% to € 84.3 million.

Sales generated with branded products in the British market recorded substantial growth of 73% to € 118.2 million (previous year:

€ 68.2 million). Branded products thereby contributed 87% to sales generated in the United Kingdom (previous year: 86%).

Sales of generics in the United Kingdom, where STADA continues to be a niche provider of selected generics with only a few active

pharmaceutical ingredients, grew despite heavy competition by a strong 56% to € 17.0 million (previous year: € 10.9 million). Generics

contributed 13% to local sales (previous year: 14%).

Back in the fourth quarter of 2013, the Group implemented a restructuring under company law in the United Kingdom, transferring the

shares in the two local sales companies Genus Pharmaceuticals Ltd. and Britannia Pharmaceuticals Ltd. to STADA UK Holdings Ltd.

With effect from January 1, 2014, this was followed by a fundamental restructuring of sales responsibilities and a stronger pooling of

competencies for the overall product portfolio of the British companies. In this context, a major portion of the branded products and the

generics portfolio of Genus Pharmaceuticals were transferred to Thornton & Ross, and Britannia Pharmaceuticals took over global sales

responsibility for the Parkinson’s medication APO-go®.

In order to strengthen the branded products sold by Thornton & Ross, the British STADA subsidiary in the second quarter of 2014 acquired

the production and distribution rights for the branded product portfolio Flexitol® 2) for the United Kingdom and Ireland3) (see “Economic Report

– Business Development and Situation – Financial Situation”).

Furthermore, STADA UK Holdings acquired the British company Internis in the fourth quarter of 2014, which is active in the prescription area

of therapeutic treatment of vitamin D3 deficiency and which has been consolidated in the STADA Group since December 19, 2014 (see

“Economic Report – Business Development and Situation – Financial Situation”).

In Spain, sales recorded a rise – despite ongoing high price competition and continued tender processes in Andalusia – of 5% to

€ 113.0 million in the reporting year (previous year: € 107.7 million). This was a result of unchanged strong volume growth both in the

Generics and the Branded Products segments.

Sales generated with generics in the Spanish market rose by 4% to € 101.0 million (previous year: € 97.2 million). Generics contributed

89% to local sales (previous year: 90%). With a market share of approx. 9.4% (previous year: approx. 9.3%), STADA occupied position 2 in

the Spanish generics market in financial year 2014, representing a significant improvement as compared to the previous year.1)

1) STADA estimate based on IMS Health data at ex-factory prices.
2) Dermatological range in the area of hand and foot care.
3) See the Company’s press release of June 30, 2014.

Management Report of the Executive Board81

Sales achieved with branded products in Spain recorded substantial growth of 14% to € 12.0 million (previous year: € 10.5 million).

Branded products contributed 11% to local sales (previous year: 10%).

In France, sales were slightly above the level of the previous year in 2014 with € 95.4 million (previous year: € 95.0 million).

Sales recorded in the French market with generics declined by 10% to € 75.5 million (previous year: € 84.3 million). In addition to the high

comparable basis of the previous year, this development was a result of strong price competition. This was especially attributable to a

fundamental regulatory change in the form of a decrease in reference prices as of September 1, 2014, which came in connection with a

significant increase of the highest possible discount in the French generics market. The maximum permitted discount amount was

substantially increased which in turn detracted from the development of sales. Overall, a general sales decrease can be observed in the

French generics market, which appears to continue in the coming months. Generics contributed 79% to local sales (pre vious year: 89%).

With a market share of approx. 3.5% (previous year: 3.5%), STADA occupied position 7 in the French generics market in financial year

2014.1)

Sales achieved with branded products in France, however, recorded a substantial rise of 86% to € 19.9 million (previous year: € 10.7 mil-

lion). Branded products contributed 21% to sales in France (previous year: 11%). This development was mainly based on the sale of

approvals and trademarks.

Market region CIS / Eastern Europe

In the market region CIS / Eastern Europe2), sales in financial year 2014 increased applying the exchange rates of the previous year,

by 5%. In euro, sales recorded a decrease of 10% to € 564.5 million as a result of negative currency effects (previous year: € 629.2 million).

Sales generated in this market region thus had a share of 27.4% of Group sales (previous year3): 31.4%). Of the sales generated by the

market region CIS / Eastern Europe, € 9.5 million was attributable to export sales (previous year: € 12.2 million). Sales adjusted for portfolio

and currency effects in this market region decreased by 1%.

For financial year 2015, applying the exchange rates of the previous year, the Executive Board expects growth in sales in the market region

CIS / Eastern Europe, also taking consideration of the acquisition of the Russian branded product portfolio Aqualor® and the consolidation of

the resulting sales as from March 1, 2014. Operating profitability adjusted for negative currency effects is expected to be above Group

average.

The development of business in the two largest markets according to sales within this market region is described below.

In Russia, sales increased in the reporting year by 4% applying the exchange rates of the previous year. As a result of a clearly negative

currency effect of the Russian ruble, sales strongly decreased in euro by 14% to € 360.7 million (previous year: € 418.8 million). The sales

decrease was primarily attributable to three factors. In addition to a substantially weaker exchange rate as compared to the previous year,

a reluctance to buy was noted among end consumers through whom approx. 92% of STADA’s sales in Russia is generated. Furthermore,

the development was influenced by a reduction in demand on the part of wholesalers. In the context of the state program for the reimburse-

ment of selected medicines for individual population groups (DLO Program), which is no longer in the focus of the sales strategy due to

continuously decreasing margins, approx. 5% of Russian sales were recorded in 2014. In addition, approx. 3% of sales were generated

directly or indirectly with other state clients, primarily via tenders. In the context of tenders, the decreased demand for medicines to treat

HIV illnesses as a result of declining hospital budgets also had a small share in the sales decrease.

1) STADA estimate based on IMS Health data at ex-factory prices.
2) So-called CEE countries (Central and Eastern Europe) including Russia.
3) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statement – 3.).

Management Report of the Executive Board | Economic Report82

Sales generated with generics in the Russian market declined by 29% to € 118.0 million (previous year: € 166.5 million). Generics

contributed 33% to local sales (previous year: 40%). With a market share of approx. 5.1% (previous year: approx. 4.7%), STADA took

position 2 in the Russian market in 2014.1)

Sales recorded in Russia with branded products declined by 4% to € 242.7 million (previous year: € 252.3 million). Branded products had

a share in sales of 67% in the Russian market (previous year: 60%).

The sales and earnings contributions of Russian business activities will continue to be affected by development of the currency relation of

the Russian ruble to the euro in the future. In addition, the increasingly bleak prospects for the Russian economy and the corresponding

strong devaluation of the Russian ruble present an increased risk in terms of consumer sentiment and consumer spending.

In order to further strengthen the Russian business activities, the Russian STADA subsidiary Nizhpharm purchased the Russian branded

product portfolio Aqualor®, which comprises ten prescription-free (OTC) product presentations based on seawater in the form of sprays and

drops with the local regulatory status of medical products for the treatment of sinusitis (infection of the paranasal sinus) and sore throat as

planned in the first quarter of 2014 after fulfillment of extensive completion conditions particularly in the areas of production documentation

and supply chain2) (see “Economic Report – Business Development and Situation – Financial Situation”).

Furthermore, Nizhpharm signed the purchase agreement for the branded products AndroDoz® und NeroDoz®, which are positioned in

the area of men’s health and have been marketed via in-licensing in the previous years, in the fourth quarter of 2014. In the current

first quarter of 2015, the purchase was completed3) (see “Economic Report – Business Development and Situation – Financial Situation”).

In Serbia, sales increased significantly by 13% in 2014 applying the exchange rates of the previous year. In euro, sales increased by 9%

to € 93.4 million due to a negative currency effect of the Serbian dinar (previous year: € 86.0 million). A general shift from generics to

branded products can be observed in the sales mix of the Serbian market.

Sales recorded with generics in Serbia increased by 7% to € 76.8 million (previous year: € 71.8 million). Since the beginning of financial

year 2014, the development in the Serbian generics market has been characterized by regulatory changes in reimbursement amounts and

reimbursement lists as well as by increasing national tenders to supply hospitals and government pharmacies. In consideration of continued

pending price reductions, the wholesale business has been holding back orders for some time now. Generics contributed 82% to sales in

Serbia (previous year: 83%). With a market share of approx. 36.1% (previous year: approx. 35.6%), STADA remained the market leader in

the Serbian market in 2014.1)

Sales recorded with branded products in Serbia recorded strong growth of 20% to € 16.6 million (previous year: € 13.8 million). Branded

products contributed 18% to local sales (previous year: 16%).

In the first quarter of 2014, the insolvency administrator of Velefarm Holding and Velefarm VFB took legal action in Belgrade’s commercial

court against Hemofarm A.D., a subsidiary of STADA Arzneimittel AG, and Velefarm Prolek, a company of the Velefarm group. Hemofarm and

STADA continue to believe that the lawsuit is unfounded.4)

1) STADA estimate based on IMS Health data at ex-factory prices.
2) See the Company’s ad hoc release of October 18, 2013 and ad hoc update of February 28, 2014.
3) See the Company’s press release of February 4, 2015.
4) See the Company’s ad hoc release of February 14, 2014.

Management Report of the Executive Board83

Overall, STADA assumes that its own operating business in the Serbian market is stable and that it offers further growth opportunities. Sales

and earnings contributions in Serbia will continue to be significantly characterized by the currency relationship of the Serbian dinar to the

euro in the future as well as by the development of the local liquidity situation of the wholesalers and distribution partners.

Market region Asia & Pacific

Sales in the market region Asia & Pacific recorded substantial growth in the reporting year of 52% to € 94.1 million (previous year1):

€ 61.9 million). This market region’s contribution to Group sales amounted to 4.5% (previous year1): 3.1%). The pleasing development is

predominately attributable to sales growth resulting from the consolidations of the Vietnamese company STADA Vietnam and the Chinese

company STADA Pharmaceuticals (Beijing) as subsidiaries. Adjusted sales in this market region were approximately at the level of the

previous year with € 60.9 million (previous year1): € 61.2 million).

For financial year 2015, the Executive Board expects a sales increase in the market region Asia / Pacific & MENA, which has been expanded

as of January 1, 2015, with operating profitability above Group average.

Management Report of the Executive Board | Economic Report84

Business Development and Situation | Financial Situation

Unchanged stable financial situation

In the Executive Board’s view, the STADA Group’s financial position continues to be stable. This estimation can be seen – as a supplement

to some of the individual items reported in the cash flow statement – by means of various key figures, which are taken from, among other

things, the liquidity analysis contained in this chapter.

Basis and goals of financial management at STADA

In general, STADA pursues a conservative financial policy characterized by long-term secured financing instruments and forward-looking

monitoring of financial risks. The goal of STADA’s financial management is to be able to provide sufficient liquidity for the operating business

at any time.

In the course of its forward-looking monitoring of the financial management, STADA has defined the “net debt to adjusted EBITDA ratio” key

figure as a dynamic debt capacity, which should not exceed 3. In the case of temporary results in excess of this, e.g. as a consequence of

growth-enhancing acquisitions, STADA strives to reach this target value again within twelve to 18 months.

The financial management also covers financial risks such as currency and interest price risks. In this area, STADA pursues the objective of

minimizing existing financial risks that arise by way of natural hedges or derivative financial instruments. STADA does not hold or issue any

derivative financial instruments for speculation purposes.

On principle, only those financial risks are hedged which have significant consequences on the Group’s cash flow. Please see the Risk

Report for more details on the management of the individual financial risks.

In the context of the Group-wide financial strategy, STADA focuses strongly on a high degree of financial flexibility. In order to achieve this

flexibility, STADA relies on various financial instruments and a diversified investor structure. The Group’s profile of maturity dates reflects a

wide spread with a high share of middle and long-term financial instruments.

The need for financing is covered with a combination of cash flow from operating activities and the borrowing of funds on the short, middle

and long-term, as well as factoring programs. There is also the opportunity of cash inflow from exercising outstanding warrants 2000/2015.

Furthermore, STADA has credit lines available as a liquidity reserve.

Successful securing of additional promissory notes

The long-term refinancing of the Group as of December 31, 2014 was provided for by a corporate bond with a term of five years that was

placed in 2010 in the amount of € 350 million with an interest rate of 4.00% p.a., which will reach maturity in April of the current financial

year. For the purpose of long-term refinancing, as of the balance sheet date, there was a five-year bond which had been placed in the

second quarter of 2013 in the amount of € 350 million with an interest rate of 2.25% p.a. Furthermore, there were promissory notes with

maturities in the area of 2015 to 2019 with a nominal value in the total amount of € 552.5 million as of December 31, 2014. In the first

quarter of 2014, STADA secured € 200 million of this with a term of five years, of which € 124 million have a fixed interest rate of 2.30%.

Management Report of the Executive Board85

A variable interest rate of currently 1.40% applies for € 76 million. In the second quarter of 2014, STADA secured further promissory notes

in the amount of € 20 million with maturity in 2019 and a variable interest rate of currently 1.33%. In the fourth quarter of 2014, STADA

secured further promissory notes in the amount of € 50 million with a term of five years and a fixed interest rate of 1.33%. Furthermore, a

considerable single loan in the amount of an equivalent of around € 83 million (in local currency as of the balance sheet date) was taken

out in Russia for the financing of the purchase of the branded product portfolio Aqualor®, which is due gradually from 2015 to 2021. Over-

all, STADA continues to have a balanced maturity dates profile and a stable financing structure based on financial instruments with

staggered maturities.

Financial liabilities exist in a currency other than the Group’s functional currency primarily at Group companies within market regions

CIS / Eastern Europe as well as Asia & Pacific.

In 2014, the Group refinanced itself at interest rates of between 0.9% p.a. and 12.0% p.a. (previous year: between 0.8% p.a. and 13.8%

p.a.). On the balance sheet date of December 31, 2014, the weighted average interest rate for non-current financial liabilities was approx.

3.3% p.a. (previous year: approx. 3.5% p.a.) and for current financial liabilities approx. 4.6% p.a. (previous year: approx. 2.1% p.a.). For all

of the Group’s financial liabilities the weighted average interest rate amounted to approx. 3.7% p.a. (previous year: approx. 3.3% p.a.).

The following table presents an overview of the structuring of financial liabilities in the STADA Group:

Remaining maturities
of financial liabilities due to banks
as of Dec. 31, 2014
in € million

Promissory notes

Bond

Amounts due to banks

Total

< 1 year

1 – 3 years

3 – 5 years

> 5 years

Total

thereof as of
Dec. 31, 2014
> 1 year
in %

50,487

349,880

48,336

448,703

231,330

103,107

334,437

269,017

347,391

52,161

668,569

39,992

550,834

697,271

243,596

1,491,701

91%

50%

80%

70%

In general, liabilities due to banks can indeed be terminated in the short term and are therefore reported under current liabilities of less than

one year. However, it must be taken into consideration that many of these credit lines have a partly long-standing history.

Liquidity analysis

In the reporting year, the Group’s liquidity was ensured at all times. The Group’s sources of liquidity were mainly attained from cash inflows

from operating activities and the borrowing of funds on the short, middle and long-term. STADA also received cash inflow from factoring

programs and from exercising outstanding warrants 2000/2015. Cash inflows from operating activities are influenced by the profitability of

business activities and by net working capital, and, among other things, by receivables. In addition to two corporate bonds, long-term credit

lines and various promissory notes, STADA maintains a liquidity reserve in the form of cash supplemented by short-term credit lines. The

short-term credit lines bilaterally agreed with various banks each have a term of twelve months and currently amount to over € 500 million.

Management Report of the Executive Board | Economic Report

Cash flow analysis

Cash flow statement (abridged) in € 000s

2014

20131)

Cash flow from operating activities

Cash flow from investing activities

Free cash flow

Cash flow from financing activities

Non-cash changes in cash and cash equivalents

Cash flow

223,810

-261,980

-38,170

83,711

-7,495

38,046

203,744

-311,982

-108,238

148,780

-6,912

33,630

Cash flow from operating activities in financial year 2014 amounted to € 223.8 million (previous year1): € 203.7 million). The increase

by € 20.1 million as compared to the previous year mainly resulted from a substantial cash-effective decrease in trade accounts receivable,

whereas a substantial cash-effective increase was recorded in the previous year, as well as from lower income tax payments. The resulting

positive effects were partially compensated by a substantial cash-effective decrease in trade accounts payable as compared to a substan-

tial cash-effective increase in trade accounts payable in the previous year. In addition, a significantly higher cash-effective decrease in

other non-current provisions was recorded in financial year 2014, which is connected to the transfer of a defined benefit plan to an external

pension fund.

Cash flow from investing activities amounted to € -262.0 million in the reporting year (previous year1): € -312.0 million). In 2014, cash

flow from investing activities was particularly influenced by high payments for investments in intangible assets, which primarily related to

the purchase of the Russian branded product portfolio Aqualor®. Furthermore, there were payments for business combinations from the

acquisition of the branded product portfolio Flexitol® as well as the acquisition of the British company Internis. Proceeds from the disposal

of intangible assets and property, plant and equipment mainly resulted from the sales of approvals and trademarks in France and Italy and

from the sale of a building in the United Kingdom. In the previous year, payments for investments in business combinations primarily resulted

from the purchase price payments made for the acquisition of the British OTC supplier Thornton & Ross as well as from the final purchase

price payments for the additional shares and the control achieved over the Vietnamese pharmaceutical company Pymepharco and for the

pharmaceutical wholesaling and commercial business acquired from Spirig Pharma, in each case following the deduction of acquired cash

and cash equivalents.

For acquisitions – for both the acquisition of consolidated companies and business combinations according to IFRS 3 as well as for

significant investments in intangible assets for the short-term expansion of the product portfolio (generally in the reporting year) – STADA

spent a total of € 202.5 million in 2014 (previous year1): € 243.2 million).

As a result of disposals, cash flow from investing activities recorded an inflow of cash and cash equivalents in the total amount of

€ 12.0 million in financial year 2014 (previous year1): € 5.4 million).

Investments in other intangible assets, i.e. investments in intangible assets in the context of the ongoing operating business and there-

fore without consideration of significant investments or acquisitions for the short-term expansion of the product portfolio, amounted to

€ 33.9 million (previous year: € 39.5 million) and primarily comprised payments for the acquisition of approvals and approval dossiers in

the reporting year.

Management Report of the Executive Board87

Payments for investments in property, plant and equipment amounted to € 37.5 million in financial year 2014 (previous year1):

€ 33.9 million).

Property, plant and equipment investments in 2014 comprised investments in production facilities, production sites and test laboratories in

the total amount of € 19.7 million (previous year1): € 27.3 million) (see “Basis of the Group – Procurement, Production and Quality

Management”).

Payments for investments in financial assets were € 0.1 million in the reporting year (previous year: € 0.7 million).

Cash flow from financing activities in the reporting year amounted to € 83.7 million (previous year1): € 148.8 million). In financial year

2014, there were proceeds from securing financial liabilities, among other things, in connection with promissory notes secured in the total

amount of € 270 million and a loan in the amount of approx. € 121 million for financing the purchase of the branded product portfolio

Aqualor®. In the previous year, higher proceeds from taking up financial liabilities were recorded, in particular due to the bond placed in the

second quarter of 2013. In addition, more financial liabilities were repaid in the previous year than in the reporting period. Dividend

distribution payments of € 39.8 million primarily related to the dividend paid to the shareholders of STADA Arzneimittel AG for financial year

2013. The distributed volume thus significantly increased as compared to the dividend for financial year 2012. In 2014, the Group further-

more received proceeds from a capital increase in the amount of € 3.0 million (previous year: € 18.3 million) in the context of the conversion

of STADA warrants to shares (see Notes to the Consolidated Financial Statements – 35.1.).

Free cash flow, i.e. cash flow from current business activities plus cash flow from investing activities, amounted to € -38.2 million in 2014

(previous year1): € -108.2 million). Free cash flow adjusted for payments for significant investments or acquisitions and proceeds from

significant disposals amounted to € 157.4 million in the reporting year (previous year1): € 133.3 million).

In total, cash flow for financial year 2014, net of all inflows and outflows of cash and cash equivalents, amounted to € 38.0 million (previous

year1): € 33.6 million).

Capital expenditure

The Group’s investments amounted to € 279.0 million in the reporting year (previous year1): € 365.0 million). Investments in property, plant

and equipment amounted to € 37.9 million in 2014 (previous year1): € 78.7 million), of which € 0.1 million (previous year: € 35.3 million)

was attributable to business combinations according to IFRS 3. In relation to sales, the share of investments in property, plant and equip-

ment was 1.8% (previous year1): 3.9% of sales). Investments in intangible assets amounted to € 241.0 million (previous year1): € 285.4 mil-

lion), of which € 85.5 million was used for business combinations according to IFRS 3 (previous year: € 228.5 million). In the reporting year,

14% of the total investment volume was thereby attributable to property, plant and equipment (previous year1): 22%) and 86% to intangible

assets (previous year1): 78%).

Active acquisition policy with attractive purchases

In financial year 2014, the STADA Group continued to pursue an active acquisition policy to further accelerate the Group’s organic growth

with external growth impulses. In this context, the Group concentrates, on the one hand, on regional expansion of business activities with a

focus on high-growth emerging markets. On the other hand, a top focus is the expansion and internationalization of the core segments, in

particular branded products as they are generally characterized by better margins and less regulatory interventions than generics.

Management Report of the Executive Board | Economic Report88

Regardless of this active purchasing policy, profitability and the purchase price must strike a good balance in the view of the Executive

Board. For larger acquisitions or cooperations with capital investments, appropriate capital measures continue to be imaginable if the

burden on the equity-to-assets ratio from such acquisitions or cooperations is too high.

The STADA Group made further progress in the context of its active acquisitions policy in the reporting year.

Purchase of the Russian branded product portfolio Aqualor®

In the fourth quarter of 2013, the Russian STADA subsidiary Nizhpharm signed a framework agreement for the purchase of the branded

product portfolio Aqualor®.1) The purchase price for the Aqualor® product package amounted to a total of € 131 million in cash. The product

package comprises ten prescription-free (OTC) product presentations based on seawater in the form of sprays and drops with the local

regulatory status of medical devices for the treatment of sinusitis (infection of the paranasal sinus) and sore throat. The purchase did not

include any production facilities or the transfer of personnel. The portfolio is mainly being sold by Butterwood Holdings Limited, a company

located in Cyprus, and ZAO Pharmamed, a Russian pharmaceutical company located in Moscow. In the first quarter of 2014 – following the

fulfillment of extensive completion conditions, in particular in the areas of product documentation and supply chain – the contract was

completed as planned for this purchase.1) Sales of the products from the branded product package have been consolidated in the STADA

Group since March 1, 2014.

Strengthening of the branded product portfolio of the British STADA subsidiary Thornton & Ross

In the second quarter of 2014, the British STADA subsidiary Thornton & Ross acquired the production and distribution rights for the branded

products portfolio Flexitol® 2) for the United Kingdom and Ireland.3) The purchase price amounted to GBP 10 million (according to the

exchange rate at the date of acquisition approx. € 12.5 million) subject to adjustments for inventory. The seller is the LaCorium group of

companies based in Sydney. In 2013, net sales generated with Flexitol® in the United Kingdom and Ireland amounted to approx. GBP 3.3 mil-

lion (according to the exchange rate at the date of acquisition approx. € 4.1 million). Product sales have been consolidated in the STADA

Group since June 16, 2014.

Furthermore, STADA UK Holdings acquired the British company Internis in the fourth quarter of 2014, which is active in the prescription area

of therapeutic treatment of vitamin D3 deficiency. The purchase price, which contains certain contingent purchase price components,

amounts to a maximum of GBP 49.0 million (applying the exchange rate at the date of acquisition approx. € 62.3 million). Sellers are

various individuals. The sales have been consolidated in the STADA Group since December 19, 2014.

Further expansion of the branded product business in Russia

In the fourth quarter of 2014, the Russian STADA subsidiary Nizhpharm signed the purchase agreement for the branded products

AndroDoz® und NeroDoz®, which are both positioned in the area of men’s health. The purchase price was RUB 526.5 million (approx.

€ 7.9 million applying the official exchange rate of the Russian central bank as of December 25, 2014). The seller is OOO PharmEnergy, a

Russian pharmaceutical company based in Moscow. Net sales generated with these two products in Russia amounted to approx. € 3.0 mil-

lion in 2014. Product sales have been consolidated in the STADA Group since 2012, as Nizhpharm had sold the products via in-licensing

before. The purchase will be completed in the current first quarter of 2015.4)

Continuation of the active acquisition policy

STADA continued the active acquisition policy in financial year 2015 as well.

1) See the Company’s ad hoc release of October 18, 2013 and ad hoc update of February 28, 2014.
2) Dermatological range in the area of hand and foot care.
3) See the Company’s press release of June 30, 2014.
4) See the Company’s press release of February 4, 2015.

Management Report of the Executive Board
89

Business Development and Situation | Assets Situation

Development of the Balance Sheet

Balance sheet (abridged)
Assets

Dec. 31, 2014
in € 000s

Dec. 31, 2014
in %

Dec. 31, 2013
in € 000s

Dec. 31, 2013
in %

Jan. 1, 20131)
in € 000s

Jan. 1, 20131)
in %

Non-current assets

Intangible assets

Property, plant and equipment

Other assets

Current assets

Inventories

Trade accounts receivable

Other assets

Cash and cash equivalents

Total assets

Equity and liabilities

Equity

Long-term borrowed capital

Other non-current provisions

Financial liabilities

Other liabilities

Short-term borrowed capital

Other provisions

Financial liabilities

Trade accounts payable

Other liabilities

2,013,819

1,631,516

305,430

76,873

1,321,639

498,785

502,794

155,851

164,209

3,335,458

60.4%

48.9%

9.2%

2.3%

39.6%

15.0%

15.1%

4.6%

4.9%

100%

2,059,989

1,641,623

318,428

99,938

1,353,193

524,374

591,678

110,978

126,163

3,413,182

60.4%

48.1%

9.3%

3.0%

39.6%

15.4%

17.3%

3.2%

3.7%

100%

1,806,292

1,417,050

269,361

119,881

1,169,679

466,496

489,567

121,083

92,533

2,975,971

60.7%

47.6%

9.1%

4.0%

39.3%

15.7%

16.4%

4.1%

3.1%

100%

Dec. 31, 2014
in € 000s

Dec. 31, 2014
in %

Dec. 31, 2013
in € 000s

Dec. 31, 2013
in %

Jan. 1, 20131)
in € 000s

Jan. 1, 20131)
in %

903,339

1,246,693

30,097

1,042,998

173,598

1,185,426

17,442

448,703

340,847

378,434

27.1%

37.4%

0.9%

31.3%

5.2%

35.5%

0.5%

13.5%

10.2%

11.3%

100%

1,010,099

1,358,414

51,478

1,140,571

166,365

1,044,669

17,536

292,484

331,661

402,988

3,413,182

29.6%

39.8%

1.5%

33.4%

4.9%

30.6%

0.5%

8.6%

9.7%

11.8%

100%

910,317

1,102,404

50,486

941,572

110,346

963,250

10,538

326,183

267,773

358,756

2,975,971

30.6%

37.0%

1.7%

31.6%

3.7%

32.4%

0.4%

11.0%

9.0%

12.0%

100%

Total equity and liabilities

3,335,458

In the Executive Board’s view, the Group’s financial position continues to be stable. This was reflected in various derived key figures as a

supplement to the items reported in the balance sheet.

Net debt was at € 1,327.5 million as of December 31, 2014 (December 31, 2013: € 1,306.8 million).

The net debt to adjusted EBITDA ratio improved to 3.1 in the reporting year (previous year1): 3.2).

Management Report of the Executive Board | Economic Report
90

As of the balance sheet date, the equity-to-assets ratio was 27.1% (December 31, 2013: 29.6%) and was thereby satisfactory in the

opinion of the Executive Board.

The balance sheet total as of December 31, 2014 decreased to € 3,335.5 million (December 31, 2013: € 3,413.2 million). The reduction

resulted in particular from intangible assets, despite the addition of assets from business combinations and product acquisitions. This

development is mainly attributable to the weak Russian ruble and a corresponding lower translation of assets reported in foreign currencies

into the Group currency euro, as well as to the impairments on goodwill recorded in financial year 2014.

Intangible assets recorded a decrease to € 1,631.5 million as of December 31, 2014 (December 31, 2013: € 1,641.6 million). The

amount of this balance sheet item is based on the Group’s long-term active acquisition policy with corresponding investments in the

acquisition of companies and products including brands and licenses as well as in the area of product development for the acquisition of

dossiers and approvals.

As of December 31, 2014, intangible assets included € 372.3 million in goodwill (December 31, 2013: € 458.0 million). There were

additions to other intangible assets from the acquisition of the Russian branded product portfolio Aqualor® – not considering impairment in

the reporting year – in the amount of € 89.4 million. In 2014, furthermore, development costs in the amount of € 28.7 million (December

31, 2013: € 20.7 million) were capitalized as internally created intangible assets (see Notes to the Consolidated Financial Statements –

25.). In financial year 2014, impairments on intangible assets were recognized in the amount of € 104.8 million (previous year: € 22.6 mil-

lion).

The decrease in property, plant and equipment as of December 31, 2014 to € 305.4 million (December 31, 2013: € 318.4 million) was

primarily based on the weakness of the Russian ruble and a corresponding lower translation of assets reported in foreign currencies into

the Group currency euro.

Other assets include various items, including, among other things, financial assets, shares in associated companies, other financial assets

and non-current assets and disposal groups held for sale.

Financial assets declined as of December 31, 2014 to € 2.0 million (December 31, 2013: € 9.0 million). This development primarily

resulted from the inclusion of the Chinese subsidiary STADA Pharmaceuticals (Beijing) in the scope of consolidation of STADA Arzneimittel

AG and the liquidation of the Swedish investment STADApharm AB.

Investments measured at equity increased to € 10.6 million (December 31, 2013: € 9.0 million). The growth of this balance sheet item

resulted exclusively from the earnings contribution of associates in the reporting year.

Other financial assets in the amount of € 98.7 million (previous year: € 77.9 million) include loan receivables and purchase price receivables.

They contain, among other things, the loan from STADA Arzneimittel AG granted to BIOCEUTICALS Arzneimittel AG which was utilized as of

the balance sheet date in the amount of € 3.3 million (December 31, 2013: € 15.6 million). This item also includes the positive market

values of derivative financial instruments, which amounted to € 33.3 million as of the balance sheet date (December 31, 2013: € 10.5 mil-

lion) and mainly resulted from the cross-currency swaps.

The decrease in inventories as of December 31, 2014 to € 498.8 million (December 31, 2013: € 524.4 million) was mainly based on the

weakness of the Russian ruble and a corresponding lower translation of assets reported in foreign currencies into the Group currency euro

as well as on balance sheet date effects.

Management Report of the Executive Board91

In specific situations STADA puts – following the principle of market proximity (see “Basis of the Group – Sales and Marketing”) – certain

range considerations deliberately aside in favor of possible operating opportunities. In individual cases this can lead to value adjustments

for inventories which burden earnings, if the utilization of opportunities cannot be realized as expected. Total burdens in the amount of

€ 33.7 million as of December 31, 2014 were incurred due to value adjustments in inventories netted with reversals (previous year1):

€ 29.9 million).

Trade accounts receivable decreased as of the balance sheet date to € 502.8 million (December 31, 2013: € 591.7 million). This resulted,

among other things, from reporting date effects as well as translation effects in the context of converting financial statements of foreign

subsidiaries with a reporting currency other than the Group currency euro. Furthermore, the factoring volume increased as of December 31,

2014 as compared to the balance sheet date of the previous year.

In certain market situations, the Group accepts, if necessary, higher current trade receivables, if this leads to opportunities for a better

market position. In the scope of its receivables management, STADA pays thorough attention to the liquidity of customers as a rule. Defaults

can, however, never be entirely ruled out (see “Risk Report”).

Cash and cash equivalents, which include cash and call deposits as well as short-term financial investments, increased as of December

31, 2014 to € 164.2 million (December 31, 2013: € 126.2 million). This development was mainly due to effects related to the balance

sheet date. Further details on the development of cash and cash equivalents can be found in the consolidated cash flow statement.

Equity decreased as of December 31, 2014 to € 903.3 million (December 31, 2013: € 1,010.1 million). Here it must be taken into account

that the Group recorded proceeds from capital increases from the conversion of STADA warrants in the amount of € 3.0 million in the

reporting year (previous year: € 18.3 million) (see “The STADA Share”).

Retained earnings including net income comprise net income for the financial year as well as earnings generated in previous periods,

provided these were not distributed, including amounts transferred to retained earnings. In addition, effects from remeasurements of the

net defined benefit liability that are recognized in other comprehensive income are reported under this item taking deferred taxes into

account. In the context of measuring the significant defined benefit obligations as of December 31, 2014 – not considering amounts

attributable to non-controlling interests – a net expense in the amount of € 15.5 million recognized in other comprehensive income after

deferred taxes resulted from the remeasurement. This is mainly based on the substantial decrease in the discount rate underlying the

measurement for different defined benefit plans in the STADA Group as of December 31, 2014 in comparison to December 31, 2013.

Other provisions include results recognized directly in equity. This relates, among other things, to foreign exchange gains and losses

resulting from the currency translation recognized in other comprehensive income of financial statements of companies included in the

Group, which are recognized in the statement of changes in shareholders’ equity under provisions for currency translation. In the reporting

year, an expense of € 131.9 million recognized directly in equity arose, which is primarily composed of the following opposing effects: On

the one hand, income recognized directly in equity from the currency translation of financial statements of companies reporting in pound

sterling has been recorded due to the appreciation of the pound sterling since December 31, 2013. On the other hand, there were higher

expenses recognized directly in equity primarily from the currency translation of financial statements of companies reporting in Russian

ruble and Serbian dinar due to the significant weakening of the Russian ruble as well as the weakening of the Serbian dinar since Decem-

ber 31, 2013. In total, other provisions decreased to € -371.9 million as of December 31, 2014 (December 31, 2013: € -241.5 million).

Management Report of the Executive Board | Economic Report92

Other non-current provisions decreased to € 30.1 million as of December 31, 2014 (December 31, 2013: € 51.5 million). The reduction

was primarily a result of a change in the defined benefit plan for the Chairman of the Executive Board and the resulting changes with regard

to the benefits awarded according to the former benefit plan. Despite the transfer of the defined benefit plan of the Chairman of the

Executive Board to an external pension fund, the necessity remains, due to the secondary liability of STADA, to treat the benefit plan as

defined benefit plan in accordance with IAS 19 and measure and recognize it accordingly. The plan assets created in the context of the

transfer lead to a provision of zero due to offsetting that must be carried out in the amount of the defined benefit obligations at the time of

the plan amendment for this benefit plan.

Financial liabilities amounted to € 1,491.7 million as of December 31, 2014 (December 31, 2013: € 1,433.1 million). The item includes,

in particular, promissory notes with a nominal value in the amount of € 552.5 million (December 31, 2013: € 436.5 million) and two bonds

with a nominal value in the amount of € 350.0 million each (December 31, 2013: two bonds of € 350.0 million each). The increase in

financial liabilities mainly resulted from securing promissory notes in the total amount of € 270 million in financial year 2014 and a loan in

the amount of approx. € 83 million at closing rate for the financing of the purchase of the branded product portfolio Aqualor®. In opposition,

financial liabilities were repaid in the current financial year.

Trade accounts payable increased to € 340.8 million as of December 31, 2014 (December 31, 2013: € 331.7 million). This development

was primarily based on temporary results of balance sheet date effects.

Remaining liabilities include, among other things, deferred tax liabilities and other financial liabilities.

Deferred tax liabilities increased as of December 31, 2014 to € 166.7 million (December 31, 2013: € 150.4 million). The increase is

primarily attributable to the acquisition of the British company Internis Pharmaceuticals Ltd. and the purchase price allocation carried out in

this context.

Other financial liabilities in the amount of € 262.7 million (December 31, 2013: € 274.1 million) include, among other things, finance lease

liabilities and liabilities from derivative financial instruments. The finance lease liabilities amounted to € 3.1 million as of December 31,

2014 (December 31, 2013: € 8.5 million). The liabilities from derivative financial instruments amounted to € 3.1 million on the balance

sheet date (December 31, 2013: € 5.6 million), and resulted from the negative market values of derivatives measured at fair value with an

effect on income, which were partly used as hedging instruments.

The decrease in other financial liabilities to € 262.7 million as of December 31, 2014 (December 31, 2013: € 274.1 million) was primarily

a result of decreased liabilities due to discount agreements, among other things due to a quicker settlement of existing discount agree-

ments. In addition, this development can be attributed to the decision to take part in tenders for discount agreements with only one German

subsidiary in the future. With this step, the Group is following the longstanding and communicated decision to participate in German tenders

for discount agreements always following the primary objective of appropriate operating profitability.

The reduction in other liabilities to € 88.9 million (December 31, 2013: € 114.3 million) mainly resulted from decreased tax liabilities.

Management Report of the Executive Board93

Business Development and Situation |
General Statements of the Executive Board on Business Development in 2014

In consideration of the challenging framework conditions in the two market regions of Germany and CIS / Eastern Europe, STADA achieved

a solid result in financial year 2014 in the Executive Board’s assessment, which was in line with the outlook published at the beginning of

the year and is based on the Group’s sustainable business model focused on market regions with long-term growth potential.

Overall, in the reporting year there were one-time special effects and effects from the measurement of derivative financial instruments

under financial income and expenses in the amount of € 128.6 million before or € 121.6 million after taxes, which include impairments on

goodwill in the amount of € 54.0 million before and after taxes as well as on further intangible assets in the amount of € 22.0 million before

or € 21.7 million after taxes as a result of the significantly changed interest rate and currency environment as well as on ongoing higher

risks in the market region CIS / Eastern Europe.1)

Despite the challenges, Group sales rose – with varying development in the individual market regions – in the reporting year by 3% to

€ 2,062.2 million (previous year2): € 2,003.9 million).

Sales of the core segment Generics decreased slightly by 1% to € 1,217.7 million in financial year 2014 (previous year2): € 1,227.9 mil-

lion). This reduction is primarily attributable to the development in the markets of Germany and Russia. Sales of the core segment Branded

Products in the reporting year recorded a significant growth of 14% to € 800.5 million (previous year2): € 704.4 million). This increase was

primarily based on the development in the markets of Italy, Belgium, the United Kingdom, Spain, France and Serbia.

The earnings development in financial year 2014 was characterized by an increase in operating performance as shown by growth in all of

the Group’s adjusted key earnings figures.

After adjusting the key earnings figures for influences distorting the year-on-year comparison resulting from one-time special effects,

adjusted EBITDA increased by 4% to € 431.9 million (previous year2): € 414.3 million). Net income, adjusted for one-time special effects

and effects from the measurement of derivative financial instruments under financial income and expenses, increased substantially by 16%

to € 186.2 million (previous year: € 160.6 million).

Adjusted EBITDA of the core segment Generics recorded growth of 7% to € 228.7 million (previous year2): € 213.4 million). Adjusted

EBITDA of the core segment Branded Products recorded an increase of 7% to € 240.0 million (previous year2): € 225.1 million).

The net debt to adjusted EBITDA ratio improved to 3.1 in financial year 2014 (previous year2): 3.2).

1) See the Company’s ad hoc release of February 19, 2015.
2) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statement – 3.).

Management Report of the Executive Board | Economic Report94

REMUNERATION REPORT

This Remuneration Report explains, in accordance with the legal requirements and the recommendations of the German Corporate

Governance Code in the version of June 24, 2014, the principles of the remuneration system for the Executive Board, Supervisory Board

and Advisory Board of STADA Arzneimittel AG as of the balance sheet date and includes individual information on the remuneration of each

Executive Board and Supervisory Board member.

Remuneration of the Executive Board

The full Supervisory Board determines the Executive Board remuneration system and the remuneration of individual Executive Board

members upon the proposal of the Human Resources Committee and reviews these regularly.

Executive Board remuneration system

The goal of the Executive Board remuneration system approved by the STADA Annual General Meeting on June 16, 2011 is to allow the

members of the Executive Board to participate appropriately in the sustainable development of the Company according to their personal

tasks and performance, the overall performance of the Executive Board as well as successes in the alignment of the economic and financial

situation of the Company under consideration of the competitive environment.

Overall, the remuneration of the Executive Board in the framework of this remuneration system is performance oriented and assessed in a

way that is competitive in domestic and international comparison and offers incentives for committed and successful performance in a

dynamic environment.

The remuneration of the Executive Board in the framework of this remuneration system is made up of remuneration not related to per-

formance and a performance related remuneration. Stock option plans and other comparable components with a long-term incentive effect

do not exist.

The non-performance related remuneration consists of an agreed basic salary paid out in twelve equal monthly installments. This annual

fixed salary is determined in accordance with the requirements of stock company law under consideration of usual market remuneration.

The members of the Executive Board receive other remuneration only in the form of fringe benefits which consist for the most part only of

the private use of a company car, contributions to health and nursing care insurance and other insurance services (accident insurance,

among other things).

In the framework of the remuneration structure, individual contractual commitments are still fundamentally possible for individual Executive

Board members, in accordance with the German Act on the Appropriateness of Executive Board Remuneration (VorstAG), regarding

additional non-performance related remuneration components, e.g. pension commitments or commitments in case of termination of activity.

In the remuneration structure, the performance related remuneration is, in principle, similarly structured for all Executive Board members;

it can, however, differentiate in the individual arrangement and amount for individual Executive Board members due to individual contractual

agreements.

Management Report of the Executive Board95

The performance related remuneration is made up of the following components for each Executive Board member in the applicable

remuneration structure:

• the variable annual bonus, which consists of an earnings related and an objectives-related bonus component and for which a cap has

been agreed upon. While the earnings related bonus component of this variable annual bonus is oriented on the Group’s adjusted EBITDA

of the respective financial year, the objectives related bonus component of the variable annual bonus remunerates for the achievement

of specific pre-determined goals, which are individually agreed upon in writing with individual Executive Board members for the respective

financial year (personal goal agreement).

• the variable long-term special remuneration, for which defined annual progress payments are to be rendered by the Company upon the

reaching of annual interim goals set out in individual contracts and which target the Group’s overall business success in a defined target

year. The long-term goal thereby taken as a basis in individual contracts, as well as the annual interim goals, are geared to a challenging

adjusted Group EBITDA under the assumed framework conditions for the period under consideration; the target year for the variable

long-term special remuneration should, at the earliest, generally be the third whole financial year after the beginning of the contract of

the respective Executive Board contract. If the long-term goal agreed upon for the variable special long-term remuneration is not reached

in consideration of the agreed corridor of a degree of goal attainment, the Company is entitled to the repayment of rendered progress

payments in the case that the interim goals of the agreed corridor are not reached. A cap for the variable special long-term remuneration

must also be agreed upon.

The current Executive Board contracts of acting Executive Board members reflect this remuneration system.

Within the concrete arrangement of the Executive Board contracts of current Executive Board members, both the long-term goal for the

variable long-term special remuneration, as well as the respective interim goals for all three Executive Board members, orient on the Group’s

long-term targets for adjusted EBITDA in financial year 2014 as published in financial year 2010.

Executive Board remuneration for financial year 2014

In addition to the applicable financial reporting principles, the following details on the remuneration granted to the Executive Board members

in the reporting year also take into account the recommendations of the German Corporate Governance Code and the exemplary charts

reporting the amount of benefits granted including fringe benefits for financial year 2014, which are contained in the Code’s version of

June 24, 2014. The possible minimum and maximum amounts are also indicated.

Management Report of the Executive Board | Remuneration Report96

The remuneration of the individual members of the Executive Board who were active for the Company in financial year 2014 is as follows:

in € 000s

Fixed compensation

Fringe benefits

Total

One-year variable compensation

Multi-year variable compensation

Long-term targets 20141)

Other

Total

Pension expenses

Total compensation

in € 000s

Fixed compensation

Fringe benefits

Total

One-year variable compensation

Multi-year variable compensation

Long-term targets 20141)

Other

Total

Pension expenses

Total compensation

Hartmut Retzlaff, Chairman of the Executive Board (on the Executive Board since 04/1993)

Benefits granted

Allocation

2014

2,000

142

2,142

848

4,146

4,994

-17,6033)

-10,467

2013

2014 (min)

2014 (max)

2,000

2,030

408

940

3,378

2,000

142

2,142

-17,603

-15,461

2,000

142

2,142

850

4,200

5,050

-17,603

-10,411

2014

2,000

142

2,142

408

8062)

1,214

-17,6033)

-14,247

2013

2,000

2,030

347

8062)

1,153

940

4,123

Helmut Kraft, Chief Financial Officer (on the Executive Board since 01/2010)

Benefits granted

Allocation

2014

2013

2014 (min)

2014 (max)

2014

2013

750

776

399

1,575

1,974

2,750

750

784

386

1,170

750

776

750

776

500

1,800

2,300

3,076

750

776

386

3002)

686

1,462

750

784

351

2502)

601

1,385

1) The reporting year corresponds to the target year defined in the context of long-term goals, so the benefits
granted from the contractually agreed long-term special remuneration for 2014 are fully attributable to the
current reporting year. Accordingly, this also includes the contractually agreed progress payments of the
long-term special remuneration upon achieving the respective interim goals from the previous years 2010 to
2013.
2) Contractually agreed performance related progress payments of the long-term special remuneration upon
achieving the respective interim goals.

3) In the context of the changed plan and the resulting changes with regard to the benefits awarded
according to the former benefit plan there were earnings from past service cost in the amount of
€ 17.6 million. In addition, an expense from administrative costs for the benefit plan in the amount of
€ 0.7 million and an expense from the adjustment of plan assets in the amount of € 1.0 million were
incurred. The balance of the two items were earnings of € 15.9 million, which were recorded in general
and administrative expenses.

Management Report of the Executive Board

Dr. Matthias Wiedenfels, Chief Business Development & Central Services Officer
(on the Executive Board since 05/2013)

Benefits granted

Allocation

2014

2013

2014 (min)

2014 (max)

2014

2013

750

777

300

1,077

495

516

250

766

750

777

750

777

300

1,077

750

777

250

1001)

350

1,127

495

516

Dr. Axel Müller, Chief Production and Development Officer (on the Executive Board until 08/2013)

Benefits granted

Allocation

2014

2013

2014 (min)

2014 (max)

2014

2013

448

462

224

686

448

462

224

686

in € 000s

Fixed compensation

Fringe benefits

Total

One-year variable compensation

Multi-year variable compensation

Long-term targets 2016

Other

Total

Pension expenses

Total compensation

in € 000s

Fixed compensation

Fringe benefits

Total

One-year variable compensation

Multi-year variable compensation

Long-term targets 2014

Other

Total

Pension expenses

Total compensation

The percentage ratio between non-performance related and performance related2) remuneration of members of the Executive Board

ranges in the area of approx. 28%3) to approx. 72%3) non-performance related and approx. 28%3) to approx. 72%3) performance related2)

remuneration.

1) Contractually agreed performance related progress payments of long-term special remuneration upon
achieving the respective interim goals.
2) Including the contractually agreed long-term special remuneration which is reported as benefits.
3) Excluding pension expenses.

Management Report of the Executive Board | Remuneration Report

Commitments to members of the Executive Board

Commitments to members of the Executive Board in case of premature or regular termination of their activity

and any associated benefits

Previously, the Executive Board contract of the Chairman of the Executive Board included an annual pension set at a fixed annual amount,

whereby after the provision commences, the monthly pension payment would have been adjusted on July 1 of every year by the percentage

of the increase in the current level of pension in the German statutory pension scheme in comparison to the previous year. Payments from

the pension commitments would have begun on request as pension payments after completion of the Executive Board contract, generally

valid until August 31, 2016, to the extent that it would not have been renewed or as disability pension if employment had ended before this

due to an occupational disability. Furthermore, a lifelong survivor’s pension was granted in case of death.

In the third quarter of 2014, the implementation method for the pension obligation for the Chairman of the Executive Board was changed.

In future it will be implemented through an independent pension fund – against a one-time contribution payment on the part of STADA. The

pension commitment was fundamentally changed in the context of outsourcing it to the pension fund. Accordingly, there is now a commit-

ment to the Chairman of the Executive Board, upon reaching the contractually agreed start of pension payments, for a lifelong pension in

the form of a lower monthly guaranteed pension as compared to the previous commitment, as well as a variable non-guaranteed partici pation

feature from which a corresponding benefit increase may result. The start of pension payments can in principle, with the corresponding

change in the amount of monthly pension payments, take place variably within a defined time period which exceeds the formerly assumed

retirement age. In addition, a lifelong survivor’s pension and a temporary orphan’s pension will be paid in case of death.

In the context of the changed plan and the resulting changes with regard to the benefits awarded according to the former benefit plan,

earnings from past service cost amounted to € 17.6 million. In addition, an expense from administrative costs for the benefit plan in the

amount of € 0.7 million and an expense from the adjustment of plan assets in the amount of € 1.0 million were incurred. Offsetting results

in earnings of € 15.9 million, which were recorded in general and administrative expenses. Despite the transfer of the defined benefit plan

of the Chairman of the Executive Board to an pension fund, the necessity remains, due to the secondary liability of STADA, to treat the

benefit plan as defined benefit plan in accordance with IAS 19 and measure and recognize it accordingly. The present value of the pension

commitments, in accordance with IFRS, was € 33.7 million as of December 31, 2014. The plan assets created in the context of the transfer

lead to a provision of zero due to offsetting that must be carried out at the time of the plan amendment for this benefit plan. Since the

pension commitment is fully funded, no further provisions are expected in the future.

The Executive Board contracts of the Chairman of the Executive Board and the Chief Financial Officer also contain a severance pay

regulation for a closely defined change of control, which, in accordance to the German Corporate Governance Code, is not higher than the

value for the remaining term of the Executive Board contract, and is limited in amount to a maximum of three years’ remuneration.

Management Report of the Executive Board99

Other commitments

The Executive Board contract of the Chairman of the Executive Board includes the proviso that, in the case of illness or accident, the

Company will continue to pay the salary of the Chairman of the Executive Board, whereby the amount of the continued payment, in the first

year after the occurrence of either case, corresponds to the fixed annual salary and the variable remuneration and, in the second or third

year, to the fixed annual salary.

For both the Chief Financial Officer and the Chief Business Development and Central Services Officer, there exists accident insurance,

which, in the case of inability to work due to illness, provides for monthly income for up to one year, up to a maximum period however until

completion of the contract and taking third-party payments into account. In the case of inability to work for more than three months, the

variable remuneration will be reduced on a pro-rata basis.

In the context of a group insurance for all three Executive Board members, there exists a so-called D&O insurance with a deductible for the

Executive Board members within the legal framework.

Benefits from third parties outside the Group, which were promised or granted to members of the Executive Board

in the reporting year with regard to their position in the Executive Board

To the Company’s knowledge, third parties outside the Group have neither promised nor granted benefits to Executive Board members in

financial year 2014 with regard to their position in the Executive Board in the reporting year.

Supervisory Board remuneration

Remuneration system for the Supervisory Board according to the Articles of Incorporation

The remuneration system of the Supervisory Board is governed by Section 18 of STADA Arzneimittel AG’s Articles of Incorporation. Section

18 of the Articles of Incorporation of February 26, 2014 applies for the reporting year, according to which, in addition to reimbursement of

expenses in the past financial year; Supervisory Board members shall receive the following remuneration:

• an annual fixed sum of € 48,000 and

• a remuneration based on the long-term success of the Company (long-term variable remuneration) in the amount of 0.02% of the

average Group earnings before taxes as reported in the consolidated financial statements of the past three financial years. The annual

cap for long-term variable remunerations is € 48,000.00.

The Chairman of the Supervisory Board receives triple this amount and his deputy twice the amount.

Supervisory Board members receive an annual fixed remuneration of € 15,000 for their committee activities for the past financial year. The

Chairman of a committee receives twice this amount in remuneration.

In addition, sales tax is payable on all Supervisory Board remuneration.

Management Report of the Executive Board | Remuneration Report100

Remuneration of the Supervisory Board in financial year 2014

The remuneration of the individual members of the Supervisory Board who were active for the Company in financial year 2014 are as

follows:

• Dr. Martin Abend € 278,900.00 (thereof € 189,000.00 non-performance related and € 89,900.00 performance related)

(previous year: € 275,400.00, thereof € 105,000.00 non-performance related and € 170,400.00 performance related)

• Carl Ferdinand Oetker € 145,500.00 (thereof € 101,100.00 non-performance related and € 44,400.00 performance related)

(previous year: € 101,800.00, thereof € 45,000.00 non-performance related and € 56,800.00 performance related)

• Dr. Eckhard Brüggemann € 77,900.00 (thereof € 47,900.00 non-performance related and € 30,000.00 performance related)

(previous year: € 81,800.00, thereof € 25,000.00 non-performance related and € 56,800.00 performance related)

• Halil Duru € 44,800.00 (thereof € 27,500.00 non-performance related and € 17,300.00 performance related)

(member of the Supervisory Board since June 4, 2014)

• Heike Ebert € 33,100.00 (thereof € 20,400.00 non-performance related and € 12,700.00 performance related)

(previous year: € 81,800.00, thereof € 25,000.00 non-performance related and € 56,800.00 performance related)

(member of the Supervisory Board until June 4, 2014)

• Dr. K. F. Arnold Hertzsch € 85,200.00 (thereof € 55,200.00 non-performance related and € 30,000.00 performance related)

(previous year: € 81,800.00, thereof € 25,000.00 non-performance related and € 56,800.00 performance related)

• Dieter Koch € 92,900.00 (thereof € 62,900.00 non-performance related and € 30,000.00 performance related)

(previous year: € 91,800.00, thereof € 35,000.00 non-performance related and € 56,800.00 performance related)

• Manfred Krüger € 72,500.00 (thereof € 47,100.00 non-performance related and € 25,400.00 performance related)

(previous year: € 173,600.00, thereof € 60,000.00 non-performance related and € 113,600.00 performance related)

(member of the Supervisory Board until June 4, 2014)

• Constantin Meyer € 85,200.00 (thereof € 55,200.00 non-performance related and € 30,000.00 performance related)

(previous year: € 81,800.00, thereof € 25,000.00 non-performance related and € 56,800.00 performance related)

• Dr. Ute Pantke € 44,800.00 (thereof € 27,500.00 non-performance related and € 17,300.00 performance related)

(member of the Supervisory Board since June 4, 2014)

• Karin Schöpper € 39,400.00 (thereof € 26,700.00 non-performance related and € 12,700.00 performance related)

(previous year: € 91,800.00, thereof € 35,000.00 non-performance related and € 56,800.00 performance related)

(member of the Supervisory Board until June 4, 2014)

• Jens Steegers € 44,800.00 (thereof € 27,500.00 non-performance related and € 17,300.00 performance related)

(member of the Supervisory Board since June 4, 2014)

Management Report of the Executive Board101

Beyond this remuneration no additional monies or benefits have been granted to members of the Supervisory Board for personally rendered

services in the context of their activities as Supervisory Board members; however, in the context of a Group insurance, there exists a

so-called D&O insurance for all members of the Supervisory Board, which reflects the legal framework of the Executive Board members,

with a deductible for the Supervisory Board members.

Remuneration of the Advisory Board

In accordance with Section 10 of the bylaws of the Advisory Board of STADA Arzneimittel AG, members of the Advisory Board receive a flat

fee of € 600 per meeting plus expenses.

Management Report of the Executive Board | Remuneration Report102

SUPPLEMENTARY REPORT

No material events have occurred since the reporting date that could have a significant effect on the Group’s business, financial and

earnings situation.

Management Report of the Executive BoardManagement Report of the Executive Board | Supplementary Report | Opportunities Report

103

OPPORTUNITIES REPORT

Opportunities management

To secure the short, medium and long-term success of the company the STADA Group carries out continuous opportunity management. In

this context STADA aims to determine and seize new growth opportunities and to secure and expand upon existing potential for growth.

STADA’s strategic success factors create the basis for utilizing growth opportunities that arise and thereby for securing sustainable Group

success. These include in particular strong product development, an international sales structure, an active acquisition policy, a functionally

organized group, efficient cost management and qualified employees.

Important strategic success factors of the STADA Group

Securing sustainable Group success

Taking advantage of growth potential

Strong
product
development

International
sales structure

Active
acquisition
policy

Functionally
organized
Group

Efficient
cost
management

Qualified
Employees

The regional organizational and management structure in the sales related areas of the STADA Group, which is organized in a strategically

centralized manner and managed decentrally, ensures that trends and requirements in the four market regions and the associated markets

can be recognized and analyzed at an early stage so that arising opportunities can be used. They are supported in this by detailed obser-

vations of both the market and the competition as well as close contact with institutions. The Group also has centrally organized processes

for the identification of opportunities, such as a Group-wide portfolio management system for identifying potential new products.

Also in the future, STADA will continue to constantly expand the existing Group portfolio – both in the core segment Generics and in the core

segment Branded Products. In this context, in addition to sales and earnings achieved in the context of new product launches, the opportunity

exists to attain an improved margin mix as well as for economy of scale effects insofar as the products can be launched with margins that

are better than the Group average or that they can be launched within the scope of existing sales structures in the individual market regions.

In particular the Branded Products segment is characterized by better margins and subject to less regulatory intervention than the generics

area. With the Group strategy “time and cheap to market” STADA pursues the goal of launching new products on the market not only at the

earliest possible time, but also at the best possible cost of sales.

104

To use the respective growth opportunities in the four market regions defined by the Group, STADA will continue to expand the global sales

network in the future as well. The Group thus intends to be able to sell products from the Group portfolio in a way which is adapted to the

different regulatory and competitive framework conditions in the individual markets of the market regions.

Furthermore, STADA continues to pursue an active acquisition policy to accelerate organic growth through targeted acquisitions. On the one

hand, the emphasis is on the regional expansion with a focus on high-growth emerging markets. On the other hand, the company focuses

on the expansion and internationalization in particular of the core segment Branded Products. In view of the increasing pressure to reduce

costs, to which the individual national health care systems in the respective markets of the four STADA market regions are exposed, the

Executive Board sees further growth opportunities particularly for branded products because they are subject to less regulatory interventions

and also characterized by better margins than generics.

With a view to further growth, the functional reporting structures with short decision- making channels and, at the same time, strong regional

market presence will continue to take a high priority in the future. This predominately applies to our sales activities, because the ability to

react in the short-term to structural, regulatory or competition-related changes plays an essential role not only for reducing risks, but also

for exploiting opportunities. In individual cases, STADA is willing to continue to pursue an aggressive pricing policy in order to achieve a

better market position and a higher market share – however, always subject to the condition that the business activities in the relevant

market of a market region are profitable or become so within a foreseeable time.

In consideration of earnings, efficient cost management will also play an important role in the future. Within the framework of continuous

cost optimization the focus will continue on cost of sales and all the associated costs, as they represent by far the Group’s largest cost item.

In order to take advantage of opportunities to reduce these costs, STADA will continue to involve suppliers in the market risks and hire

suppliers from low-cost countries.

In addition, STADA sees significant opportunity in qualified employees, as they will continue in the future to have a significant share in the

ongoing success of the Group with their extensive expertise, their long-standing experience and their strong commitment.

Management Report of the Executive BoardManagement Report of the Executive Board | Opportunities Report | Risk Report

105

RISK REPORT

As an international pharmaceutical company STADA is part of a global business community and is thus exposed to a variety of risks in a

dynamic market environment. STADA understands risks as potential future developments or events that could lead to a negative deviation

from STADA’s projected business objectives.

STADA defines the management of risks as a permanent task of entrepreneurial activities. For this reason, STADA’s Executive Board

implemented an ongoing risk management system that is integrated into the value-based management and existing organizational structure

of the Group and that is based upon a globally recognized framework concept, the “Enterprise Risk Management – Integrated Framework”

(2004) developed by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The risk management system is

therefore an integral component of business processes and company decisions.

The risk strategy is based on STADA’s company strategy. It aims to put the Executive Board in the position to recognize risks at an early

stage so they can take control of them in due time. The risk strategy is practiced within all business segments of the STADA Group.

Risk management

As a stock corporation based in Germany, STADA is subject to German risk management legislation such as Section 91 (2) of the German

Stock Corporation Act. The Executive Board has established a Group-wide risk management system to ensure compliance to the relevant

legislation as well as to guarantee the effective management of risks. The risk management system aims to systematically and regularly

identify risks that are significant for STADA and that may jeopardize its continued existence, to assess their effects on the Group and

determine possible measures that can be initiated in due time if necessary. At the same time, the risk management system is intended to

guarantee sufficient security to ensure that STADA’s goals, particularly financial, operational and strategic goals, can be reached according

to plan. STADA’s risk management system represents an essential element in the entrepreneurial decision-making process and has there-

fore been implemented as an integral component of business processes throughout the STADA Group. The company-wide standard and

integrated approach to the management of risks is intended to ensure the effectiveness of Group-wide risk management and make it

possible to aggregate risks and provide transparent reporting.

106

The fundamental components of the Group-wide risk management system are:

1. The Risk Management department, which is vertically and horizontally integrated in the Company and is responsible for planning and

further development of the risk management system (including the Group-wide establishment of the risk management software “R2C

– Risk to Chance”), as well as the methods and procedures used to identify and assess risks and supporting the local risk confidants.

2. The local risk confidants who identify and assess risks (including measures) and document and update them in the risk management

system (bottom-up communication); they are integrated in all corporate units and subsidiaries throughout the Group.

3. Written and oral queries (top-down communication) sent to the decentrally organized responsible risk confidants by the Risk

Management department on current topics and the risk situation in the individual areas of the Group..

4. The company specific risk management guide, which defines the risk management process, the responsibilities within the risk

management process and the risk management system.

5. Risk reporting at Group and individual-company level.

STADA’s Group-wide risk management covers STADA Arzneimittel AG and companies in which STADA holds a stake of at least 50% even

if they are not consolidated. Insofar as recognizable risks to the Group arise at subsidiaries in which STADA holds a stake of less than 50%,

these risks are also recorded in the Group’s risk management system.

Only risks are recorded in the risk management system. Opportunities are not recorded in the risk management system along the lines of

risks. The identification and evaluation of opportunities takes place in the respective business environments. Opportunities are indicated in

the Opportunities Report within the Management Report of this Annual Report.

Management Report of the Executive Board107

Risk management process

The risk management process at STADA comprises the phases of risk identification, risk measurement, risk control, risk aggregation, risk

monitoring and risk reporting.

Phase 1

Phase 2

Risk
identification

Risk
measurement

Phase 3

Risk
control

Phase 4

Phase 5

Risk
aggregation

Risk
monitoring

Phase 6

Risk
reporting

Phase 1: Risk identification

Within the “risk identification” phase, all of STADA’s corporate units and subsidiaries systematically record all possible future developments

or events that could have substantial impact on STADA’s business model or change STADA’s risk profile. These possible future develop-

ments or events are allocated to a category in the company-specific risk atlas. These individual risks are identified, on the one hand, via

self-assessment of the risk confidants (bottom-up) and, on the other hand, via written and verbal inquiry of the Risk Management depart-

ment (top-down). Close cooperation between the Risk Management department and the risk confidants in the individual business areas and

worldwide locations is meant to ensure the individual risks are defined uniformly and that the conditions are present that make thorough

risk management possible throughout all departments and countries.

Phase 2: Risk measurement

In the “risk measurement” phase, the respective risk confidant analyzes the cause and effect structure and then, individually or in coopera-

tion with the Risk Management department, an evaluation is prepared for every individual identified risk. The quantitative evaluation of

individual risks is based on probability and impact; the evaluation should take consideration of potential direct damage as well as indirect

results caused by individual risks when they arise. In an additional step, each evaluated individual risk is subjected to a plausibility test by

the Risk Management department. Any inconsistencies uncovered by the plausibility test are discussed and resolved by the Risk Manage-

ment department and the responsible risk confidant in cooperation.

Phase 3: Risk control

In the “risk control” phase, the risk confidants, individually or in cooperation with the Risk Management department, identify potential

measures of risk avoidance, reduction, transfer and/or compensation. The measures identified can relate to the cause (preventative) as well

as to the effect (reactive). In some cases, the acceptance of an individual risk can be approved as a measure. In an additional step, each

identified measure is subjected to a plausibility test by the Risk Management department. Any inconsistencies uncovered by the plausibility

test are discussed and resolved by the Risk Management department and the responsible risk confidant in cooperation.

Management Report of the Executive Board | Risk Report108

Phase 4: Risk aggregation

In the “risk aggregation” phase, the causes of the individual risks are analyzed by the Risk Management department in an initial step.

Following on from the analysis, individual risks with identical or similar causes are aggregated for the sake of increased transparency. The

risk descriptions and probability of risks grouped into one risk aggregate item are closely analyzed and mutual compatibility ensured.

Phase 5: Risk monitoring

In the “risk monitoring” phase, the development of risks, as well as the implementation and effectiveness of the identified measures, is

continuously monitored by the risk confidants, who are supported by the Risk Management department. For individual, potentially high-risk

business processes, the Risk Management department accompanies the operational implementation, also in an observational role.

Phase 6: Risk reporting

In the “risk reporting” phase, the Risk Management department prepares quarterly risk reports based on the individual risks identified, and

the risk aggregates where separate, recipient-oriented reports are prepared for the Executive Board, the Vice Presidents and the Managing

Directors and made available in a timely manner. The risk report for the Executive Board is also passed on to the Supervisory Board.

Significant individual risks and risk aggregates indicated in the recipient-oriented report are jointly discussed by the Executive Board and

the Supervisory Board and if required, measures to counter risks are addressed. Any new significant risks or risk aggregates that appear

between reports within the scope of the risk management system are immediately provided via ad-hoc reporting to the Executive Board and,

if necessary, the Supervisory Board.

The risk management system run by STADA is regularly reviewed and evaluated by Internal Auditing for compliance with the statutory

framework conditions and Group-internal guidelines. In the scope of auditing the annual financial statements, STADA’s auditor also reviews

and evaluates whether the early risk detection system, which is integrated in the risk management system, is generally suitable to recognize

risks that may jeopardize the company’s continued existence at early stage. The auditor has confirmed that STADA’s early risk detection

system conforms to the legal requirements.

Significant features of the internal control and risk management system as relates to the Group accounting process

The Group-wide internal control risk management system with regard to the financial reporting process (ICRMS) is a component

of STADA’s comprehensive Group-wide risk management system. It follows the objective of ensuring the accuracy and reliability of financial

reporting (bookkeeping, separate and consolidated financial statements and management reports) by implementing appropriate and

effective procedures and controls, in accordance with relevant accounting standards and in compliance with Group-internal guidelines. This

involves the combination of central system organization and control as well as local responsibility for individual sub-processes.

Responsibility for the introduction as well as the functionality of the ICRMS rests with the Executive Board of STADA Arzneimittel AG. The

appropriateness and effectiveness of the ICRMS is assessed by the Executive Board at the end of each financial year at a minimum.

Management Report of the Executive Board109

The consolidated financial statements are prepared on the basis of Group uniform accounting guidelines laid down by the Corporate

Accounting department and a Group uniform accounting plan. New developments in the area of accounting standards are monitored on an

ongoing basis. Insofar as these are relevant for STADA, the accounting guidelines and the chart of accounts are adjusted accordingly. The

changes are communicated promptly to all companies included in the consolidated financial statements.

The primary control functions for the significant accounting processes are carried out by the respective plausibility tests integrated in the

programs. The software systems used are protected against unauthorized external access by appropriate IT systems. In addition, authori-

zation procedures ensure that internally, only the relevant individuals in each case have access to the individual systems.

In addition to the software-supported systems, manual plausibility tests and verification of the completeness and accuracy of data and

calculations are carried out at all Group levels. All separate financial statements of Group companies, which are included in STADA’s

consolidated financial statements, are generally subject once a year to an audit or review by the auditor. In addition, the auditor also carries

out a review of the half-year reports of the significant consolidated Group companies.

The functions of the departments significantly involved in the financial reporting process, the Group Accounting department for the

consolidated financial statements and the Accounting department for the separate financial statements are organized separately within the

finance department.

In the context of internal auditing activities as an additional component of the internal control system, the appropriateness and effectiveness

of the ICRMS is subjected to regular Group-wide audits, thus ensuring the reliability and functionality of the control mechanisms as well as

the appropriateness and effectiveness of the risk management system and compliance with Group-internal guidelines.

As a controlling body by way of its Audit Committee, the Supervisory Board also regularly monitors the reporting process and the effective-

ness of the control system, the risk management system, the internal auditing system and the audit of the financial statements.

The extent and focus of the established ICRMS is thus fully in line with STADA’s company-specific requirements. In the view of the Executive

Board, STADA has an appropriate and adequate monitoring system, which includes the necessary components of ICRMS for the Group. In

the context of a cost benefit analysis of each ICRMS however, limitations in relation to its effectiveness must be tolerated. In addition – even

in the case of existing control mechanisms considered as effective – the possibility of errors or an incorrect assessment of risks cannot be

completely excluded.

Period of assessment

The period of assessment for this Risk Report is generally 24 months in the future to the extent that no other period is stated in individual

cases. The assessment of the individual risks relates to December 31, 2014. There were no relevant changes after the balance sheet date,

which would have required a change in the presentation of STADA’s risk situation. It can, however, on principle not be ruled out that further,

also essential individual risks will arise in the development of business during the risk assessment period, which can add to the individual

risks stated in the following.

Management Report of the Executive Board | Risk Report110

Evaluation of risk categories

From the STADA Executive Board’s current perspective, relevant anticipated risks to the Group’s business activities include the individual

risks summarized according to risk categories below. By grouping together similar individual risks, the individual risks are aggregated to a

greater extent than they are for the purpose of internal controlling with the help of risk-management software. Unless otherwise indicated,

all individual risks described affect all company segments (Generics, Branded Products and Commercial Business) to varying extents.

In order to determine which risk categories are most likely to endanger the continued existence of the STADA Group, individual risks are

classified according to their estimated or derived probability and impact in relation to STADA’s business, financial and earnings situation.

The scales used for the measurement of these two indicators are presented in the charts below:

Probability

0% <

2% <

10% <

30% <

50% <

70% <

Probability

≤ 2%

≤ 10%

≤ 30%

≤ 50%

≤ 70%

Description

very low

low

noticeable

reasonable

probable

high

Impact

Description

0 € ≤

Impact

≤ € 800,000

marginal

€ 800,000 <

Impact

≤ € 2,500,000

noticeable

€ 2,500,000 <

Impact

≤ € 5,000,000

moderate

€ 5,000,000 <

Impact

≤ € 10,000,000

significant

€ 10,000,000 <

Impact

serious

STADA only quantitatively evaluates and reports individual risks on the basis of probability and the potential impact of the risk, regardless of

the risk categorization. For this reason, internal controlling only takes place at the individual risk level and not the level of aggregated risk

categories. For presentation purposes within this Risk Report, the evaluated individual risks are converted into annual figures. The converted

individual risks are summarized by aggregated risk category and weighted by classification “high”, “moderate” and “low”.

The following risks are generally presented as net risks, that is, risks including the steps taken to counteract them.

Management Report of the Executive Board
111

Environmental and industry risks

STADA is active in the health care and pharmaceuticals market in market regions and market segments which are characterized, among

other things, by high price sensitivity, continued margin pressure, intense competition and continuously changing regulatory framework

conditions. Of primary importance to STADA are risks related to changes in market conditions on the basis of intense competition or related

to changes to structures and mechanisms outside of STADA’s influence in the individual national markets of the respective market regions

or market segments. Particular attention in this regard is paid to the STADA core segments of Generics and Branded Products.

Some competitors, as a result of their financial and/or organizational resources and/or production capabilities and/or sales strength and/or

market power can influence market conditions in a negative manner for STADA. This relates in particular to such activities of competitors

that influence, pricing (for example in tenders for discount agreements), product range and scope of service and/or delivery and discount

conditions, in order to secure or improve their own competitive position. In addition, market conditions can also be influenced by the

appearance of new competitors.

At the same time, a change in market conditions is also possible as a result of increased purchasing power of individual customers or

customer groups (such as doctors, pharmacists, patients, health insurance organizations, buying groups, pharmacy chains, wholesalers,

mail-order companies), which could intensify competition regarding price, service, and condition terms as well as result in more unfavorable

framework conditions of tenders for discount agreements.

STADA may therefore be faced with the choice of either selling at non cost covering prices in individual national markets of the respective

market regions or foregoing substantial sales and accepting value adjustment and destruction of inventories that are no longer required.

The loss of these sales may lead to a deterioration of the earnings situation for existing sales, for example due to a lower utilization of

existing capacities or a worsened quantity scale in the case of external procurement.

To make use of opportunities, STADA is principally willing to accept, if necessary, losses in individual markets of respective market regions

and/or for selected products or product groups, for example in market regions with major growth potential for sales and/or earnings or with

strategic and/or operating necessity to maintain or expand its own market position. These losses may also be higher than anticipated as a

result of competition, customer behavior or government regulation.

STADA operates active risk minimization by comprehensively monitoring the market activity of all market participants and on the basis of

the observations indicating courses of action.

STADA places this in the “moderate” risk category.

Corporate strategy risks

STADA’s corporate strategy is mainly focused on growth and internationalization in the health care and pharmaceutical market in the core

segments Generics and Branded Products. With regard to costs and risks, STADA generally does not conduct any own research on, or

marketing of new active pharmaceutical ingredients, but rather focuses on the development and marketing of products with active

ingredients – generally active pharmaceutical ingredients – which are free from commercial property rights, particularly patents.

Management Report of the Executive Board | Risk Report
112

STADA’s growth strategy is linked to the risk that STADA might encounter difficulties in connection with certain operational and/or financial

requirements, which cannot, or not to a sufficient extent, operatively be met. In the event that the Group’s facilities, human resources,

internal structures, management tools, or financial resources cannot keep pace with the Group’s growth, STADA may be affected in a

materially adverse manner.

New companies and products acquired in the past or in the future or acquired or self-created other assets may not be integrated into the

Group as planned, or only at higher costs than originally expected, and/or intended synergy effects may not be achieved, or not achieved in

the intended amount. Furthermore, acquired companies and/or products may not generate the results anticipated in the market. Further-

more, there could be unexpected difficulties in introducing acquired products into new markets or in maintaining their existing market

positions. Any of the above-mentioned issues can particularly lead to the impairment of assets.

The implementation of a fundamentally growth-oriented corporate strategy requires significant outside financing. In financing ongoing

business activities and, in particular, the intended future expansion, there is an inherent risk that the Group may only be able to obtain

capital or loans under disadvantageous conditions, or not at all.

In principle, internationally active companies, such as STADA, face the risk of having to react differently and possibly with substantial effort

to legal and fiscal conditions that vary from region to region or country to country and are subject to change, to the relevant specific market

environment, as well as outside of the euro area to the different currency.

It may be difficult for STADA to enforce its own claims under the law of a country where STADA undertakes business at affordable costs and

without any materially adverse effects on business in this country. If, contrary to expectations, it turns out that this is not the case in a

country where STADA undertakes business, this can have materially adverse effects for the business activity in this country, but also for the

Group as a whole in the case of internationally linked business processes.

As STADA transfers and provides goods and services within the Group, there is a risk that tax authorities in individual countries assess the

relevant transfer prices differently and address retroactive tax claims against a company in the STADA Group.

Moreover, there is the risk that conditions which are relevant for the Group’s international operating activities – especially the conditions of

fiscal laws – may be changed by national or supranational regulations in a way that affects STADA in a materially adverse manner. In

addition, in connection with the internationalization, there is the risk that the political conditions in individual countries generally and for

STADA or the Group’s business activity specifically are changed in a materially adverse manner due, for example, to international tensions

or internal political developments in individual countries where STADA does business. Furthermore, parts of STADA’s business activities,

especially in the areas of product development and procurement, may be related to the USA and may, in the Company’s view, be subject to

elevated legal risks there as compared to other countries, particularly in the areas of liability and patent litigation. This may be associated

there with substantial additional costs, in particular for legal counsel. The same applies to disputes in the USA resulting from agreements

with third parties as well as a violation of confidentiality regarding company and trade secrets.

Management Report of the Executive Board113

Furthermore, a fundamental corporate strategic risk, thus also relating to STADA, is the fact that markets, market regions and market

segments on which a company strategically focuses develop differently to expectations. Even if STADA undertakes all efforts to carefully

analyze these expectations in advance, relying thereby also partly on external data and evaluations, assessment errors by STADA, due, for

example, to insufficient data available, unexpected regulatory or competitive influences, new technological developments or changed social

and macro and/or micro economic trends cannot be ruled out, which may be associated with substantial, primarily adverse effects for the

Group or individual Group companies.

STADA places this in the “low” risk category.

Regulatory risks

The health care and pharmaceuticals market is characterized by a large number of regulations. Changes to or the removal of existing

regulations or the passing of new regulations (in particular, regulations on a national or supranational level relating to market structure,

pricing and/or approvals of public health care system products for example as a result of court decisions or legislative changes) can have

significant economic and strategic effects on STADA’s business success. Of primary importance for STADA are regulations on a national or

supranational level relating to market structure, pricing and/or approvals of public health care system products.

For this reason, the risk exists for STADA’s business model that investments that rely on the continuation of existing market structures may

prove of no value after regulatory intervention or existing market positions may even be jeopardized. This relates for example to STADA’s

individual national sales structures, which are geared to the different national regulatory conditions with regard to the marketing, as well as

the sale and trade of pharmaceutical products, but also changes in the direct or indirect purchasing power of individual customers or

customer groups or changed purchasing behavior.

In many markets of the respective market regions, the prices of pharmaceutical products are subject to state supervision and regulation. In

some markets, governments also exert a direct influence on pricing. This can mean that as a result of national regulations, the prices of

pharmaceutical products are regulated directly (for example through statutory price reductions) or indirectly (for example through reference

prices, mandatory discounts, terms and/or requirements concerning discounts, the creation of framework conditions stimulating more

intense competition) or influenced by supranational regulations. Pricing pressure as a result of state reimbursement systems can reduce

the profitability of individual products and in individual cases make the market introduction of a new product unprofitable. STADA assumes

that the extent of price regulation and pricing pressure will continue or even increase.

Fundamentally, the risk exists for all products in the health care market, but for pharmaceutical products in particular, of exclusion or

reduction of cost reimbursement as a result of regulatory intervention under the respective national health systems. This can result in the

profitability of individual products being reduced and in individual cases, the market introduction of a new product becoming unprofitable.

Management Report of the Executive Board | Risk Report114

Moreover, the risk exists for pharmaceutical products that framework conditions in pharmaceutical legislation or provisions concerning

commercial property rights or other provisions that are relevant for the expansion of the product portfolio can be changed through national

or supranational regulations in a way that affects STADA in a materially adverse manner. Similar risks exist also for other partially regulated

product categories in the health care market such as, for example, medicinal products.

Exact predictions concerning the introduction and scope of potential changes in national or supranational regulations as well as their effects

on the market structures and/or business processes which are of relevance for STADA are not possible since the introduction and scope of

such regulations depend on the political process of the country in question or on court decisions and after such regulations have become

effective, the consequences are also influenced to a large degree by the reactions of the market participants affected. Changes in the

regulatory environment in STADA’s main markets by sales volume are continuously analyzed. Depending on the extent of state regulation,

it could become necessary to adjust the business model.

STADA places this in the “moderate” risk category.

Product portfolio risks

The continuous expansion of the product portfolio plays an essential role for the competitive position and business success at STADA.

Associated with this is the risk that due to unexpected events and/or the faulty implementation of activities preparing market entry – such

as product development and approval – products to be added to STADA’s product portfolio are, contrary to plans, not or belatedly or only at

higher development and/or production costs than originally assumed launched on the market. Reasons for this can include additional

requirements of approval authorities, direct government price controls or additional approvals for reimbursement via the relevant national

health system. The risks of development and approval processes for new products are continuously identified and evaluated.

In addition, meticulous observance of relevant legislation is extremely important for the development and approval of every individual

product. For generics, this also particularly applies to a great extent to the observance of commercial property rights (such as patents, SPCs

and “data exclusivity”). If individual legislative requirements are violated, the result may be a delay or even prevention of the launch of a new

product due to legal steps taken by competitors or rejection by the approval authorities. To the extent that STADA has offered products by

assuming legal clearance and in the course of court decisions it turns out that this assumption was wrong, there is the risk that STADA has

to take launched products at significant costs off the market, adjust the value of and destroy inventories which had existed already and those

taken back as well as meet significant damage claim payments if, for example, commercial property rights were infringed.

Despite intensive testing, it is possible that potential side effects or initially hidden defects of existing products are only uncovered after

approval or during marketing or that new scientific findings or evaluations could lead to an unfavorable risk/benefit analysis which would

result in the necessity to remove the product from the market either completely or in part. Such a sales stop can be voluntary act of

responsibility or also due to legal or government steps. Additionally, legal proceedings and associated damage claims as a result of possible

side effects or initially hidden defects could significantly burden earnings.

STADA places this in the “low” risk category.

Management Report of the Executive Board115

Legal risks

STADA’s business activities are subject to risks resulting from existing or potential future legal disputes. Risks that occur in relation to legal

disputes are identified, evaluated and communicated on a continuous basis.

STADA’s business activity, in particular in the core segment Generics, is associated with an elevated risk of legal disputes regarding

commercial property rights (especially patents and SPCs) as well as allegations of violations of company or trade confidentiality and such

disputes may be initiated by third parties with respect to STADA or by STADA with respect to third parties. Such events could result in

considerable costs, in particular when such proceedings occur in the USA. Moreover, they could result in significant damage claims and/or

a temporary or permanent ban on the marketing of particular products.

If there is a serious risk of future claims, STADA creates product-specific provisions considered to be commensurate with potential damage

claims, which amounted to a total volume of € 0.3 million for the Group as of December 31, 2014 (December 31, 2013: € 0.6 million). In

principle, STADA cannot guarantee that the provisions made will be sufficient for individual instances or in total.

STADA’s business activities engender risks associated with liability claims. Should specific Group products prove to be defective and/or to

cause undesirable side effects or should individual services or activities of the Group be carried out in a faulty way, this could result in

substantial damage claim liabilities and in the restriction or withdrawal of the product approvals concerned or in the withdrawal of the

service approvals. There is, in principle, no assurance that the insurance policies maintained by the Group, depending on type and scope,

will offer sufficient protection against all possible damage claims or losses.

In addition, STADA is subject to a jurisdiction risk which can turn out to be considerably more adverse than initially expected by STADA. This

risk relates to both those trials in which STADA itself is a participant as well as third-party trials in which judgments could have an indirect,

materially adverse impact on STADA and/or the market environment that is relevant for STADA. This applies in particular to decisions relating

to competition law and anti-trust law, tax law, patent law and to the implementation of individual regulatory requirements in the provision of

health care at a national and/or supranational level.

In addition, there is a legal risk resulting from the legal action that the insolvency administrator of Velefarm Holding and Velefarm VFB has

taken in Belgrade’s commercial court against Hemofarm A.D., a subsidiary of STADA Arzneimittel AG, and Velefarm Prolek, a company of

the Velefarm group in the first quarter of 2014.1) In the lawsuit, the insolvency administrator demands that certain agreements and

statements from the years 2010 and 2011 reached between Hemofarm and companies of the Serbian wholesale group Velefarm with

regard to the insolvent assets of Velefarm Holding and Velefarm VFB be declared invalid and demands repayments to the insolvent assets.

In September 2010, Hemofarm, Velefarm Holding and Velefarm VFB signed a restructuring plan regarding Velefarm Holding and Velefarm

VFB`s receivables held by Hemofarm. The intention of this restructuring plan was to put Velefarm in a position to gradually repay the still

outstanding trade receivables held by Hemofarm over a period of several years (see ad hoc release of September 28, 2010). The insolvency

procedures of Velefarm Holding and Velefarm VFB were initiated in the year 2012 and the same insolvency administrator was appointed as

representative of both companies. In the lawsuit, the insolvency administrator claims that by completing this restructuring plan and acces-

sory agreements and actions, Hemofarm disadvantages other creditors of Velefarm Holding and Velefarm VFB. In addition, the insolvency

administrator demands repayment of all advantages received to the insolvent assets of Velefarm Holding and Velefarm VFB plus interests

and costs for legal proceedings. In the statement of claim, these amounts are quantified with approx. € 54.2 million (in local currency

applying the exchange rate at that time). However, it has to be taken into consideration that Hemofarm as creditor of the insolvent assets

1) See the Company’s ad hoc release of February 14, 2014.

Management Report of the Executive Board | Risk Report116

would retrieve a quota of the insolvent assets in a significant amount. The conditions for the prejudicial treatment of creditors are not met

in the present case. The restructuring plan between Hemofarm, Velefarm Holding and Velefarm VFB was implemented by Hemofarm in

compliance with all legal provisions and served for the restructuring of the Velefarm group and not the prejudicial treatment of other

creditors. In particular, the implementation of the restructuring plan meant that Hemofarm, as one of the Velefarm group’s largest creditors,

would have to make substantial write-offs. In reaching this assessment, Hemofarm is among others relying on an expert opinion from a

well-known local law office. Hemofarm and STADA continue to believe that the lawsuit is unfounded.

STADA places this in the “moderate” risk category.

Performance-related risks

The Group’s own production facilities are subject to the risk of defective or inefficient planning and production processes as well as to

production faults and breakdowns as a result of this or external influence. This could have a materially adverse effect on costs, competitive-

ness, supply availability and the associated expectations regarding units sold, sales and earnings as well as the image with clients.

Although STADA undertakes all efforts to carry out exclusively safe business processes – particularly in the areas of product development,

production and logistics – it can, in principle, not be ruled out that unexpected disruptions occur in the context of such processes, possibly

endangering the health of employees from STADA or third parties and/or resulting in environmental damage, since STADA regularly works

with hazardous substances in the development, production and examination of products from the Group portfolio, especially in case of

drugs. It cannot be ruled out that the preventive measures and insurances taken do not provide sufficient coverage in the case of a

damaging event.

In the core segment Generics, individual national markets are increasingly characterized by very large volume fluctuation that regularly

arises in the context of tenders by governmental institutions or public health insurance organizations. Even though STADA undertakes every

effort to avoid delivery bottlenecks and/or an unintentional increase in inventories (e.g. via scenario calculations and a specific operational

positioning of the respective supply chain), such events cannot generally be ruled out in consideration of the comprehensive portfolio.

External suppliers, contract manufacturers, sales licensees and other contractors have been integrated into STADA’s business processes to

a considerable extent, particularly in the areas of product development, procurement, production, and packaging, logistics as well as sales,

though also to an increasing extent in other areas. Furthermore, the Group is taking increasing advantage of the opportunity of having also

services which are essential for the Group’s success performed by third parties, with whom cooperations are entered into. In addition,

STADA had specifically licensed German pharmacies to undertake the final packaging of partially packed products delivered by STADA in

their own pharmacies. This license currently applies to two branded products. When third parties are incorporated into the Company’s

business processes, the risk arises that individual business or cooperation partners may not comply properly or at all with their obligations

or that they may terminate their agreements with the Company, resulting in material adverse effects for STADA. Moreover, STADA could

become liable for infringements on the part of business or cooperation partners.

STADA is dependent on global developments with respect to purchase prices for active ingredients or auxiliary materials required as well

as on the prices negotiated with contract manufacturers in the case of products produced by these companies; these prices may fluctuate

significantly, also depending on the product. To limit the risk of market-related margin losses due to falling selling prices, STADA partly

makes use of instruments towards suppliers that involve them in the market price risk such as price escalation clauses linking procurement

prices to current selling prices, retroactive negotiations or the agreement of special procurement prices for special sales volumes, in the

Management Report of the Executive Board117

context of tenders, for example. However, it cannot be ruled out that procurement cost increases and/or supply shortages in the case of

individual products will have materially adverse effects on the Group’s sales and/or profit margins.

Numerous contracts in the STADA Group include – especially in the areas of product development and production as well as for distribution

rights – so-called “Change of Control” clauses, which usually provide both contracting parties, as is usual in the industry, with reciprocal

extraordinary termination rights for agreements concluded by the parties in the case that one of the contracting partners becomes subject

to a so-called change of control (change of majority shareholder), e.g. after a successful takeover offer. In the case of a change of control

in the STADA Group this could result in material adverse effects for STADA if contracting parties make use of such extraordinary termination

rights, in particular if the extent of these terminations is beyond individual cases.

STADA places this in the “moderate” risk category.

Human resources risks

STADA depends to a large extent on the commitment, motivation and abilities of its employees. The loss of specialists and managers in key

positions could have significant adverse effects on the development of the Group. The Group’s continued success also depends on its

ability, in competition with other companies, to attract and keep qualified employees in the future for the long term regardless of demo-

graphic challenges. Country and industry-specific fluctuation risks must be proactively identified and addressed specifically to maintain

success and critical skills and competencies within the company. STADA counters these risks on the one hand through global staff devel-

opment and succession processes through which the potential of the employees is systematically identified and promoted. In addition,

STADA uses targeted development activities to support both young and experienced highly qualified employees in their career development

and to develop and retain performance-critical skills in the company.

It is STADA’s expressed goal that all business processes and Group activities be carried out exclusively within the framework of respective

laws in force. To this end, within the scope of the compliance system established at STADA, all employees are regularly, and to an extent

adjusted to the scale of their individual areas of responsibility, trained and instructed. It can, however, not be completely ruled out that

employees, in the execution of business processes deviating from the Group regulation of full compliance, act negligently or intentionally in

breach of legal regulations and that such breaches affect the business activities of the Group and/or individual subsidiaries or the business,

financial and earnings situation of STADA in a materially adverse manner, e.g. following the discovery of such legal breaches through the

imposition of damages and/or compensation and/or the payment of fines, exclusion from tenders or damage to reputation.

STADA places this in the “low” risk category.

Risks in relation to information technology

STADA’s strategic goals can only be achieved by optimal alignment and appropriate support using a variety of IT systems and processes.

Therefore, the Group has to make continuous investments to appropriately adapt these complex and high-performing systems to changing

business processes.

Global IT applications in process control thereby form the basis for the delivery of products to the global customers of the STADA Group as

agreed upon. In the event that information technology processes of the Group are, despite all precautions, insufficient and/or inefficient, this

could have materially adverse effects on business processes at STADA. Variations in the quality of internal IT services can also lead to

Management Report of the Executive Board | Risk Report118

failure of business-critical IT applications that would have a direct impact on STADA’s ability to deliver. Similarly, the failure of a data center

could affect the quality of service or lead to a complete failure of critical applications.

The abuse of digital technology and the Internet as a means to perpetrate new types of crime, i.e. cybercrime as a whole (e-crime), is

developing at great speed and represents a further challenge. This can result in threats such as the failure of central IT systems, the

disclosure of confidential data from development and business activities, manipulation of IT systems in process control or increased strain

on and/or impairment of IT systems through virus attacks. This scenario also includes the temporary takeover of exposed systems by

hackers and consequently the possible revocation of pharmaceutical approval due to the deficient validation of relevant IT systems. Such

unauthorized data access, misuse or loss of data could also have materially adverse effects on the Group.

Currently, the gradual conversion of various information technology systems (IT systems) to an integrated SAP system is being carried out

in the Group. Generally, when introducing new or converting existing IT systems, there is an elevated risk that unanticipated events occur

which, during the initial phase and also during the integration and expansion phase, can have materially adverse effects on the course of

business processes and thus could influence business activities of the Group and/or of individual Group companies in a materially adverse

manner.

STADA places this in the “low” risk category.

Economic risks

STADA’s business success is also generally dependent on economic influences because an economic downturn can regularly intensify the

already prevalent cost pressure in national health care systems and thereby potentially significantly increase the speed and extent of

regional regulatory measures to contain costs. As a result, adverse characteristics for STADA such as state-required price reductions,

particularly for prescription drugs, cannot be ruled out.

Moreover, sales volume and sales of Group products or product lines are particularly sensitive to changes in the economic environment, for

which the consumer is not reimbursed as part of the individual national health insurance system but must bear a major part or all of the

costs. In the scope of STADA’s product portfolio this is true in particular for drugs used for self-medication, for products without a pharma-

ceutical character as well as for services offered and for prescription drugs in market regions containing countries without a comprehensive

state health care system, such as Russia in the market region CIS / Eastern Europe.

Another material risk for STADA lies in the area of corporate finance. Parameters in this area significantly influencing Group success such

as financing possibilities, interest rates, inflation rate, currency ratios and client liquidity can be subject to distinct economic influences and

thereby also have a material adverse effect on STADA’s business success in case of an economic downturn. Furthermore, liquid financial

markets for refinancing are an important precondition for STADA’s acquisition policy. In case of disruptions of the financial markets – no

matter whether globally or regionally in market regions that are important for STADA – materially adverse effects for the Group cannot be

ruled out.

In addition, STADA generally conducts business transactions not against cash payment, but on an invoicing basis to numerous debtors.

Thus, the fundamental, partly also cyclical commercial risk of debtor default is associated with this. STADA therefore strives to maintain

business relations only with business partners of impeccable financial standing and in addition, partly uses suitable measures to safeguard

Management Report of the Executive Board119

itself against default risk, such as guarantees, loan insurances or the transfer of assets. However, it cannot be ruled out that these measures

are insufficient and non-payments of individual debtors, and therefore burdens from one-time special effects, arise to a significant extent.

In addition, there is the risk that in a difficult economic environment, national health care systems delay or fail to make payments to STADA

or business partners of STADA and that, as a result, directly or indirectly increased default risks arise.

The conflict between Russia and Ukraine has led to an additional risk for the development of the world economy and the STADA Group since

2014. This risk has increased macroeconomic uncertainty and in particular had a negative effect on the business climate, the consumer

confidence and the demand of the wholesalers in these markets for the STADA Group. It is currently unclear how long the political upheaval

and related decreased demand from consumer and wholesalers might last. If the crisis continues there may be further decreases in sales

in these markets as well as further impacts due to a depreciation of the respective currencies (see “Financial Risks”) which will have a

negative impact on the earnings situation and financial performance of the STADA Group.

Another risk lies in the value of the assets in the consolidated balance sheet, in particular goodwill and other intangible assets. They are

subject to thorough and detailed reviews. Within the scope of an annual impairment test, the value of the goodwill as well as the other

intangible assets with determinable and indeterminable useful lives is reviewed. In addition, in the case of specific indications, both

intangible assets as well as property, plant and equipment are subject to a case-related impairment test. Generally, it can not be ruled out

here that in the annual impairment tests or in the case-related impairment tests carried out over the course of the year that, for example,

as a result of new findings in approvals or changes to the market conditions in individual market regions or individual countries of a market

region, a relevant impairment may occur.

In the case of a global financial and economic crisis, the economic-related cyclical risks indicated above can increase considerably.

STADA places this in the “low” risk category.

Financial risks

To the extent that it is possible, STADA counters financial risks with finance policy methods and a specific risk management.

The basic principles of financial policy and of financial risk management are determined or confirmed at least once annually by the Executive

Board in the context of the budget process. Furthermore, all transactions above a certain limit determined to be relevant by the Executive

Board must first be approved by the Executive Board. The Executive Board is also regularly informed of the nature, scope and amount of

current risks. With a view to assets, liabilities and planned transactions, these risks relate in particular to changes in exchange rates and

interest rates. It is the objective of financial risk management to limit these market risks of ongoing operative and finance-related activities.

For this purpose, depending on the assessment of the financial risk, selected derivative and non-derivative hedging instruments are used.

However, on principle only financial risks are hedged which have significant consequences on the Group’s cash flow.

Management Report of the Executive Board | Risk Report
120

Liquidity risks result if STADA does not hold sufficient liquidity. They may result, for example, from the loss of existing cash items, lack of

availability of credit, reduced access to financing markets or fluctuation in the operational development of business. The goal of the liquidity

management is to ensure solvency at all times as well as the financial flexibility of the STADA Group by way of maintaining a sufficient

supply of liquidity reserves and having free credit lines. STADA finances itself with short-term and long-term borrowings from banks,

promissory notes, bonds and factoring. Furthermore, STADA has solid operating cash flow and further bilateral credit contracts with various

banks (credit lines), which can be utilized as needed.

STADA’s Group and balance sheet currency is the euro. Due to the international alignment of business activities, STADA is however subject

to risks arising from exchange rate fluctuations.

These risks consist of potential changes in value, especially of receivables and liabilities in a currency other than the respective functional

currency as a result of exchange rate fluctuation (transaction risk).

STADA counters risks from currency related cash flow fluctuations with derivative financial instruments, which are exclusively used to hedge

currency risks resulting from operating activities, financial transactions and investments. Derivative financial instruments are neither held

nor issued for speculation purposes.

In addition to natural hedges, STADA generally employs different financial derivatives to counter the risks associated with assets, liabilities

and anticipated future cash flows denominated in foreign currency. In the reporting year, STADA made use of foreign-exchange futures

contracts and interest / currency swaps. The maturity dates of futures contracts are thereby selected to match the Company’s anticipated

cash flows. The remaining term of the contracts is currently up to three years.

Additional risks occur when exchange rate fluctuations in the consolidated financial statements lead to an accounting effect as a result of

the conversion of a balance sheet items as well as the conversion of earnings and expenses of international Group companies with a

different functional currency than euro (translation risk). In this connection, the current political conflict between Ukraine and the Russian

Federation could indirectly continue to have a negative influence on the earnings situation and exchange rates. The appreciation of the euro

as compared to the other currencies is generally negative and depreciation is generally positive. Exchange rate risks primarily result from

activities in the following currencies: Russian ruble, pound sterling and Serbian dinar. This risk is not hedged.

According to a currency sensitivity analysis within the scope of regulations of IFRS 7 based on the foreign currency items outstanding as of

the balance sheet date, an appreciation or devaluation of the euro compared to the currencies of relevance for the Group of 10% would

have led to an effect on earnings of expenses in the amount of € 7.1 million (previous year: € 7.6 million) or of income in the amount of

€ 7.1 million (previous year: € 7.6 million). Of these effects on earnings, € -0.6 million or € 0.6 million relate to the Russian ruble, € -1.5 mil-

lion or € 1.5 million relate to the Kazakhstani tenge, € -2.8 million or € 2.8 million to the Ukrainian hryvnia and € 1.3 million or € -1.3 mil-

lion to the Serbian dinar.

In principle, it cannot be ruled out that hedging strategies against currency risks turn out to be insufficient, wrong or suboptimal.

STADA is subject to interest risks from financial assets and financial debts, primarily in the Euro zone and Russia.

Management Report of the Executive Board121

In order to minimize the effects of significant interest rate fluctuations, STADA manages the interest rate risk for the financial liabilities

denominated in euro with hedging transactions. STADA calculates existing interest rate risks using sensitivity analyses, which show the

effects of changes in market interest rates on interest payments, interest income and expenses as well as equity.

A sensitivity analysis according to the regulations of IFRS 7 has shown that an increase in market interest rates of 100 basis points in

financial year 2014 would have led to a burden on earnings in the amount of € 0.5 million (previous year: € 2.1 million) and a decrease in

market interest rates of 100 basis points would have led to an improvement of earnings in the amount of € 0.4 million (previous year:

€ 2.0 million).

In financial year 2014, to hedge the interest rate risk, there were cash flow hedges in the form of interest-rate swaps.

Derivative financial instruments are neither held nor issued for speculation purposes.

In addition, STADA may be exposed to a default risk in its operating business or as a result of financing activities if contracting parties fail

to meet their obligations.

To avoid default risks in financing activities, on the one hand respective credit management processes are in place, and on the other hand

such transactions are generally only concluded with counterparties of impeccable financial standing.

Risks of default exist as a result of the supply of goods and services. In addition, there is the risk that in a difficult economic and financial

environment, national health care systems delay or fail to make payments to STADA or business partners of STADA and that, as a result,

directly or indirectly increased default risks arise.

STADA therefore strives to maintain business relations only with business partners of impeccable financial standing and in addition, partly

uses suitable measures to safeguard itself against default risk, such as guarantees, letters of credit, credit insurance or the transfer of

assets. However, it cannot be ruled out that these measures are insufficient and non-payments of individual debtors, and therefore burdens

from one-time special effects, arise to a significant extent. Past due receivables in the operating area are continuously monitored and

potential default risks are anticipated through the creation of valuation adjustments.

In the context of a hypothetical risk assessment, there are also other price change risks related to market prices. However, as of the balance

sheet date, STADA only recognizes available-for-sale financial assets, whose fair values are determined based on market prices, to a minor

extent.

STADA takes advantage of an international network and carries out strategic Group functions centrally through STADA Arzneimittel AG. Thus

an overarching tax transfer pricing model for the billing of the corresponding intercompany services is of increasing importance. Possible

risks of non-recognition of these transfer prices for tax purposes are limited by the introduction of appropriate communication methods and

an overarching definition of transfer pricing in the form of a Group guideline. However, non-recognition of transfer prices can not be

completely ruled out.

Management Report of the Executive Board | Risk Report122

Furthermore, STADA has obligations in connection to pension plans. The present value of benefit obligations according to IFRS is influenced

by changes in relevant valuation parameters, for example, interest rate changes or future salary increases. Thus, there is a risk of relevant

valuation parameters changing in a way that is unfavorable for STADA and as a result, the present value of the retirement benefits increases

significantly.

In general, it cannot be ruled out that the financial policy methods and the specific financial risk management implemented by STADA and

described above, prove insufficient to avoid all financial risks and the materially adverse effects for STADA that are potentially associated

with them.

STADA places this in the “moderate” risk category.

Other risks

STADA is in possession of a number of trade and business secrets that must be treated with confidentiality. STADA makes use of

confidentiality agreements with employees, external alliance partners, service providers as well as with certain other contractual partners in

order to safeguard these. However, there is no guarantee that these agreements and other protective measures taken to ensure business

and trade secrecy actually represent effective protection or that they will not be violated. In addition, there is no assurance that business

and trade secrets will not become known to competitors by other means. This may have adverse material effects on the Group.

Like any company, STADA as a Group and the STADA subsidiaries in the market regions or markets are subject to additional general

business risks such as unexpected disruptions in infrastructure, strikes, accidents, natural disasters, sabotage, criminal activities, terrorism,

war and other unforeseeable materially adverse influences. STADA protects itself against such risks to the extent possible and financially

reasonable through appropriate insurance policies. However, it cannot be ruled out that these insurances are insufficient.

Should STADA no longer fulfill the necessary criteria according to IFRS 10 (“Consolidated Financial Statements”) for control, and thereby for

consolidation, of subsidiaries due to particular capital constraints or other measures – such as may come as a result of political or military

conflict – STADA would have to deconsolidate these companies. The resulting effects depend on the significance of the affected companies

for STADA and could result in materially adverse effects for the Group.

STADA places this in the “low” risk category.

Management Report of the Executive BoardSummary evaluation of risks

Risk category

Environmental and industry risks

Corporate strategy risks

Regulatory risks

Product portfolio risks

Legal risks

Performance-related risks

Human resources risks

Risks in relation to information technology

Economic risks

Financial risks

Other risks

123

Risk classification by STADA

moderate

low

moderate

low

moderate

low

moderate

low

In the event that one or more of the above-mentioned risks should materialize or newly occur in the development of business, this could

respectively have materially adverse effects on the Group’s business activities. In particular, respectively material adverse effects on

STADA’s business, financial and earnings situation could be associated with this.

The assessment of the overall risk situation is the result of the consolidated consideration of all significant individual risks on the basis of

the applied risk management. The risk environment of STADA has changed as compared to the previous year, as a result of the geopolitical

development of the conflict between Russia and Ukraine that led to an increased uncertainty of the macroeconomic and political situation.

From today’s perspective, however, no risks are discernible which, individually or as a whole, could jeopardize the continuance of the Group.

Management Report of the Executive Board | Risk Report124

TAKEOVER-RELEVANT INFORMATION

In accordance with Section 315 (4) HGB, STADA is obligated to disclose the following information in the Annual Report:

Composition of share capital, rights and obligations / restrictions associated with shares, which affect the transfer of shares

As of December 31, 2014, share capital consisted of 60,626,700 ordinary shares, each with an arithmetical share of share capital of

€ 2.60 per share.

These ordinary shares of the Company are exclusively registered shares with restricted transferability, which, under the Articles of Incorpo-

ration, can only be entered into the share registry with the approval of the Company and which, in accordance with the Articles of Incorpo-

ration, grant one vote each in the Annual General Meeting. Shareholders are only those who are registered as such in the share registry and

only such persons are authorized to participate in the Annual General Meeting and to exercise their voting rights.

Shares acquired by employees within the scope of the employee stock option program are subjected to a three-year lockup period.

Appointment and dismissal of Executive Board members / Amendments to the Articles of Incorporation

The Executive Board is appointed and dismissed exclusively in accordance with legal regulations.

The Articles of Incorporation do not provide special provisions on the appointment or dismissal of individual and all members of the Executive

Board. Only the Supervisory Board is responsible for the appointment and dismissal. It appoints members of the Executive Board for a

maximum of five years. A repeated appointment or extension of the term is allowed, for a maximum of five years each.

The Articles of Incorporation may generally be amended through a resolution of the Annual General Meeting.

The amendment takes effect with the entry of the amendment to the Articles of Incorporation into the commercial register. Amendments to

Articles of Incorporation require, according to Section 179 (1) of the German Stock Corporation Act (AktG), a resolution of the Annual General

Meeting, provided no other majority is foreseen, a majority of three-fourths of the share capital represented in the vote pursuant to Section

179 (2) AktG. Insofar as a change to the purpose of the company is affected, the Articles of Incorporation may call for a large majority. The

Articles of Incorporation exercise in Section 23 (1) the possibility of a deviation pursuant to Section 179 (2) AktG and stipulate that, unless

otherwise provided by mandatory provisions of the German Stock Corporation Act, resolutions shall be passed by a simple majority of the

votes cast and, insofar as a majority of the share capital is represented at the time the resolution is passed, with a simple majority of the

capital present insofar as this is legally permissible. In case of a tie, a motion shall be deemed denied.

Furthermore, the Supervisory Board is authorized in accordance with Section 32 of the Articles of Association to resolve on amendments

and additions to the Articles of Incorporation which relate only to their wording.

Management Report of the Executive Board125

Authorizations of the Executive Board to issue or buy back shares

The Executive Board was authorized by the Annual General Meeting on June 5, 2013 to raise new authorized capital. The resolution

authorizes the Executive Board, with the approval of the Supervisory Board, to increase the share capital of the Company on one or more

occasions by June 4, 2018, by up to € 77,134,304.00 through the issue of up to 29,667,040 registered shares with restricted transfer

ability against contributions in cash and/or in kind. The Executive Board is authorized, with the approval of the Supervisory Board, to

determine the content of the share rights, the individual details of the capital increase as well as the conditions of the share issue in

particular the issue price. The Executive Board has not made use of this authorization to date.

On June 5, 2013, furthermore, the Annual General Meeting authorized the Executive Board, on one or more occasions until June 4, 2018,

to issue bearer and/or registered bonds with warrants and/or convertible bonds, participation rights and/or participating bonds (or a

combination of these instruments) (collectively “bonds”) in an aggregate nominal amount of up to € 1,000,000,000.00 with or without

limiting the term, and to grant the holders or creditors of the bonds with warrants and/or convertible bonds a proportionate amount of the

share capital of up to € 69,188,340.00 for a total of up to 26,610,900 of the Company’s registered shares with restricted transferability in

accordance with the more detailed provisions of the terms of the bonds. For the purposes of servicing these bonds, the Annual General

Meeting on June 5, 2013 conditionally increased the share capital by up to € 69,188,340.00 by issuing up to 26,610,900 registered

shares with restricted transferability and carrying a dividend right as of the beginning of the financial year in which they are issued. The

Executive Board, with approval of the Supervisory Board, is authorized to determine the further details of implementation of the conditional

capital increase (Conditional Capital 2013). The Executive Board has not made use of this authorization to date.

The share capital of the Company was conditionally increased as of December 31, 2014 by up to € 4,585,152.00 by issuing up to

1,763,520 registered shares with restricted transferability (Conditional Capital 2004/I). The conditional capital increase will be effected only

insofar as the holders of warrants exercise their option rights.

Following the resolution adopted at the Annual General Meeting on June 5, 2013, in accordance with Section 71(1) no. 8 AktG, the Company

was authorized from June 6, 2013 until June 5, 2018 to acquire own shares of up to 10% of the share capital. The Executive Board has

not made use of this authorization to date.

Significant agreements on condition of a change of control

In case of a change of control resulting from a takeover offer to the company, there are, in accordance with common business practice,

possibilities of termination for certain credit contracts, the lenders of several credit contracts, the issued corporate bonds and of the issued

promissory notes (see “Economic Report – Business Development and Situation – Financial Situation”).

For the agreement of the company with members of the Executive Board in the case of a change of control, please refer to the Remuneration

Report in this Annual Report.

Management Report of the Executive Board | Takeover-Relevant Information126

PROGNOSIS REPORT

Proven business model with sustainable growth potential

STADA’s proven business model has been characterized by a constant and sustainable development for years. In light of the overall

successful development, the Executive Board will maintain the Group’s strategic orientation also in the future. The business activities,

therefore, will continue to focus on products with off-patent active ingredients in selected segments of the pharmaceutical market. The

Group’s two core segments will continue to be Generics and Branded Products. Apart from the regional expansion of its business activities,

STADA will, in growth and earning aspects, focus increasingly on the promising area of biosimilars in the Generics segment. In the core

segment Branded Products, the main focus is both on expansion and on internationalization.

In view of the Executive Board, the Group activities thereby also remain focused on market regions with long-term growth opportunities in

future. As these can vary depending on economic, regulatory and competitive framework conditions in the individual market regions from

year to year, the sales and earnings development will continue to be influenced by various and, in part, opposing factors in financial year

2015. For details on the expectations of the Executive Board as relates to the opportunities and risks in the individual market regions, please

refer to the segment reporting in this Annual Report (see “Economic Report – Business Development and Situation – Earnings Situation –

Development of Segments – Information by Market Region”).

In principle, a slowdown or temporary decline in growth cannot be ruled out if difficult framework conditions accumulate. In view of the

strategical success factors, however, the Executive Board sees clear opportunities for further growth also in the future.

Overall economic outlook

For 2015, the IMF expects a moderate increase in economic activity with a rise in global economic growth in the amount of 3.5%.1)

Estimates show economic development for emerging markets at 4.3%, whereas growth of 6.8% in China is expected.1) IMF forecasts

growth of 2.4% for advanced economies.1) In this context, GDP in the USA is expected to grow by 3.6%, while forecasts for economic

development in EU countries assume an increase of 1.2%.1) According to estimates, GDP will grow by 1.3% in Germany, by 0.9% in France,

by 2.0% in Spain and by 0.4% in Italy.1) In the so-called CIS countries (Commonwealth of Independent States), GDP is expected to decrease

by 1.4% in 2015 with a minus of 3.0% in Russia. For the region Emerging and Developing Europe2), experts anticipate growth of 2.9% with

a plus of 1.0% in Serbia3).

The ECB also sees the prospect of moderate recovery in the Euro zone in 2015. Domestic demand should benefit from the monetary policy

measures, the ongoing improvements in financing conditions and from the lower energy prices supporting real disposable income.4) Export

demand is expected to benefit from the global recovery.4) Nevertheless, Euro zone unemployment will remain high, and the changes that

need to be made to both public and private sector budgets will continue to burden economic development.4) Overall, the ECB increasingly

stresses the risks for private investments and for the insufficient progress made in the context of structural reforms in Euro zone countries.

The STADA Executive Board continuously monitors worldwide economic developments – with a consistent view to the resulting opportunities

and risks for the Group. From today’s perspective, the Executive Board sees no reason to question STADA’s fundamental business model.

1) Source: International Monetary Fund: World Economic Outlook of January 2015.
2) Including Bulgaria, Croatia, Lithuania, Poland, Romania, Serbia, Turkey and Hungary.
3) Source: International Monetary Fund: World Economic Outlook of October 2014.
4) ECB Monthly Bulletin of December 2014.

Management Report of the Executive Board127

Industry specific outlook

In the Executive Board’s assessment, numerous national health care and, in particular, pharmaceutical markets will continue to provide high

growth opportunities that are relatively independent of economic activity. On the one hand, this is based on general growth drivers in the

form of the global population increase, an aging society in industrialized nations and further medical progress. On the other hand, the growth

opportunities are based on generics-specific drivers such as progressive generics penetration as a result of increasing spending restraints

in individual national health systems and continuous patent expirations. This also applies to the future-oriented field of biopharmaceuticals

with high sales and earnings potential.

In view of the continually rising demand in the health care market and the fact that drugs are viewed as relatively efficient compared to

other treatment methods, further growth continues to be expected for the international pharmaceutical market in the future. According to

forecasts, sales in the global pharmaceutical market will increase by 5% to 7% per year until 2019.1)

In the view of the Executive Board, the Generics segment, in particular, has growth opportunities within the pharmaceutical market, as

generics ensure a cost-effective medicative therapy without any loss in quality and thus counteract increasing cost pressure in the individual

health care markets. Furthermore, the potential available for generics competition is increasing due to the continuous expiration of patents

and other commercial property rights.

This estimation is also confirmed by the forecasts of IMS Health, according to which annual growth for the global generics market will be

as high as 7.4%2) until 2019. It should, however, be taken into account that the actual growth rates of reported sales in markets where

significant discounts must be granted, could be substantially below gross sales generally recorded by the market research institutions

before discounts.

In view of the sales volume for newly available active pharmaceutical ingredients for generics competition between 2015 and 2018 in the

largest pharmaceutical markets by sales in Europe – Germany, France, Italy, the United Kingdom and Spain within the two STADA market

regions Germany and Central Europe – which, according to market research figures, amount to more than € 12.1 billion, the Executive

Board call for further growth opportunities in the EU generics market.3)

This assumption is supported by estimates from IMS Health as well, according to which annual generics growth in the EU amounts to an

average of 5.4%1) from 2014 to 2016. For selected markets in Eastern Europe4) of the market regions Central Europe and CIS / Eastern

Europe, IMS Health expects annual average generics growth of 5.8%5) until 2019. In Russia, estimates from IMS Health, after the start of

the CIS crisis, call for average generics growth of 9.2%5) from 2015 to 2019.

In the Generics area, biosimilars in particular will play an increasingly important role in the future, since they can contribute significantly to

a relief of the individual national health care markets. Overall, twelve of the strongest biologics in terms of sales will have lost their patent

protection by 20206). In the current year, a paradigm shift is pending in this connection since, for the first time ever, there will be more

patent expirations among biopharmaceutical products than chemical-synthetic products. By 2018, biopharmaceuticals valued at a total of

around € 51 billion will have lost their patent worldwide.7) In view of the potential this area offers, the STADA Group consequently continues

in the context of its biosimilar activities to pursue its strategy of relying on cooperations with highly specialized partners in order to expand

its portfolio at favorable conditions with high-quality products.

1) IMS Market Prognosis, September 2014; IMS Market Prognosis Global, September 2014; IMS Syndicated
Analytics Service (September) 2014; prepared for STADA February 2015.
2) IMS Market Prognosis, September 2014; IMS Market Prognosis Global, September 2014; IMS Syndicated
Analytics Service (September) 2014; prepared for STADA February 2015. The market data on Generics
fluctuates – in some cases substantially – due to differing market definitions from source to source.
3) STADA estimate of sales volumes in 2014 at ex-factory prices for active pharmaceutical ingredients for
which STADA from today’s perspective expects the patents or other commercial property rights relevant for
generics competition to expire by 2018, based on data provided by various international market research
institutes. STADA’s expectations as to the date of availability of active pharmaceutical ingredients for Generics
competition are continuously being reviewed from a legal perspective and may in the future significantly
differ from today’s expectations (as of: March 1, 2015) as expressed in this data. The actual sales volumes
becoming available for generics competition at the respective dates are subject to fluctuations as a result of
changing market success, legal situations or market structures, among other factors.

4) Russia, Serbia, Ukraine, Kazakhstan, Bosnia-Herzegovina.
5) IMS MIDAS (September) 2014; IMS Syndicated Analytics: Forecasting Premium Support Service prepared
for STADA, February 2015.
6) Source: “Deutsches Ärzteblatt” (a German medical journal) of March 14, 2014; 111 (11): A-452 / B-388 /
C-372: “Biosimilars: Das Wettrennen ist in vollem Gange” (“Biosimilars: The race is well underway”).
7) Source: “Pro Generika – Generika und Biosimilars in Deutschland, Marktdaten Pro Generika 2013”
(“Pro Generics – generics and biosimilars in Germany, market data Pro Generics 2013”).

Management Report of the Executive Board | Prognosis Report128

In growth and earning aspects, STADA has been increasingly promoting the expansion and internationalization of the Branded Products

segment, as it is generally subject to less regulatory intervention and is characterized by substantially more attractive margins than the

Generics segment. This is due, on the one hand, to the relief of the global health care systems since non-prescription drugs are, with only

a few exceptions, not reimbursable. On the other hand, the number of so-called “self-improvers”, who rely on self-medication in health care

and, with a growing tendency, spend more money on that, is increasing particularly in the Western industrialized nations.

For the global OTC market, IMS Health predicts annual growth of 6.9%1) until 2019. For the European OTC market, experts forecast an

increase of up to 0.9%.1)

Challenges and risks

In addition to the growth opportunities mentioned in this Annual Report, the Group is also confronted with operating challenges and risks

which are detailed in the segment reporting and the regional development in individual markets of the respective market regions as a well

as in the Risk Report, among other locations. In the view of the Executive Board, many of these challenges and risks result from the

structures and mechanisms of the market segments and market regions which the Group cannot influence and in which the Group is active.

As these are, however, to large extent inseparably linked to the structural growth opportunities, it will remain impossible to avoid them in

future in order to optimally utilize these growth opportunities (see “Basis of the Group – Business Model” and “Risk Report”).

The business model of STADA is generally oriented toward the health care market with demand that is relatively independent of the

economy. Therefore, the international economic conditions generally have less of a direct influence on the business development of the

Group than the respective regulatory environment in the individual markets of the four STADA market regions. Despite this, the Group will

continue to be confronted by specific consequences of economic effects in the future in addition to the general challenges and risks

associated with the business model (see “Risk Report”).

From today’s perspective, the Executive Board does not see any challenges or risks that would jeopardize the existence of the Group.

Basis of the prognosis

The outlook for financial year 2015 takes account of the events known when this Annual Report was prepared that could have an effect on

the business development of the STADA Group. It is also based on the details on the overall economic outlook and the industry-specific

outlook.

Furthermore, the forecast was mainly based on the following assumptions:

• Predominately unchanged regulatory framework conditions in the most important markets of the four STADA market regions

• Optimization of procurement prices for primary materials

• The continued possibility to immediately launch new products upon patent expiration

• Largely unchanged tax situation in the countries where STADA has Group companies

1) IMS Market Prognosis, September 2014; IMS Market Prognosis Global, September 2014; IMS Syndicated
Analytics Service (September) 2014; prepared for STADA February 2015. IMS MIDAS (September) 2014.

Management Report of the Executive Board129

Summarizing outlook

STADA’s business model is generally geared towards markets with long-term growth potential in the health care and pharmaceutical

markets. Inseparably linked to this, however, are risks and challenges resulting in particular from changed or additional state regulation and

intensive competition. In view of this, in the Executive Board’s assessment, far-reaching regulatory interventions, a high level of competition,

default risks and significant margin pressure can continue to occur in individual markets of the respective market regions in the future. The

latter applies primarily to the increasing volume of business activities in the Generics core segment characterized by tenders.

In addition, the Group will continue to be confronted by non-operational influence factors in future. As a consequence, relevant Group

currency relations, in particular of the Russian ruble, the Serbian dinar and the British pound sterling to the euro, will affect the Group’s

future development in financial year 2015. Furthermore, STADA will have to deal with residual effects of the global financial and economic

crisis as well as the effects of the CIS crisis. Against this backdrop, the Group certainly continues to prepare itself, within the realm of

possibility, for specific potential risks in this regard, such as a significantly increased default risk of business partners, subsidies to

crisis-prone competitors that distort competition or strong volatility in interest rate levels and currency relations that are relevant for the

Group. However, in view of the residual effects of the global financial and economic crisis as well as the effects of the CIS crisis, resulting

burdens such as one-time special effects from impairment losses on intangible assets and property, plant and equipment, payment defaults,

non-operational burdens on earnings from currency influences, in particular from the devaluation of the Russian ruble and the Ukrainian

hryvnia, as well as a curbed or further decreasing demand in the Russian pharmaceuticals market cannot be ruled out. With regard to the

existing sanctions against Russia, STADA does not currently see any significant direct effects on the Group’s business activities.

Overall, the future sales and earnings development of the Group will continue in future to be characterized by both growth-stimulating and

challenging framework conditions in the individual markets of STADA’s respective market regions. In the current financial year, the Group

has been confronted with very difficult framework conditions, especially as a result of the CIS crisis. In light of this, for financial year 2015,

the Excexutive Board expects to be able to achieve slight growth in Group sales adjusted for currency and portfolio effects. Due to the recent

developments of the Russian ruble and increased risks in connection with consumer mood and the general market situation, it anticipates

a decreased earnings contribution from Russia. Taking these developments into account and based on current currency relations, the

Executive Board expects a substantial decrease in adjusted EBITDA and adjusted net income. The Executive Board expects the ratio of net

debt, excluding further acquisitions, to adjusted EBITDA to be at a level of nearly 3 in 2015.

Management Report of the Executive Board | Prognosis Report130

STADA Consolidated Financial Statements131

CONSOLIDATED INCOME STATEMENT

CONSOLIDATED STATEMENT

OF COMPREHENSIVE INCOME

CONSOLIDATED BALANCE SHEET

CONSOLIDATED CASH FLOW STATEMENT

CONSOLIDATED STATEMENT OF

CHANGES IN SHAREHOLDERS’ EQUITY

NOTES TO THE

CONSOLIDATED FINANCIAL STATEMENTS

General Information

Notes to the Consolidated Income Statement

Notes to the Consolidated Balance Sheet

Other Disclosures

132

133

134

135

136

138

168

180

212

RESPONSIBILITY STATEMENT

AUDITOR’S REPORT

GLOSSARY FROM A TO Z

FINANCIAL CALENDAR

PUBLISHING INFORMATION

OVERVIEW OF SALES

FIVE-YEAR CONSOLIDATED
FINANCIAL SUMMARY

237

238

239

241

242

244

245

STADA Consolidated Financial Statements | Table of Contents132

CONSOLIDATED INCOME STATEMENT

Consolidated Income Statement
for the period from Jan. 1 to Dec. 31 in € 000s

2014

Previous year1)

Note

Sales

Cost of sales

Gross profit

Selling expenses

General and administrative expenses

Research and development expenses

Other income

Other expenses

Expenses in connection with the “STADA – build the future” project

Operating profit

Result from investments measured at equity

Investment income

Financial income

Financial expenses

Financial result

Earnings before taxes

Income taxes

Earnings after taxes

thereof

•

distributable to shareholders of STADA Arzneimittel AG (net income)

distributable to non-controlling shareholders

Earnings per share in € (basic)

Earnings per share in € (diluted)

2,062,247

1,070,441

991,806

458,381

152,817

56,905

20,067

155,243

2,003,912

1,024,475

979,437

488,162

159,537

55,473

53,754

72,629

9,064

188,527

248,326

1,595

132

4,833

70,393

-63,833

124,694

54,586

70,108

64,562

5,546

1.07

1.05

3,700

340

6,865

69,930

-59,025

189,301

66,490

122,811

121,426

1,385

2.04

2.00

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

STADA Consolidated Financial Statements

STADA Consolidated Financial Statements | Consolidated Income Statement | Consolidated Statement of Comprehensive Income

133

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

Consolidated Statement of Comprehensive Income
in € 000s

2014

Previous year

Note

Earnings after taxes

70,108

122,811

Items to be recycled to the income statement in future:

Currency translation gains and losses

-125,206

-61,366

thereof

• income taxes

Gains and losses on available-for-sale financial assets

thereof

• income taxes

Gains and losses on hedging instruments (cash flow hedges)

thereof

• income taxes

Items not to be recycled to the income statement in future:

Remeasurements of the net defined benefit liability

thereof

• income taxes

Other comprehensive income

Consolidated comprehensive income

thereof

•

distributable to shareholders of STADA Arzneimittel AG

distributable to non-controlling shareholders

1,613

1,519

-563

-15,617

5,294

-139,304

-69,196

-81,555

12,359

779

-1

2,349

-899

1,900

-820

-57,118

65,693

66,329

-636

35.

46.

36.

134

CONSOLIDATED BALANCE SHEET

Consolidated Balance Sheet as of Dec. 31 in € 000s
Assets

Dec. 31, 2014

Dec. 31, 2013

Jan. 1, 20131)

Note

Non-current assets

Intangible assets

Property, plant and equipment

Financial assets

Investments measured at equity

Other financial assets

Other assets

Deferred tax assets

Current assets

Inventories

Trade accounts receivable

Income tax receivables

Other financial assets

Other assets

Non-current assets and disposal groups held for sale

Cash and cash equivalents

Total assets

2,013,819

1,631,516

305,430

2,036

10,569

11,729

3,130

49,409

2,059,989

1,641,623

318,428

8,991

8,974

27,785

3,570

50,618

1,806,292

1,417,050

269,361

12,463

44,042

16,158

1,165

46,053

1,321,639

1,353,193

1,169,679

498,785

502,794

30,711

86,943

37,866

331

164,209

3,335,458

524,374

591,678

24,836

50,096

34,475

1,571

126,163

3,413,182

466,496

489,567

31,209

36,919

50,879

2,076

92,533

2,975,971

Equity and liabilities

Dec. 31, 2014

Dec. 31, 2013

Jan. 1, 20131)

Equity

Share capital

Capital reserve

Retained earnings including net income

Other provisions

Treasury shares

Equity attributable to shareholders of the parent

Shares relating to non-controlling shareholders

Non-current borrowed capital

Other non-current provisions

Financial liabilities

Other financial liabilities

Other liabilities

Deferred tax liabilities

Current borrowed capital

Other provisions

Financial liabilities

Trade accounts payable

Income tax liabilities

Other financial liabilities

Other liabilities

Total equity and liabilities

903,339

157,629

490,401

561,376

-371,851

-1,504

836,051

67,288

1,246,693

30,097

1,042,998

5,259

1,640

166,699

1,185,426

17,442

448,703

340,847

33,726

257,403

87,305

1,010,099

157,151

487,843

552,663

-241,497

-1,542

954,618

55,481

1,358,414

51,478

1,140,571

12,988

2,937

150,440

1,044,669

17,536

292,484

331,661

30,569

261,067

111,352

910,317

154,264

472,459

458,924

-184,467

-1,572

899,608

10,709

1,102,404

50,486

941,572

24,528

3,054

82,764

963,250

10,538

326,183

267,773

25,633

219,519

113,604

3,335,458

3,413,182

2,975,971

25.

26.

27.

28.

30.

31.

20.

32.

29.

20.

30.

31.

33.

34.

Note

35.

36.

37.

39.

40.

20.

41.

37.

38.

20.

39.

40.

STADA Consolidated Financial Statements

STADA Consolidated Interim Financial Statements | Consolidated Balance Sheet | Consolidated Cash Flow Statement

135

CONSOLIDATED CASH FLOW STATEMENT

Consolidated Cash Flow Statement in € 000s

Dec. 31, 2014

Dec. 31, 20131)

Note

Net income

Depreciation and amortization net of write-ups of non-current assets

Income taxes

Interest income and expenses

Result from associates

Result from the disposals of non-current assets

Additions to / reversals of other non-current provisions

Currency translation income and expenses

Other non-cash expenses and gains

Gross cash flow

Changes in inventories

Changes in trade accounts receivable

Changes in trade accounts payable

Changes in other net assets, unless attributable to investing or financing activities

Interest and dividends received

Interest paid

Income tax paid

Cash flow from operating activities

Payments for investments in

•

intangible assets

property, plant and equipment

financial assets

shares in consolidated companies

business combinations according to IFRS 3

Proceeds from the disposal of

•

intangible assets

property, plant and equipment

financial assets

shares in consolidated companies

Cash flow from investing activities

Borrowing of funds

Settlement of financial liabilities

Dividend distribution

Capital increase from share options

Changes in non-controlling interests

Changes in treasury shares

Cash flow from financing activities

Changes in cash and cash equivalents

Changes in cash and cash equivalents due to Group composition

Changes in cash and cash equivalents due to exchange rates

Net change in cash and cash equivalents

Balance at beginning of the period

Balance at end of the period

70,108

228,521

54,586

69,151

-1,595

-43

-17,039

29,415

214,001

647,105

-57,959

629

-18,339

-237,705

4,709

-66,275

-48,355

223,810

-181,397

-37,453

-65

122,811

130,193

66,490

66,446

-3,700

521

4,337

16,535

182,319

585,952

-55,723

-72,611

48,160

-169,720

6,390

-65,717

-72,987

203,744

-52,976

-33,895

-709

24.

20.

19.

17.

36.

16.

19.

32.

29.

38.

42.

25.

26.

27.

-55,054

-229,754

8./42.

25.

26.

27.

42.

37.

35.

42.

8,007

3,953

-261,980

734,224

-612,098

-42,495

3,029

1,006

83,711

45,541

2,116

-9,611

38,046

126,163

164,209

3,416

1,481

455

-311,982

930,421

-770,302

-31,177

18,264

1,537

148,780

40,542

-123

-6,789

33,630

92,533

126,163

136

CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY

Consolidated Statement of Changes in Shareholders’ Equity in € 000s

2014

Balance as of Dec. 31, 2014

Dividend distribution

Capital increase from share options

Changes in treasury shares

Changes in retained earnings

Changes in non-controlling interests

Changes in the scope of consolidation

Other income

Net income

Balance as of Jan. 1, 2014

Previous year

Balance as of Dec. 31, 2013

Dividend distribution

Capital increase from share options

Changes in treasury shares

Changes in retained earnings

Changes in non-controlling interests

Changes in the scope of consolidation

Other income

Net income

Balance as of Jan. 1, 2013

Retained

earnings

including

net income

561,376

-39,832

-254

-15,763

64,562

552,663

-29,620

Number of
shares

Share
capital

Capital
reserve

Provisions for

currency

translation

Provisions

available

for sale

Provisions

for cash flow

hedges

Equity

attributable to

relating to

Treasury

shareholders of

non- controlling

the parent

interests

60,626,700

157,629

490,401

-369,906

-1,967

-1,504

184,200

478

2,551

60,442,500

157,151

487,843

-131,860

-238,046

1,519

-3,486

-1,542

60,442,500

157,151

487,843

-238,046

-3,486

-1,542

1,110,240

2,887

15,377

59,332,260

154,264

472,459

1,933

121,426

458,924

-59,374

-178,672

2,349

-5,835

-1,572

-13

-5

836,051

-39,832

3,029

-254

-146,117

64,562

954,618

-29,620

18,264

-55,097

121,426

899,608

Group

equity

903,339

-42,495

3,029

2,111

-254

-139,304

70,108

1,010,099

-31,177

18,264

-57,118

122,811

910,317

67,288

-2,663

2,111

6,813

5,546

55,481

-1,557

-2,021

1,385

10,709

46,965

STADA Consolidated Financial Statements

CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY

Consolidated Statement of Changes in Shareholders’ Equity in € 000s

Number of

capital

Capital

reserve

60,626,700

157,629

490,401

184,200

478

2,551

60,442,500

157,151

487,843

60,442,500

157,151

487,843

1,110,240

2,887

15,377

Retained
earnings
including
net income

561,376

-39,832

-254

-15,763

64,562

552,663

-29,620

2014

Balance as of Dec. 31, 2014

Dividend distribution

Capital increase from share options

Changes in treasury shares

Changes in retained earnings

Changes in non-controlling interests

Changes in the scope of consolidation

Other income

Net income

Previous year

Balance as of Jan. 1, 2014

Balance as of Dec. 31, 2013

Dividend distribution

Capital increase from share options

Changes in treasury shares

Changes in retained earnings

Changes in non-controlling interests

Changes in the scope of consolidation

Other income

Net income

Balance as of Jan. 1, 2013

Provisions for
currency
translation

Provisions
available
for sale

Provisions
for cash flow
hedges

Equity
attributable to
shareholders of
the parent

Shares
relating to
non- controlling
interests

Treasury
shares

-369,906

-1,967

-1,504

-131,860

-238,046

-13

1,519

-3,486

-1,542

-238,046

-3,486

-1,542

836,051

-39,832

3,029

-254

-146,117

64,562

954,618

-29,620

18,264

-55,097

121,426

899,608

67,288

-2,663

2,111

6,813

5,546

55,481

-1,557

46,965

-2,021

1,385

10,709

59,332,260

154,264

472,459

1,933

121,426

458,924

-59,374

-178,672

-5

2,349

-5,835

-1,572

137

Group
equity

903,339

-42,495

3,029

2,111

-254

-139,304

70,108

1,010,099

-31,177

18,264

46,965

-57,118

122,811

910,317

STADA Consolidated Financial Statements | Consolidated Statement of Changes in Shareholders’ Equity

138

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
General Information

1. Corporate information

STADA Arzneimittel Aktiengesellschaft (STADA Arzneimittel AG) as parent company of the STADA Group (hereafter referred to as “STADA”),

based in Stadastrasse 2–18, 61118 Bad Vilbel, is an internationally oriented company based in Germany, which is active worldwide in the

health care and pharmaceuticals market, especially in the core segments of Generics and Branded Products.

The consolidated financial statements of STADA Arzneimittel AG for financial year 2014 were approved for publication by the Executive

Board on March 23, 2015.

2. Basis of preparation

The consolidated financial statements prepared for STADA Arzneimittel AG as parent company as of December 31, 2014, were prepared in

accordance with the International Financial Reporting Standards (IFRS) and interpretations published by the International Accounting

Standards Board (IASB) and the International Financial Reporting Standards Committee (IFRIC), as applicable in the European Union (EU), as

well as in accordance with the supplementary provisions pursuant to Section 315a (1) of the German Commercial Code (HGB).

The financial year corresponds to the calendar year. The individual financial statements of the companies included in the scope of con-

solidation are prepared as of the same date as the consolidated financial statements.

The structure of the consolidated income statement follows the cost-of-sales method, according to which expenses incurred in generating

sales are divided into functional areas. In the statement of comprehensive income, use was made of the option to present this separately

from the consolidated income statement. The balance sheet classification distinguishes between non-current and current assets and

liabilities, some of which are presented in detail in the notes according to their maturities.

The consolidated financial statements are prepared in euro. Unless otherwise indicated, figures in the notes are shown in euro thousands

(€ 000s). Rounding is thus necessary, although this of course is not significant in its nature.

3. Consequences of new or amended standards and interpretations

In financial year 2014, STADA observed and, if relevant applied the following pronouncements or amendments to pronouncements published

by the IASB and endorsed by the EU which were first applicable in financial year 2014, which had no or no significant effect on the

presentation of STADA’s business, financial, earnings situation or cash flow:

• IAS 32 “Financial Instruments: Presentation”:

The amendment clarifies requirements for the netting of financial assets and financial liabilities on the balance sheet.

The right to netting on the balance sheet must exist as of the balance sheet date.

• IAS 36 “Impairment of Assets”:

The amendment contains a clarification that the reporting of a recoverable amount is only required of those cash-generating units for

which an impairment loss or reversal has been recognized within the current reporting period.

STADA Consolidated Financial Statements139

• IAS 39 “Financial Instruments: Recognition and Measurement”:

In order to improve the transparency and regulatory supervision of OTC derivatives, companies are, in certain circumstances,

required to clear derivatives to central counterparties. Despite novation, derivatives can remain designated as hedging instruments

under certain conditions.

• IFRIC 21 “Levies”:

The standard concerns the question of the accounting of public levies which do not represent income tax in the sense of IAS 12

and clarifies when the obligation to pay such levies should be recognized as a liability in the financial statements.

In May 2011, the IASB adopted the new standards IFRS 10 “Consolidated Financial Statements”, IFRS 11 “Joint Arrangements” and IFRS

12 “Disclosure of Interests in Other Entities”. IFRS 10 replaces the consolidation requirements of the former IAS 27 “Consolidated and

Separate Financial Statements” and SIC-12 “Consolidation – Special Purpose Entities” and introduces a uniform consolidation model for all

subsidiaries. IFRS 11 governs the accounting for joint operations and joint ventures and thus replaces IAS 31 “Interests in Joint Ventures”

and SIC-13 “Jointly Controlled Entities – Non-Monetary Contributions by Venturers”. The former option to proportionately consolidate joint

ventures is eliminated in favor of mandatory application of the equity method. In the context of IFRS 12, disclosure requirements for sub-

sidiaries, joint arrangements, associates and unconsolidated special purpose entities are combined, expanded and replaced. The new

regulations, which were adopted in European law in 2012, are applicable in the EU to financial years beginning on or after January 1, 2014.

In June 2012, IASB published transition guidance adopted into European law in April 2013 (amendments to IFRS 10, IFRS 11 and IFRS 12)

for the standards adopted in May 2011 of IFRS 10 “Consolidated Financial Statements”, IFRS 11 “Joint Arrangements” and IFRS 12

“Disclosure of Interests in Other Entities”. In the context of these amendments, the transition guidance in IFRS 10 was clarified and

additional simplification was ensured in all three standards. The significant change here results from IFRS 11 “Joint Arrangements”. Joint

ventures, which have been proportionately consolidated to date, are to be accounted for using the equity method as of financial year 2014,

as well as retrospectively in the context of adjusting previous year figures. The proportionate share of assets and liabilities of these com-

panies will thereby no longer be included in the consolidated balance sheet and the proportionate share of aggregated earnings of these

units will be disclosed under one item within the income statement, whereas a disclosure was to be made under the relevant income and

expense items in accordance with currently valid regulations.

For STADA, the initial application of the new standards has resulted in retroactively applicable changes in relation to the consolidation of

joint ventures in accordance with IFRS 11. Up until the time of its change in status to subsidiary in the past financial year, STADA Vietnam,

previously consolidated on a pro rata basis, was included in STADA’s consolidated financial statements retroactively according to the equity

method up until the time control was acquired by STADA in accordance with IFRS 11 in connection with IAS 8 and in connection with IAS 1.

As a result of the consolidation of this company as a subsidiary in the context of the control achieved over STADA Vietnam as of the fourth

quarter of 2013, there were no more joint ventures within the scope of consolidation of STADA as of December 31, 2013. As a result, there

have been no effects for STADA in financial year 2014 as a result of this changed accounting policy.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements140

In the context of the retrospective adjustments carried out in accordance with the new standard IFRS 11 in connection with IAS 8 as well

as in connection with IAS 1, balance sheet items changed as of January 1, 2013 as follows:

Consolidated Balance Sheet (abridged)
in € 000s

Adjustments in
accordance with
new IFRS 11

Jan. 1, 2013
adjusted

Jan. 1, 2013

Non-current assets

Intangible assets

Property, plant and equipment

Investments measured at equity

Other non-current assets

Current assets

Inventories

Trade accounts receivable

Other current assets

Cash and cash equivalents

Total assets

Equity and liabilities

Non-current borrowed capital

Financial liabilities

Other non-current borrowed capital

Current borrowed capital

Financial liabilities

Trade accounts payable

Other current borrowed capital

Total equity and liabilities

1,802,176

1,417,083

273,822

34,885

76,386

1,180,645

475,311

492,143

120,461

92,730

2,982,821

910,317

1,102,911

941,572

161,339

969,593

328,519

268,973

372,101

2,982,821

4,116

-33

-4,461

9,157

-547

-10,966

-8,815

-2,576

622

-197

-6,850

-507

-6,343

-2,336

-1,200

-2,807

-6,850

1,806,292

1,417,050

269,361

44,042

75,839

1,169,679

466,496

489,567

121,083

92,533

2,975,971

910,317

1,102,404

941,572

160,832

963,250

326,183

267,773

369,294

2,975,971

STADA Consolidated Financial Statements

Due to the retrospective adjustments, the following changes resulted for the income statement in financial year 2013:

141

Consolidated Income Statement
for the period from Jan. 1 to Dec. 31 in € 000s

Sales

Cost of sales

Gross profit

Selling expenses

General and administrative expenses

Research and development expenses

Other income

Other expenses

Expenses in connection with the “STADA – build the future” project

Operating profit

Result from investments measured at equity

Investment income

Financial income

Financial expenses

Financial result

Earnings before taxes

Taxes on income

Earnings after taxes

thereof

•

distributable to shareholders of STADA Arzneimittel AG (net income)

distributable to non-controlling shareholders

Earnings per share in € (basic)

Earnings per share in € (diluted)

Adjustment in
accordance with a
change in
methodology and
amended
standard IFRS 11

-10,499

-5,677

-4,822

-610

-468

-227

110

-184

-3,223

2,929

-149

3,098

-125

2013

2,014,411

1,030,152

984,259

488,772

160,005

55,700

53,644

72,813

9,064

251,549

771

340

6,845

70,079

-62,123

189,426

66,615

122,811

121,426

1,385

2.04

2.00

2013
adjusted

2,003,912

1,024,475

979,437

488,162

159,537

55,473

53,754

72,629

9,064

248,326

3,700

340

6,865

69,930

-59,025

189,301

66,490

122,811

121,426

1,385

2.04

2.00

In addition, STADA did not apply a number of further pronouncements and amendments to pronouncements that were adopted by the IASB,

the application of which, however, was not mandatory in financial year 2014.

In May 2014, IASB published the new standard IFRS 15 “Revenue from Contracts with Customers”. IFRS 15 governs the revenue recognition

for contracts with customers in a 5-step model and in particular replaces the existing standards IAS 11 “Construction Contracts” and IAS 18

“Revenue”. IFRS 15 is to be applied for financial years beginning on or after January 1, 2017. The adoption into European law is still

pending. The impact of the new standard for revenue recognition on the business, financial and earnings situation is still currently under

review.

From today’s perspective no or no significant effects on the consolidated financial statements are expected from the future application of

the further standards and interpretations not yet applied.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements

142

4. Changes in accounting policies

With the exception of the changed accounting policies listed in Note 3, there were no changes to accounting policies with significant

consequences for the presentation of STADA’s business, financial and earnings situation or cash flow in financial year 2014.

5. Scope of consolidation

All significant subsidiaries, joint ventures and associated companies are included in the consolidated financial statements. Subsidiaries are

companies that are directly or indirectly controlled by STADA and are therefore fully consolidated. Control exists if STADA Arzneimittel AG or

its subsidiaries are in control of an investee, are exposed to variable backflows and, due to control over existing rights, are able to

substantially influence the investee’s variable backflows. Control is usually substantiated by a share of voting rights of more than 50%.

Joint arrangements are characterized by joint control by two or more parties and should be classified as either joint operations or as joint

ventures. In joint operations, the parties that exercise joint control possess the rights to assets and liabilities included in the agreement. In

joint ventures, however, the parties involved possess rights to the company’s net assets. Joint ventures are to be included in the consolidat-

ed financial statements using the equity method.

As a result of changing the status of the company STADA Vietnam J.V. Co., Ltd., which was previously consolidated as a joint venture and

as a result of the deconsolidation of STADA Import/Export in financial year 2013, there were no longer any joint ventures in STADA’s scope

of consolidation. The consolidation of STADA Vietnam J.V. Co., Ltd. is carried out regardless of their capital share of 50% as a subsidiary

due to the fact that STADA controls this company on the basis of agreements in accordance with corporate law.

Associated companies are companies over which STADA is able to exercise significant influence and are not subsidiaries or joint ventures.

They are included in the consolidated financial statements in accordance with the equity method.

Subsidiaries, joint ventures and associated companies whose influence, both individually and as a whole, on the business, financial and

earnings situation of the STADA Group is insignificant, are not consolidated or accounted for using the equity method. Investments in these

companies are accounted for either at fair value or at amortized cost under financial assets. Accumulated, the sales and balance sheet

total of these companies make up less than 1% of total Group sales and the balance sheet total.

STADA Consolidated Financial Statements143

Changes in the scope of consolidation resulted regarding the number of subsidiaries, joint ventures and associated companies included in

financial year 2014 and are as follows:

Number of companies in the scope of consolidation

Germany

outside

Total

January 1, 2014

Acquisitions

Disposals

December 31, 2014

Changes in the scope of consolidation as of December 31, 2014 as compared to December 31, 2013 resulted from the merger of the

consolidated subsidiary S.A. Neocare N.V., Brussels, Belgium, with S.A. Eurogenerics N.V., Brussels, Belgium, also a consolidated sub-

sidiary, in the second quarter of 2014.

This did not have any effect on the Group’s business, financial and earnings situation.

Furthermore, in the first quarter of 2014, the contract for the purchase of the Russian branded product portfolio Aqualor® was completed

as planned. The Aqualor® product sales have been consolidated in the STADA Group since March 1, 2014. In this context, STADA’s Russian

subsidiary OOO Aqualor has also been included in the scope of consolidation of STADA Arzneimittel AG.

In addition, the Chinese subsidiary STADA Pharmaceuticals (Beijing) Ltd., Beijing, China, has been included in the scope of consolidation of

STADA as of January 1, 2014.

These changes also did not have any significant effect on the Group’s business, financial and earnings situation.

Furthermore, the British company Internis Pharmaceuticals Ltd., London, United Kingdom, which had been previously acquired, was included

as a subsidiary in the scope of consolidation of STADA in the fourth quarter of 2014. For details on the impact of this merger on STADA’s

consolidated financial statements see Note 8.

As in the previous year, the aforementioned chart includes BIOCEUTICALS Arzneimittel AG, which is included in the consolidated financial

statements as an associated company according to the equity method. STADA holds 15.86% of the shares in this company. The significant

influence is therefore not directly due to the amount of shares held, but instead is related in particular to the identity of part of the manage-

ment personnel between BIOCEUTICALS Arzneimittel AG and STADA Arzneimittel AG. Details on the relationship between BIOCEUTICALS

Arzneimittel AG and STADA are included in the Notes on related party disclosures (see Note 48.2.).

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements144

As in the previous year, the aforementioned chart also includes both French companies Pharm Ortho Pedic SAS and AELIA SAS, pursuant

to shareholdings of 25.0% and 20.0% acquired by STADA, which are included in the consolidated financial statements as associated

companies in accordance with the equity method. The following condensed financial information is given for these three associates:

in € million

Share of result from continuing operations

Share of result from discontinued operations

Share of other comprehensive income

Share of comprehensive income

Aggregate carrying amount

2014

1.6

10.6

2013

0.8

9.0

As of December 31, 2014, there continued to be a guarantee on the part of STADA amounting to € 25.0 million towards Hospira Inc., Lake

Forest, Illinois, USA, in connection with a supply agreement between Hospira and the shares in the associated company BIOCEUTICALS

Arzneimittel AG, which are recognized under the equity method.

There are significant non-controlling interests in the Vietnamese subsidiaries Pymepharco Joint Stock Company and STADA Vietnam J.V. Co

of the STADA Group.

In the following, the influence of other shareholders in these subsidiaries as of December 31, 2014 is presented:

Name of subsidiary

Pymepharco

STADA Vietnam

Headquarters /
place of founding

Vietnam

The disclosures for the previous year are as follows:

Result of
non-controlling
interests in 2014
in € 000s

1,570

3,196

Share in
voting rights

59.0%

50.0%

Accumulated
non-controlling
shares as of
Dec. 31, 2014
in € 000s

24,730

30,996

Name of subsidiary

Pymepharco

STADA Vietnam

Headquarters /
place of founding

Vietnam

Result of
non-controlling
interests in 2013
in € 000s

928

-45

Share in
voting rights

59.0%

50.0%

Accumulated
non-controlling
shares as of
Dec. 31, 2013
in € 000s

19,481

26,226

STADA Consolidated Financial Statements

145

In the following, the financial information of both subsidiaries as of December 31, 2014 and for financial year 2014 is summarized:

in € 000s

Pymepharco

STADA Vietnam

in € 000s

Pymepharco

STADA Vietnam

Assets as of December 31, 2014

Liabilities as of December 31, 2014

non-current

current

non-current

current

52,921

46,453

35,055

32,332

8,947

6,258

8,411

5,609

Earnings in 2014

Distributable
to STADA

Distributable
to non-controlling
interests

Total earnings
in 2014

Dividends to
non-controlling
interests
in 2014

656

2,634

1,570

3,196

10,896

14,035

384

2,143

Sales

41,348

43,304

The result of Pymepharco and STADA Vietnam distributable to STADA contains impairments on goodwill which have been accounted for in

accordance with the partial goodwill method in the context of achieving control.

For the previous year, the following disclosures are made regarding the summarized financial information:

in € 000s

Pymepharco

STADA Vietnam

in € 000s

Pymepharco

STADA Vietnam

Assets as of December 31, 2013

Liabilities as of December 31, 2013

non-current

current

non-current

48,922

43,813

28,838

26,750

8,754

5,756

current

12,029

7,636

Earnings in 2013

Distributable
to STADA

Distributable to
non-controlling
interests

Total earnings
in 2013

Dividends to
non-controlling
interests
in 2013

1,335

-45

928

-45

-982

-1,769

265

Sales

42,769

10,218

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements

146

For financial year 2013, disclosures for the company STADA Vietnam are given, each first beginning with its consolidation in the fourth

quarter of 2013, which took place in to the context of STADA achieving control. Until the time of its change in status to a subsidiary in the

past financial year, STADA Vietnam, previously proportionately consolidated as a joint venture, was included in STADA’s consolidated

financial statements retroactively according to the equity method until the time that control was achieved by STADA in accordance with

IFRS 11 in connection with IAS 8 and IAS 1.

Subsidiaries, joint ventures and associated companies as well as all non-consolidated and other investments are included in the consolidated

financial statements as investments and listed below.

Direct investments of STADA Arzneimittel AG:

Name of the company, registered office

Share in capital

Form of consolidation

BEPHA Beteiligungsgesellschaft für Pharmawerte mbH, Bad Vilbel, Germany

BIOCEUTICALS Arzneimittel AG, Bad Vilbel, Germany

Ciclum Farma, Unipessoal, LDA, Paco de Arcos, Portugal

Crinos S.p.A., Milan, Italy

EG Labo - Laboratoires Eurogenerics SAS, Boulogne-Billancourt, France

EG S.p.A., Milan, Italy

Grunenthal Ukraine LLC., Kiev, Ukraine1)

Laboratorio STADA, S.L., Barcelona, Spain

Mobilat Produktions GmbH, Pfaffenhofen, Germany

AO Nizhpharm, Nizhny Novgorod, Russia

OOO Hemofarm, Obninsk, Russia

OOO STADA Marketing, Nizhny Novgorod, Russia

Oy STADA Pharma Ab, Helsinki, Finland

STADA Arzneimittel Gesellschaft m.b.H., Vienna, Austria

STADA d.o.o., Ljubljana, Slovenia

STADA d.o.o., Zagreb, Croatia

STADA Egypt Ltd., Cairo, Egypt

STADA (Shanghai) Company Management Consulting Co. Ltd., Shanghai, China

STADA GmbH, Bad Vilbel, Germany

STADA LUX S.à R.L., Luxembourg, Luxembourg

STADA PHARMA Bulgaria EOOD, Sofia, Bulgaria

STADA PHARMA CZ, s.r.o., Prague, Czech Republic

STADA Pharma International GmbH, Bad Vilbel, Germany

STADA Pharma Services India Private Ltd., Mumbai, India

STADA PHARMA Slovakia s.r.o., Bratislava, Slovakia

STADA Pharmaceuticals (Asia) Ltd., Hong Kong, China

STADA Pharmaceuticals Australia Pty Ltd., Sydney, Australia

STADA Poland Sp. z o.o., Piaseczno, Poland

STADA Service Holding B.V., Etten-Leur, The Netherlands

STADApharm GmbH, Bad Vilbel, Germany

STADA UK Holdings Ltd., Newbury, United Kingdom

1) Currently in the process of liquidation.

100%

15.86%

100%

96.77%

100%

98.87%

100%

10%

100%

75%

100%

85%

100%

subsidiary

associated company

subsidiary

not included

subsidiary

not included

subsidiary

not included

subsidiary

not included

subsidiary

not included

subsidiary

STADA Consolidated Financial Statements147

Indirect investments of STADA Arzneimittel AG through EG Labo - Laboratoires Eurogenerics SAS:

Name of the company, registered office

Share in capital

Form of consolidation

AELIA SAS, Saint Brieuc, France

Laboratoires d’études et de recherches en oligo éléments thérapie SA,
Boulogne-Billancourt, France

Pharm Ortho Pedic SAS, Pellouailles Les Vignes, France

20%

associated company

100%

25%

subsidiary

associated company

Indirect investments of STADA Arzneimittel AG through STADA UK Holdings Ltd.:

Name of the company, registered office

Share in capital

Form of consolidation

Clonmel Healthcare Ltd., Clonmel, Ireland

Internis Pharmaceuticals Ltd., London, United Kingdom

Pegach AG, Egerkingen, Switzerland

Sundrops Ltd., Huddersfield, United Kingdom

Thornton & Ross Ltd., Huddersfield, United Kingdom

100%

subsidiary

Indirect investments of STADA Arzneimittel AG through STADA UK Holdings Ltd. and Thornton & Ross Ltd.:

Name of the company, registered office

Share in capital

Form of consolidation

LCM Ltd., Huddersfield, United Kingdom

Thornton & Ross Ireland Ltd., Dublin, Ireland

Zeroderma Ltd., Huddersfield, United Kingdom

100%

subsidiary

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements

148

Indirect investments of STADA Arzneimittel AG through BEPHA Beteiligungsgesellschaft für Pharmawerte mbH:

Name of the company, registered office

ALIUD PHARMA GmbH, Laichingen, Germany

cell pharm Gesellschaft für pharmazeutische und diagnostische Präparate mbH,
Bad Vilbel, Germany

Crinos S.p.A., Milan, Italy

Croma Medic, Inc., Manila, The Philippines

EG S.p.A., Milan, Italy

Grippostad GmbH, Bad Vilbel, Germany

IIP Institut für Industrielle Pharmazie Forschungs- und Entwicklungsgesellschaft mbH,
Aschaffenburg, Germany

STADA Nordic ApS (previously PharmaCoDane ApS), Herlev, Denmark

S.A. Eurogenerics N.V., Brussels, Belgium

STADA CEE GmbH, Bad Homburg, Germany

STADA Egypt Ltd., Cairo, Egypt

STADA Pharma Services India Private Ltd., Mumbai, India

STADA (Thailand) Company, Ltd., Bangkok, Thailand

STADAvita GmbH, Bad Homburg, Germany

Indirect investments of STADA Arzneimittel AG through STADA GmbH:

Share in capital

Form of consolidation

100%

3.23%

100%

1.13%

100%

25%

100%

3.42%

100%

25%

15%

60%

100%

subsidiary

not included

subsidiary

not included

subsidiary

Name of the company, registered office

STADA Medical GmbH, Bad Vilbel, Germany

Share in capital

Form of consolidation

100%

subsidiary

Indirect investments of STADA Arzneimittel AG through STADA Service Holding B.V.:

Name of the company, registered office

Share in capital

Form of consolidation

Centrafarm Nederland B.V., Etten-Leur, The Netherlands

Hemofarm A.D., Vrsac, Serbia

Pymepharco Joint Stock Company, Tuy Hoa, Vietnam

S.A. Eurogenerics N.V., Brussels, Belgium

STADA MENA DWC-LLC, Dubai, United Arab Emirates

100%

49%

96.58%

100%

subsidiary

not included

STADA Consolidated Financial Statements

149

Indirect investments of STADA Arzneimittel AG through STADA Service Holding B.V. and Centrafarm Nederland B.V.:

Name of the company, registered office

Share in capital

Form of consolidation

Centrafarm Services B.V., Etten-Leur, The Netherlands

Healthypharm B.V., Etten-Leur, The Netherlands

HTP Huisapotheek B.V., Etten-Leur, The Netherlands

Neocare B.V., Etten-Leur, The Netherlands

Quatropharma Holding B.V., Etten-Leur, The Netherlands

100%

subsidiary

Indirect investments of STADA Arzneimittel AG through STADA Service Holding B.V., Centrafarm Nederland B.V.

and Quatropharma Holding B.V.:

Name of the company, registered office

Centrafarm B.V., Etten-Leur, The Netherlands

Share in capital

Form of consolidation

100%

subsidiary

Indirect investments of STADA Arzneimittel AG through STADA Pharmaceuticals (Asia) Ltd.:

Name of the company, registered office

Share in capital

Form of consolidation

CIG (Hong Kong) Ltd., Hong Kong, China

STADA Import/Export International Ltd., Hong Kong, China

STADA Pharmaceuticals (Beijing) Ltd., Beijing, China

STADA Vietnam J.V. Co., Ltd., Ho Chi Minh City, Vietnam

STADAPHARMA HEALTHCARE INC., Makati City, The Philippines

Well Light Investment Services JSC, Ho Chi Minh City, Vietnam

70%

51%

83.35%

50%

40%

49%

not included

subsidiary

not included

subsidiary

Indirect investments of STADA Arzneimittel AG through STADA Pharmaceuticals (Asia) Ltd. and Well Light Investment Services JSC:

Name of the company, registered office

Share in capital

Form of consolidation

Pymepharco Joint Stock Company, Tuy Hoa, Vietnam

10%

subsidiary

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements150

Indirect investments of STADA Arzneimittel AG through STADA Service Holding B.V. and Pymepharco JSC and/or indirect investments of

STADA Arzneimittel AG through STADA Pharmaceuticals (Asia) Ltd.; through Well Light Investment Services JSC and Pymepharco JSC:

Name of the company, registered office

Share in capital

Form of consolidation

Dak Nong Pharmaceutical JSC, Dak Nong, Vietnam

Phu Yen Export Import Pharmaceutical JSC, Phu Yen, Vietnam

Quang Tri Pharmaceutical JSC, Quang Tri, Vietnam

43%

20%

22.8%

not included

Indirect investments of STADA Arzneimittel AG through STADA UK Holdings Ltd. and Clonmel Healthcare Ltd.:

Name of the company, registered office

CNRD 2009 Ireland Ltd., Dublin, Ireland

Crosspharma Ltd., Belfast, United Kingdom

Genus Pharmaceuticals Holdings Ltd., Newbury, United Kingdom

STADA Financial Investments Ltd., Clonmel, Ireland

Share in capital

Form of consolidation

50%

100%

not included

subsidiary

Indirect investments of STADA Arzneimittel AG through STADA UK Holdings Ltd.; Clonmel Healthcare Ltd. and Genus Pharmaceuticals

Holdings Ltd.:

Name of the company, registered office

Share in capital

Form of consolidation

Britannia Pharmaceuticals Ltd., Newbury, United Kingdom

Genus Pharmaceuticals Ltd., Newbury, United Kingdom

100%

subsidiary

STADA Consolidated Financial StatementsIndirect investments of STADA Arzneimittel AG through AO Nizhpharm:

Name of the company, registered office

Share in capital

Form of consolidation

151

Dialogfarma LLC, Moscow, Russia

Hetmak FZCO, Dubai, United Arab Emirates1)

Nizhpharm-Kazakhstan TOO DO, Almaty, Kazakhstan

Nizhpharm-Ukraine DO, Kiev, Ukraine

OOO Aqualor

OOO Hemofarm, Obninsk, Russia

OOO STADA CIS, Nizhny Novgorod, Russia

OOO STADA Marketing, Nizhny Novgorod, Russia

OOO STADA PharmDevelopment, Nizhny Novgorod, Russia

STADA M&D S.R.L., Bucharest, Romania

UAB STADA-Nizhpharm-Baltija, Vilnius, Lithuania

ZAO Makiz-Pharma, Moscow, Russia

ZAO Skopinpharm, Ryazanskaya obl., Russia

50%

100%

90%

100%

90%

100%

not included

subsidiary

Indirect investments of STADA Arzneimittel AG through Laboratorio STADA, S.L.:

Name of the company, registered office

STADA, LDA, Paco de Arcos, Portugal

Share in capital

Form of consolidation

98%

not included

Indirect investments of STADA Arzneimittel AG through Ciclum Farma, Unipessoal, LDA:

Name of the company, registered office

STADA Genericos, S.L., Barcelona, Spain

STADA, LDA, Paco de Arcos, Portugal

Share in capital

Form of consolidation

100%

not included

1) Currently in the process of liquidation.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements152

Indirect investments of STADA Arzneimittel AG through STADA Service Holding B.V. and Hemofarm A.D.:

Name of the company, registered office

Hemofarm Arabia Ltd., Damascus, Syria

Hemofarm Banja Luka d.o.o., Banja Luka, Bosnia-Herzegovina

Hemofarm Komerc d.o.o., Skopje, Macedonia1)

Hemofarm Sabac d.o.o., Sabac, Serbia

Hemofarm S.a.r.l., Constantine, Algeria

Hemomont d.o.o., Podgorica, Montenegro

Hemopharm GmbH Pharmazeutisches Unternehmen, Bad Homburg, Germany

Jinan Pharmaceuticals Co., Jinan, China

STADA Hemofarm d.o.o., Zagreb, Croatia1)

STADA HEMOFARM S.R.L., Temesvar, Romania

STADA IT Solutions d.o.o., Belgrade, Serbia

Velefarm A.D., Belgrade, Serbia

Vetfarm A.D., Belgrade, Serbia

Share in capital

Form of consolidation

50%

91.50%

99.18%

100%

40%

71.02%

100%

35.50%

100%

19.65%

15%

not included

subsidiary

not included

subsidiary

not included

subsidiary

not included

subsidiary

not included

Indirect investments of STADA Arzneimittel AG through STADA Service Holding B.V.; Hemofarm A.D. and

Hemopharm GmbH Pharmazeutisches Unternehmen:

Name of the company, registered office

Share in capital

Form of consolidation

PharmaSwyzz Germany GmbH, Bad Homburg, Germany

100%

not included

Indirect investments of STADA Arzneimittel AG through STADA UK Holdings Ltd. and Pegach AG:

Name of the company, registered office

Spirig HealthCare AG, Egerkingen, Switzerland

Share in capital

Form of consolidation

100%

subsidiary

The exemption rule stated in Section 264 (3) HGB was applied to ALIUD PHARMA GmbH, BEPHA Beteiligungsgesellschaft für Pharmawerte

mbH, cell pharm Gesellschaft für pharmazeutische und diagnostische Präparate mbH, STADA GmbH, STADA Medical GmbH, STADA CEE

GmbH, STADApharm GmbH, STADAvita GmbH, STADA Pharma International GmbH and Mobilat Produktions GmbH.

1) Currently in the process of liquidation.

STADA Consolidated Financial Statements153

6. Principles for the consolidation of subsidiaries, joint ventures and associated companies

According to IFRS, business combinations are to be accounted for using the acquisition method. Assets, liabilities and contingent liabilities

from business combinations are generally recognized in full – irrespective of the amount of the shareholding – as of the acquisition date at

their fair values. If the acquisition costs of the subsidiary acquired exceed the proportionate newly measured net assets of the acquiree,

STADA recognizes the positive difference as goodwill. After critical examination of the premises underlying the purchase price allocation, a

negative difference is recognized in income in the period of the acquisition. In a business combination achieved in stages, it is necessary to

carry out a revaluation through profit or loss of the shares previously held at the date control was achieved. The shares of non-controlling

interests are disclosed in the amount of their share in net assets of the subsidiary.

The acquisition of additional shares from an existing controlling position in a subsidiary is recognized directly in equity in accordance with

IFRS 10, as it is a transaction between the equity investors.

Subsidiaries are generally included in the consolidated financial statements from the acquisition date to the end of control by the parent

company. Receivables and payables, expenses and income, as well as earnings between the companies included in the consolidated

financial statements are eliminated, intercompany value adjustments and provisions are released. If these consolidation measures result in

deviations between the IFRS carrying amounts and the tax base of assets and liabilities, deferred tax liabilities are recognized.

Shares in associated companies are recognized according to the equity method at acquisition cost on the date when joint control is

established (joint ventures) or when significant influence was established (associated company) and carried forward from this date in the

amount of the proportionate share of earnings in the financial year. A positive difference determined during the purchase price allocation is

recognized as goodwill in the carrying amount of the investment in the associated company. A negative difference is recognized in income

in the period of the acquisition in the results from associated companies. Profit and loss from transactions with associated companies is

recognized in the consolidated financial statements only according to the share of minority interests.

If indications arise from the application of IAS 39 that the carrying amount determined using the equity method might be impaired, an im-

pairment test is carried out and, if applicable, an impairment loss in the amount of the difference between the carrying amount and the

recoverable amount is recognized. The recoverable amount is the higher of the fair value less cost to sell and the value in use of the shares

in an associated company.

7. Currency translation

The functional currency of STADA Arzneimittel AG is the euro and represents the reporting currency of the Group.

In the separate financial statements of companies included in the consolidated financial statements, foreign currency transactions are

translated into the functional currency at the exchange rate applicable at the time of the transactions. On every balance sheet date,

monetary items are translated using the closing rate and non-monetary items are translated using the transaction rate. Resulting currency

translation differences are recognized in income as exchange gains or losses.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements154

The translation of the companies included in the consolidated financial statements with a functional currency other than the euro into the

Group functional currency is carried out using the closing rate method. Assets and liabilities are generally translated using the closing rate,

while individual components of equity are translated using the historical rates at their respective dates of inflow from the Group’s perspec-

tive. The income and expenses of the income statements are translated – and thereby also the resulting translation of the annual results to

be entered in equity – using the average exchange rate of the period.

Currency translation differences arising from the use of different exchange rates are recognized directly in equity in the “Provisions for

currency translation”. These provisions are released and recognized in income if Group companies leave the scope of consolidation.

The exchange rate development of currencies important to STADA to the euro can be seen in the following chart:

Closing rate on Dec. 31
in local currency

Average rate for
the reporting period

2014

2013

±%

2014

2013

0.77890

0.83310

72.35890

45.24887

120.91898

114.81056

19.23447

11.35718

1.21409

1.37671

-7%

+60%

+5%

+69%

-12%

0.80640

0.84974

52.56082

42.58944

117.23329

113.12217

15.40541

10.86012

1.32989

1.33012

±%

-5%

+23%

+4%

+42%

Significant currency relations
in local currency to € 1

Pound sterling

Russian ruble

Serbian dinar

Ukrainian hryvnia

US Dollar

8. Business combinations

In financial year 2014, the following significant business combinations in the sense of IFRS 3 occurred, for which the preliminary purchase

price allocation is described in more detail below.

In the second quarter of 2014, STADA purchased the production and distribution rights for the branded product portfolio Flexitol® including

the associated sales structures from the LaCorium group of companies. STADA achieved control upon conclusion of the contract on

June 16, 2014.

The purchase price for the acquisition of the production and distribution rights including the associated sales structures totaled GBP 8.3 mil-

lion (approx. € 10.3 million) including adjustments for inventory in the amount of GBP 1.7 million (approx. € 2.2 million), and was completely

paid in cash or cash equivalents. The acquired product portfolio comprises 15 prescription-free (OTC) and prescribable (OTX) products in

the area of hand and foot care.

STADA Consolidated Financial Statements

155

In the context of the purchase price allocation, goodwill in the amount of approx. € 1 resulted from the business combination and is broken

down as follows:

in € million

Purchase price for 100% of the shares in the production and distribution rights approx.

Proportionate fair values of the assets and liabilities acquired incl. fair value of adjustments for inventory approx.

Goodwill

10.3

0.0

For the assets acquired and liabilities assumed in the context of the business combination, the following fair values were recognized at the

acquisition date:

Fair values in € million

Intangible assets

Inventories

Assets

Trade accounts payable

Liabilities

12.5

0.8

13.3

3.0

Fair values were determined on the basis of observable market prices. To the extent that market prices could not be determined, income or

cost-oriented procedures were used for the measurement of acquired assets and liabilities assumed.

Sales generated in the market region Central Europe with the branded product portfolio Flexitol® since the acquisition date amounted to

approx. € 2 million in financial year 2014. The operating profit of this business combination adjusted for the effects of the purchase price

allocation (approx. € 0.3 million) amounted to approx. € 1 million in financial year 2014. If STADA had acquired the branded product

portfolio Flexitol® on January 1, 2014, sales of approx. € 4 million and operating profit, adjusted for effects from the purchase price

allocation (about € 0.6 million), of approx. € 2 million would have been achieved on a linear extrapolation in financial year 2014.

Another significant business combination resulted in the context of acquiring the British company Internis Pharmaceuticals Limited, London,

United Kingdom, which is active in the prescription area of therapeutic treatment of vitamin D3 deficiency. STADA achieved control upon

conclusion of the contract on December 19, 2014.

The purchase price amounts to a maximum of GBP 49.0 million (applying the exchange rate at the date of acquisition approx. € 62.3 mil-

lion) and was completely paid in cash or cash equivalents. It contains certain contingent purchase price components. The conditional

purchase price components amount to a total of GBP 20.0 million and divide equally into two purchase price conditions. The first purchase

price condition is to obtain regulatory drug approval. The final purchase price is determined by the date of achieving the approval. The

determination of the final purchase price of the second purchase price component depends on certain changes regarding competitive

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements156

parameters and determined sales targets. The amount recognized as of the acquisition date for conditional consideration amounts to

GBP 20.0 million. It is very likely that the regulatory drug approval will be obtained at an early date and, therefore, the competitive parameters

will not have changed at that time. A range of GBP 0 to 20.0 million is assumed for the conditional purchase price components, while the

risk of a deviation of GBP 20.0 million is estimated as very low. As of the balance sheet date, GBP 39.0 million had been already paid.

Due to the short amount of time between the acquisition and the balance sheet date, the entire purchase price allocation for this business

combination is to be regarded as provisional. In the context of the preliminary purchase price allocation, goodwill in the amount of approx.

€ 8.9 million resulted from the business combination and is broken down as follows:

in € million

Purchase price for 100% of the shares of the company approx.

Proportionate fair values of the assets and liabilities acquired approx.

Goodwill

62.3

53.4

8.9

Goodwill here results primarily from the expansion of the presence in the market region Central Europe, from taking over a highly qualified

workforce and from a possible expansion of the sales activities in the market region Central Europe.

For the assets acquired and liabilities assumed in the context of the business combination, the following preliminary fair values were

recognized at the acquisition date:

Fair values in € million

Intangible assets

Other non-current assets

Trade accounts receivable

Other current assets

Cash and cash equivalents

Assets

Deferred tax liabilities

Other non-current liabilities

Other current liabilities

Liabilities

63.0

1.0

2.6

1.3

4.9

72.8

12.1

2.3

5.0

19.4

Fair values were determined on the basis of observable market prices. To the extent that market prices could not be determined, income or

cost-oriented procedures were used for the measurement of acquired assets and liabilities assumed.

STADA Consolidated Financial Statements157

Sales generated in the market region Central Europe with the company Internis since the acquisition date amounted to approx. € 0.4 million

in financial year 2014. The operating profit of this business combination adjusted for the effects of the purchase price allocation (approx.

€ 0.0 million) amounted to approx. € 0.1 million in financial year 2014. If STADA had acquired the company on January 1, 2014, sales of

approx. € 13 million and operating profit, adjusted for effects from the purchase price allocation (about € 2 million), of approx. € 5 million

would have been achieved on linear extrapolation in financial year 2014.

9. Accounting policies

STADA’s consolidated financial statements are based on uniform accounting policies. The basis for these are the accounting requirements

which are mandatory for all companies included in the consolidated financial statements and which are described in more detail below.

Sales are recognized when goods have been delivered or services rendered, provided that it is reasonably probable that measurable

economic benefits will flow to the entity and that the substantial risks and rewards of ownership have been transferred to the buyer. It must

also be possible to reliably measure the Company’s own costs incurred or to be incurred.

Sales are recognized before taxes and after deduction of revenue reductions (rebates or discounts) at fair value of the consideration received

or receivable. Expenses from the creation of provisions for warranties are deducted from sales on the basis of estimated amounts. The

estimates are based on experience regarding amounts used in the past. The estimated expense from the creation of provisions is determined

as a percentage of sales. Discounts to health insurance organizations are also recognized with a reduction on sales based on the respective

contract in force.

Income and expenses from the same transactions are generally recognized in the same period. Expenses related to accruals for future

revenue reductions are thus recorded in the period in which the sales are realized.

Cost of sales includes the costs of conversion of the products sold and the purchase price of commercial goods sold or given free of

charge. The expense is recognized in the period in which the associated income is realized. In addition, cost of sales also includes costs

directly attributable to the commercial goods (e.g. cost of materials and personnel expenses), overhead costs (e.g. depreciation of produc-

tion equipment and regulatory drug approvals and licenses) as well as value adjustments of excess or obsolete inventories.

Research expenses are costs that are incurred in relation to the research activity of a company that aims to provide new scientific or

technical findings. The product portfolio of the STADA Group continues to focus on products that do not require the Group to conduct its

own research. Just as in the previous years, no research expenses were thus incurred in financial year 2014.

Development expenses consist of expenses involved initially in the technical implementation of theoretical discoveries in production and

production processes and ultimately their commercial implementation.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements158

As a rule, the objective of a development process at STADA is to obtain national or multinational regulatory drug approval. Development

costs relative to approvals for new drugs obtained by STADA result in capitalization as intangible assets if all the following preconditions

are met:

• It is technically possible to complete the asset (generally, achieve regulatory approval), enabling it to become available for use or sale.

• The intention and ability exist as well as the necessary resources to complete the asset and to use or sell it in the future.

• The intangible asset provides the Group with a future economic benefit.

• It must be possible to reliably calculate the development costs of the intangible asset.

STADA immediately recognizes development costs not eligible for capitalization as expense in the periods in which they are incurred. These

include expenses for technical and regulatory maintenance of products sold.

Interest income is reported in the income statement as a component of financial income. In this regard, both interest income and interest

expenses for all financial instruments measured at amortized cost as well as interest-bearing financial assets classified as available for sale

are recognized on the basis of the effective interest rate.

Dividends received from companies not included in the consolidated financial statements are disclosed within the investment income. This

shall be recognized when the shareholder’s right to receive payment is established.

Income taxes include actual taxes on income as well as deferred taxes. The tax receivables and liabilities recognized in the balance sheet

include demands or liabilities for income taxes in Germany and outside Germany from financial year 2014 as well as from previous years,

if applicable. The tax receivables and liabilities are calculated on the basis of tax rates effective as of the balance sheet date or known and

already concluded for the future in the countries in which the taxable income is generated.

Deferred taxes are created for temporary differences between the tax base of the assets or liabilities and their valuation rate in the IFRS

financial statements as well as for tax loss carryforwards. Deferred tax assets are recognized to the extent that it is probable that a taxable

profit will result against which the temporary difference can be utilized. Deferred tax liabilities are recognized for temporary differences

taxable in the future. STADA determines deferred taxes on the basis of tax rates applicable at the balance sheet date or those that have

already been resolved and communicated for the future. Deferred tax receivables and liabilities are offset if these relate to the same taxation

authority.

The tax expense in the period is recognized in the income statement, provided the changes in value that are recognized directly in equity

are not affected. To the extent that there are changes in the tax rate with an effect on deferred taxes, the resulting effects are recognized in

the period in which they arise.

STADA Consolidated Financial Statements159

Goodwill is not amortized over the period of useful life. Instead, an impairment test is performed at least once per year (impairment-only

approach). For this purpose, goodwill is allocated to cash-generating units aggregated into market regions below the segment level, where

a cash-generating unit corresponds to a market region within the three operating segments of the STADA Group for the purpose of an

impairment test of goodwill.

STADA carries out impairment tests for capitalized goodwill at least once a year. Additional reviews also take place if indications of impair-

ment become apparent. During the impairment test, the carrying amount of each cash-generating unit is compared with its recoverable

amount. The carrying amount of a cash-generating unit comprises the carrying amounts of all assets and liabilities attributable to the

valuation unit including the carrying amount of goodwill to be tested. If the recoverable amount of a cash-generating unit is lower than the

carrying amount, an impairment loss results. The recoverable amount is generally defined as the higher of the fair value less costs to sell,

if measurable, and the value in use of the cash-generating unit. The discounted cash flow method is used to determine the value in use,

applying an individual interest rate for each cash-generating unit and a detailed planning period of three years. For the period after this

three-year detailed planning horizon, a specific estimated growth rate in the amount of the expected long-term inflation rate is assumed.

Significant assumptions which are taken in order to determine the value in use include assumptions regarding sales development, regulatory

conditions, investments, the discount rate, currency relations as well as the growth rate. These assumptions are taken individually according

to the individual situations for every cash-generating unit and are partly based on internally determined assumptions which reflect both past

experience and include external market data.

Other intangible assets with determinable useful lives are recognized at cost and amortized on a straight-line basis over the period of their

useful life. Amortization shall begin when the asset is available for use, i.e. when it is in the condition necessary for it to be capable of

operating in the intended manner. The useful life of regulatory drug approvals, trademarks, licenses, dossiers with data for drug approvals

or in preparation of drug approvals, software, concessions, property rights and similar rights is between three and 30 years. If on the balance

sheet date, there are indications that these assets are impaired, the recoverable amount of the asset is re-evaluated and impairment losses

are recognized according to the difference to the carrying amount. If the reasons for recognizing an impairment loss cease to exist,

corresponding write-ups are carried out up to a maximum of the amortized cost.

Intangible assets with indeterminable useful lives are not amortized. In the context of annual impairment tests and additionally in all cases

where there are indications of impairment, the recoverable amounts of these assets are compared with their carrying amounts and if

necessary, an impairment loss is recognized. For this purpose, the fair value of the asset less costs to sell was determined using the relief

from royalty method. At STADA, this affects the umbrella brand Hemofarm capitalized in the context of the acquisition of the Hemofarm

group, as well as the umbrella brand Pymepharco capitalized in the context of achieving control over Pymepharco. Intangible assets that are

not yet available for use are also generally put through annual impairment tests. Furthermore, in each reporting period, an audit is carried

out to check whether the reasons for recognizing an indefinite useful life continue to exist.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements160

Internal development costs are capitalized in accordance with the criteria in IAS 38. Capitalized development costs consist mainly of costs

that can be allocated to the projects, such as the costs of individuals working in development, material costs, external services and directly

allocable overhead costs. Internally created intangible assets are amortized on a straight-line basis over their useful life (generally 20 years).

Property, plant and equipment is reported at cost less depreciation and any impairment losses plus write-ups. Depreciation shall begin

when the asset is available for use and is accordingly in the condition necessary for it to be capable of operating. Subsequent acquisition

costs are capitalized. Capitalization requires that a future economic benefit will flow to the company and that the cost of the asset can be

reliably measured. Expenses for repairs and maintenance which do not represent significant replacement investments are recognized as

expenses in the financial year in which they are incurred.

Items of property, plant and equipment are depreciated according to their useful life using the straight-line method. The depreciation period

may be up to 50 years in the case of buildings, eight to 20 years in the case of technical facilities and three to 14 years for other plant and

office furniture and equipment. The component approach, according to which every significant component of property, plant and equipment

with different useful lives, must be depreciated separately, is not applied at STADA due to a lack of relevance. To the extent necessary,

impairment losses are recognized pursuant to IAS 36; these are reversed if the reasons for the original recognition of an impairment loss

no longer exist.

Borrowing costs that are directly attributable to the acquisition or production of a qualifying asset are capitalized as part of the cost of the

intangible asset or property, plant and equipment. Other borrowing costs are not capitalized. Where acquisitions are made in a currency

other than the respective functional currency, subsequent changes in exchange rates have no impact on the recording of original costs.

Impairments on other intangible assets and property, plant and equipment exist when the recoverable amount of an asset is lower

that its carrying amount. At each balance sheet date, STADA assesses whether indications for impairment are apparent. If this is the case,

e.g. if certain defined critical values are exceeded, the asset’s recoverable amount is determined. The recoverable amount is the higher of

the asset’s fair value less costs to sell and its value in use, where the value in use is calculated with a discounted cash flow method. Under

this procedure, future cash flows of intangible assets are discounted at the weighted average cost of capital, which is determined individually

for various market regions with specific parameters. Expenses arising from impairments are recognized under “Other expenses”.

For the purpose of impairment tests of other intangible assets and property, plant and equipment, cash-generating units within the STADA

Group are defined at the level of individual assets within the reportable segments of Branded Products, Generics and Commercial Business.

If the reasons for an impairment no longer exist, the corresponding write-ups are carried out up to a maximum of the carrying amounts

determined at amortized cost. Income from write-ups is reported under the item “Other income”.

STADA Consolidated Financial Statements161

Leases are classified either as operating lease or as finance lease, depending on whether the significant risks and rewards of ownership

remain with the lessor or with the lessee. The lease is not recognized in the lessee’s balance sheet in case of operating leases. STADA

records the lease payments for these leases in the income over the lease term. Assets from finance leasing are, on initial recognition,

recognized at the lower of the fair value of the lease and the present value of minimum lease payments, and are depreciated according to

their estimated useful lives or shorter contractual period. An amount is reported as lease liability, when, on initial recognition, it corresponds

to the lease’s carrying amount and is extinguished and carried forward in subsequent periods with a constant effective interest rate. The

interest that is part of the lease installment is recognized as an expense.

In addition, in case of sale and leaseback transactions that represent a finance lease, any excess of sales proceeds over the carrying amount

is deferred and recognized in the income statement over the lease term.

The total value of capitalized leases is not of material significance for STADA when compared with the total volume of fixed assets.

Under financial assets, STADA recognizes shares in non-consolidated, affiliated companies, other investments as well as held-to-maturity

securities. Shares in associated companies and other investments are classified as available-for-sale financial assets and are generally

reported at fair value with no effect on income. If no quoted market prices in an active market are available to measure these shares and

their fair value therefore cannot be determined reliably, they are measured at amortized cost. If any objective indications of impairment are

determined, these are quantified by means of an impairment test and recognized in profit or loss in accordance with IAS 39.

Inventories include such assets that are held for sale in the ordinary course of business (finished goods), that are in the process of

production for such sale (work in progress), and that are consumed in the production process or in the rendering of services (materials and

supplies). Inventories are measured at the lower of cost and net realizable value. Costs are calculated based on weighted average costs.

Costs of sales include both costs that are directly incurred in production and overheads that can be allocated to the production process,

including reasonable depreciation on production facilities. Financing costs are not included, but are instead recognized as an expense in the

period in which they occur. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of

completion and the estimated costs necessary to make the sale.

Financial assets can be broken down into the following categories in accordance with IAS 39: loans and receivables, financial assets at

fair value through profit or loss, available-for-sale financial assets and held-to-maturity investments. Financial assets are accounted for and

measured pursuant to IAS 39. Accordingly, financial assets are, as a rule, initially recognized at fair value. In addition, for financial assets

which are subsequently measured at amortized cost, transaction costs directly attributable to the acquisition are to be taken into account.

Different measurement policies apply for subsequent measurement in accordance with the applicable categories for financial assets

pursuant to IAS 39.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements162

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market.

They are allocated to current assets to the extent that they are due for settlement within twelve months after the balance sheet date. STADA

reports loans and receivables under “Trade accounts receivable”, “Other financial assets” and “Cash and cash equivalents”. They are

measured at amortized cost using the effective interest method.

STADA reports receivables from derivatives which, if applicable, may also be part of hedge accounting, as financial assets at fair value

through profit or loss. Assets in this category are reported under the “Other financial assets” item. They are measured at fair value. If these

assets do not have a quoted market price in an active market, fair value is determined with appropriate measurement models. This includes

the application of discounted cash flow methods, which are largely based on input parameters observable in the market. Changes in the fair

values are recognized in profit and loss at the time of the increase or decrease in value.

Held-to-maturity financial investments include non-derivative assets with fixed or determinable payments and a fixed term that STADA

intends to hold to maturity. They are measured at amortized cost using the effective interest method. STADA reports these assets in financial

assets under the item “Other financial assets”.

Available-for-sale financial assets are non-derivative assets that are not allocated to any of the above categories. In particular, they

comprise, in addition to shares in affiliated companies and other investments included in financial assets, equity securities which are

recognized under “Other financial assets”. They are measured at fair value, with recognition of changes under “Provisions available for sale”

directly in equity. These measurement results are reclassified through profit and loss upon sale or valuation allowance of these assets. There

must be objective evidence that there is a significant or continuing decrease in fair value below cost. Usually, published price quotations can

be used for determining fair value.

Trade accounts receivable are measured at amortized cost less impairments using the effective interest rate method. Impairments are

made in the form of individual impairments and general individual impairments for specific defaults and expected default risks resulting from

the insolvency of customers. To quantify the expected default risk, STADA determines the expected future cash flows from receivables

grouped by debtor. To this end, the maturity structures of net receivables and experience relating to derecognition of receivables in the past,

the creditworthiness of the customers as well as changes in payment conditions are taken into account. In addition, a trade credit insurance

that covers part of the loss in case of default is to be taken into consideration for various Group companies. The required impairment thus

determined reduces the assets’ carrying amounts through recognition of an impairment account.

The loss is recognized in profit and loss under “Other expenses”. Bad debts are derecognized against the impairment account. Subsequent

cash receipts for receivables already derecognized are presented net of expenses.

STADA Consolidated Financial Statements163

Non-current assets and disposal groups held for sale are classified as held for sale, if the related carrying amount will be recovered

principally through a sale transaction rather than through continuing use, and if the sale is regarded as highly probable. Measurement of

these assets is based on the lower of carrying amount and fair value less costs to sell.

Cash and cash equivalents include cash and call deposits as well as short-term and highly liquid financial investments with a maximum

term of 90 days from the purchase date, which can be converted to cash immediately and are subject only to minor price fluctuation risks.

They are measured at amortized cost. Cash and cash equivalents are reported in accordance with their definition in IAS 7.

Other assets, which are not based on any contractual rights involving the direct or indirect exchange of cash, are recognized under the item

other assets.

STADA maintains defined benefit plans in various countries, according to which the amount of pension benefits depends on the employees’

pensionable remuneration and the length of their service or which contain guarantees not permitting recognition as defined contribution

plan. Pension obligations are measured in accordance with actuarial principles of the projected unit credit method. The pension provisions

recognized in the balance sheet correspond to the present value of the defined benefit obligation on the balance sheet date less the fair

value of plan assets adjusted for the effect resulting from any effect of limiting the benefit asset. The calculation includes, apart from earned

pensions and entitlements, future salary and pension increases as well. For German Group companies, pension obligations are calculated

based on the biometric accounting principles of the Heubeck 2005G mortality tables. Outside Germany, country-specific mortality tables are

used. Future pension benefits are subject to individual pension agreements. The discount rate shall be based on market yields on high

quality corporate bonds with fixed interest rates at the end of the reporting period. In countries where there is no deep market in such

corporate bonds, the discount rate is determined on the basis of market yields on government bonds.

The standard IAS 19 only permits actuarial gains and losses to be recognized directly in equity. It differentiates between gains and losses

due to changes in demographic assumptions, due to changes in financial assumptions as well as due to experience-based amendments.

They are recognized directly in equity in the period in which they occur (“Other comprehensive income”). The relevant amounts are reported

separately in the consolidated statement of comprehensive income. For the calculation of the portion of the interest income on plan assets

recognized through profit or loss, the standard IAS 19 requires the application of the discount rate underlying the obligation. The remainder

of the actual income from plan assets is to be recognized directly in other comprehensive income. The current service cost is recorded in

staff costs of the individual functional areas. All past service cost that arises in the financial year shall be recognized im mediately through

profit or loss.

Various Group companies additionally grant their employees defined contribution plans. Here, Group companies pay defined contributions

to independent institutions due to legal or contractual requirements or on a voluntary basis; liabilities beyond this do not exist. Contributions

to be paid for the respective plans are recognized as expense in the respective period in the relevant functional areas.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements164

The other non-current provisions contain anniversary provisions as other long-term employee benefits. Commitments to anniversary

payments are recognized in accordance with the guidelines in IAS 19 as other long-term employee benefits. In contrast to pension

provisions, actuarial gains and losses are not recognized without an effect on the income statement. Such potential gains and losses are

immediately recognized as income or expenditure in the relevant functional area. Furthermore, there is a working time accounts plan which

is accounted for in the same way as commitments to anniversary payments.

Other provisions are made by STADA if there are current legal or constructive obligations to third parties arising from past events and

probably can lead to an outflow of resources embodying economic benefits that can be reliably determined. An outflow of resources

embodying economic benefits is considered as probable if it is more likely than not. Other provisions are recognized in an amount that,

taking into account all recognizable risks, offers the best possible estimate of expenditures necessary to fulfill the obligations. Any existing

reimbursement claims by third parties are not netted with other provisions. Expenses from the creation of provisions are allocated to

functional costs according to where they arise. If changes in estimates result in a reduction of the obligation, the other provisions are

reversed on a pro rata basis and recognized in profit and loss under the item where the original expense was recognized.

STADA reports all other provisions as current liabilities, because a settlement date within twelve months of the balance date is expected.

The amounts recognized are not discounted. Liabilities incurred due to outstanding accounts or obligations vis-à-vis personnel and tax

authorities, as well as other liabilities are not recorded as provisions, but under “Trade accounts payable” or “Other liabilities”.

Differentiated from provisions, there are contingent liabilities for possible obligations based on past events but which will not become

manifest until the occurrence of one or more uncertain future events, which are not under STADA’s control. In addition, there are also

contingent liabilities for current obligations, for which however the associated outflow of resources is not considered probable or the amount

of the obligation cannot be adequately estimated. In accordance with IAS 37, such contingent liabilities are not recognized.

Financial liabilities are measured on initial recognition at fair value plus transaction costs directly attributable to the acquisition. For

financial liabilities that subsequently continue to be measured at fair value, any transaction costs are recognized as an expense in the period

in which they occur. This relates to the accounting of derivative financial instruments with negative market values that are not part of an

effective hedging relationship and allocated to the category “at fair value through profit or loss” in accordance with IAS 39. STADA reports

these liabilities in the “Other financial liabilities” item. Here, those derivative financial instruments are also included which serve to hedge

interest rate and currency risks resulting from operating activities, financial transactions and investments, and which are also measured at

fair value in accordance with the regulations of IAS 39 on hedge accounting. Unless market prices are available, fair value is determined

with measurement models based on discounted cash flow models.

STADA Consolidated Financial Statements165

Derivative financial instruments exist at STADA in the context of derivatives measured at fair value with an effect on income as well as

in the context of derivative hedging instruments. In each case, depending on whether the market value of the derivatives is positive or

negative, they are recognized under the item “Other financial assets” or “Other financial liabilities” (see accounting policies for financial

assets and financial liabilities). Cash flow hedges, fair value hedges and hedges of net investments in a foreign operation can generally be

recognized as derivative hedging instruments in the context of hedge accounting in accordance with IAS 39.

At STADA, cash flow hedges are used to hedge against fluctuations of cash flows associated with a recognized asset or a recognized liability

or a highly probable planned transaction. Changes in the fair value of these hedging instruments are recognized in the amount of the

effective part of the hedging relationship directly in equity under “Provisions for cash flow hedges”. A transfer to the income statement takes

place in the period when the underlying hedged item becomes effective. The ineffective part of the changes in value is, however, recognized

directly in the income statement.

In the context of fair value hedges, the risk of a change in fair value of recognized assets or recognized liabilities or fixed off balance liabilities

is hedged. Changes in the fair value of these hedging transactions are recorded in profit and loss like changes in the fair value of the

underlying hedged items. If the requirements for hedge accounting are no longer met, the carrying amounts of the previously hedged items

are adjusted on the basis of their remaining terms. Hedges of net investments in a foreign operation are treated according to the same

accounting policies as cash flow hedges.

STADA regularly reviews the effectiveness of the hedging relationships as a prerequisite for hedge accounting pursuant to IAS 39. A hedging

transaction is in general considered to be effective, if changes in fair value of the hedging transaction are both prospectively and retro-

spectively within a range of 80% to 125% of the offsetting changes in fair value of the hedged item.

STADA measures all other financial liabilities, in particular trade accounts payable as well as financial liabilities, at amortized cost using the

effective interest method.

STADA has so far not made use of the option to designate financial liabilities on initial recognition as financial liabilities to be recognized at

fair value through profit or loss.

Other liabilities, which are not based on any contractual rights involving the direct or indirect exchange of cash, are recognized under the

item “Other liabilities”.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements166

10. Estimates, assumptions and discretion in the application of accounting principles

The presentation of the business, financial and earnings situation in the consolidated financial statements is determined by recognition and

valuation methods. To a certain extent, STADA makes estimates and assumptions relating to the future that are based on past experience

as well as other factors that are considered to be appropriate in the particular circumstances. Although the estimates and assumptions are

constantly re-evaluated, estimates derived in this way may differ from actual circumstances. The significant estimates, accounting judgments

and related assumptions for the accounting issues concerned are detailed below.

As part of purchase price allocations in business combinations, goodwill is the difference between the acquired net assets valuated accord-

ing to IFRS 3 and the consideration transferred plus the fair value of the previously held shares and the amount recognized of non-controlling

shareholders. Various valuation methods are used for this, which are primarily based on estimates and assumptions.

STADA carries out an impairment test for capitalized goodwill at least once a year. The discounted future cash flows of the cash-generating

units aggregated to market regions below the segment level, which are based on certain assumptions, are to be determined for this

purpose. The discounted cash flow method is used to determine the value in use, applying an individual interest rate for each cash-

generating unit and a detailed planning period of three years based on approved budgets. For the period after this three-year detailed

planning horizon, a specific estimated growth rate in the amount of the expected long-term inflation rate is assumed. The budget values for

future financial years, which are subject to some uncertainty due to unforeseeable future legal developments and developments in the

health care market, as well as the parameters determined in the context of current market information but also as a best possible estimate

mean that the assessment of impairment may differ from actual circumstances, and despite good forecasts in the reporting year an

impairment requirement may be necessary in subsequent years.

For items of property plant and equipment and intangible assets, the expected useful lives and associated amortization or depreciation

expenses are determined on the basis of the expectations and assessments of management. If the actual useful life is less than the

ex pected useful life, the amount of depreciation or amortization is adjusted accordingly. As part of the determination of impairment losses

on fixed assets, estimates relating to the cause, timing and amount of the impairments are also made. Particularly in the context of impair-

ment tests for yet unused approvals, which are recognized as advance payments, the growth rates applied for the present value test as well

as the long-term price and cost development of active pharmaceutical ingredients are based on best possible estimates. This also applies

to the impairment tests of other intangible assets with indefinite useful lives.

Development costs are capitalized based on the assessment of whether the capitalization requirements of IAS 38 are met. Planning

calculations are necessary to determine the future economic benefit, which are by their nature subject to estimates and may therefore

deviate from actual circumstances in the future.

STADA makes valuation allowances on receivables in order to anticipate losses expected in relation to insolvency of customers. The maturity

structure of the net receivables and past experience in relation to bad debts as well as the customers’ creditworthiness are used as the

criteria for evaluating the appropriateness of the valuation allowances. This does not, however, exclude the possibility that the actual

derecognitions will exceed the expected valuation allowances due to a significant worsening in the financial situation of the customer.

Accounting judgments and estimates regarding the assessment of the value of receivables relate particularly to impaired receivables from

debtors in CEE countries.

STADA Consolidated Financial Statements167

STADA operates in various countries and is obliged to pay respective income taxes in each tax jurisdiction. In order to calculate the income

tax provisions and the deferred taxes in the Group, the expected income tax as well as the temporary differences resulting from the different

treatment of certain items according to IFRS and their accounting in accordance with tax law are each to be determined on the basis of

assumptions. If the final taxation imposed deviates from the assumed values, this has a corresponding effect on actual and deferred taxes

and thus on the business, financial and earnings situation of the Group in the respective period. Furthermore, increasing importance within

the STADA Group is being allotted to a comprehensive tax transfer-pricing model for the payment of intercompany services. Potential risks

of non-recognition of these transfer prices for tax purposes is limited by way of the introduction of corresponding agreement procedures

and a comprehensive definition of transfer prices in the form of a Group guideline.

When determining the fair values of derivatives and other financial instruments, for which no market price in an active market is available,

valuation models based on input parameters observable in the market are applied. The cash flows which are already fixed or calculated by

means of the current yield curve using so-called “forward rates” are discounted to the measurement date with the discount factors

determined by means of the yield curve valid on the balance sheet date.

The amount of pension obligations from defined benefit plans is calculated using actuarial methods. This procedure is based upon

assumptions, among other things, regarding the discount rate, life expectancy and future salary and pension increases. Changes to these

assumptions can significantly influence the amount of future pension expenses.

The creation of other provisions is based on the assessment of management regarding the probability and amount of an outflow of

resources. STADA creates provisions if there is a present external obligation and a probable outflow of resources, i.e. if it is more likely to

occur than not. Provisions in relation to pending legal disputes are created based on how STADA estimates the prospects of success. The

determination of provisions for damages is also associated with substantial estimates, which can change due to new information. The same

applies for the recognition of the amount of contingent liabilities.

Expenses from the creation of provisions for warranties are considered in sales and charged against income. Estimated values based on

past experience are used for this purpose. This means that the actual expenses for warranties may differ from the estimate and sales would

accordingly turn out to be higher or lower. The same applies for the consideration of discounts (e.g. discounts to health insurance

organizations) prescribed by law and due to other regulatory requirements, which are recognized with a reduction on sales based on the

respective underlying contract with an estimated amount in expectation of probable sales.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements
168

Notes to the Consolidated Income Statement

11. Sales

STADA’s sales primarily result from the supply of products. For information on the reporting of sales, please refer to the details included in

Accounting Policies.

In 2014, the increase in sales compared to 2013 was primarily a result of the good sales development in the market regions Central Europe

and Asia & Pacific. This development was mainly characterized by the acquisition of the British OTC supplier Thornton & Ross as well as the

consolidations of the Vietnamese company STADA Vietnam and the Chinese company STADA Pharmaceuticals (Beijing). Exchange rate

effects and portfolio changes had a total influence of € 47.3 million on sales in the reporting year. For information on how sales are broken

down according to segments and market regions, please refer to Segment Reporting in Note 43.

12. Cost of sales

Cost of sales is divided into the following items:

in € 000s

Material expenses

Impairment, depreciation and amortization

Expenses from inventory write-downs

Remaining cost of sales

Total

2014

20131)

853,464

100,779

33,747

82,451

834,810

86,265

29,945

73,455

1,070,441

1,024,475

Impairment, depreciation and amortization in the amount of € 100.8 million (previous year1): € 86.3 million) mainly inlcudes depreciation

and amortization on intangible assets, the ownership of which represents a necessary condition for the marketing of the products manu-

factured – in particular drug approvals.

Expenses from inventory write-downs included inventories written down to net realizable value netted with reversals. The reversals amounted

to € 9.3 million in financial year 2014 (previous year1): € 7.3 million).

13. Selling expenses

Selling expenses comprise in addition to the costs for sales departments and sales force also the costs for advertising and marketing

activities including samples for doctors. They also include all costs for logistics that occur for completed final products. Discounts in the form

of free retail packages, so-called discounts in kind, – if possible under the legal regulations in a national market – are not included. The

resulting expenses are recognized as a part of cost of sales.

STADA Consolidated Financial Statements169

In the reporting year, marketing expenses in the amount of € 186.4 million (previous year1): € 196.6 million) corresponded to a share of

41% in selling expenses (previous year1): 40%). In addition, selling expenses included depreciation in the amount of € 7.4 million (previous

year: € 7.7 million).

14. General and administrative expenses

Personnel and material costs of service and administrative units are reported under general and administrative expenses, unless they have

been charged to other functional areas as internal services.

In 2014, the general and administrative expenses included depreciation in the amount of € 10.2 million (previous year1): € 10.6 million).

General and administrative expenses decreased in the reporting year by a total of € 6.7 million. The decrease was a result of net earnings

in the amount of € 15.9 million, primarily from past service cost, in connection with a change in the defined benefit plan for the Chairman

of the Executive Board and the resulting changes with regard to the benefits awarded according to the former benefit plan.

15. Research and development expenses

For information on the composition of research and development expenses, please refer to the details included in Accounting Policies.

In financial year 2014, research and development expenses increased by € 1.4 million compared to the previous year.

The research and development expenses include depreciation in the amount of € 2.6 million (previous year1): € 2.6 million). Development

costs for new products in the amount of € 27.5 million (previous year: € 18.8 million) were capitalized in financial year 2014 (see the note

on the item “Intangible assets”).

16. Other income

Other income is divided into the following items:

in € 000s

Income in connection with business combinations

Income from write-ups

Income from disposal of non-current assets

Currency translation gains

Remaining other income

Total

2014

20,024

20,067

20131)

36,831

546

16,377

53,754

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements170

The income in connection with business combinations in the previous year resulted from the control achieved over the Vietnamese

pharmaceutical companies Pymepharco and STADA Vietnam and the related purchase price allocations, including effects from the dissolu-

tion of the respective provisions for currency translation. In connection with the acquisition of the British OTC supplier Thornton & Ross,

furthermore, negative goodwill was recognized from the purchase price allocation for this business combination in the previous year. No

such income was recognized in financial year 2014.

The remaining other income includes such items as income from damage claim payments received and other income not directly asso ciated

with functional costs, which comprises many insignificant individual items in the Group companies.

17. Other expenses

Other expenses are broken down as follows:

in € 000s

Expenses from valuation allowances on accounts receivable

Losses on the disposal of non-current assets

Currency translation expenses

Impairment losses on non-current assets excluding goodwill

Impairment losses on goodwill

Remaining other expenses

Total

2014

3,809

29,415

47,723

59,808

14,488

155,243

20131)

9,388

521

16,535

23,617

22,568

72,629

Expenses for valuation allowances on accounts receivable were recognized netted with the corresponding income from their reversal.

Other expenses include impairment losses on non-current assets excluding goodwill in the amount of € 47.7 million (previous year:

€ 23.6 million). In addition, impairment losses on goodwill regarding the market regions CIS / Eastern Europe as well as Asia / Pacific &

MENA were recorded in the reporting year. These impairment losses were considered by STADA as a special effect of financial year 2014.

The item also included net currency translation expenses in the amount of € 29.4 million in the reporting year (previous year1): € 16.5 mil-

lion). This development is especially attributable to the strong devaluation of the significant currencies of the market region CIS / Eastern

Europe and the resulting currency translation expenses, which are reported as one-time special effects.

Within remaining other expenses, personnel expenses are recognized in the amount of € 5,8 million (previous year: € 9.4 million).

STADA Consolidated Financial Statements171

18. Expenses in connection with the “STADA – build the future” project

Expenses in connection with the “STADA – build the future” project, which were reported as special effects and recorded separately in the

consolidated income statement since financial year 2010, amounted to € 9.1 million in the previous year and primarily included burdens

from external consulting services, related follow-up projects as well as unscheduled personnel expenses in the framework of this project.

In financial year 2014, no expenses were incurred in connection with the “STADA – build the future” project, as it was successfully

con cluded at the end of financial year 2013.

19. Financial result

The result from investments measured at equity in financial year 2014 relates to the companies BIOCEUTICALS Arzneimittel AG, Pharm

Ortho Pedic SAS and AELIA SAS, which are accounted for using the equity method. In the previous year, this also related – in the context of

the retrospective adjustments carried out in accordance with the new standard IFRS 11 – to the Vietnamese company STADA Vietnam,

which has been consolidated as subsidiary since the fourth quarter of 2013.

Investment income primarily relates to profit distributions from companies not included in the consolidated financial statements.

Financial income and financial expenses are composed of the interest result and other financial income and other financial expenses.

The interest result developed as follows:

in € 000s

Interest income

Interest expense

Interest result

thereof: from financial instruments of the valuation categories in accordance with IAS 39:

• Loans and receivables

• Financial assets at fair value through profit and loss

• Held-to-maturity investments

• Available-for-sale financial assets

• Financial liabilities measured at amortized costs

2014

1,242

70,393

-69,151

20131)

3,484

69,930

-66,446

1,242

3,484

-68,431

-67,915

In addition, the interest result in financial year 2014 includes an interest expense from other non-current provisions, which comprises

interest income on plan assets as well as interest expenses from pension obligations and other non-current provisions, in the amount of

€ 2.0 million (previous year: € 2.0 million).

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements172

In financial year 2014, the Group refinanced itself at interest rates of between 0.9% p.a. and 12.0% p.a. (previous year: between 0.8% p.a.

and 13.8% p.a.). On the balance sheet date of December 31, 2014, the weighted average interest rate for non-current financial liabilities

was approx. 3.3% p.a. (previous year: approx. 3.5% p.a.) and for current financial liabilities approx. 4.6% p.a. (previous year:

approx. 2.1% p.a.). For all of the Group’s financial liabilities the weighted average interest amounted to approx. 3.7% p.a. (previous year:

approx. 3.3% p.a.).

Interest payments partially resulting from interest rate swaps designated by STADA as hedging instruments in cash flow hedges are not

netted for each swap contract and are recognized as interest income or interest expense in the valuation category of the associated under-

lying hedged item. For the reporting period, this exclusively concerns financial liabilities which are valued at amortized costs.

Borrowing costs capitalized as part of the cost of qualifying assets amounted to € 0.7 million in financial year 2014 (previous year:

€ 0.5 million). A capitalization rate of 3.1% for intangible assets (previous year: 3.6%) was taken as a basis.

Other financial income and other financial expenses consist of the following:

in € 000s

Other financial income

thereof

• from the measurement of financial instruments

Other financial expenses

thereof

• from the measurement of financial instruments

2014

3,591

2013

3,381

The result from the measurement of financial instruments in the reporting period resulted from interest rate swaps and interest rate / currency

swaps measured at fair value through profit or loss. There was a net relief on earnings in the amount of € 3.6 million before or € 3.6 million

after taxes. In the previous year, there was a net relief on earnings from the measurement of derivative financial instruments in the amount

of € 3.4 million before or € 2.5 million after taxes. The measurement of interest rate hedge transactions thereby depends on the develop-

ment of the money market interest rate.

STADA Consolidated Financial Statements20. Income taxes

Actual income taxes in the income statement relate to taxes in Germany and abroad as follows:

in € 000s

Actual taxation

Germany

Outside Germany

Deferred taxes

Germany

Outside Germany

173

2014

46,032

872

45,160

8,554

12,046

-3,492

20131)

66,388

314

66,074

102

-1,984

2,086

The item income taxes includes taxes on income and earnings paid or owed in the individual countries as well as deferred taxes. Other

taxes that cannot be meaningfully attributed to the sales, administration or research and development functions are included in Other

expenses.

Actual income taxes can be divided according to timing as follows:

2014

46,032

49,159

2,371

5,498

2014

8,554

10,726

-2,172

20131)

66,388

71,270

398

5,280

20131)

102

9,933

-9,831

in € 000s

Actual income taxes

Tax expense in the current period

Tax expense from previous periods

Tax income from previous periods

The deferred taxes are as follows:

in € 000s

Deferred taxes

from temporary differences

from interest carryforwards

from loss carryforwards

from tax credits

from others

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements174

The income tax rate amounted to 43.8% for financial year 2014. The income tax rate in the previous year was 35.1%1).

The following overview explains how the income tax expense reported in the income statement was calculated from the expected income

tax expense. The expected income tax expense is calculated by applying the weighted expected Group average tax rate on the earnings

before taxes and takes into account for all domestic and foreign companies the respective tax rates depending on their applicable national

and legal forms.

in € 000s

Earnings before taxes

Weighted expected Group average tax rate (in %)

Expected income tax expense

Adjustments to the expected income tax expense

Tax effects from non-deductible impairment on investments and goodwill

Tax effects from loss carryforwards

Tax effects from previous years

Effects from tax rate changes / deviation from Group tax rate

Tax effects from non-deductible expenses and tax-free earnings

Other tax effects

Income tax expense shown on the income statement

Effective tax rate (in %)

2014

20131)

124,694

23.3%

29,111

9,635

-3,127

899

21,857

-3,877

54,586

43.8%

189,301

25.1%

47,539

1,872

-1,119

-4,890

-828

22,008

1,908

66,490

35.1%

Tax effects from non-deductible impairments of investment and goodwill hereby result mainly from impairments of goodwill in the market

regions CIS / Eastern Europe and Asia / Pacific & MENA.

The expenses not deductible for tax purposes primarily result from the limited tax deductibility of operating expenses for payments in

connection with investments.

The actual income taxes and deferred taxes recognized in the balance sheet were as follows:

in € 000s

Income tax receivables

Income tax liabilities

Dec. 31, 2014

Dec. 31, 2013

30,711

33,726

24,836

30,569

STADA Consolidated Financial Statementsin € 000s

Deferred tax assets

Deferred tax liabilities

Deferred taxes as of December 31

Difference compared to previous year

thereof

• recognized in income

• recognized directly in equity

• acquisitions / disposals / changes in the scope of consolidation

• currency translation differences

175

Dec. 31, 2014

Dec. 31, 20131)

49,409

166,699

-117,290

-17,468

-8,554

6,344

-11,257

-4,001

50,618

150,440

-99,822

-63,111

-102

-940

-62,630

561

Deferred taxes result from the following balance sheet items and loss carryforwards:

in € 000s

Intangible assets

Property, plant and equipment

Financial assets

Inventories

Receivables

Other assets

Other non-current provisions

Other provisions

Liabilities

Loss carryforwards

Total

Offsetting

Deferred taxes as per balance sheet

Dec. 31, 2014
Deferred
tax assets

Dec. 31, 2013
Deferred
tax assets

Dec. 31, 2014
Deferred
tax liabilities

Dec. 31, 2013
Deferred
tax liabilities

1,811

1,260

1,704

16,835

12,036

1,309

4,540

3,955

299

15,728

59,477

-10,068

49,409

1,976

1,625

1,545

14,437

6,210

4,668

8,659

2,006

5,206

12,857

59,189

-8,571

50,618

147,438

137,599

7,944

2,110

370

8,869

172

5,035

4,808

176,767

-10,068

166,699

8,816

3,645

748

2,574

107

5,424

159,011

-8,571

150,440

Deferred tax liabilities reported by STADA result, among other things, from deferred taxes in the context of purchase price allocations carried

out under IFRS 3. Deferred tax liabilities increased as compared to the previous year primarily as a result of the acquisition of the British

company Internis.

Tax advantages that are highly probable and expected from the future utilization of tax loss carryforwards are recognized under “Deferred

taxes from loss carryforwards”.

Tax loss carryforwards are only capitalized if their future utilization is highly probable. Tax loss carryforwards capitalized as of the

December 31, 2014 reporting date amounted to € 60.1 million in financial year 2014 (previous year: € 54.0 million).

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements176

The deduction of operating expenses for interest, which is limited under German tax law (so-called interest barrier), led to no net interest

expense not deductible for tax purposes in 2014 (previous year: € 25.2 million) and therefore to no additional tax burden (previous year:

€ 6.1 million).

Income taxes paid or owed increased by a total of € 0.1 million (previous year: reduction by € 1.1 million) through the utilization of previ-

ously unrecognized tax loss carryforwards from previous years for which no deferred taxes have been recognized so far and through tax

loss carryforwards from the current financial year for which no deferred taxes have been recognized.

The future usable tax loss carryforwards are listed in the following chart according to their expiry date:

in € 000s

Loss carryforward expiry date within

• 1 year

• 2 years

• 3 years

• 4 years

• 5 years

• more than 5 years

• unlimited carryforward

Dec. 31, 2014

Dec. 31, 2013

1,427

779

1,062

56,836

465

532

635

5,352

46,996

No deferred taxes were recognized for the following loss carryforwards and temporary differences as it is not probable that they will be

realized in the foreseeable future:

in € 000s

Loss carryforward expiry date within

• 1 year

• 2 years

• 3 years

• 4 years

• 5 years

• more than 5 years

• unlimited carryforward

Temporary differences

Dec. 31, 2014

Dec. 31, 2013

1,163

14,955

243

278

332

780

814

STADA Consolidated Financial Statements177

21. Income distributable to non-controlling interests

in € 000s

Earnings after taxes

• thereof distributable to shareholders of STADA Arzneimittel AG (net income)

• thereof distributable to non-controlling interests

Dec. 31, 2014

Dec. 31, 2013

70,108

64,562

5,546

122,811

121,426

1,385

Net income relating to non-controlling interests pertains to the subsidiaries STADA Thailand, STADA Import/Export International, STADA

Vietnam J.V., Pymepharco, STADA Pharmaceuticals (Beijing) Ltd., Hemomont and Hemofarm Banja Luka.

22. Earnings per share

The basic and diluted earnings per share are as follows:

Basic earnings per share

Net income (in € 000s)

Adjustment

Adjusted net income (basic) (in € 000s)

Average number of registered shares with restricted transferability issued (in unit shares)

Average number of treasury shares (in unit shares)

Adjusted average number of shares (basic) (in unit shares)

Basic earnings per share (in €)

2014

64,562

2013

121,426

60,499,412

59,664,983

90,911

93,024

60,408,501

59,571,959

1.07

2.04

Basic earnings per share are calculated by dividing the adjusted net income distributable to the shareholders of STADA Arzneimittel AG by

the time-weighted average number of registered shares with restricted transferability outstanding.

Diluted earnings per share

Adjusted net income (basic) (in € 000s)

Dilutive effects on profit from share options (after taxes) (in € 000s)

Adjusted net income (diluted) (in € 000s)

Adjusted average number of shares (in unit shares)

Potentially diluting shares from share options (in unit shares)

Average number of shares (diluted) (in unit shares)

Diluted earnings per share (in €)

2014

64,562

60,408,501

860,909

2013

121,426

59,571,959

998,668

61,269,410

60,570,627

1.05

2.00

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements178

Diluted earnings per share are generally calculated with the formula used to calculate the basic earnings per share. They are also adjusted

for the effect of outstanding share options on the basis of the average share price of the financial year. This is carried out based on the

assumption that all potentially dilutive share options are exercised. Details on currently valid equity instruments are included in the notes on

equity.

23. Number of employees and personnel expenses

The average number of employees at STADA by functional area and functional sub-area is as follows:

Marketing / Sales

Logistics

Finance / IT

Production / Quality management2)

Procurement / Supply chain

Product development

Administration2)

Entire Group

Personnel expenses (in € million)

2014

2,938

400

670

4,442

311

571

877

10,209

305.1

20131)

2,768

343

636

3,353

296

524

921

8,841

319.6

The average number of employees in the reporting year was above the level of the previous year at 10,209 (previous year1): 8,841). This

increase was mainly based on the acquisition of the British OTC supplier Thornton & Ross as of September 1, 2013 and the control achieved

over STADA Vietnam as of October 10, 2013. Furthermore, the inclusion of STADA Pharmaceuticals (Beijing) Ltd., China, in the scope of

consolidation as of January 1, 2014 and an increase in the number of employees at the Serbian Hemofarm A.D. as a consequence of

increased production capacities contributed to this development. On the balance sheet date, the STADA Group’s number of employees in

2014 totaled 10,363 (previous year: 9,825).

Personnel expenses, which are included in expenses of the individual functional areas according to their functional relevance, decreased in

financial year 2014 to € 305.1 million (previous year1): € 319.6 million). The decrease was a result of earnings recorded within personnel

expenses from past service cost in connection with a change in the defined benefit plan for the Chairman of the Executive Board and the

resulting changes with regard to the benefits awarded according to the former benefit plan.

1) The previous year’s figures have been adjusted in accordance with the new IFRS 11 in connection with
IAS 8 as well as in connection with IAS 1 (see Notes to the Consolidated Financial Statements – 3.).
2) In 2013, facility management staff were placed exclusively into the functional area Administration.
In 2014, facility management staff in production were allocated to the functional area Production / Quality
management and the remaining facility management staff were assigned to the functional area
Administration.

STADA Consolidated Financial Statements24. Depreciation, amortization and impairment losses

Depreciation, amortization and impairment losses are included in expenses of the individual functional areas according to their functional

relevance and can be attributed to intangible assets, property, plant and equipment as follows:

179

in € 000s

Depreciation / amortization

Intangible assets

Property, plant and equipment

Impairment losses

Intangible assets

thereof:

• Goodwill

Property, plant and equipment

thereof:

• land and buildings

• other fixtures and fittings, tools and equipment

Financial assets

thereof:

• investments

2014

20131)

120,990

87,694

33,296

107,531

104,781

59,808

136

2,614

107,122

78,130

28,992

23,617

22,626

920

The impairment of intangible assets concerns various drug approvals and trademarks.

The impairments on goodwill recorded in financial year 2014 relate to goodwill of the market region CIS / Eastern Europe as well as of the

market region Asia / Pacific & MENA.

The impairments of financial assets in the reporting year primarily relate to the carrying amounts of STADApharm AB in Sweden. These

impairments in the previous year primarily related to the carrying amounts of IIP Institut für Industrielle Pharmazie Forschungs- und

Entwicklungsgesellschaft mbH and STADA Pharmaceuticals Australia Pty Ltd.

Depreciation and amortization increased by 12.9% compared to the previous year. More information on amortization, depreciation and

impairment losses is included in the Notes on non-current assets.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements
180

Notes to the Consolidated Balance Sheet

25. Intangible assets

Intangible assets developed as follows in financial year 2014:

2014
in € 000s

Cost as of Jan. 1, 2014

Currency translation

Changes in the scope of consolidation

Additions

Additions from business combinations according to IFRS 3

Disposals

Transfers

Regulatory drug
approvals,
trademarks,
customer
relationships,
software,
licenses and
similar rights

1,619,982

-37,342

113,366

36,691

16,160

28,218

Goodwill

470,770

-34,756

825

9,035

Cost as of Dec. 31, 2014

1,744,755

445,874

Accumulated amortization as of Jan. 1, 2014

Currency translation

Changes in the scope of consolidation

Amortization

Impairment losses

Disposals

Write-ups

Transfers

Accumulated amortization as of Dec. 31, 2014

Residual carrying amounts as of Dec. 31, 2014

Residual carrying amounts as of Dec. 31, 2013

539,239

-24,293

87,694

42,366

10,057

574

635,523

1,109,232

1,080,743

12,776

987

59,808

73,571

372,303

457,994

Payments made
and capitalized
development
costs for current
projects

160,209

-5,282

41,317

39,796

701

-28,218

207,121

57,323

-2,146

2,607

-574

57,140

149,981

102,886

Total

2,250,961

-77,380

155,508

85,522

16,861

2,397,750

609,338

-25,452

87,694

104,781

10,127

766,234

1,631,516

1,641,623

STADA Consolidated Financial Statements

181

Additions from business combinations according to IFRS 3, which relate to the fair values determined in the context of the purchase price

allocations, resulted from the acquisition of the British OTC supplier Internis with € 72.7 million, as well as from the purchase of the branded

product portfolio Flexitol® with € 12.8 million.

Included in intangible assets in the previous year were software and software licenses in the amount of € 2.6 million, which were recognized

with the present value of the minimum lease payments in accordance with IAS 17 in the context of a sale-and-leaseback transaction

and which have been amortized on schedule. At the end of the term of the lease contract, an existing purchase option was utilized. The

respective assets have been fully amortized as of the balance sheet date of December 31, 2014.

The umbrella brand Hemofarm capitalized in 2006 in the context of the acquisition of the Hemofarm group is included in recognized

trademarks as an intangible asset with an indefinite useful life, as STADA intends to make continuing use of it. As at December 31, 2014,

it has a carrying amount of € 47.6 million (previous year: € 50.2 million). The change compared to the previous year figure is a result of

different exchange rates. In the context of the impairment test of December 31, 2014, a royalty rate of 2% and a discount rate of 14.2%

was used. No necessity for impairment was found for the reporting year.

In the context of the control achieved over Pymepharco in the previous year, furthermore, the umbrella brand Pymepharco was capitalized

as an intangible asset with an indefinite useful life as a trademark, as STADA intends to continue the utilization of the trademark. As at

December 31, 2014, it has a carrying amount of € 9.1 million (previous year: € 8.0 million). The change is a result of different exchange

rates. In the context of the impairment test of December 31, 2014, a royalty rate of 2% and a discount rate of 16.5% was used. No neces-

sity for impairment was found for the reporting year.

Borrowing costs capitalized in 2014 for intangible assets and directly attributable to the acquisition or the production of a qualifying asset

amounted to € 0.7 million (previous year: € 0.5 million). In financial year 2014, the capitalization rate taken as a basis for determining

borrowing costs eligible for capitalization was 3.1% (previous year: 3.6%).

Development costs of € 28.7 million were capitalized in the reporting year (previous year: € 20.7 million). Capitalized development costs

consist mainly of costs that can be allocated to the projects, such as the costs of individuals working in development, material costs and

external services, together with directly allocable overhead costs. Internally created intangible assets are amortized on a straight-line basis

over their useful life, generally 20 years. STADA immediately recognizes development costs that do not qualify for capitalization as expense

in the period in which they are incurred (see Note 15.). In financial year 2014, these development costs amounted to € 56.9 million

(previous year1): € 55.5 million).

Amortization on intangible assets mainly relates to regulatory drug approvals as well as trademarks and is recognized in the income

statement primarily under cost of sales. In the reporting year, this related to an amount of € 87.7 million (previous year1): € 78.1 million).

In financial year 2014, impairments on intangible assets were recognized in the total amount of € 104.8 million (previous year: € 22.6 mil-

lion). They mainly include impairment on goodwill in the amount of € 54.0 million and additional intangible assets in the amount of

€ 22.0 million as a result of the significantly changed interest rate and currency environment as well as on ongoing higher risks in the

market region CIS / Eastern Europe.

Details on changes in the scope of consolidation can be found in the note on the scope of consolidation (see Note 5.).

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements182

Intangible assets developed as follows in the previous year:

20131)
in € 000s

Cost as of Jan. 1, 2013

Currency translation

Changes in the scope of consolidation

Additions

Additions from business combinations according to IFRS 3

Disposals

Transfers

Regulatory drug
approvals,
trademarks,
customer
relationships,
software,
licenses and
similar rights

1,309,293

-24,083

21,191

287,360

6,688

32,909

Goodwill

468,926

-16,828

18,672

Cost as of Dec. 31, 2013

1,619,982

470,770

Accumulated amortization as of Jan. 1, 2013

Currency translation

Changes in the scope of consolidation

Amortization

Impairments

Disposals

Write-ups

Transfers

Accumulated amortization as of Dec. 31, 2013

Residual carrying amounts as of Dec. 31, 2013

Residual carrying amounts as of Dec. 31, 2012

459,145

-7,185

78,130

13,425

4,380

546

650

539,239

1,080,743

850,148

13,153

-377

12,776

457,994

455,773

The following amortization expense is expected for the intangible assets in the next five years:

Payments made
and capitalized
development
costs for current
projects

160,322

-1,638

29,207

6,535

1,625

-32,592

160,209

49,192

-405

9,201

-650

57,323

102,886

111,130

in € 000s

2015

2016

2017

2018

2019

Total

1,938,541

-42,549

50,398

312,567

8,313

317

2,250,961

521,490

-7,967

78,130

22,626

4,395

546

609,338

1,641,623

1,417,051

Expected
amortization

85,178

86,688

87,287

87,546

86,650

STADA Consolidated Financial Statements

183

The subsequent chart shows which cash-generating units the capitalized goodwill can be attributed to:

in € million

Market region Germany

Market region Central Europe

Market region CIS / Eastern Europe

Market region Asia / Pacific & MENA

Total

Residual
carrying amount
Generics segment
Dec. 31, 2014

Residual
carrying amount
Branded Products
segment
Dec. 31, 2014

Residual
carrying amount
Commercial
Business segment
Dec. 31, 2014

Residual
carrying amount
Total
Dec. 31, 2014

12.4

126.8

31.9

11.5

182.6

15.1

97.1

66.5

10.2

188.9

0.0

0.8

27.5

223.9

98.4

22.5

372.3

In the previous year, the capitalized goodwill for cash-generating units was as follows:

in € million

Market region Germany

Market region Central Europe

Market region CIS / Eastern Europe

Market region Asia & Pacific

Total

Residual
carrying amount
Generics segment
Dec. 31, 2013

Residual
carrying amount
Branded Products
segment
Dec. 31, 2013

Residual
carrying amount
Commercial
Business segment
Dec. 31, 2013

Residual
carrying amount
Total
Dec. 31, 2013

12.4

125.7

100.7

9.6

248.4

15.6

96.6

91.6

5.1

208.9

0.0

0.7

28.0

222.3

192.3

15.4

458.0

For the purposes of impairment tests for capitalized goodwill, STADA defines cash-generating units as the respective market regions within

the operating segments in accordance with the strategic planning and control of the Group.

In comparison with the previous year, there were the following significant changes in the carrying amounts of goodwill:

• The increase in goodwill of the cash-generating unit market region Central Europe, Branded Products segment, resulted from the

acquisition of the British company Internis. In opposition, the reclassification of goodwill to the market region Asia / Pacific & MENA,

Branded Products segment, due to a change in management responsibility that resulted from a strategic reallocation led to a reduction

in goodwill.

• The decrease in goodwill of the cash-generating unit market region CIS / Eastern Europe, Generics segment, mainly results from the

necessity for impairment in the amount of € 54.0 million as of December 31, 2014 resulting from an extraordinary impairment test

carried out in the reporting year. The impairment resulted from the aggravation of the economic situation in Russia at the end of the year,

with a massive decline of the Russian ruble and a significant interest increase by the Russian central bank. The update of the parameters

that derived from it, particularly of currency relations, interest rates and country risks for market conditions as of December 31, 2014 led

to a value in use of € 375.4 million, which was below the carrying amount. The additional reduction in goodwill results from exchange

rates changes, in particular from a devaluation of the Russian ruble.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements

184

• The decrease in goodwill of the cash-generating unit market region CIS / Eastern Europe, Branded Products segment, fully results from

exchange rate changes, particularly from a devaluation of the Russian ruble.

• The increase in goodwill of the cash-generating unit market region Asia / Pacific & MENA, Branded Products segment, results from the

reclassification of goodwill from the market region Central Europe, Branded Products segment, due to a change in management

responsibility that resulted from a strategic reallocation. In opposition, an impairment in the amount of € 5.8 million resulted from the

impairment tests carried out in the reporting year due to existing knowledge and expectations related to the market and competitive

environment. The value in use of the cash-generating unit as of September 30, 2014 was at € 70.1 million.

In the context of the regular impairment tests for capitalized goodwill of September 30, 2014, the discounted cash flow method is used

to determine anticipated cash inflows, applying the following parameters defined for the individual cash-generating units according to

segment:

Each relating to segments,
defined as cash-generating units

Market region Germany

Market region Central Europe

Market region CIS / Eastern Europe

Market region Asia / Pacific & MENA

In the previous year, the applied parameters were as follows:

Each relating to segments,
defined as cash-generating units

Market region Germany

Market region Central Europe

Market region CIS / Eastern Europe

Market region Asia & Pacific

Growth rates
of forward-
projection
phase 2014
in %

1.7%

4.0%

4.2%

Growth rates
of forward-
projection
phase 2013
in %

1.9%

5.2%

6.2%

WACCs 2014
Generics
segment
in %

WACCs 2014
Branded Products
segment
in %

8.8%

11.1%

16.1%

20.2%

8.9%

10.9%

16.0%

20.2%

WACCs 2013
Generics
segment
in %

WACCs 2013
Branded Products
segment
in %

8.9%

11.2%

15.5%

22.1%

9.4%

11.0%

15.1%

22.0%

WACCs 2014
Commercial
Business
segment
in %

20.6%

WACCs 2013
Commercial
Business
segment
in %

23.4%

The discounted cash flow method is used to determine the value in use of the cash-generating units, applying an individual interest rate for

each cash-generating unit and a detailed planning period of three years. This detailed planning period reflects the assumptions for short

and mid-term market developments. For the period after this three-year detailed planning horizon, a specific estimated growth rate in the

amount of the expected long-term inflation rate is assumed. The detailed planning period for the determination of the value in use is based

on assumptions in light of past experience supplemented by current internal developments and verified through external market data and

analyses. The most important assumptions include the development of future sales prices, amounts and costs, the influence of the regulatory

STADA Consolidated Financial Statements

185

market environment, investments, market shares, exchange rates and growth rates. Significant changes to the above-described assump-

tions would influence the determination of the value in use of the cash-generating units. Possible changes to these assumptions would

negatively influence the cash-generating units as a result of continued strong competition and regulatory interventions. The discount rates

applied are determined on the basis of external factors derived from the market and adjusted for the respective predominant risks of the

cash-generating units.

Changes in the calculation parameters used for the impairment tests may influence the fair values of cash-generating units. The following

table shows what additional impairments would have come for the different cash-generating units as a result of a 1.0 percentage point

higher discount rate, a decrease in the growth rate of 0.5 percentage points and a decrease in EBIT of 10.0 percentage points:

Generics segment sensitivity analysis
Effects on impairment in € million

Market region Germany

Market region Central Europe

Market region Asia / Pacific & MENA

WACC
+1.0 percentage
points

Growth rate
-0.5 percentage
points

aEBIT
-10.0 percentage
points

0.6

2.6

Branded Products segment sensitivity analysis
Effects on impairment in € million

Market region Germany

Market region Central Europe

Market region Asia / Pacific & MENA

WACC
+1.0 percentage
points

Growth rate
-0.5 percentage
points

aEBIT
-10.0 percentage
points

4.2

1.7

5.6

For the Commercial Business segment, there would have been no impairment in any of the market regions as a result of the sensitivity

analysis.

With a reduction in discount rates of 1.0 percentage points, an increase in the growth rate of 0.5 percentage points and an increase in EBIT

of 10.0 percentage points, there would have been the following lower impairments.

Branded Products segment sensitivity analysis
Effects on impairment in € million

Market region Germany

Market region Central Europe

Market region CIS / Eastern Europe

Market region Asia / Pacific & MENA

WACC
-1.0 percentage
points

Growth rate
+0.5 percentage
points

aEBIT
+10.0 percentage
points

-3.8

-0.9

-4.7

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements

186

Due to the massive decline of the Russian ruble since the fourth quarter 2014 and a significant increase of interest rates by the Russian

central bank in December 2014, there were indications for an impairment. For this reason, an extraordinary impairment test was carried

out for the cash-generating unit market region CIS / Eastern Europe, Generics segment, and for the cash-generating unit market region

CIS / Eastern Europe, Branded Products segment, as of December 31, 2014. The parameters used to determine the value in use in the

scope of the regular impairment test as of September 30, 2014 were updated, particularly regarding currency relations, interest rates as

well as country risks for current market conditions, as of the new balance sheet date.

The discounted cash flow method was used to determine the anticipated cash inflows, applying the following parameters defined for the

individual cash-generating units according to segment:

According to segment, defined as cash-generating unit

Growth rates
forward
projected phase
2014
in %

WACCs 2014
Generics
segment
in %

WACCs 2014
Branded Products
segment
in %

WACCs 2014
Commercial
Business
segment in %

Market region CIS / Eastern Europe

4.0

16.7

Changes in the calculation parameters used for the impairment tests may influence the fair values of cash-generating units. The following

table shows what additional impairments would have come for the market region CIS / Eastern Europe as a result of a 1.0 percentage point

higher discount rate, a decrease in the growth rate of 0.5 percentage points and a decrease in EBIT of 10.0 percentage points:

Sensitivity analysis market region CIS / Eastern Europe
Effect on impairment in € million

Generics segment

Branded Products segment

WACC
+1.0 percentage
points

Growth rates
-0.5 percentage
points

aEBIT
-10.0 percentage
points

37.4

11.9

48.0

The following table shows what lower impairments would have come for the market region CIS / Eastern Europe as a result of a 1.0 per-

centage point lower discount rate, an increase in the growth rate of 0.5 percentage points and an increase in EBIT of 10.0 percentage

points:

Sensitivity analysis market region CIS / Eastern Europe
Effect on impairment in € million

Generics segment

Branded Products segment

WACC
-1.0 percentage
points

Growth rates
+0.5 percentage
points

aEBIT
+10.0 percentage
points

-45.8

-13.1

-48.0

STADA Consolidated Financial Statements

187

26. Property, plant and equipment

Property, plant and equipment developed as follows in financial year 2014:

2014
in € 000s

Cost as of Jan. 1, 2014

Currency translation

Changes in the scope of consolidation

Additions

Additions from business combinations according to IFRS 3

Disposals

Reclassification from non-current assets held for sale
and disposal groups

Transfers

Cost as of Dec. 31, 2014

Accumulated depreciation as of Jan. 1, 2014

Currency translation

Changes in the scope of consolidation

Depreciation

Impairments

Disposals

Write-ups

Reclassification from non-current assets held for sale
and disposal groups

Transfers

Accumulated depreciation as of Dec. 31, 2014

Residual carrying amounts as of Dec. 31, 2014

Residual carrying amounts as of Dec. 31, 2013

Land,
leasehold
rights and
buildings
including
buildings on
third-party
land

Plant and
tools and
machinery
equipment

260,684

-10,478

4,449

1,143

8,393

1,141

6,520

255,066

88,107

-3,570

7,287

136

3,330

108

88,738

166,328

172,577

199,611

-15,583

556

7,790

1,101

11,636

202,977

115,832

-11,104

15,364

1,049

106

119,149

83,828

83,779

Other
fixtures
and fittings,
tools and
equipment

105,510

-7,282

204

4,284

4,503

1,742

99,965

62,604

-3,360

10,645

3,714

-214

65,961

34,004

42,906

Advance
payment and
construction
in progress

19,166

-2,577

24,653

-19,898

21,270

19,166

Total

584,971

-35,920

5,209

37,870

14,071

1,141

579,278

266,543

-18,034

33,296

136

8,093

273,848

305,430

318,428

Property, plant and equipment included assets from finance leases, primarily relating to cars and vehicles, in the amount of € 1.5 million

(previous year: € 5.8 million), which, in accordance with IAS 17, were recognized at the present value of minimum lease payments and have

since been subjected to depreciation.

As in the previous year, no borrowing costs were capitalized in financial year 2014 for property, plant and equipment.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements

188

Property, plant and equipment developed as follows in the previous year:

20131)
in € 000s

Cost as of Jan. 1, 2013

Currency translation

Changes in the scope of consolidation

Additions

Additions from business combinations according to IFRS 3

Disposals

Reclassification to non-current assets held for sale
and disposal groups

Transfers

Cost as of Dec. 31, 2013

Accumulated depreciation as of Jan. 1, 2013

Currency translation

Changes in the scope of consolidation

Depreciation

Impairments

Disposals

Write-ups

Reclassification to non-current assets held for sale
and disposal groups

Transfers

Accumulated depreciation as of Dec. 31, 2013

Residual carrying amounts as of Dec. 31, 2013

Residual carrying amounts as of Dec. 31, 2012

Plant and
tools and
machinery
equipment

Other
fixtures
and fittings,
tools and
equipment

Advance
payment and
construction
in progress

Land,
leasehold
rights and
buildings
including
buildings on
third-party
land

231,635

-5,270

4,043

22,706

439

8,009

169,813

-6,103

5,697

23,578

899

7,525

93,086

-2,747

6,572

6,807

3,719

5,511

260,684

199,611

105,510

73,840

-1,428

6,790

8,851

151

88,107

172,577

157,795

107,776

-3,838

12,837

792

-151

115,832

83,779

62,037

57,453

-1,312

9,365

2,973

62,604

42,906

35,633

Total

508,430

-15,181

43,325

54,003

5,289

-317

584,971

239,069

-6,578

28,992

8,922

3,862

266,543

318,428

269,361

13,896

-1,061

27,013

912

232

-21,362

19,166

13,896

STADA Consolidated Financial Statements

189

27. Financial assets

Financial assets developed as follows in financial year 2014:

2014
in € 000s

Cost as of Jan. 1, 2014

Currency translation

Changes in the scope of consolidation

Additions

Disposals

Reclassification from non-current assets held for sale and disposal groups

Transfers

Cost as of Dec. 31, 2014

Accumulated impairments as of Jan. 1, 2014

Currency translation

Changes in the scope of consolidation

Impairments

Disposals

Write-ups

Reclassification from non-current assets held for sale and disposal groups

Transfers

Accumulated impairments as of Dec. 31, 2014

Residual carrying amounts as of Dec. 31, 2014

Residual carrying amounts as of Dec. 31, 2013

Shares in
associated
companies
and other
investments

Other
financial assets

26,956

-630

-4,397

3,135

18,859

17,976

-656

2,622

3,119

16,823

2,036

8,980

Total

26,970

-630

-4,397

3,149

18,859

17,979

-656

2,622

3,122

16,823

2,036

8,991

Financial assets are primarily the carrying amounts of those shares in non-consolidated investments which are entirely measured at

amortized cost for lack of available market prices. There is currently no intention to sell these financial assets. Held-to-maturity financial

investments were included under other financial assets.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements

190

Financial assets developed as follows in the previous year:

2013
in € 000s

Cost as of Jan. 1, 2013

Currency translation

Changes in the scope of consolidation

Additions

Disposals

Reclassification from non-current assets held for sale and disposal groups

Transfers

Cost as of Dec. 31, 2013

Accumulated impairments as of Jan. 1, 2013

Currency translation

Changes in the scope of consolidation

Impairments

Disposals

Write-ups

Reclassification from non-current assets held for sale and disposal groups

Transfers

Accumulated impairments as of Dec. 31, 2013

Residual carrying amounts as of Dec. 31, 2013

Residual carrying amounts as of Dec. 31, 2012

Shares in
associated
companies
and other
investments

Other
financial assets

27,446

-323

215

709

1,091

26,956

18,043

-311

920

676

17,976

8,980

9,403

3,063

-131

-2,918

3,060

Total

30,509

-454

215

709

1,091

-2,918

26,970

18,046

-311

920

676

17,979

8,991

12,463

STADA Consolidated Financial Statements

191

28. Investments measured at equity

The disclosure relates to the accounting of shares in the associated companies BIOCEUTICALS Arzneimittel AG, as well as Pharm Ortho

Pedic SAS and AELIA SAS, using the equity method. Investments measured at equity developed as follows in financial year 2014 compared

with the previous year:

in € 000s

As of Jan. 1

Increase in investment share

Reclassifications due to the changed status of Pymepharco and STADA Vietnam

Result from associates

Elimination of dividend income

Currency translation differences

As of Dec. 31

2014

8,974

1,595

10,569

20131)

44,042

-38,431

3,700

-337

8,974

In the previous year, investments in associates decreased due to the control achieved as of January 1, 2013 of the subsidiary Pymepharco,

which was previously included in the consolidated financial statements as an associated company and has been consolidated as a sub-

sidiary as of 2013. In addition, the decrease in financial year 2013 resulted from the control achieved over Vietnamese company STADA

Vietnam, which – in the context of the retrospective adjustments carried out in accordance with the new standard IFRS 11 – was measured

at equity up until the time control was acquired and has been consolidated as a subsidiary since the fourth quarter of 2013.

29. Trade accounts receivable

Trade accounts receivable are composed as follows:

in € 000s

Trade accounts receivable from third parties

Trade accounts receivable from non-consolidated companies

Valuation allowances vis-à-vis third parties

Total

Dec. 31, 2014

Dec. 31, 2013

619,433

791

-117,430

502,794

717,551

134

-126,007

591,678

As of December 31, 2014, there are trade accounts receivable due after one year in the amount of € 1.4 million (previous year: none).

Collateral exists for a portion of trade accounts receivable whose value was not impaired in the form of mortgages, bank or corporate

guarantees, assignments of receivables as well as pledged inventories. Furthermore, there is commercial credit insurance for certain

markets and customers.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements192

The following non-impaired trade accounts receivable were past due at the balance sheet date:

thereof:
neither
impaired nor
past due as at
the balance
sheet date

448,358

508,035

Carrying
amount

502,794

591,678

thereof: not impaired as at the balance sheet date and
past due in the following time periods:

up to
30 days

25,619

36,564

between
31 and 90
days

19,905

22,590

between
91 and 180
days

5,569

8,836

more than
180 days

3,343

15,653

in € 000s

Dec. 31, 2014

Dec. 31, 2013

There were no recognizable indications as of the balance sheet date that the debtors would not meet their payment obligations. Therefore,

the trade accounts receivable which are not impaired and not past due are considered to be unconditionally recoverable. There are also no

indications of impairment for the overdue receivables that have not been impaired.

Overall, valuation allowances on trade accounts receivable developed as follows:

in € 000s

As of Jan. 1

Added

Utilized

Reversed

Changes in the scope of consolidation

Currency translation differences

As of Dec. 31

30. Other financial assets

Other financial assets are composed as follows:

in € 000s

Loan receivables

Outstanding purchase price receivables

Derivative financial assets

Available-for-sale financial assets

Other financial assets

Total

Dec. 31, 2014

Dec. 31, 20131)

126,007

125,068

9,796

9,037

2,625

-6,711

117,430

8,115

2,971

1,585

278

-2,898

126,007

Dec. 31, 2014

Dec. 31, 2013

Total

4,882

2,870

33,250

57,641

98,672

thereof:
current

4,882

1,810

29,551

50,671

86,943

Total

16,755

4,025

10,520

46,535

77,881

thereof:
current

1,042

3,347

10,204

35,457

50,096

STADA Consolidated Financial Statements

193

Loans primarily include loans granted by STADA Arzneimittel AG to BIOCEUTICALS Arzneimittel AG. As of the balance sheet date, € 3.3 mil-

lion (previous year: € 15.6 million) of the available credit line facility had been used.

The outstanding purchase price receivables in financial year 2014 and also primarily in the previous year relate to the still outstanding

installments from the sale of a product portfolio in Italy.

The derivative financial assets include the positive market values of cross-currency swaps as well as of currency futures contracts (see Note

47.7.). Available-for-sale financial assets are shares that are measured at fair value based on market prices.

The remaining financial assets include accruals for price compensations in connection with tender contracts in the amount of € 36.6 million,

receivables from the German factoring business in the amount of € 6.2 million and also comprise many insig nificant individual items in the

Group companies.

As of December 31, 2014, other financial assets include impairments in the amount of € 0.6 million (previous year: € 0.0 million). There

are no outstanding amounts for non-impaired other financial assets as in the previous year.

31. Other assets

Other assets are composed as follows:

in € 000s

Other receivables due from the tax authorities

Prepaid expenses / deferred charges

Assets from overfunded pension plans

Remaining assets

Total

Dec. 31, 2014

Dec. 31, 2013

Total

16,239

13,389

109

11,259

40,996

thereof:
current

16,239

11,252

10,375

37,866

Total

15,910

13,444

665

8,026

38,045

thereof:
current

15,910

11,369

7,196

34,475

Remaining assets comprise many insignificant individual items in the Group companies.

Remaining assets are impaired in the amount of € 7.1 million (previous year: € 6.2 million).

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements

194

32. Inventories

Inventories can be subdivided as follows:

in € 000s

Materials and supplies

Work in progress

Finished goods

Advance payments

Total

Dec. 31, 2014

Dec. 31, 2013

93,958

24,858

374,986

4,983

498,785

106,133

27,413

382,584

8,244

524,374

The decrease in inventories primarily resulted from a weak Russian ruble and a corresponding low translation of assets reported in foreign

currency into the Group currency euro as well as from reporting date effects.

In financial year 2014, impairments netted with reversals were made on the net realizable value of inventories in the amount of € 33.7 mil-

lion (previous year1): € 29.9 million), which were already deducted from the amounts shown above through profit and loss. In financial year

2014, reversals here amounted to € 9.3 million (previous year1): € 7.3 million).

33. Non-current assets and disposal groups held for sale

In financial year 2014, assets held for sale in the amount of € 0.3 million (previous year: € 1.6 million) included real estate of a STADA

subsidiary in Serbia. Thereof, € 0.2 million (previous year: € 1.3 million) is allocated to the Generics operating segment and € 0.1 million to

the Branded Products operating segment (previous year: € 0.3 million).

34. Cash and cash equivalents

Cash and cash equivalents include cash on hand and call deposits as well as short-term and highly liquid financial investments with a

maximum term of 90 days from the purchase date. In certain countries, specific transactions are subjected to special monitoring in the

context of the requirements of the respective national bank or foreign exchange acts in force. Restrictions on disposal for cash and cash

equivalents extending beyond this do not exist.

The increase in cash and cash equivalents from € 126.2 million as of December 31, 2013 to € 164.2 million as of December 31, 2014 is

primarily due to reporting date effects. Further details on the development of cash and cash equivalents can be found in the consolidated

cash flow statement.

35. Equity and liabilities

Group equity amounted to € 903.3 million as of the balance sheet date (previous year: € 1,010.1 million). This corresponds to an equity- to-

assets ratio of 27.1% (previous year: 29.6%).

STADA Consolidated Financial Statements195

35.1. Share capital

As of December 31, 2014, share capital amounted to € 157,629,420.00 (December 31, 2013: € 157,150,500.00) and was divided into

60,626,700 registered shares with restricted transferability (December 31, 2013: 60,442,500), each with an arithmetical share of share

capital of € 2.60 per share, and is fully paid.

Each registered share grants one vote in the Annual General Meeting.

The increase in the number of shares in 2014 was due to the exercise of 9,210 options from STADA warrants 2000/2015 in 2014.

The number of shares as of December 31, 2014 thereby increased by 184,200 to 60,626,700 and the share capital of STADA Arznei-

mittel AG increased by € 478,920.00 to € 157,629,420.00. As of December 31, 2014 88,176 warrants 2000/2015 for the subscription

of 1,763,520 registered shares with restricted transferability continued to be outstanding.

As of December 31, 2014, authorized share capital and conditional capital were comprised as follows:

Registered shares
with restricted
transferability

Amount in €

Purpose

77,134,304.00

29,667,040

Increase of share capital (until June 4, 2018)

4,585,152.00

1,763,520

Settlement of subscription rights from share options
(STADA warrants 2000/2015)

Settlement of options and/or conversion rights (until June 4,
2018) in connection with issued bonds with warrants and/or
convertible bonds, participation rights and/or participating
bonds in the total nominal amount of up to € 1.0 billion, or in
the scope of a guarantee assumed for bonds with warrants
and/or convertible bonds, participation rights and/or
participating bonds issued by subordinate Group companies

69,188,340.00

26,610,900

Authorized capital

Conditional capital 2004/I

Conditional capital 2013

35.2. Capital reserve

Changes in the capital reserve of the Group are shown in the consolidated statement of changes in equity and include in particular the

capital reserve of STADA Arzneimittel AG. Differences to the capital reserve determined according to the provisions of German commercial

law primarily result from the recognition at their market value of the shares of STADA Arzneimittel AG newly issued in 2003 as well as the

associated treatment of issuing costs, which were deducted from the capital reserve.

35.3. Retained earnings including net income

Retained earnings including net income comprise net income for the financial year as well as earnings generated in previous periods,

provided these were not distributed, including amounts transferred to retained earnings. In addition, revaluations of net debt from defined

benefit plans that were recognized directly in equity are reported under this item taking deferred taxes into account.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements

196

In the context of measuring the defined benefit obligations as of December 31, 2014, a net expense in the amount of € 15.5 million after

deferred taxes – not considering amounts attributable to non-controlling interests – resulted from the remeasurement. It is mainly based

on the substantial decrease in the discount rate for various defined benefit plans in the STADA Group underlying the measurement of De-

cember 31, 2014 in comparison to December 31, 2013.

35.4. Other provisions

Other provisions include results recognized directly in equity. This relates, among other things, to foreign exchange gains and losses

resulting from the currency translation with no effect on income of financial statements of companies included in the Group, which are

recognized in the statement of changes in equity under the currency translation reserve. The provisions available for sale and the provisions

for cash flow hedges include the results from the measurement at fair value of financial instruments categorized as available for sale, and

the measurement results from cash flow hedges from the effective portion of the hedge, allowing for deferred taxes respectively.

The reduction of other provisions as compared to the previous year is primarily composed of opposing effects. On the one hand, an increase

in other provisions from the currency translation of financial statements of companies reporting in pound sterling was recorded. This was

primarily due to the appreciation of the British pound sterling since December 31, 2013. On the other hand, there was a significantly

higher decrease in other provisions, which primarily resulted from the currency translation of financial statements of companies reporting

in the Russian ruble and Serbian dinar as a consequence of the significant weakening of both the Russian ruble and Serbian dinar since

December 31, 2013.

35.5. Treasury shares

As of the balance sheet date, the Company held 89,835 treasury shares (previous year: 91,989), each with an arithmetical par value of

€ 2.60 per share, which is equivalent to 0.15% (previous year: 0.15%) of the share capital. In financial year 2014, 2,154 treasury shares

were sold at an average price of € 31.62 per share within the scope of an employee stock option program.

35.6. Shares relating to non-controlling shareholders

Shares of non-controlling shareholders relate to minority interests of other shareholders in the subsidiaries STADA Thailand, STADA Import/

Export International, STADA Vietnam, Pymepharco, STADA Pharmaceuticals (Beijing), Well Light Investment Services, Hemomont and

Hemofarm Banja Luka.

STADA Consolidated Financial Statements197

36. Other non-current provisions

Other non-current provisions made by STADA as of the balance sheet date in Germany and outside Germany include pension provisions and

other non-current provisions in the form of anniversary provisions and provisions for working time accounts as follows:

in € 000s

Germany

Outside Germany

Total

Dec. 31, 2014

Dec. 31, 2013

13,155

16,942

30,097

37,955

13,523

51,478

In Germany, STADA has plan assets in the form of a reinsurance police, which are used to serve the pension entitlements of a small number

of former employees. In addition, there are plan assets for a pension obligation which was outsourced to a pension fund. All further pension

entitlements are financed internally in the scope of pension provisions. In addition, there are plan assets in a few foreign subsidiaries in the

form of, among others, government bonds and securities funds.

In Germany, plan assets were increased by additional contributions in financial year 2014. This led to a decrease in provisions.

In financial year 2014, the plan assets of an international subsidiary exceeded their pension obligations, with a result that, as in the previous

year, these assets in excess were reported under other assets as assets from overfunded pension plans in the amount of € 0.1 million

(previous year: € 0.7 million).

Plan assets were as follows divided according to investment type:

Share of plan assets in € 000s

Cash and cash equivalents

Equity securities

Debt securities

Real estate

Derivatives

Shares in investment funds

Insurance policies

Other

Total

2014

3,179

4,612

13,891

1,441

15,273

62,604

348

101,348

2013

358

8,827

8,539

1,324

13,483

30,106

1,094

63,731

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements
198

The plan assets, which have a quoted market price, consist of the following:

Share of plan assets (quoted market price) in € 000s

Cash and cash equivalents

Equity securities

Debt securities

Real estate

Derivatives

Shares in investment funds

Insurance policies

Other

Total

For German Group companies, pension obligations developed as follows:

Projected benefit obligations for pension commitments in € 000s

As of Jan. 1

Current service cost

Past service cost

Plan settlements

Interest cost

Benefits paid from plan assets

Benefits paid by employer

Revaluations:

•

Gains (-) / losses (+) due to changed demographic assumptions

Gains (-) / losses (+) due to changed financial assumptions

Gains (-) / losses (+) due to experience-based changes

As of Dec. 31

2014

3,179

4,612

13,891

1,441

12,990

348

36,461

2014

49,794

-17,603

1,640

-112

-488

15,411

3,803

52,474

2013

358

8,827

8,539

1,021

10,565

143

29,453

2013

49,035

969

1,754

-98

-472

-974

-420

49,794

STADA Consolidated Financial StatementsFor international Group companies, pension obligations developed as follows:

Projected benefit obligations for pension commitments in € 000s

As of Jan. 1

Current service cost

Past service cost

Plan settlements

Interest cost

Benefits paid from plan assets

Benefits paid by employer

Employee contributions

Insurance premiums for death and disability benefits

Business combinations

Reclassifications

Revaluations:

•

Gains (-) / losses (+) due to changed demographic assumptions

Gains (-) / losses (+) due to changed financial assumptions

Gains (-) / losses (+) due to experience-based changes

Currency changes

Other

As of Dec. 31

199

2014

61,395

1,559

-1,500

-379

2,564

-2,648

-586

457

-142

864

108

12,606

-13

1,182

-5

75,462

20131)

39,745

1,622

842

122

1,776

-594

-685

429

-95

20,821

-2,961

463

-155

61,395

The negative past service cost (as income) is primarily attributable to plan changes in plan in Serbia, the Netherlands and Russia. In Serbia,

the definition of pensionable salary was changed, in the Netherlands, the pension plan was adapted to the tax regulations applicable as of

2015 and in Russia, the effect mainly resulted from a settlement of plans.

The fair value of plan assets underlying the pension obligations developed as follows for German group companies:

Fair value of plan assets in € 000s

As of Jan. 1

Interest income

Employer contributions

Employee contributions

Pension payments

Actuarial gains (+) / losses (-) on plan assets (not included in interest result)

Other

As of Dec. 31

2014

12,011

408

25,188

-112

3,076

-1,252

39,319

2013

11,051

396

604

-98

12,011

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements200

The fair value of plan assets underlying the pension obligations developed as follows for international Group companies:

Fair value of plan assets in € 000s

As of Jan. 1

Interest income

Employer contributions

Employee contributions

Pension payments

Insurance premiums for death and disability benefits

Business combinations

Reclassifications

Actuarial gains (+) / losses (-) on plan assets (not included in interest result)

Currency changes

Other

As of Dec. 31

2014

51,720

2,062

1,168

457

-2,648

-142

7,832

1,642

-138

62,029

2013

29,828

1,317

1,506

429

-594

-95

20,102

-952

349

-170

51,720

The amount of the pension provisions recognized as of the balance sheet date for companies with plan assets is therefore as follows:

in € 000s

Projected benefit obligations for pension commitments

Fair value of plan assets

Net obligation

Effect from the limit on a defined benefit asset according to IFRIC 14

Net liability recognized in balance sheet

2014

2013

117,152

101,348

15,804

157

15,961

104,239

63,731

40,508

251

40,759

The amount of the pension provisions recognized as of the balance sheet date for companies without plan assets is therefore as follows:

in € 000s

Projected benefit obligations for pension commitments

Net liability recognized in balance sheet

2014

10,784

2013

6,950

STADA Consolidated Financial Statements201

Expenses for defined benefit plans on net income totaled € 15.1 million in financial year 2014 (previous year: expenses in the amount of

€ 5.4 million) and consisted of the following components:

in € 000s

Current service cost

Past service cost

Plan settlements

Net interest expense:

•

Interest expense (DBO)

Interest income (plan assets)

Interest income from reimbursement

Interest expense (+) / interest income (-) from the limit on an asset

Administration costs

Other

Total

2014

1,588

-19,103

-379

4,204

-2,470

117

954

2013

2,591

842

122

3,530

-1,713

-15,079

5,439

The actual return on plan assets amounted to € 3.5 million in financial year 2014 (previous year: € 0.5 million) for German group companies

and € 9.9 million for international group companies (previous year: € 0.4 million).

The following actuarial parameters were used as a basis for measuring the German pension obligations and pension costs:

Parameters for pension obligations for German Group companies (weighted)

Dec. 31, 2014

Dec. 31, 2013

Discount rate

Salary trend

Benefits trend

Inflation

2.0%

1.9%

1.4%

1.8%

3.7%

3.0%

1.8%

2.0%

The change in the average salary and pension trends can be attributed to the outsourcing of the pension commitment to a pension fund.

For this pension commitment, a long-term discretionary participation in the active phase as a salary trend and in the performance phase as

a pension trend is assumed.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements202

The following actuarial parameters were used as a basis for measuring the international pension obligations and pension costs:

Parameters for pension obligations for international Group companies (weighted)

Dec. 31, 2014

Dec. 31, 2013

Discount rate

Salary trend

Benefits trend

Inflation

2.71%

2.5%

0.8%

1.9%

4.25%

2.9%

1.7%

2.2%

The lower average pension trend as compared to the previous year mainly resulted from the decrease in the pension trends in the United

Kingdom, Russia and the Netherlands.

A sensitivity analysis was carried out in which only one assumption was changed in each case and all other assumptions were not changed.

In the following, the change in the defined benefit obligation of the pension obligations (DBO) for German Group companies is presented

according to a change in the discount rate, salary trends and pension trends.

Change in the defined benefit obligation for pension obligations (DBO)
as of December 31, 2014 (€ 52,474,000) according to changed assumptions in € 000s

Discount rate +0.5%

Discount rate -0.5%

Salary trend +0.5%

Salary trend -0.5%

Pension trend +0.5%

Pension trend -0.5%

2014

-5,355

6,261

4,696

-4,005

5,975

-5,164

2013

-4,449

5,150

-21

4,409

-3,869

The higher sensitivity of the salary trend can be attributed to the outsourcing of a pension commitment to a pension fund. For this pension

commitment, a long-term discretionary participation in the active phase as a salary trend is assumed.

STADA Consolidated Financial Statements

203

In the following, the change in the defined benefit obligation of the pension obligations (DBO) for international Group companies is presented

according to a change in the discount rate, salary trends and pension trends.

Change in the defined benefit obligation for pension obligations (DBO)
as of December 31, 2014 (€ 75,462,000) according to changed assumption in € 000s

Discount rate +0.5%

Discount rate -0.5%

Salary trend +0.5%

Salary trend -0.5%

Pension trend +0.5%

Pension trend -0.5%

2014

-6,470

7,530

809

-623

3,509

-1,826

2013

-5,052

5,726

635

-608

3,159

-2,573

As of December 31, 2014, the weighted duration of the pension obligations amounts to 23 years (previous year: 20 years) for German Group

companies and 19 years (previous year: 18 years) for international Group companies.

In the coming financial years, the following payments from the Company and from plan assets overall are expected for defined benefit plans:

Expected pension payments according to maturity dates in € 000s

Germany

Outside Germany

Less than one year

Between 1 and 2 years

Between 2 and 3 years

Between 3 and 4 years

Between 4 and 5 years

Between 5 and 10 years

602

596

599

647

903

2,832

2,310

2,582

2,925

2,824

8,262

13,316

For the coming financial year, employer contributions, consisting of direct pension payments and contributions to the plan, are expected in

the amount of € 0.8 million for German companies and € 1.7 million for international Group companies.

The regulations of the standard IAS 19 require a presentation of the benefit plans that generate obligations for the company. For the STADA

Group, pension plans in Germany, the Netherlands, the United Kingdom and Switzerland account for the largest share of total obligations

with 87%. Accordingly, the following details focus more on these countries.

In Germany, the legal framework for company pension plans is provided by the Company Pensions Act (Betriebsrentengesetz – BetrAVG) in

which minimum legal requirements are attached to company pension plans. Regulation and legal precedents within labor law must also be

followed. The pension plans are predominantly based upon the final salary and are concluded with newly hired employees. Plan participants

are primarily beneficiaries. Benefits are paid out in the form of a pension.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements

204

In Germany, STADA has plan assets in the form of reinsurance policies and in the form of assets in a pension fund. As of December 31,

2014, plan assets amounted to € 39.3 million and were composed of three different plans. There are no plan assets for two additional plans.

In the context of risk assessment, the life expectancy of plan participants plays a smaller role in Germany, as the – regarding its amount –

material obligation including associated risks was outsourced in financial year 2014. There is also the common risk, furthermore, of the

interest rate development and the risk that the real future salary development exceeds the salary development derived from assumptions

taken in the evaluation.

In the third quarter of 2014, the implementation method for the pension obligation for the Chairman of the Executive Board was changed.

It will be implemented through an independent pension fund in the future. The pension commitment has been fundamentally changed in the

context of outsourcing it to the pension fund. Accordingly, there is now a commitment to the Chairman of the Executive Board, upon

reaching the contractually agreed start of pension payments, for a lifelong pension in the form of a lower monthly guaranteed pension as

compared to the previous commitment as well as a variable non-guaranteed participation feature from which a corresponding benefit

increase may result. The start of pension payments can in principle – with the corresponding change in the amount of monthly pension

payments – take place variably within a defined time period, which exceeds the formerly assumed retirement age. In addition, a lifelong

survivor’s pension and a temporary orphan’s pension will be paid in case of death. In the context of the changed plan and the resulting

changes with regard to the benefits awarded according to the former benefit plan there were earnings from past service cost in the amount

of € 17.6 million. In addition, an expense from administrative costs for the benefit plan in the amount of € 0.7 million and an expense from

the adjustment of plan assets in the amount of € 1.0 million were incurred. The balance of the two items were earnings of € 15.9 million,

which were recorded in general and administrative expenses. Despite the transfer of the defined benefit plan of the Chairman of the

Executive Board to an pension fund, the necessity remains, due to the secondary liability of STADA, to treat the benefit plan as defined

benefit plan in accordance with IAS 19 and measure and recognize it accordingly. The plan assets created in the context of the transfer lead

to a provision of zero due to offsetting that must be carried out at the time of the plan amendment for this benefit plan. Because the pension

commitment is fully funded, no further provisions are expected in the future.

Pension legislation in the Netherlands requires pension plans to be backed by assets to the extent that the vested benefits are completely

covered. The underlying average career pension plan in the Netherlands is, in part, financed via insurance contributions that are designed

to fulfill the aforementioned requirement. The plan is open for new employees and contains benefits that fall due in case of retirement or

early death.

In the Netherlands, the pension plan is, in part, financed via contributions to an insurance company. Assets received by the insurance

company thereby cannot be allocated to specific participating companies. In particular, the assets cannot be determined by a quoted active

market price. In practice, the assets are estimated according to the amount of vested benefit obligations. As of December 31, 2014, plan

assets amounted to € 22.8 million.

The Dutch company pays annual pension contributions. In the process, life expectancy risk and interest rate risk are transferred to the

insurance company. The insurance company also assumes the risk of investing the contributions. These risks are assumed by the insurance

company for the entire term of the contract. If, for example, the discount rate used by the insurance company in its calculations should

change, a new contract could be concluded that applies the new discount rate to underlie only future contributions received.

STADA Consolidated Financial Statements205

Not all risks have been transferred to the insurance company. Dutch law specifies that former employees have the right to transfer their

pension entitlements to the pension plan of a new employer. If the evaluation assumptions applied in the transfer differ from the originally

applied assumptions of the insurance, the company could be required to pay an additional contribution payment.

From January 1, 2015, new limits for annual attribution rates approved for tax purposes have been in effect in the Netherlands; a cap for

the maximum pensionable salary was also introduced. In order to comply with legal requirements, the pension plan has been adjusted

accordingly. The effect of the resulting changes was recognized as past service cost. Overall, there was income.

In the United Kingdom, STADA provides its employees defined benefit plans that are concluded for new hires. The employees can also no

longer earn an additional increase in their entitlements. The pension plan plans are subject to the UK Trust Law and the UK Pension

Regulator. The pension plans are monitored by trustees who determine the investment strategy. The trustees are also responsible for

fulfilling the legally required pension plan funding and thereby ensure sufficient assets to cover the technical provisions of the plan. The

pension plan is subject to risks relating to the discount rate and participant life expectancy as well as inflation risk, if these values develop

contrary to expectations. If the discount rate is low, the level of funding decreases which may require the payment of additional contributions.

There is a financing risk in plan assets in that plan assets could develop contrary to expectations and plan assets could therefore only

compensate in part for changes in the obligations.

In financial year 2014, the investment strategy in the United Kingdom was changed to the extent that the titles held in the investment

category of equity securities, which are generally subject to a higher volatility risk, as well as titles held in the investment category of real

estate were sold and reinvested in low-risk classes of investment. As of December 31, 2014, plan assets amounted to € 23.9 million. All

assets have quoted market prices on an active market.

In Switzerland, every employer must offer its employees a pension plan according to federal pension law (Bundesgesetz über die berufliche

Alters-, Hinterlassenen- und Invalidenvorsorge – BVG). Employees whose salary exceeds the entry limit are obliged to be insured – this is

re-determined periodically. The BVG requires a minimum plan (the “BVG minimum”) that must always be covered. STADA’s Swiss benefit

plan includes benefits in case of death, disability, departure and upon reaching retirement age. The annual pension is calculated based on

a savings account and conversion rate determined according to the age of retirement. Plan participants can opt for a capital option.

The Swiss benefit plan includes three sub-plans. Retirement benefits had already been envisaged by two of the sub-plans, one sub-plan

only provided for a lump sum benefit. This sub-plan has been changed so that as of now the contractually agreed benefits will be paid not

only in the form of a lump sum, but an option for payment in the form of a pension was introduced. The effect of the plan change was

recognized as past service cost.

The contributions for defined contribution plans, which are reported as expense in the respective period in the relevant functional areas,

amounted to € 23.9 million in financial year 2014.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements206

The other non-current provisions developed as follows:

Other non-current provisions in € 000s

As of Jan. 1

Current service cost

Past service cost

Plan settlements

Interest cost

Benefits paid

Business combinations

Revaluations

•

Gains (-) / losses (+) due to changed demographic assumptions

Gains (-) / losses (+) due to changed financial assumptions

Gains (-) / losses (+) due to experience-based changes

Currency changes

Reclassifcations

As of Dec. 31

2014

3,104

315

-59

218

-324

-7

-257

115

3,243

2013

2,565

268

171

-78

197

-307

-50

290

-127

3,104

The following actuarial parameters were used as a basis for measuring the other long-term provisions:

Parameters for other long-term provisions for international Group companies (weighted)

Dec. 31, 2014

Dec. 31, 2013

Discount rate

Salary trend

Inflation

6.5%

4.0%

3.2%

7.8%

4.5%

4.1%

STADA Consolidated Financial Statements207

37. Financial liabilities

Financial liabilities are comprised as follows in accordance with their remaining terms as of the balance sheet date:

in € 000s

Remaining terms
up to 1 year

Remaining terms over
1 year to 3 years

Remaining terms over
3 years to 5 years

Remaining terms over
5 years

Liabilities
promissory notes

Amounts
due to banks

Liabilities
from bond

Total

Dec. 31,
2014

Dec. 31,
2013

Dec. 31,
2014

Dec. 31,
2013

Dec. 31,
2014

Dec. 31,
2013

Dec. 31,
2014

Dec. 31,
2013

50,487

97,770

48,336

194,714

349,880

448,703

292,484

231,330

237,581

103,107

37,709

349,488

334,437

624,778

269,017

99,592

52,161

69,554

347,391

346,633

668,569

515,779

39,992

Financial liabilities

550,834

434,943

243,596

301,991

697,271

696,121

1,491,701

1,433,055

The increase in financial liabilities mainly resulted from securing promissory notes in financial year 2014 in the total amount of € 270 million

and a loan in the amount of approx. € 83 million as of the balance sheet date for the financing of the purchase of the branded product

portfolio Aqualor®. In opposition, financial liabilities were repaid in the current financial year.

The contractually agreed undiscounted cash flows, as of the balance sheet date December 31, 2014, from interest payments and repay-

ment of financial liabilities for the coming years can be seen in the following chart:

2015

Interest
rate
variable

Interest
rate fixed

2016

Interest
rate
variable

> 2016

Interest
rate
variable

Repay-
ment

Interest
rate fixed

Repay-
ment

Interest
rate fixed

38,676

14,274

453,786

20,376

11,731

223,764

52,244

27,203

818,516

in € 000s

Cash flows from
financial liabilities

The following projection of cash flows from financial liabilities was generated in the previous year:

2014

Interest
rate
variable

Interest
rate fixed

2015

Interest
rate
variable

> 2015

Interest
rate
variable

Repay-
ment

Interest
rate fixed

Repay-
ment

Interest
rate fixed

37,560

5,130

297,172

31,878

4,642

414,338

35,238

5,935

726,433

in € 000s

Cash flows from
financial liabilities

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements

208

For the financial liabilities existing as of the balance sheet date, a repayment in accordance with the maturity disclosed in the balance sheet

was generally assumed. For current liabilities due to banks, an extension of existing credit lines was partly assumed. The variable interest

payments from the promissory notes were determined based on the interest rate last fixed before December 31, 2014.

Internal measures to ensure the necessary liquidity for repayment of financial liabilities are detailed in the notes on the management of

liquidity risk (see Note 47.5.).

38. Trade accounts payable

Trade accounts payable are composed as follows:

in € 000s

Dec. 31, 2014

Dec. 31, 2013

Trade accounts payable to third parties

Trade accounts payable to non-consolidated Group companies

Advances received on orders from third parties

Liabilities from outstanding accounts

Total

271,765

200

1,660

67,222

340,847

263,391

7,112

1,950

59,208

331,661

Of the total amount of trade accounts payable, € 0.1 million (previous year: € 0.1 million) are due after one year.

The increase of trade accounts payable was primarily based on balance sheet date effects and the resulting derivable cash flows.

39. Other financial liabilities

Other financial liabilities are broken down as follows:

in € 000s

Outstanding purchase price liabilities

Finance lease liabilities

Liabilities from derivative financial instruments

Other financial liabilities

Total

Dec. 31, 2014

Dec. 31, 2013

Total

32,233

3,081

3,124

224,224

262,662

thereof:
current

32,233

1,056

348

223,766

257,403

Total

6,595

8,467

5,619

253,374

274,055

thereof:
current

5,890

4,460

405

250,312

261,067

STADA Consolidated Financial Statements

209

In the reporting year, the outstanding purchase price liabilities primarily resulted, as in the previous year, from installments which were not

yet due for the acquisition of branded products in Russia. Furthermore, the outstanding contingent purchase price payment for the

acquisition of the British company Internis is included in financial year 2014.

Finance lease liabilities, such as for vehicles and passenger vehicles amount to € 3.1 million (previous year: € 8.5 million). Liabilities for

sale-and-leaseback transactions for software and software licenses recognized in the previous year no longer exist as of the balance-sheet

date December 31, 2014. Considering interest in the amount of € 0.6 million (previous year: € 1.7 million), lease installments payable in

sub sequent years total € 3.7 million (previous year: € 10.2 million). The lease liabilities are due as follows:

in € 000s

Remaining terms up to 1 year

Remaining terms over 1 year to 3 years

Remaining terms over 3 years to 5 years

Remaining terms over 5 years

Total

3,706

10,207

Lease installments

Interest

Liabilities
finance lease

Dec. 31,
2014

Dec. 31,
2013

Dec. 31,
2014

Dec. 31,
2013

Dec. 31,
2014

Dec. 31,
2013

1,371

2,335

5,197

4,535

475

315

310

625

737

978

1,056

2,025

1,740

3,081

4,460

3,557

450

8,467

In addition, the negative market values of derivatives measured at fair value through profit or loss were reported in liabilities from derivative

financial instruments. In financial year 2014, this continued to relate, as in the previous year, to interest rate swaps, which are used as

hedging instruments and, in addition, cross-currency swaps and currency forwards (see Note 47.7.). Within the scope of the maturity date

analysis, the following contractually agreed remaining terms result for these derivative financial liabilities:

in € 000s

Remaining terms up to 1 year

Remaining terms over 1 year to 3 years

Remaining terms over 3 years to 5 years

Remaining terms over 5 years

Total

Derivative
financial liabilities

Dec. 31, 2014

Dec. 31, 2013

348

2,776

3,124

405

4,785

429

5,619

Remaining financial liabilities include liabilities from discount agreements of German STADA companies in the amount of € 192.1 million

(previous year: € 214.7 million) and furthermore comprise many insignificant individual items in the Group companies. The remaining

financial liabilities fall due in the amount of € 223.8 million (previous year: € 250.3 million) within one year, in the amount of € 0.5 million

after one year and up to five years (previous year: € 3.1 million).

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements

210

The contractually agreed undiscounted cash flows, as of the balance sheet date December 31, 2014, from interest payments and repay-

ment of finance lease liabilities and for the liabilities from derivative financial instruments for the coming years can be seen in the following

chart:

in € 000s

Cash flows from
liabilities finance leases

Cash flows from derivatives

Interest
rate fixed

315

2,185

2015

Interest
rate
variable

2016

Interest
rate
variable

2017 – 2019

Interest
rate
variable

Repay-
ment

Interest
rate fixed

Repay-
ment

Interest
rate fixed

1,056

206

1,187

956

104

1,185

The following projection of cash flows from finance lease liabilities as well as derivatives was generated in the previous year:

in € 000s

Cash flows from
liabilities finance leases

Cash flows from derivatives

Interest
rate fixed

737

3,079

2014

Interest
rate
variable

2015

Interest
rate
variable

2016 – 2018

Interest
rate
variable

Repay-
ment

Interest
rate fixed

Repay-
ment

Interest
rate fixed

4,460

511

2,088

1,241

492

1,103

Repay-
ment

1,069

Repay-
ment

2,766

Included were all financial instruments used by STADA which existed as of December 31, 2014 and for which payments had already been

contractually agreed.

Further details on liabilities from derivative financial instruments can be found in the notes on financial instruments (Note 46. and Note

47.7.).

40. Other liabilities

Other liabilities were comprised as follows:

in € 000s

Tax liabilities

Personnel related liabilities

Other liabilities

Total

Dec. 31, 2014

Dec. 31, 2013

Total

1,949

46,521

40,475

88,945

thereof:
current

1,949

46,145

39,211

87,305

Total

17,031

48,919

48,339

114,289

thereof:
current

17,031

47,968

46,353

111,352

STADA Consolidated Financial Statements

Personnel-related liabilities relate to € 0.4 million in accruals in connection with partial retirement agreements as of December 31, 2014

(previous year: € 1.0 million).

Remaining liabilities comprise many insignificant individual items in the Group companies.

211

41. Other provisions

Other provisions are composed as follows:

in € 000s

Provisions set aside for damages

Warranties

Total

Dec. 31, 2014

Dec. 31, 2013

343

17,099

17,442

604

16,932

17,536

Provisions set aside for damages include possible utilization from pending legal disputes including the associated legal costs and developed

as follows:

in € 000s

As of Jan. 1

Added

Utilized

Reversed

Currency translation differences

As of Dec. 31

Provisions for warranties developed as follows:

in € 000s

As of Jan. 1

Added

Utilized

Reversed

Changes in the scope of consolidation

As of Dec. 31

Dec. 31, 2014

Dec. 31, 2013

604

1,721

1,964

343

1,024

340

731

-29

604

Dec. 31, 2014

Dec. 31, 2013

16,932

5,138

3,897

1,074

17,099

9,514

12,966

1,879

3,669

16,932

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements
212

Other Disclosures

42. Notes to the cash flow statement

Cash flow from operating activities consists of changes in items not covered by capital expenditure, financing, changes in exchange rates

from the conversion of foreign financial statements or transactions in foreign currencies or through changes in the scope of consolidation

and measurement. Cash flow from operating activities amounted to € 223.8 million in the reporting year (previous year1): € 203.7 million).

The increase by € 20.1 million as compared to the previous year mainly resulted from a substantial cash-effective decrease in trade

accounts receivable, whereas a substantial cash-effective increase was recorded in the previous year, as well as from lower income tax

payments. The resulting positive effects were partially compensated by a substantial cash-effective decrease in trade accounts payable as

compared to a substantial cash-effective increase in trade accounts payable in the previous year. In addition, a significantly higher cash-

effective decrease in other non-current provisions was recorded in financial year 2014, which is connected to the transfer of a defined

benefit plan to an external pension fund.

Cash flow from investing activities reflects the cash outflows for investments reduced by the inflows from disposals. This amounted to

€ -262.0 million in the reporting year (previous year1): € -312.0 million).

In financial year 2014, payments for investments in intangible assets in the amount of € 181.4 million (previous year: € 53.0 million) were

made, of which € 147.5 million (previous year: € 13.5 million) related to significant investments in intangible assets for the short-term

expansion of the product portfolio. Acquisition-related sales growth was generally associated with these investments in the reporting year.

Proceeds from the disposal of non-current assets in the financial year amounted to € 12.0 million (previous year1): € 5.4 million).

In financial year 2014, cash flow from investing activities was particularly influenced by high payments for investments in intangible assets,

which primarily related to the purchase of the Russian branded product portfolio Aqualor®. Furthermore, there were payments for business

combinations from the purchase of the branded product portfolio Flexitol® and the acquisition of the British company Internis. Proceeds from

the disposal of intangible assets mainly resulted from the sale of approvals and trademarks in France and Italy. Proceeds from the dis posal

of property, plant and equipment primarily related to the sale of a building in the United Kingdom. In the previous year, payments for invest-

ments in business combinations primarily resulted from the purchase price payments made for the acquisition of the British OTC supplier

Thornton & Ross as well as from the final purchase price payments for the additional shares and the control achieved over the Vietnamese

pharmaceutical company Pymepharco and for the pharmaceutical wholesaling and commercial business acquired from Spirig Pharma, in

each case following the deduction of acquired cash and cash equivalents.

Cash flow from financing activities amounted to € 83.7 million in financial year 2014 (previous year1): € 148.8 million) and encompasses

payments from changes in financial liabilities, dividend distribution payments and payments for treasury shares as well as additions to

shareholders’ equity. In the reporting year, there were proceeds from securing financial liabilities, among other things, in connection with

promissory notes secured in financial year 2014 in the total amount of € 270 million and a loan in the amount of approx. € 121 million for

financing the purchase of the branded product portfolio Aqualor®. In the previous year, higher proceeds from taking up financial liabilities

were recorded, in particular due to the bond placed in the second quarter of 2013. Furthermore, more financial liabilities were repaid in the

previous year than in the reporting period.

STADA Consolidated Financial Statements213

Dividend distribution payments of € 39.8 million primarily related to the dividend paid to the shareholders of STADA Arzneimittel AG for

financial year 2013. A significant increase was thus achieved in the distributed volume as compared to the dividend for financial year 2012.

Proceeds from the capital increase are the result of the exercise of STADA warrants 2000/2015 (see Note 35.1.).

Free cash flow as the sum of cash flow from operating activities and cash flow from investing activities amounted to € -38.2 million in

financial year 2014 (previous year1): € -108.2 million) and is therefore still significantly characterized by a high volume of acquisitions.

Free cash flow, adjusted for effects from payments for significant investments and acquisitions and effects of proceeds from significant

disposals is calculated as follows:

in € 000s

Cash flow from operating activities

Cash flow from investing activities

+ Payments for investments in business combinations according to IFRS 3

+ Payments for significant investments in intangible assets for the short-term expansion

of the product portfolio

˙∕. Proceeds from the disposal of intangible assets in significant disposals

Adjusted free cash flow

2014

20131)

223,810

-261,980

55,054

147,487

6,960

157,411

203,744

-311,982

229,754

13,450

1,700

133,266

43. Segment information

The measurement approaches for segment reporting are in accordance with the financial reporting methods used in the IFRS consolidated

financial statements. Services between the segments are charged based on market prices.

Segmentation within the STADA Group is based on sales differentiation. Thus, the allocation to the individual segments is determined to a

large extent by the sales positioning. If this positioning changes for parts of the product portfolio, associated sales are reallocated.

Generally, STADA’s operating segments are divided into the two core segments, Generics and Branded Products, as well as into the

non-core segment Commercial Business.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements

214

Pursuant to STADA’s segment definition, which has been used since 2006, Generics are products for the health care market – usually with

a drug character – which contain one or several active ingredients whose commercial property rights have expired or will expire shortly and

whose sales positioning complies with one of the two following criteria:

• The product is offered by emphasizing its low price, usually in contrast to the product of another supplier which contains the identical

active pharmaceutical ingredient,

• the product is an integral part of a marketing concept targeting more than one product and indication for primarily prescription

products with active ingredients whose commercial property rights have usually expired.

According to STADA’s segment definition, which has been used since 2006, Branded Products are products for the health care market

which contain one or several active ingredients whose commercial property rights have usually expired and whose sales positioning

complies with one of the two following criteria:

• The product is sold under a product-specific brand name and with emphasis on specific product characteristics which aim at a unique

position of the product in contrast to competitive products and other Group products,

• the product is part of a marketing concept for primarily non-prescription products which are mainly sold under a product-specific brand

name and with emphasis on different specific product characteristics which aim at a unique position of the product in contrast to

competitive products and other Group products.

STADA also conducts business and has equity interests in fields outside the core segments. As a rule, the objective of these activities is to

supplement and support the Group’s activities in the core segments. Transactions that mainly involve trading and selling – such as in

wholesaling activities – are grouped together in the Commercial Business segment. All other income, expenses and assets, which cannot

be directly allocated to the segments, as well as the elimination of sales between segments are recognized under the reconciliation Group

holdings / other and consolidation.

Disclosures on significant non-cash items include impairments on inventories and receivables; they do not, however, include depreciation

and amortization as well as the offsetting of impairments and write-ups. In addition, further non-cash items, particularly non-cash effects

from accruals for health insurance organization billings are included here. Reporting of the segment liabilities and non-current segment

assets is waived, as this is without relevance for Group monitoring and for Group reporting.

STADA Consolidated Financial Statements43.1. Information by operating segment

in € 000s

Generics

External sales

Sales with other segments

Total sales

Operating profit

Depreciation / amortization

Impairment losses

Reversals

215

2014

20131)

1,217,729

1,227,894

571

1,218,300

108,314

50,743

63,924

888

1,228,782

154,367

45,775

5,103

Other significant non-cash items within operating result

-221,153

-225,233

Branded Products

External sales

800,558

704,366

Sales with other segments

Total sales

Operating profit

Depreciation / amortization

Impairment losses

Reversals

Other significant non-cash items within operating result

Commercial Business

External sales

Sales with other segments

Total sales

Operating profit

Depreciation / amortization

Impairment losses

Reversals

Other significant non-cash items within operating result

Reconciliation
Group holdings / other
and consolidation

External sales

Sales with other segments

Total sales

Operating profit

Depreciation / amortization

Impairment losses

Reversals

Other significant non-cash items within operating result

Group

External sales

Sales with other segments

Total sales

Operating profit

Depreciation / amortization

Impairment losses

Reversals

Other significant non-cash items within operating result

800,558

138,206

59,444

33,896

-32,430

43,960

871

139

-170

-571

-58,864

10,664

9,711

16,418

704,366

160,171

50,631

5,000

176

2,136

41,045

1,327

226

-561

30,607

-888

29,719

-67,539

10,490

13,513

370

22,312

2,062,247

2,003,912

2,062,247

2,003,912

188,527

120,990

107,531

-237,335

248,326

107,122

23,617

546

-201,346

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements

216

43.2. Reconciliation of segment results to net profit

in € 000s

Operating segment profit

Reconciliation Group holdings / other and consolidation

Result from investments measured at equity

Investment income

Financial income

Financial expenses

Earnings before taxes, Group

43.3. Reconciliation of segment assets to Group assets

in € 000s

Segment assets

Reconciliation Group holdings / other and consolidation

Other non-current assets

Current assets

Total assets, Group

43.4. Information by country

2014

20131)

247,391

-58,864

1,595

132

4,833

70,393

124,694

315,865

-67,539

3,700

340

6,865

69,930

189,301

Dec. 31, 2014

Dec. 31, 2013

1,863,967

1,890,259

75,015

74,837

1,321,639

3,335,458

78,783

90,947

1,353,193

3,413,182

in € 000s

Germany

Russian Federation

United Kingdom

Italy

Belgium

Other regions

Total, Group

Development of sales
by the company’s registered office

Non-current assets

2014

20131)

Dec. 31, 2014

Dec. 31, 2013

462,565

381,958

185,179

180,895

150,127

701,523

483,120

436,015

114,585

169,106

147,736

653,350

599,702

221,847

468,059

43,955

7,774

595,609

641,858

225,447

324,690

54,767

9,264

704,025

2,062,247

2,003,912

1,936,946

1,960,051

STADA Consolidated Financial Statements

217

In the presentation of sales by the company’s registered office, sales to third parties are shown according to the invoicing company’s

registered office of the countries listed.

Disclosures on assets by country relate to parts of the non-current assets (intangible assets, property, plant and equipment).

43.5. Information about major customers

In accordance with IFRS 8.34, a company must provide notification when sales revenues from business activities from a single external

customer amount to at least 10% of the company’s total sales revenues. As in the previous year, this related to no customer in the reporting

year.

44. Contingent liabilities

Contingent liabilities describe possible obligations with respect to third parties which result from past events and which may lead to a future

outflow of resources depending on specific events. As of the balance sheet date, these contingent liabilities were considered improbable

and are therefore not recognized.

STADA has contingent liabilities, among other things, in connection with patent risks for certain active pharmaceutical ingredients and

associated pending or impending proceedings. The resulting possible obligations amounted to approx. € 18.9 million (previous year:

€ 11.1 million), from which, in addition to the contingent liabilities for patent risks reported in the Annual Report 2013, further contingent

liabilities in the amount of € 5.6 million in the market region Central Europe and in the amount of € 2.8 million in the market region

CIS / Eastern Europe resulted. Former contingent liabilities for patent risks in the amount of € 0.6 million in the market region Central Europe

no longer exist however, as a settlement was reached for this issue due to a lost patent dispute and any additional potential obligations were

satisfied by a settlement payment. Provisions were not created for contingent liabilities as the probability of an outflow of assets is under

50%. Outflows potentially resulting from these risks would generally be short-term.

Furthermore, in the first quarter of 2014, the insolvency administrator of Velefarm Holding and Velefarm VFB submitted a lawsuit to

Belgrade’s commercial court against Hemofarm A.D., a subsidiary of STADA Arzneimittel AG, and Velefarm Prolek, a company of the Vele-

farm group.1) The statement of claim names potential repayments to the insolvent assets, which could result from this claim, with amounts

quantified at approx. € 54.2 million (in local currency translated using the currency exchange rate at that time). However, it has to be taken

into con sideration that Hemofarm as creditor of the insolvent assets would retrieve a quota of the insolvent assets in a significant amount.

Hemofarm and STADA continue to believe that the lawsuit is unfounded. For this reason no provisions were made for this purpose.

1) See the Company’s ad hoc release of February 14, 2014.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements218

45. Other financial obligations

In addition to the contingent liabilities, there were other future financial obligations, which can be broken down as follows:

in € 000s

Operating lease liabilities

Other financial obligations

Total

Dec. 31, 2014

Dec. 31, 2013

72,892

31,536

104,428

70,973

166,705

237,678

Liabilities from operating leases relate particularly to IT equipment and vehicles. In addition, there are liabilities from long-term rental

agreements for office buildings with an average contract term of 4 years.

The total of future minimum lease payments under operating leases amounted to € 72.9 million as of the end of the financial year (previous

year: € 71.0 million) and can be broken down according to remaining term as follows:

in € 000s

Remaining terms up to 1 year

Remaining terms over 1 year to 5 years

Remaining terms over 5 years

Total

Operating lease

Dec. 31, 2014

Dec. 31, 2013

25,280

36,909

10,703

72,892

22,370

33,120

15,483

70,973

Lease payments in the amount of € 29.2 million (previous year1): € 29.5 million) were recognized as an expense in financial year 2014.

STADA Consolidated Financial Statements

219

As of December 31, 2013, other financial obligations consisted of an obligation of Nizhpharm amounting to € 131.0 million toward

Butterwood Holdings Limited, Cyprus, for the purchase of the Russian branded product portfolio Aqualor® 1), whereby the completion of the

contract was still subject to comprehensive completion conditions as of December 31, 2013. As of December 31, 2014, this other financial

obligation no longer exists, as the residual amount of the purchase price liability still outstanding as of December 31, 2014 of € 13.1 million

has been recorded in the balance sheet under other financial liabilities.

Furthermore there is still a guarantee amounting to € 25.0 million towards Hospira Inc., Lake Forest, Illinois, USA, in connection with a

supply agreement between Hospira and the shares in the associated company BIOCEUTICALS Arzneimittel AG which are recognized under

the equity method.

STADA, as guarantor, has recognized these guarantees in the reporting year as financial guarantees in accordance with IAS 39 at their fair

value in the amount of € 0.3 million (previous year: € 0.3 million). Utilization of these guarantees granted is currently not expected.

Furthermore, the remaining financial liabilities included, among other things, additional guarantees assumed by the STADA Group.

1) See the Company’s ad hoc release of October 18, 2013 and ad hoc update of February 28, 2014.

STADA Consolidated Financial Statements | Notes to the Consolidated Financial Statements220

46. Disclosures about financial instruments

46.1. Carrying amounts, valuation rates and fair values according to valuation categories

The following disclosures are made on carrying amounts, valuation rates and fair values by valuation category, whereby the following

abbreviations are made pursuant to IAS 39: LaR (loans and receivables), HtM (held-to-maturity investments), AfS (available-for-sale financial

assets), FAHfT (financial assets held for trading), FLHfT, (financial liabilities held for trading) and FLAC (financial liabilities measured at

amortized cost).

Valuation rate balance sheet
in accordance with IAS 39

Carrying
amount
Dec. 31,
2014

Valuation
category
pursuant
to IAS 39

Amortized
cost

Fair value
not included
in the
income
statement

Fair value
included in
the income
statement

Valuation
rate in
accordance
with IAS 17

164,209

502,794

2,065

33,250

65,393

339,187

243,596

550,834

697,271

3,081

2,666

458

256,457

732,396

2,065

33,250

2,087,345

458

LaR

HtM

AfS

FAHfT

LaR

FLAC

n/a

FLHfT

FLAC

LaR

HtM

AfS

FAHfT

FLAC

FLHfT

164,209

502,794

2,036

65,393

339,187

243,596

550,834

697,271

256,457

732,396

2,036

2,087,345

2,666

33,250

458

33,250

458

3,081

in € 000s

Assets

Cash and cash equivalents

Trade accounts receivable

Held-to-maturity financial assets

Available-for-sale financial assets

Derivative financial assets without hedging relationship

Other financial assets

Equity and liabilities

Trade accounts payable

Amounts due to banks

Promissory notes

Bonds

Liabilities financial leasing

Derivative financial liabilities with hedging relationship

Derivative financial liabilities without hedging relationship

Other financial liabilities

Thereof aggregated according to valuation categories
in accordance with IAS 39:

Loans and receivables

Held-to-maturity investments

Available-for-sale financial assets

Financial assets held for trading

Financial liabilities measured at amortized cost

Financial liabilities held for trading

Valuation rate balance sheet

in accordance with IAS 39

Carrying

amount

year

Fair value

not included

in the

income

Amortized

cost

statement

Fair Value

Dec. 31,

2014

Fair value

included in

the income

statement

Valuation

rate in

accordance

with IAS 17

Fair value

Dec. 31,

2013

164,209

502,794

2,065

33,250

65,393

339,187

245,914

592,749

715,750

3,081

2,666

458

126,163

591,678

9,026

10,520

67,315

329,711

301,991

434,943

696,121

8,467

4,748

871

10,520

126,163

591,678

8,980

67,315

329,711

301,991

434,943

696,121

8,467

4,748

871

256,457

259,969

732,396

785,156

2,065

33,250

9,026

10,520

8,980

2,150,057

2,022,735

458

871

10,520

871

126,163

591,678

9,026

10,520

67,315

329,711

305,168

471,285

714,042

8,467

4,748

871

259,969

785,156

9,026

10,520

2,080,175

871

STADA Consolidated Financial Statements

46. Disclosures about financial instruments

46.1. Carrying amounts, valuation rates and fair values according to valuation categories

The following disclosures are made on carrying amounts, valuation rates and fair values by valuation category, whereby the following

abbreviations are made pursuant to IAS 39: LaR (loans and receivables), HtM (held-to-maturity investments), AfS (available-for-sale financial

assets), FAHfT (financial assets held for trading), FLHfT, (financial liabilities held for trading) and FLAC (financial liabilities measured at

amortized cost).

Derivative financial assets without hedging relationship

2,036

33,250

Valuation rate balance sheet

in accordance with IAS 39

Carrying

amount

Dec. 31,

2014

Valuation